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Blood pressure is one of the most important modifiable risk factors for stroke. 
Although the influence of an individual’s average blood pressure (BP) on their 
overall stroke risk is well established, visit-to-visit blood pressure variability (BPV) - 
variation in blood pressure from one clinic visit to the next- may be an independent 
risk factor for stroke. The influence of BPV on stroke risk in the general population 
is not fully understood, nor is it known whether associations with BPV vary by 
pathological stroke type. Very large prospective studies, including exposure 
measurements of BP and BPV as well as accurate identif cation, confirmation and 
sub-classification of large numbers of stroke cases during follow-up, are needed to 
test the associations between BP parameters, stroke and its main pathological types.  
UK Biobank (UKB) is a very large prospective cohort study of ~500,000 middle 
aged adults recruited from England, Scotland, and Wales between 2006 and 2010. 
Participants completed a detailed baseline assessment at recruitment (which included 
self-report of prior stroke and BP measurement). Follow up for health-related 
outcomes (including new occurrences of stroke) in UKB relies on linkages to routine 
coded datasets for hospital admissions, death regist ations and primary care data. 
Coded primary care data could also be used to capture novel exposures, like blood 
pressure variability (BPV).  
In this thesis, I aimed to investigate how large pros ective epidemiological studies 
such as UK Biobank might be used to investigate the influence of BP, and in 
particular BPV, on stroke and its types and subtypes. I did this through advancing 
understanding of the identification and characterisation of stroke cases in large 
prospective studies, and of obtaining measures of BPV from linked primary care 
data. Specifically, I aimed:  
(1) to evaluate the accuracy of patient self-report of stroke, the accuracy of routinely 
available coded healthcare data for stroke, and the reliability and feasibility of 
ischaemic stroke classification systems for large epidemiological studies such as 
UKB;  
  x 
(2) to identify prevalent and early incident stroke cases in UKB using multiple 
overlapping sources of coded data, and determine the proportions of cases 
classified into main pathological types of stroke;  
(3) to explore the feasibility of using coded primary care data to obtain  measures of 
BPV in UKB.  
Methods 
(1) I performed a series of systematic reviews of published data on (i) the accuracy 
of patient self-report of stroke, (ii) the accuracy for stroke and its main 
pathological types (ischaemic stroke, intracerebral haemorrhage, subarachnoid 
haemorrhage) of International Classification of Disea es (ICD) coded hospital 
admissions and death certificates, and Read coded primary care records, and 3) 
the inter-rater reliability of ischaemic stroke classification systems.   
(2) Informed by this work I identified prevalent and early incident stroke cases in 
UKB using linked coded hospital and death registration data as well as self-report 
data. In a sub cohort of participants, I was able to assess the additional role in 
case identification of linked coded primary care data.  I compared the numbers of 
potential stroke cases ascertained by multiple overlapping combinations of these 
data and examined the proportions classified into the main pathological stroke 
types.  
(3) Finally, I analysed data from about 10,000 Welsh UKB participants with linked 
coded primary care data to identify those in whom visit-to-visit BPV could be 
measured using coded systolic blood pressure values (BP). I explored the 
association between frequency of visits with coded BP values and: participant 
characteristics; time between visits; mean BPV; standard deviation of BPV (SD 
BPV). I also calculated within-individual agreement between coded BP and UKB 
baseline assessment BP.  
Results 
(1) From my systematic reviews I found that self-report accuracy was strongly 
influenced by characteristics of the study population. In populations with low 
stroke prevalence up to 75% of self-reported strokes w re false positives. ICD 
codes for cerebrovascular diseases had a broad range of accuracy for stroke and 
  xi 
its main pathological types, but appropriately select d, ‘stroke specific’ ICD 
codes were consistently >70% accurate when compared to an independent 
reference standard for stroke. Few studies assessed the accuracy of either primary 
care data or combinations of data sources for stroke.  
The overall inter-observer reliability of ischaemic stroke classification systems 
ranged from moderate to almost perfect. Study charateristics other than 
classification system accounted for much of the variation in reliability. 
Additional features which enhanced reliability included use of clear rules, data 
abstraction protocols, computerised assignment, and reduced number of subtype 
categories.  
(2) The prevalence of stroke in UK Biobank based on linked ICD coded hospital 
admissions data and participant self-report was ~1.7%. The majority of these 
prevalent stroke cases were of ‘unspecified’ stroke typ . Incident strokes 
captured by ICD codes were mostly hospital admitted cases, but a smaller 
additional proportion were fatal cases not detected in hospital admissions data. 
The majority (~89%) of ICD coded incident strokes were a specified pathological 
type. In the sub-cohort of UKB participants with additional primary care data 
linkage ~20% of potential incident stroke cases were detected by coded primary 
care data alone.  
(3) Among Welsh UKB participants with linked primary care data, around two thirds 
had sufficient coded data to estimate visit-to-visit BPV any time before 
recruitment, and just under half had sufficient coded ata to estimate BPV during 
the 5 years before recruitment. Selecting participants with more visits reduced 
generalizability, but there was good variability in BPV amongst those selected 
(standard deviation in BPV range ~5mmHg to ~7mmHg), and reasonable 
agreement between coded BP and BP recorded at the UKB baseline assessment 
(intra class correlation coefficient 0.53, 95% CI 0.52 to 0.55). 
 
Conclusions 
This work will inform the approaches to stroke outcomes ascertainment and the 
measurement of a novel exposure, blood pressure variability, in UK Biobank. This 
will enable future exploration of the associations between blood pressure parameters, 
  xii 
stroke, and its main types and sub-types in UK Biobank.  Investigating these 
associations will improve our understanding of causal pathways for the different 
pathological types and sub-types of stroke and underpin increasingly targeted 
strategies to modify BP for stroke prevention.  
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Chapter 1 Introduction 
• Stroke is a major cause of death and disability worldwide. 
• The main pathological types and subtypes of stroke may differ in their risk 
factor associations. 
• UK Biobank (UKB), a very large prospective cohort study, provides the 
perfect opportunity to reliably test these associations.  
• Blood pressure (BP) is one of the most important modifiable risk factors for 
stroke. Visit-to-visit BP variability (BPV) - variation in BP from one clinic 
visit to the next - may confer an additional independ nt risk of stroke.  
• Investigating the associations between BP/BPV and the main stroke types 
and subtypes will improve our understanding of stroke aetiology and 
underpin increasingly targeted strategies for stroke prevention.  
• My work is divided into three sections: 
A) Systematic reviews: informing the development of accurate and scalable 
methods for the ascertainment, confirmation and classification of stroke 
cases in UK Biobank.  
B) Ascertainment of stroke and its main pathological types in UK Biobank: 
exploring the contribution of multiple overlapping sources of coded 
healthcare data to the identification of prevalent and early incident stroke. 
C) Measurement of a novel exposure, blood pressure variability: exploring 
the feasibility of using routinely collected coded primary care data to 
measure BPV amongst UKB participants.   
 
1.1 Stroke epidemiology 
1.1.1 The global burden of stroke 
Stroke is the second commonest cause of death worldide, and a major cause of 
global disability.(Lozano et al. 2012) In the UK stroke is the most common cause of 
severe disability amongst adults, and the third comm nest cause of death.(Adamson, 
Beswick and Ebrahi 2004, Murray et al. 2013) The long term consequences of stroke 
negatively impact patients, their families and society. Half of stroke survivors are left  
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with physical disability, cognitive impairment, or mood disorder,(Ch'Ng, French and 
McLean 2008) which can lead to depression, anxiety and social withdrawal amongst 
patients and their carers.(Murray, Young and Forster 2007) Stroke already accounts 
for an estimated £9 billion per year cost to the UK economy from hospital treatment, 
community care, disability payments and loss of income.(Saka, McGuire and Wolfe 
2009)  
The global burden of stroke has grown in the last 10-20 years due to rising stroke 
incidence in low and middle income countries, an agein  population, and increased 
longevity.(Lopez and Mathers 2006, Murray et al. 201 , Feigin et al. 2014) This 
problem is projected to increase exponentially in the years ahead as the 
epidemiological shift towards non-communicable diseases continues, stroke survival 
improves, and patients live longer with disability.(Mukherjee and Patil 2011, 
Magnusson 2009) Reducing the burden of chronic diseases has therefore become a 
major global health priority. The World Health Organisation (WHO) has a strategic 
aim to reduce mortality from non-communicable diseases by 2% by 
2015.(Magnusson 2009) Improving primary prevention of stroke, the second largest 
contributor to this global epidemic, is a key component of this aim.    
1.1.2 Epidemiological definitions of stroke  
The World Health Organisation (WHO) defines stroke as  
‘rapidly developing clinical signs of focal (or global) 
disturbance of cerebral function, lasting more than 24 hours, 
or leading to death, with no apparent cause other than of 
vascular origin’.   
(Hatano 1976, Aho et al. 1980) Stroke is a form of ‘cerebrovascular disease’, a 
broader diagnostic term which also includes Transient Ischaemic Attack (TIA), sub-
dural and extra-dural haemorrhage, and other vasculr onditions affecting the 
brain.(Whisnant et al. 1990) TIA is a ‘transient’ version of stroke. The distinction 
between stroke and TIA (WHO definition, above), hastr ditionally been based on 
symptom duration.  A neurological deficit of presumed vascular origin is ‘stroke’ if 
symptoms persist more than 24 hours, and ‘TIA’ if symptoms resolve within 24 
hours, provided non-vascular diagnoses have been excluded. Although this 24 hour 
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cut-off was chosen arbitrarily, the ‘symptom-based’ definition of stroke ensures that 
the diagnoses (stroke versus TIA) are made consistetly. Diagnostic consistency is 
an important requirement for epidemiological comparisons.(Sudlow and Warlow 
1996)  
It is increasingly recognised that some TIAs show evid nce of infarction on brain 
imaging.(Ay et al. 2005b) This has led to the development of a new ‘tissue-based’ 
definition of stroke, which relies on the detection of brain infarction to diagnose 
‘stroke’, irrespective of symptom duration (<24 hours).(Albers et al. 2002) This 
definition re-classifies cases of ‘TIA with infarction’ as stroke. However, the choice 
and timing of brain imaging is a crucial determinant of the ability to detect infarction 
in stroke (or TIA), with MRI being more sensitive for early ischaemic change than 
CT.(Chalela et al. 2007) If the ‘tissue-based’ definition is used, the number of cases 
diagnosed as stroke (including TIA with infarction) will depend on the choice and 
availability of brain imaging, which might vary from one region to another.(Brown, 
Rudd and McGovern 2003b) This definition is therefo more susceptible to global 
and regional differences in clinical practice. By contrast the ‘symptom-based’ 
definition relies on a competently taken medical history (focused on the nature, onset 
and duration of symptoms), but not on variable access to imaging or other 
technology, meaning that it can be applied more consistently, and is equally 
applicable in resource poor settings, irrespective of access to brain imaging.  
1.1.3 Pathological types and subtypes of stroke 
Stroke is a heterogeneous clinical syndrome. The World Health Organisation has 
divided stroke into four pathological types – cerebral infarction (or ischaemic 
stroke), intracerebral haemorrhage (blood vessel ruptu e with bleeding within brain 
tissue), subarachnoid haemorrhage (blood vessel rupture with bleeding within the 
subarachnoid space), and unspecified type.(Aho et al. 1980) In recent community 
based studies in the UK, around 80% of strokes are ischaemic, 10% are due to 
primary intracerebral haemorrhage, 5% subarachnoid haemorrhage, and 5% 
unspecified.(Rothwell et al. 2004)  
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The main types of stroke can be further broken down into different anatomical or 
aetiological subtypes. Around 50% of ischaemic strokes can be attributed to large 
artery atherosclerosis, 25% to small vessel disease, 20% to cardiac emboli, and 5% to 
other rare causes.(Warlow et al. 2003) Intracerebral haemorrhage can be classified 
into supra tentorial (lobar and non-lobar haemorrhage), cerebellar haemorrhage, 
brainstem haemorrhage and intra-ventricular haemorrhage, and subarachnoid 
haemorrhage can be classified into aneurysmal and no -a eurysmal subtypes (Figure 
1.1). 
 
Figure 1.1 Stroke classification. The main pathological types and sub-types of stroke. 
*The main pathological types of stroke 
†Subarachnoid haemorrhage and intracerebral haemorrhage together make up ‘haemorrhagic stroke’.  
‡Pathological sub-types of stroke. There is also an ‘uncertain’ subtype (not shown). 
§Supratentorial haemorrhage can be further divided into lobar and non-lobar haemorrhage.  
 
The main types of stroke share common risk factors,(Warlow et al. 2003) but 
evidence suggests that some of these risk factors may associate more strongly with 
haemorrhagic or ischaemic stroke types.(Asia Pacific Cohort Studies Collaboration 
2005, O'Donnell et al. 2010)  
Furthermore, there is evidence from case-control studies for differences between 
ischaemic stroke subtypes in their associations with vascular risk factors, genetic 
polymorphisms, blood brain barrier integrity, and retinal vasculature 
morphology,(Jackson et al. 2010, Gschwendtner et al. 2009, Bellenguez et al. 2012, 
Wardlaw et al. 2009, Doubal et al. 2009, Lindley et al. 2009) and evidence of 
differences between these stroke subtypes in their prognosis with respect to vascular 
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outcomes including myocardial infarction and recurrent stroke.(Jackson et al. 2009) 
There is also evidence for different genetic and non-genetic risk factors for lobar 
versus non-lobar intracerebral haemorrhage.(Jackson and Sudlow 2006, Biffi et al. 
2010) These differences may point to different mechanistic pathways for the 
different stroke types and subtypes. If better understood, these different pathways 
may provide potential new targets for drug development, and in the long term, a 
more stratified approach to the prevention of stroke.  
1.2 The association between blood pressure and 
stroke 
1.2.1 Mean blood pressure and stroke 
Blood pressure is one of the most important modifiable risk factors for 
stroke.(Lawes, Vander Hoorn and Rodgers 2008) There is a steep log-linear 
relationship with stroke such that sustained reductions in usual BP of 20mmHg 
systolic/10mmHg diastolic approximately halve total stroke risk in middle to old 
age.(Lewington et al. 2002) The influence of BP on stroke risk in general is well 
established, but there remain uncertainties about whe her this differs between the 
pathological types and subtypes, and if so in what way. Stronger associations have 
been suggested between BP and intracerebral haemorrhage versus ischaemic 
stroke,(Asia Pacific Cohort Studies Collaboration 2005) lacunar ischaemic stroke 
versus other ischaemic subtypes,(Jackson et al. 2010) and lobar versus non-lobar 
intracerebral haemorrhage,(Jackson and Sudlow 2006) but robust evidence for such 
differences is limited.  
1.2.2 Blood pressure variability and stroke 
While the most comprehensive evidence to date focuses on associations with usual 
(long-term average) systolic, diastolic and mean BP,(Lewington et al. 2002, Asia 
Pacific Cohort Studies Collaboration 2005) recent work also suggests independent 
effects of episodic hypertension and medium to long-term BP fluctuations.(Rothwell 
et al. 2010b) Evidence that BP variability independtly influences stroke risk may 
have important implications for BP monitoring and treatment. For example, some 
anti-hypertensive medications reduce BP variability more than others.(Rothwell et al. 
2010a) Better understanding of the associations between various BP parameters and 
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stroke, its types and subtypes, should both improve our understanding of 
type/subtype specific causal pathways and underpin increasingly targeted strategies 
to modify BP for stroke prevention. 
1.2.3 Limitations of previous studies  
Previous studies which examined the associations between usual (mean) blood 
pressure and the main types and subtypes of stroke have had a number of limitations.  
Retrospective studies (recruiting patients with stroke +/- controls) had relatively 
crude measures of BP and other exposures, and were pron to recall and control 
selection bias.(Jackson and Sudlow 2005, Jackson et al. 2010, O'Donnell et al. 2010) 
Individual prospective studies have generally been too small to address associations 
between BP and stroke reliably.  Collaborative meta-an lyses of prospective studies 
provided adequate sample sizes, but had other limitations including pooling of 
heterogeneous data, outcome selection bias, and incomplete or inaccurate 
classification of stroke types/subtypes.(Lewington et al. 2002, Asia Pacific Cohort 
Studies Collaboration 2005) Most stroke outcomes were ascertained from death 
certificates and/or hospital discharge data, meaning that fatal strokes were 
overrepresented, and non-hospitalised non-fatal stroke cases were not included. This 
may have led to over selection of haemorrhagic stroke cases, which are more likely 
to be fatal than ischaemic strokes,(Andersen et al. 2009) and under selection of 
lacunar ischaemic strokes, which are less likely to be hospitalised than non-lacunar 
ischaemic stroke.(Schulz and Rothwell 2003, Bejot et al. 2013, Giroud et al. 1997) 
Furthermore, information on main pathological type was available for only around 
half of the stroke outcomes in these studies, and further stroke classification into 
subtypes was not possible.  
1.3 Stroke in clinical practice  
1.3.1 Diagnosis of stroke 
There is no ‘gold standard’ test for the diagnosis f troke. The most accurate 
approach  requires expert assessment of the presenting clinical syndrome aided by 
appropriately timed brain imaging.(Warlow et al. 2003) Brain imaging (CT or MRI) 
is useful to exclude ‘stroke mimics’, but such imaging is not uniformly available, and 
requires appropriate timing and expert interpretation. Even if every stroke patient had 
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brain imaging, CT or MRI would fail to demonstrate  relevant stroke lesion in some 
of the milder cases of stroke.  Clinical assessment is therefore the most important 
aspect of stroke diagnosis. However, agreement between physicians is 
imperfect,(Kessler et al. 1991) and around 30% of potential strokes admitted to 
hospital leave with a non-cerebrovascular diagnosis.(Hand et al. 2006b) Even 
amongst experts up to 5% of initial stroke diagnoses ar  incorrect.(Ricci, Celani and 
Righetti 1994)  
1.3.2 Diagnosis of TIA  
The diagnosis of TIA is even more challenging. In the majority of cases the 
symptoms and signs of TIA have already resolved by the time the patient attends for 
assessment.  Diagnosis depends almost entirely on the ability of the physician to 
elicit an accurate history. A wide array of conditions mimic TIA including focal 
seizure, migraine, labyrinthitis, and functional symptoms.(Nadarajan et al. 2014) It is 
therefore not surprising that the reliability of diagnosis is poor, even amongst 
experts.(Castle et al. 2010) 
For some research studies it may not be important to dis inguish between TIA and 
stroke. TIA and stroke share many common risk factors and common secondary 
prevention strategies. In the acute phase (first few hours) of presentation, patients 
with TIA or stroke are often grouped together with the diagnosis ‘acute brain attack’, 
before a formal diagnosis is made. However if diagnostic accuracy is important for a 
study it may be sensible to separate stroke from TIA. his is because stroke 
diagnosis, albeit imperfect, is more accurate than TIA diagnosis, and less likely to 
introduce false positive diagnoses.  If the aim is to maximise positive predictive 
value (see 1.4.3), then inclusion of TIA risks inclusion of a wide variety of potential 
TIA mimics. The WHO definition of stroke is also preferable, because this is less 
susceptible to the availability and timing of investigation, and is more consistent 
when applied across multiple settings.  
1.3.3 Pathways of care in the UK 
In the UK, ~150,000 individuals have a stroke each year.(Townsend et al. 2012) 
Between 60% to 90% of stroke patients are admitted to hospital,(Schulz and 
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Rothwell 2003), but this is likely to vary by region (and potentially by stroke 
pathology).  
In England, Scotland, and Wales ~80% of hospital admitted patients are admitted to 
expert led stroke units,(SSCA 2015, SSNAP 2015) and the remainder are treated on 
general medical wards with or without specialist input. The majority of hospitalised 
patients receive brain imaging (CT or MRI) but clinical practice varies by region. 
National targets require 90% of patients admitted to hospital with stroke to have had 
brain imaging within 24hours of admission.(SSNAP 2015, SSCA 2015) Investigation 
of patients is likely to be more complete amongst patients treated in specialist units.  
Non-hospitalised strokes include fatal cases (not reaching hospital prior to death), 
and mild cases, not severe enough to warrant hospital admission and often with rapid 
and complete or near complete recovery. Non-fatal, non-hospitalised stroke patients 
have access to expert led diagnosis and investigation through referral (by general 
practitioners or acute medical physicians) to dedicated stroke outpatient clinics. 
However, depending on local referral patterns and patient specific factors, some of 
these non-hospitalised patients might never receive an ‘ xpert’ diagnosis, instead 
being treated by their GP (perhaps in a residential or care home setting), or by 
physicians in hospital without referral to acute stroke services. Depending on the 
structure of local stroke services, there is therefore potential for regional variation in 
the accuracy of ‘stroke diagnoses.  
1.4 UK Biobank 
1.4.1 Background and aims 
UK Biobank is a very large population-based prospectiv  cohort study which was 
designed to allow the assessment of the relevance of many different exposures to 
many different outcomes.(Collins 2012) Common conditions, like stroke, have 
numerous genetic and environmental determinants.(Manolio, Bailey-Wilson and 
Collins 2006) Very large studies, generating large numbers of outcomes for adequate 
statistical power, are required to study the modest individual effects of these 
determinants and the complex interactions between th m.(Burton et al. 2009)  
33 
Chapter 1: Introduction 
UK Biobank fulfils the key requirements of an ideal study of disease 
aetiology.(Grimes and Schulz 2002) These include: 
• prospective study design, with accurate measurement of the relevant exposures 
and covariates before the occurrence of outcomes, to avoid reverse causality;  
• selection of non-disease controls from the same population as the cases, to avoid 
control selection bias;  
• repeat measures of baseline parameters and covariates in a subset of the cohort 
during follow-up, to correct for regression dilution bias, where the strength of the 
association  is underestimated;  
• very large sample size (hundreds of thousands of participants), accruing a large 
enough number of disease outcomes (thousands overall) fo  sufficient statistical 
power;  
• accurate confirmation and detailed sub-classification of disease outcomes. 
1.4.2 Participant recruitment 
Around 500,000 participants aged 40-69 years were recruited to UK Biobank 
between April 2007 and July 2011.(Sudlow et al. 2015) Invitations were sent by post 
to potential participants inviting them to attend one of 22 assessment centres in 
England, Scotland and Wales. A detailed baseline ass ssment was conducted at the 
recruitment visit. This included a touch-screen questionnaire, a brief nurse-led 
interview, physical examination, and collection of blood, urine and saliva to be 
stored for future genetic and biochemical analyses. Around 20,000 to 25,000 
participants are recalled every few years to repeat this assessment, enabling 
adjustment for measurement error and variation in baseline parameters over time.   
Table 1.1 shows the baseline characteristics of the UK Biobank population, including 
prevalent conditions at recruitment.(http://biobank.ctsu.ox.ac.uk/crystal/) In general, 
participants were better educated and less socioecon mically deprived than the rest 
of the UK (healthy cohort-effect) but all socioeconomic strata were represented. 
Participants were 46% male, 85% urban, 94.5% white (the remaining 5.5% reflecting 
ethnic mix for the UK), ~60% in paid employment, 57% aged 40-49, and 43% aged 
50-69.  
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Table 1.1 Baseline characteristics of the UKB population 
Characteristic(s) UKB participants (n & %) *  
Gender 
  Male 





  40-49 
  50-59 






  England 
  Scotland 





Prevalent conditions at recruitment† 
  Diabetes 
  Myocardial infarction 
  Pulmonary Disease 
  Stroke 
  Rheumatoid arthritis 
 
26,000  (5) 
12,000  (2) 
12,000  (2) 
7,000  (1) 
6,000  (1) 
Smoking status† 
  Current smoker 
  Ex-smoker 
  Never smoked 
 




  White 
  Asian 
  Black 
  Chinese 
  Mixed 









  Paid employment 
  Retired 
  Unemployed 
  Disability allowance 








  University degree 
  A level/equivalent 
  O level/equivalent 
  Vocational qualification(s) 







Townsend deprivation index 
  Mean -1.3 (standard deviation 3, range -6.3 to 11) 
 
*Amongst 502, 523 recruited participants, rounded to the nearest integer 
†Self-reported at the UKB baseline assessment and cofirmed by  
trained interviewer, rounded to the nearest 1,000. 
‡Participants were able to select more than one category.  
§Unpaid voluntary work, family/childcare, student, or no answer.   
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While UK Biobank participants are not representative of the general population (and 
hence cannot be used to provide representative disease prevalence and incidence 
rates), the large sample size and heterogeneity of exposure measures included, allow 
for valid scientific inferences of associations betw en exposures and health outcomes 
that are generalizable to the wider population.(http://www.ukbioabank.ac.uk/wp-
content/uploads/2017/03/access-maters-representativeness-1.pdf) 
 
1.4.3 Follow-up strategy 
UK Biobank (UKB) participants have consented to follow-up of all health-related 
outcomes through linkages to National Health Servic data including electronic 
hospital, death certificate, and primary care data, nd detailed medical record data. 
By the end of 2017 around 5,000 incident stroke cass re expected to have occurred 
in UKB, rising to 9,000 cases by 2022 (estimates based on UK age- and sex-specific 
rates, adjusted for potential losses to follow-up and the healthy cohort 
effect).(Sudlow et al. 2015) 
The challenge UK Biobank faces is the accurate ident fication, confirmation and sub-
classification of these many thousands of cases of a wide range of diseases, including 
stroke, from within a cohort of half a million individuals. Firstly, the approach needs 
to be feasible, meaning that where possible, involvement of expert researchers is 
minimised, costs are reduced, and the availability of resources is taken into account 
(given that follow-up is based on data collected during routine NHS care). Secondly, 
the approach needs to be scalable and geographically generalizable, and therefore 
must operate consistently across England, Scotland and Wales, despite potential 
variation in clinical practice, data collection processes and/or data structure between 
these three countries. Finally, the approach needs to be future proof, meaning that it 
can adapt to future changes in diagnostic practice, and/or NHS structure.  These 
considerations need to be balanced with diagnostic accuracy, recognising that 
misdiagnosis/misclassification of disease outcomes will reduce statistical power to 
detect differences in exposure-outcome relationships between them.(Jaffar et al. 
2003a, Choi et al. 2002a)  
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With these challenges in mind, UK Biobank has proposed a staged approach to 
outcomes adjudication. Using stroke as an exemplar disease, the first stage will use 
cohort-wide linkages to coded electronic health reco d data to identify as many 
potential cases as possible. This stage should have re sonably high sensitivity, which 
is the proportion of ‘true stroke’ cases in the UKB population which are detected. 
The second stage will confirm which of the potential cases already identified, are 
‘true stroke cases’. This stage should maximise Positive Predictive Value (PPV), 
which is the proportion of potential strokes (identified by coded data or other 
sources) which are confirmed cases. This stage might use combinations of coded data 
or coded data plus brain imaging to confirm stroke versus non-stroke, or identify the 
main stroke type. The final stage will involve sub-classification of confirmed stroke 
cases into their main pathological types and subtypes. This is likely to require 
detailed review of individual hospital case records and primary care records.  
Progression through each of these stages results in fewer numbers of cases (fewer 
confirmed cases need to be classified than the number of potential cases requiring 
confirmation), but more detailed assessment is requi d (more time and information 
is required to classify into ischaemic or haemorrhagic subtypes than to confirm 
stroke versus non-stroke). 
The disease outcomes identified in UKB will be made vailable to future researchers, 
allowing them to construct nested case-control or case-cohort studies, in order to 
answer specific research questions. The emphasis in d ease outcomes ascertainment, 
confirmation and sub-classification is therefore on detecting as large a number of 
cases as possible without compromising positive predictive value. Maintaining 
sensitivity will optimise the number of stroke cases available for future analyses, and 
will preserve statistical power. Maximising PPV (minimising false positive cases), 
will increase statistical power, because misclassificat on of outcomes reduces 
statistical power to detect exposure-outcome relationships. Some false negatives can 
be tolerated, because these will be diluted in the larger control population, with much 
more limited impact on statistical power.  
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1.5 Summary and aims 
UKB provides the perfect opportunity to overcome th limitations of previous 
epidemiological studies, and to better understand the associations between BP 
parameters (mean BP, and BP variability) and the main types and sub-types of 
stroke. My aims in this thesis were, firstly, to investigate and develop accurate, 
scalable methods for the ascertainment, confirmation and sub-classification of stroke 
cases in large prospective studies, like UK Biobank. Secondly, I aimed to explore 
methods to identify a novel exposure, blood pressure va iability, in large populations, 
using primary care coded data. The thesis is divided nto three main sections.  
Section A. Systematic reviews: using evidence to in form the strategy 
for ascertainment, confirmation and sub-classificat ion of strokes in 
large prospective studies.  
I present the results of two systematic reviews which investigate what is known from 
existing studies about the accuracy of routinely avail ble coded healthcare data 
(Chapter 2), and patient self-report (Chapter 3) for stroke and its main types. I focus 
on assessment of sensitivity and PPV (see staged approach to outcomes adjudication, 
1.4.3). Finally, I present results of a systematic review investigating the reliability 
and feasibility of ischaemic stroke classification systems for large epidemiological 
studies (Chapter 4) 
Section B. Cross referencing analyses: investigatin g routinely available 
sources of stroke cases in UK Biobank.  
I present the process of creating a ‘stroke case definition’ using primary care coded 
data (Chapter 5). I then present cross-referencing analyses which explore the 
contribution of various data sources (hospital data, de th certificate data, primary 
care data and self-report) to stroke diagnoses in a subset of Welsh UK Biobank 
participants (Chapter 6).  
Section C. Assessing the potential of coded primary  care data to 
capture blood pressure variability in UK Biobank.  
I present a review of the evidence from existing published studies for a potential 
association between blood pressure variability and risk of stroke (Chapter 7). I then 
go on to explore the feasibility of using coded primary care data to measure the novel 
exposure of blood pressure variability among UK Biobank participants (Chapter 8). 
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Ultimately, this work should enable future analyses of the associations between a 
wide range of exposures (or risk factors) - in particular, blood pressure parameters 














Chapter 2: Accuracy of coded healthcare data for ident fying stroke cases in large 
epidemiological studies. 
Chapter 2 Accuracy of coded healthcare data 
for identifying stroke cases in large 
epidemiological studies: a 
systematic review. 
• Follow-up in UK Biobank is initially through linkages to coded national 
health care data. 
• Our knowledge of the accuracy of these data for ident fying and confirming 
stroke cases is incomplete.  
• The ideal follow-up strategy in UK Biobank would identify as many true 
stroke cases as possible (adequate sensitivity) without introducing too many 
false positives (maximising positive predictive value, PPV). 
• In this chapter I present the results of a systematic review of the accuracy of 
coded healthcare data for stroke and its main pathological types. 
•  I used a comprehensive search strategy, critically appraised study quality, 
and assessed the influence of the codes selected on sensitivity and PPV.  
• I conclude that appropriately selected ‘stroke specific’ odes are sufficiently 
accurate (high PPV) for identifying stroke cases when further confirmation 
steps are not available. There were insufficient data on the accuracy of 
primary care coded data or multiple overlapping data sources for stroke.   
 
2.1 Introduction 
Long-term follow-up in UK Biobank is chiefly through linkages to coded national 
health care data.(Sudlow et al. 2015) For health-related outcomes such as stroke, UK 
Biobank aims to maximise statistical power to detect g nuine associations in nested 
case-control or case-cohort studies. This requires a strategy that identifies cases 
representative of the spectrum of the disease being studied with adequate sensitivity, 
and that maximises positive predictive value (PPV, the proportion of cases that are 
true positives). UK Biobank aims to fulfil these requirements by using multiple 
sources of coded data (primary care, hospital and death certificate data) to ascertain 
possible stroke cases, and then to implement algorithms, using combinations of 
coded data, supplemented where required by more detailed medical record review, to 
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epidemiological studies. 
confirm and sub-classify cases of stroke. An important first step in developing such 
algorithms is to understand the accuracy of the coded data sources.  
2.1.1  Routinely collected and coded national healt hcare data  
In most countries, including the UK, hospital admissions and death certificates are 
coded using the International Classification of Disea es 
(ICD).(http://apps.who.int/classifications/icd10/browse/2010/en , 
http://www.cdc.gov/nchs/icd.htm , http://www.icd9data.com/) The primary ICD code 
identifies the main condition treated during a hospital admission, or the underlying 
cause of death. Secondary codes record additional diagnoses relevant to an 
admission, or contributing to death. Figure 2.1 shows ICD codes for cerebrovascular 
diseases. The shaded boxes show which ICD codes most closely match the World 
Health Organisation (WHO) definition of stroke (Hatano 1976) or of one of its three 
main pathological types: ischaemic stroke, intracerebral haemorrhage (ICH), and 
subarachnoid haemorrhage (SAH).  
Although not all of these codes represent a diagnosis of the clinical syndrome of 
stroke, many studies which have looked at determinants of stroke using linked ICD-
coded datasets have included all cerebrovascular disease codes in the relevant ICD 
coding chapter, implicitly assuming that they are all codes for stroke.  Over the last 
10 years, European countries have switched from ICD-9 to ICD-10, while North 
America uses ICD-9-CM (a clinically-modified version f ICD-9). Primary care data 
in the UK are coded by general practitioners using the Read coding system, which 
encodes diagnoses, symptoms, signs, procedures, prescri tions and other 
administrative data.(Chisholm 1990, Stuart-Buttle e al. 1996) 
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Figure 2.1 International Classification of Diseases (ICD) codes for cerebrovascular disease. 
*433: occlusion/stenosis of pre-cerebral arteries with or without infarction. 
†434: thrombosis/embolism of cerebral arteries with or without infarction.  
Codes in blue text denote ICD-9 codes which most closely represent stroke when subdivided using 
additional coding available in the clinically modified version of ICD-9 (ICD-9-CM). In ICD-9-CM, 
‘with infarction’ (433.x1, 434.x1) is distinguished from ‘without infarction’ (433.x0, 434.x0). 
‡436: acute, ill-defined cerebrovascular disease 
¶a pathological term for ischaemic stroke 
§G46: not a diagnostic code; may be used for the presenting symptoms of either stroke or TIA. 
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To inform approaches to ascertainment, confirmation and sub-classification of stroke 
in UK Biobank and other large epidemiological studies, I performed a systematic 
review of published studies of the accuracy of coded h alth record data for stroke 
and its main pathological types (ischaemic stroke, intracerebral haemorrhage, 
subarachnoid haemorrhage). I chose not to include transient ischaemic attacks 
(TIAs), which are clinically harder to diagnose accurately, with poor agreement even 
amongst experts,(Ferro et al. 1996b) and of substantially less public health impact 
than strokes. I used the traditional, epidemiological ‘symptom-based’ definition of 
stroke (symptom duration >24 hours) to distinguish stroke from TIA.(Hatano 1976) 
The more recent, alternative ‘tissue-based’ definitio  relies on the presence of brain 
infarction to diagnose stroke, irrespective of symptom duration (<24hours).(Albers et 
al. 2002) Accurate diagnosis of brain infarction depends on the availability, choice, 
and timing of brain imaging, which may vary between different centres. (Brown, 
Rudd and McGovern 2003a) I chose to use the ‘sympto-based’ definition to 
maximise comparability between different studies. 
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2.3 Methods 
The study protocol is displayed in Appendix 2.7 
2.3.1 Search strategy 
I searched Medline and Embase from 1990 to November 2013 for studies which 
compared electronic health record data cerebrovascular disease codes against a 
second data source for stroke or its main types. I u ed a combination of medical 
subject heading and text word terms for ‘cerebrovascul r disease’, ‘stroke’, ‘medical 
records’, ‘clinical coding’, and ‘validation studies’ (Appendix 2.7.2). I also reviewed 
bibliographies of included primary studies and relevant reviews, as well as lists of 
publications from the Clinical Practice Research 
Datalink(http://www.cprd.com/Bibliography/Researchpapers.asp) and The Health 
Improvement Network(http://www.ucl.ac.uk/pcph/research-groups-themes/thin-
pub/publications) websites to identify additional studies evaluating accuracy of 
primary care data.  
2.3.2 Eligibility criteria 
Included studies had to have assessed International Classification of Diseases (ICD) 
or Read coded events against a reference standard data source for stroke, or of one or 
more of its three major pathological types,(Figure 2.1) defined according to WHO or 
equivalent definitions.(Hatano 1976) Studies had to report which codes were 
validated and either their positive predictive value (PPV) or data from which it could 
be calculated. I excluded studies with less than 50 coded events (since these would 
have limited precision) and studies in highly selected populations at increased risk 
(e.g. those with vascular risk factors or known vascular disease) of stroke because of 
the influence of stroke prevalence on PPV. An epidemiologist colleague (Dr Ian 
Grant)  reviewed all titles and abstracts to select potentially relevant studies for 
inclusion. I independently reviewed a subset of 10% of these titles and abstracts. We 
both independently reviewed full texts of potentially relevant studies and selected 
studies for inclusion. Any areas of uncertainty from this two phase study selection 
process were discussed and resolved with my supervisor, Professor Cathie Sudlow.   
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2.3.3 Data extraction and analysis 
I extracted and tabulated information from each included study on: first author and 
publication year; geographic setting (country); age(m an and/or range) of included 
cases (coded events); data source (hospital, death c rtificates, primary care); coding 
system and version; codes used to identify cases; diagnostic position of these codes 
in the electronic health record (primary versus secondary); number of cases (coded 
events) compared against the reference standard; reference standard used; PPV and, 
where reported or calculable, sensitivity, specificity, and negative predictive value 
(NPV) of codes. I only extracted sensitivity, specificity and NPV values where the 
reference standard was a population-based stroke register which had clearly aimed to 
include all stroke cases in the population under study. 
I assessed study level quality with a modified version of the Quality Assessment of 
Diagnostic Studies tool (QUADAS-2),(Whiting et al. 2011) adapted from a recent 
systematic review of the validity of myocardial infarction diagnoses in administrative 
databases.(McCormick et al. 2014) I used this to assess reporting quality, 
generalisability to the UK population (because I sought to recommend codes for UK 
Biobank), and risk of bias. The study protocol (Appendix 2.7.12) provides a detailed 
list of questions and scoring methods. An overall quality score (0-14) was derived by 
combining scores for reporting quality, generalisablity, and low risk of bias. I did 
not exclude studies on the basis of quality assessmnts.  
I calculated 95% confidence intervals for PPV, sensitivity, specificity and NPV 
values in Stata (version 12) using the Wilson method for binomial 
proportions.(Brown, Cai and DasGupta 2001) For stroke and each of its main 
pathological types, I assessed the influence on PPV (and, where available, 
sensitivity) of the codes used to identify stroke cases, and of other study 
characteristics, using visual inspection of tabulated data and forest plots, and making 
within-study comparisons where possible to minimise bias. I did not undertake 
formal meta-analyses or meta-regression because of th  substantial heterogeneity 
between studies in their settings, methods and reporting. 
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2.4 Results  
2.4.1 Studies identified 
A total of 39 studies fulfilled my inclusion criteria (Figure 2.2). Of these, 37 were of 
ICD-coded hospital data, death certificates, or both.(Ives et al. 1995, 
Lakshminarayan et al. 2009, Leibson et al. 1994, Reker t al. 2001, Rosamond et al. 
1999, Roumie et al. 2008, Derby et al. 2000, Derby t al. 2001, Liu et al. 1999, Mayo 
et al. 1993, Klatsky et al. 2005, Tirschwell and Longstreth 2002, Wahl et al. 2010, 
Goldstein 1998, Benesch et al. 1997, Johnsen et al.2002, Appelros and Terent 2011, 
Krarup et al. 2007, Tolonen et al. 2007, Ellekjær et al. 1999, Leone et al. 2004, 
Stegmayr and Asplund 1992, Spolaore et al. 2005, Haesebaert et al. 2013, Aboa-
Eboule et al. 2013, Palmieri et al. 2007a, Sinha et al. 2008, Wright et al. 2012, 
Davenport, Dennis and Warlow 1996, Mant, Mant and Winner 1997, Barer 1996, 
Panayiotou et al. 1993, Hasan, Meara and Bhowmick 1995, Kirkman et al. 2009, 
Koster et al. 2013a, Harriss et al. 2011, Rinaldi et al. 2003) Only two were of Read 
coded primary care data.(Ruigomez, Martin-Merino and Garcia Rodriguez 2010, 
Gaist et al. 2013) 
2.4.2 Characteristics of studies of hospital and de ath 
certificate (ICD-coded) data 
Study characteristics are displayed in Table 2.1. The 37 studies were from North 
America, Europe, (eight UK based), and Australia. They assessed ICD code versions 
9, 10, or both. Most studies used hospital data only, but one was of death certificates 
only, and six used both. The majority of studies sought cases of stroke, 14 sought 
ischaemic stroke, five haemorrhagic stroke (ICH or SAH), four ICH, and four SAH. 
The range of codes used varied widely. To identify stroke cases, the largest number 
of studies used the whole range of cerebrovascular disease codes (either with or 
without codes for transient ischaemic attack [TIA]), but others used stroke-specific 
codes. Several others used various miscellaneous grps of cerebrovascular codes to 
identify stroke cases, while a further four did notinclude SAH in their definition of 
stroke and so excluded SAH codes. The diagnostic position of codes was recorded by 
31 studies, of which 11 used the primary position al e. Reference standards were 
either review (generally by a specialist physician) of the hospital or primary care 
records or a hospital discharge summary, or comparison with a population- or 
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hospital-based stroke register. Stroke register cases were identified using 
administrative data (generally multiple overlapping sources), with ‘hot pursuit’ and 
confirmation by expert medical record review 
 
Figure 2.2 Selection of studies  
*Additional studies identified from review articles. 
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Table 2.1 Characteristics of studies validating ICD codes from hospital and death certificate data forst oke and its pathological types.* 
Study Country Age 
(range) 































Canada - 430-434, 436, 437 9 H 96 P Medical 
Record 
 
72 76   (67 to 83) 8 
Liu 
1999 
Canada - 430-438 
 
9 H 862 P/S Medical 
Record¶ 
 
487 56   (53 to 60) 8 
430-438 
 
 621 P 
 
417 67   (63 to 71)  
430-438 
 
 327 P/S 151 46   (41 to 52)  
430-438 
 
 213 P 
 
129 61   (54 to 67)  
Leibson 
1994 






225 60   (55 to 65) 11 
430-438  462 P/S 
 
249 54   (49 to 58)  
430-438  
 





239 -  
430-438  - P/S 290 -  
Rosamond 
1999 




326 31   (28 to 34) 12 
430-434 
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Study Country Age 
(range) 


































9-CM H 671 - Medical 
Record** 
279 42   (38 to 45) 6 
430, 431, 433, 434, 436  334 -  198 
 
59   (54 to 64)  




 491 P/S Inpatient 
register 
 
254 52   (47 to 56)  
431.x, 433.x1, 434.x1  200 P/S  150 
 





















  833 P 550 66   (63 to 69)  
430, 431, 434, 436 
 
  411 P/S 371 90   (87 to 93)  










Italy - 430-434, 436-438 
 
9 H 3619 P/S Medical 
Record 
1296 36   (34 to 37) 9 
430-434, 436-438  2174 
 





Italy  342, 430-438 9 
 
 
H+D 2793 P/S Population 
register 
 












90     (88 to 92) 12 
430-438 H 5101 P/S  3492 69    (67 to 70)  
Ellekjaer 
1999 




9 H 759 P/S Population 
Register 
 















94 80  (72 to 87) 8 
Hasan 
1996 




68  (61 to 75) 9 
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Study Country Age 
(range) 





























Australia 40-69 430-438, I60-I69 
 
9 +10 D 119 P Medical 
Record 
 
72 61  (52 to 69) 12 
430-431, 433-434, I60, 
I61, I63, I690, I691, I693  
 
 61 P 
 
54 89  (78 to 94)  
430-438, I60-I69 
 
 - P/S - -  
Johnsen 
2002 
Denmark 50-64  
 







565 P/S Medical 
Record 
 
325 58 10 






- I60-I69, G45 
 
10 H 236 - Medical 
Record 
               
153‡‡ 65‡‡ (59 to 71) 9 








40-79 I60-I69 10 H + D 250 P/S Medical 
Record 
 
191 76    (71 to 81) 11 
Roumie 
2008 





231 P/S Medical 
Record** 
 
205 89    (84 to 92) 9 

















35-74 431, 432, 434, 435, 436, 
437 
9 H 3811 P/S Medical 
Record*** 
 






35-74 431, 432, 434, 436, 437 9 H 2124 P Medical 
Record*** 









3773 63      (61 to 64) 9 
431, 432, 434, 436, 437  4445 
 
P   85       (84 to 86)  
*Davenport   
1996 
UK  ≥ 18 431, 433-438 9 H 557 P Inpatient 
Register 
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Study Country Age 
(range) 





























UK - 431, 433, 434, 436 9 H 340 - Hospital 
Register 
 










- 431, 432.9, 434, 436, 
437.0, 437.1, 437.9 
















US ≥ 65 
 











90    (81 to 95) 8 
*Appelros  
2011  
Sweden - I61, I63, I64 10 
 
D 98 - Population 
Register 
 
78 80    (71 to 86) 11 
I61, I63, I64 H 328 - 318 97    (94 to 98)  
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Register 
40 39    (30 to 49) 12 
H 1426 P/S  1224 86    (84 to 88)  
H + D 1526 P/S  1264 
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Study Country Age 
(range) 































US - 433, 434, 436 9-CM H 550 P/S Medical 
Record 
234 43    (38 to 47) 4 
433, 434, 436  379  P  199  53    (47 to 57)  
434, 436  250 P/S 216 86    (82 to 90)  
434, 436  203 P 183 90    (85 to 94)  
433, 434  521 P/S 210 40    (36 to 45)  
 
 
  433, 434   361 P  183 51    (46 to 56)  
433  295 P/S 18 6       (4 to 9)  
433  176 P 16 9       (6 to 14)  
434  226 P/S 192 85    (80 to 89)  




US - 434 9-CM H 108 P Discharge 
summary*** 
88 82    (73 to 88) 7 
434.x1  106 P 86 82    (73 to 87)  
433, 434, 436  175 P 106 61    (53 to 68)  
434, 436 127 P 104 82    (74 to 88)  
Rosamond 
1999 
US 45-64  
 





252 45    (41 to 49) 12 
434, 436  294 216 73    (68 to 78)  
433  266 36 14    (10 to 18)  
434  186 143 77    (70 to 82)  
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Study Country Age 
(range) 
































- 434, 436  9 H 180 P/S Inpatient 
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128 71    (64 to 77) 9 
434, 436  157 P 119 76    (69 to 82)  
436  177 P/S 125 71    (64 to 77)  
436  154 
 



















8 6       (3 to 11) 11 
433   89 P 7 8       (4 to 15)  
434   202  P/S 176 87    (82 to 91)  





 57 P/S 40 70    (57 to 80) 
 
 
434, 436   259  P/S  216 83    (78 to 87)  
 - 434, 436    236  P  205 87    (82 to 91)  
433, 434,  
 
  393 P/S 224 57    (52 to 62)  














Norway ≥ 15 436 9 
 
H 313   P/S Stroke register 
 
206 66    (61 to 71) 9 
434, 436 
 
402   261 
 
65    (60 to 69)  
436 89 55 
 








433.x1, 434.x1, 436 9-CM H 150 P Medical 
Record 












113  P/S Medical record 
 
99 88    (80 to 92)    10 
I63, I64 313 238 76    (71 to 80)  
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Study Country Age 
(range) 






























Denmark - I63, I64 10 H 138 - Medical record 
 
96g 70    (61 to 77) 9 
I64  105 - 64g 61    (51 to 70)  
Wright 
2012 
UK - I63 10 H 190 P/S GP record¶                                                                                                                              164 86 (81 to 90) 10
I63, I64 309 242 78    (73 to 83)  
I64 
 





 ≥ 20 433.X1, 434.X1, 436§§ 9-CM H+D i) 50¶¶ P/S Medical 
Record 
45 90       (79 to 96) 9 
433.X1, 434.X1, 436§§  Ii) 50¶¶ P/S 46 91    (81 to 98)  
433.X1, 434.X1, 436 
 
 iii) 50¶¶ 
 




US - 433.x1, 434.x1, 436, 
437.1, 437.9 
9-CM H 200 - Medical record 
 
175 87    (82 to 91) 9 
Haesbert 
2013 






313 95    (92 to 97) 11 
*Tonolen 
2007 
Finland 25-74 433, 434, I63 9 +10 H+D 
 
2711 P/S Hospital 
register 
2223 82    (81 to 83) 5 
433, 434, 436, I63,  I64   2900 2407 83    (82 to 84)  




US 45-64 430, 431 9-CM H 63  P/S Medical 
Record 
 
















Norway ≥ 15 
 
430, 431 9 H 
 
69 P/S Stroke 
Register 
 
51 74    (62 to 83) 9 
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Study Country Age 
(range) 














































65    (52 to 75) 10 




US ≥ 20 430§§ 9-CM H+D i)  51¶¶ P/S Medical 
Record 
43 86    (72 to 92) 9 
  430§§  ii) 51¶¶ P/S 46 89    (79 to 97) 
  430 
 
 iii)51¶¶ P 48 94    (84 to 98) 
Tonolen 
2007 
Finland 25-74 430, I60 
  















- I60 10 H 1169 P Discharge 
summary 
1123 96   (95 to 97) 8 
Wright 
2012 
UK - I60 10 H 78 P/S GP record¶         
 
                                                                                                                                              
75 96    (89 to 99) 10 




Italy - 431 
 
9 H 110  P/S Inpatient    
register 
 
82 75   (66 to 82) 11 
    102 P 78 76   (67 to 84) 
Ellekjaer  
1999 
Norway ≥ 15 
 
431 9 H 56 P/S Stroke 
Register 












UK - I61 
 
10 H 978 P Discharge 
summary 
938 96   (94 to 97) 8 
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PPV: Positive Predictive Value; H: Hospital data; D: Death certificates; H+D: both; P: Primary position code; P/S: Primary or Secondary position code. 
* Italics indicate studies using miscellaneous groups of codes (not included in either ‘stroke codes’ or ‘all cerebrovascular diseases codes’ groups, Figure 2.1), or 
studies excluding SAH 
†Number of ICD coded events compared against the reference standard. 
‡Population register: population based stroke registr, Hospital register: inpatient and outpatient stroke register, Inpatient register: inpatient stroke register. Medical 
Record: definite or probable stroke diagnoses confirmed by review of medical records (excludes ‘possible’ stroke). Medical records were reviewed by stroke 
physicians or neurologists, unless otherwise specified. 
§Quality score (total 14). See Appendix 2.7.12 for questions and scoring methods.  
¶Medical record reviewed by ‘cardiovascular researche s’. 
** Medical record reviewed by ‘trained data abstractors’. 
††431, 432, 434, 436 primary position, or rehabilitaton code primary position AND 430-438 secondary position, OR 433, 434 primary position AND 430-438 
secondary position. 
‡‡Mean value calculated from published data. 
§§If > 1 code per discharge they were chosen in the following hierarchy: SAH>ICH>IS>TIA 
¶¶One code for each discharge chosen from: i) First 9 discharge diagnoses ii) First 2 discharge diagnoses iii) Primary discharge code chosen 
*** Abstracts of the medical record reviewed by ‘study ph sician’. 
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2.4.3 Quality assessment 
Results of the quality assessment are displayed in Table 2.2. Quality scores ranged 
from 4 to 12 (median 9, interquartile range 8 to 11).  With respect to reporting 
quality, participant selection criteria and coding al orithms were generally well 
reported, but only ten studies acknowledged the potntial for uncertainty of the 
reference standard diagnosis in their results.(Rosam nd et al. 1999, Derby et al. 
2001, Mayo et al. 1993, Klatsky et al. 2005, Wahl et al. 2010, Appelros and Terent 
2011, Sinha et al. 2008, Davenport et al. 1996, Mant et al. 1997, Koster et al. 2013b) 
With respect to generalisability to the UK population, only eight studies were 
conducted in the UK. However, all the other studies w re based in high income 
countries, among populations of predominantly European origin with broadly similar 
health care provision, and are therefore likely to be broadly generalizable (from a 
global perspective) to population-based studies in these types of settings (including 
the UK). Of the UK-based studies, two had suboptimal generalisability because all 
coded discharges were taken from a single hospital department,(Panayiotou et al. 
1993, Hasan et al. 1995) while for the other six generalisability was unclear due to 
incomplete reporting.(Sinha et al. 2008, Wright et al. 2012, Davenport et al. 1996, 
Mant et al. 1997, Barer 1996, Kirkman et al. 2009) 
With respect to risk of bias, only five studies achieved the optimum 
score.(Rosamond et al. 1999, Appelros and Terent 2011, Stegmayr and Asplund 
1992, Aboa-Eboule et al. 2013, Harriss et al. 2011) Incomplete reference standard 
data (due to a variable proportion of missing or irretrievable records)(Ives et al. 1995, 
Lakshminarayan et al. 2009, Leibson et al. 1994, Roumie et al. 2008, Derby et al. 
2001, Liu et al. 1999, Klatsky et al. 2005, Goldstein 1998, Benesch et al. 1997, 
Johnsen et al. 2002, Krarup et al. 2007, Tolonen et al. 2007, Ellekjær et al. 1999, 
Spolaore et al. 2005, Rinaldi et al. 2003, Palmieri et al. 2007b, Sinha et al. 2008, 
Wright et al. 2012, Barer 1996, Kirkman et al. 2009, Koster et al. 2013b) and lack of 
or inadequate blinding of adjudicators to the coded iagnosis (Ives et al. 1995, 
Lakshminarayan et al. 2009, Reker et al. 2001, Roumie et al. 2008, Derby et al. 2001, 
Liu et al. 1999, Mayo et al. 1993, Klatsky et al. 2005, Goldstein 1998, Benesch et al. 
1997, Johnsen et al. 2002, Appelros and Terent 2011, Tolonen et al. 2007, Ellekjær 
et al. 1999, Leone et al. 2004, Spolaore et al. 2005, Rinaldi et al. 2003, Haesebaert et 
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al. 2013, Sinha et al. 2008, Wright et al. 2012, Panayiotou et al. 1993, Hasan et al. 
1995) were the most common potential causes of bias.
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Table 2.2 Quality assessment of included studies 











































































































































  (14) 
Reker ☺ ☺  ☺  3     ?     ? 0     ☺ ☺    ? ☺ 3 6 
Aboa-Eboule ☺ ☺ ☺ ☺    4     ? ☺ 1 ☺ ☺ ☺ ☺ ☺ ☺ 6 11 
Sinha ☺ ☺ ☺ ☺ ☺ 5 ☺    ? ☺ 2   ☺ ☺ ☺ ☺ 4 11 
Wahl ☺   ☺ ☺ 3  ☺      ? 1 ☺ ☺ ☺ ☺    ? ☺ 5 9 
Rinaldi ☺ ☺ ☺ ☺  4  ☺ ☺ 2   ☺  ☺ ☺ 3 9 
Benesch  ☺ ☺   2     ?    ? 0    ?  ☺ ☺   ?  2 4 
Klatsky ☺ ☺ ☺ ☺ ☺ 5     ? ☺ 1   ☺ ☺ ☺ ☺ 4 10 
Goldstein ☺ ☺  ☺  3     ?    ? 0   ☺ ☺ ☺ ☺ 4 7 
Koster ☺ ☺ ☺ ☺ ☺ 5  ☺ ☺ 2  ☺ ☺ ☺ ☺ ☺ 5 12 
Hasan ☺ ☺ ☺ ☺  4 ☺     ? 1 ☺  ☺ ☺    ? ☺ 4 9 
Derby ☺ ☺ ☺ ☺ ☺ 5  ☺ ☺ 2   ☺ ☺ ☺ ☺ 4 11 
Derby ☺ ☺ ☺ ☺ ☺ 5  ☺   ☺ 2   ☺ ☺ ☺ ☺ 4 11 
Rosamond ☺  ☺ ☺ ☺ 4  ☺ ☺ 2 ☺ ☺   ☺ ☺ ☺ ☺ 6 12 
Barer ☺     1 ☺    ? ☺ 2   ? ☺ ☺ ☺ ☺ ☺ 5 8 
Haesebart ☺ ☺ ☺ ☺  4  ☺ ☺ 2 ☺  ☺ ☺ ☺ ☺ 5 11 
Johnsen ☺ ☺ ☺ ☺  4  ☺ ☺ 2   ☺ ☺ ☺ ☺ 4 10 
Appelros ☺  ☺ ☺  3  ☺ ☺ 2 ☺ ☺ ☺ ☺ ☺ ☺ 6 11 
Tirschwell ☺ ☺  ☺  3  ☺    ? 1 ☺ ☺ ☺ ☺   ?    ☺ 5 9 
Davenport ☺ ☺ ☺ ☺ ☺ 5 ☺   ?     ? 1 ☺ ☺ ☺  ☺ ☺ 5 11 
Stegmayr ☺ ☺ ☺ ☺  4  ☺ ☺ 2 ☺ ☺ ☺ ☺ ☺ ☺ 6 12 
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Liu ☺ ☺ ☺   3    ?  ☺   1   ?  ☺ ☺ ☺ ☺ 4 8 
Kirkman ☺ ☺ ☺   3 ☺ ☺  2   ?  ☺ ☺  ☺ 3 8 
Palmieri ☺ ☺ ☺   3  ☺   ? 1   ?  ☺ ☺ ☺ ☺ 4 8 
Mant ☺ ☺ ☺ ☺  4 ☺   ? ☺ 2 ☺ ☺    ☺  ☺ ☺ 5 11 
Mayo ☺ ☺  ☺ ☺ 4    ?   ? 0 ☺  ☺ ☺   ? ☺ 4 8 
Panayiotou ☺ ☺  ☺  3 ☺  ☺ 2   ☺ ☺   ? ☺ 3 8 
Wright ☺   ☺ ☺ ☺ ☺ 5 ☺ ☺   ? 2   ☺ ☺   ? ☺ 3 10 
Sporalore ☺   ☺ ☺   3  ☺    ☺ 2   ?  ☺ ☺ ☺ ☺ 4 9 
Roumie ☺ ☺ ☺ ☺  4    ? ☺ 1     ☺ ☺ ☺ ☺ 4 9 
Krarup ☺  ☺ ☺  3  ☺ ☺ 2  ☺ ☺ ☺   ? ☺ 4 9 
Harriss ☺ ☺ ☺ ☺  4  ☺ ☺ 2 ☺   ☺ ☺ ☺ ☺ ☺ 6 12 
Ellekjaer ☺ ☺ ☺   3  ☺ ☺ 2   ?  ☺ ☺ ☺ ☺ 4 9 
Tonolen ☺ ☺    2  ☺   ? 1   ?  ☺   ?   ? ☺ 2 5 
Leone ☺ ☺ ☺ ☺  4  ☺ ☺ 2 ☺  ☺ ☺ ☺ ☺ 5 11 
Ives ☺  ☺   2  ☺ ☺ 2   ?  ☺   ☺ ☺ ☺ 4 8 
Lakshminar. ☺ ☺ ☺   3  ☺ ☺ 2   ?  ☺ ☺ ☺ ☺ 4 9 
Leibson ☺ ☺ ☺ ☺  4  ☺ ☺ 2 ☺ ☺ ☺  ☺ ☺ 5 11 
 
☺High reporting quality/High generalizability/Low risk of bias  Low reporting quality/Low generalizability/High risk of bias    ? Unclear 
generalizability/Unclear risk of bias.  Rules for assessment of study quality are displayed in Appendix 2.7.12. 
*Were the selection criteria clearly described? 
 †Was execution of the index test described in sufficient detail to allow replication of the test?  
‡Was execution of the reference standard described in sufficient detail to permit its replication?  
§If participants were excluded from the final analysis, were they described and were the reasons for this exclusion explained?  
¶Were uninterpretable/intermediate results reported?  
** Was the study UK-based? 
63 
Chapter 2: Accuracy of coded healthcare data for ident fying stroke cases in large epidemiological studies. 
 ††Was the spectrum of patients selected representative of the patients who will receive the diagnosis in practice?  
‡‡Were the same clinical data available when test results were interpreted as would be available when used in practice?  
§§Did the whole sample, or a random selection of the sample, receive verification using a reference standard of diagnosis?  
¶¶Were the reference standard results interpreted without knowledge of the results of the index test?  
*** Was the reference standard independent of the index test?  
†††Did all patients receive the same reference standard regardless of the index test result?  
‡‡‡ Is the reference standard likely to correctly classify the target condition?  
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2.4.4 Accuracy of ICD coded events 
The range of PPVs reported for various codes used to identify stroke or one of its 
main pathological types was very broad, reflecting considerable heterogeneity of 
study characteristics.  Results were particularly variable for all stroke (PPV 31-97%) 
and for ischaemic stroke (PPV 6-95%), while they appeared more consistent for 
haemorrhagic stroke (PPV 73-89%), SAH (PPV 86-96%) and ICH (PPV 71-96%), 
although based on fewer studies.  
Within study comparisons.  Only six studies used a population based reference 
standard and, of these, only four (all from Scandinavian countries)(Appelros, 
Hogeras and Terent 2003, Ellekjær et al. 1999, Stegmayr and Asplund 1992, Koster 
et al. 2013a) provided sufficient data to calculate sensitivity, specificity and negative 
predictive value (NPV) of codes for stroke. Sensitivit es for identifying stroke were 
around 80% or more using general cerebrovascular or str ke specific codes from 
either hospital data or hospital data combined withdeath certificates, but – 
unsurprisingly – sensitivity was much lower for death certificates alone (Table 2.3). 
There were no data on sensitivity for the main pathological types of stroke. 
Where calculable, specificity and NPV were uniformly high (range 96-99.9%), 
reflecting the relatively small proportion of false n gative strokes (amongst all non 
stroke and code negative numbers, respectively).(Appelros and Terent 2011, Ellekjær 
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Country ICD code group Code 
source 
Reference standard* Coded events compared against the 
reference standard† (n) 
Sensitivity  
(% & 95% CI) 
Specificity 
(% & 95% CI) 
PPV 
(% & 95% CI) 
NPV 
(% & 95% CI) 
































  H  318 10 123,116 59 84 (80-88) 99.9 (99.98-99.99) 97 (94-98) 99.9 (99.93-99.96) 































H 1224 202 508,447 127 91 (89-92) 99.9 (99.95-99.97) 86 (84-88) 99.9 (99.97-99.98) 
















































































D: death certificates; H: hospital data; H + D: both 
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Several within study comparisons showed that the groups of codes with the highest 
PPVs (68-90%) for all types of stroke combined were 430, 431, 434, 436 (ICD-9) or 
I60, I61, I63, I64 (ICD-10) (Table 2.4). Compared with general cerebrovascular 
codes (ICD-9 430-438, or ICD-10 I60-I69+/-G45), selection of these stroke specific 
codes gave consistently higher PPVs (absolute increase of 17-30%) (Table 2.4). 
Stroke specific codes inevitably identified fewer coded events than general 
cerebrovascular ones (numbers fell by a third to over a half, Table 2.4), but the 
impact on sensitivity appeared limited (absolute decrease of 5%) in the one study that 
provided data on this.(Ellekjær et al. 1999) 
Table 2.4 Effect on PPV of codes used to identify stroke: within-study comparisons* 
Study Codes Diagnosis sought Coded events PPV  
(%, & 95% CI)  
Johnsen 
2002 
I60-I69 + G45 CVD 565 58 (58-62) 
I60, I61, I63, I64 Stroke 378 79 (75-83) 
Krarup         
2007† 
I60-I69 + G45 CVD 236 69 (59-71) 
I60, I61, I63, I64 Stroke 164 86 (76-88) 
Ellekjaer 
1999 
430-438 CVD 759 49 (45-52) 
430, 431, 434, 436 Stroke 508 68 (64-72) 
Leone 
2004 
430-438 CVD 1017 60 (57-63) 
430, 431, 434, 436 Stroke 411 90 (87-93) 
 
 CVD= Cerebrovascular disease 
*If there was more than one result per code group, results are shown for the largest number of cases 
assessed.   
†Mean PPV taken from range of values in original publication. 
 
For identifying ischaemic stroke, codes I63 (ICD-10) or 434 (ICD-9) achieved 
reasonably high PPVs (range 66 to 88%), (Rosamond et al. 1999, Goldstein 1998, 
Benesch et al. 1997, Johnsen et al. 2002, Leone et al. 2004, Haesebaert et al. 2013, 
Wright et al. 2012) while code 433 (ICD-9) performed consistently poorly in studies 
which assessed it (PPV range 6% to 14%).(Rosamond et al. 1999, Benesch et al. 
1997, Leone et al. 2004) The addition of codes for unspecified type of stroke (436 
[ICD-9] or I64 [ICD-10]) to ischaemic stroke codes increased the number of coded 
events identified within each study, with in general ither no change or only a few % 
absolute decrease in PPV (Table 2.5).(Rosamond et al. 1999, Goldstein 1998, 
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Benesch et al. 1997, Johnsen et al. 2002, Krarup et al. 2007, Tolonen et al. 2007, 
Ellekjær et al. 1999, Leone et al. 2004, Rinaldi et al. 2003, Wright et al. 2012)  
Table 2.5 Effect on PPV of codes used to identify ischaemic stroke: within study comparisons* 
Study Codes Diagnosis sought Coded 
events 
PPV              




































































Ischaemic and unspecified stroke 






6   (3-11) 
436 57 70 (57-80) 
434, 436 














Ischaemic and unspecified stroke 





433 266 14 (10-18) 
436 
434, 436 















Ischaemic and unspecified stroke 
















































433, 434, I63 
433, 434, 436, I63, I64 
 
Ischaemic stroke 



















Ischaemic and unspecified stroke 












*If there was more than one result per code, results are hown for the largest number of cases assessed.   
†Mean PPV taken from range of values in original publication. 
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Eight studies (all of ICD-9 codes) assessed influence of coding position on PPV for a 
variety of ICD-9 code groups (cerebrovascular disease codes, ischaemic stroke codes, 
or haemorrhagic stroke codes).(Lakshminarayan et al. 2009, Leibson et al. 1994, 
Roumie et al. 2008, Liu et al. 1999, Tirschwell and Longstreth 2002, Benesch et al. 
1997, Leone et al. 2004, Rinaldi et al. 2003) Restriction to the primary position code 
(versus inclusion of codes from the primary or secondary diagnostic position) 
increased the PPV, but by no more than about 5-10% in all but two studies 
(Lakshminarayan et al. 2009, Liu et al. 1999) (Table 2.6).  
Table 2.6 Influence of diagnostic position on PPV  
Study ICD code group Diagnostic position Coded 
events (n) 
PPV  
(% & 95% CI) 
Leone  
2004 
430-438 Primary or Secondary 1017 60 (57-63) 
Primary 833 66 (63-69) 
Lakshminarayan  
2009 
431, 432, 434, 436, 
437 
Primary or Secondary 6032 63 (61-64) 
Primary 4445 85 (84-86) 
Leibson  
1994 
430-438 Primary or Secondary 462 54 (49-58) 
Primary 377 60 (55-64) 
  Roumie 
  2008 
  430, 431, 433.x1, 
  434.x1, 436 
 






    85 (84-92) 
 
    97 (93-98) 
Liu 
1999 
430-438 Primary or Secondary 862 56 (53-60) 
Primary 621 87 (63-70) 
  Rinaldi 
  2003 
  434, 436 Primary or Secondary 180 71 (64-77) 
Primary 157 76 (69-82) 
  Tirschwell 
  2002 
  430 Primary or Secondary* 51* 86 (74-93) 
Primary* 51* 94 (84-98) 
  Benesch 
  1997 
  433, 434, 436 Primary or Secondary 550 43 (39-47) 
Primary 379 53 (48-58) 
 
*A single code was selected from 51 hospital discharges: Primary or Secondary: used the hierarchy 
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It was not possible directly to assess the influence of code position on sensitivity, but 
restriction to the primary position reduced the number of coded events identified by 
around 10-30%. 
Comparisons between groups of studies reporting PPV  for stroke and 
its main types. The PPV of codes for stroke and its main types, stratified 
according to the code group(s) selected (see below), are displayed in Figures 2.3 to 
2.5. They display results of studies which identified: stroke events using either a 
broad selection of cerebrovascular codes or stroke-specific codes (Figure 2.3); 
ischaemic stroke events, using either codes for ischaemic and unspecified type of 
stroke or for ischaemic stroke alone (Figure 2.4.); and haemorrhagic stroke events 
using codes for ICH and SAH together or separately (Figure 2.5.). Informed by our 
within-study comparisons, results exclude studies which included the poorly 
performing ICD-9 code 433 among the stroke-specific or ischaemic stroke codes, 
except those which used the clinical modification 433.x1 (Figure 2.1, Table 2.5, 
Figure 2.4).  
For each of stroke and its main pathological types, PPVs of >90% were achieved in 
some studies (Figures 2.3 to 2.5). In line with results from within-study comparisons 
(Table 2.4), stroke-specific codes yielded higher PPVs for stroke (range 68-90%) 
than general cerebrovascular disease codes (range 31-80%) (Figure 2.3), while PPVs 
for ischaemic stroke were slightly higher with codes for ischaemic stroke alone 
(range 66-95%) than with codes for ischaemic and unspecified stroke (range 65-
90%), but identified smaller numbers of outcomes (Figure 2.4). Codes for 
haemorrhagic stroke, and for ICH and SAH separately, performed consistently well 
or very well (PPV range 65-96%) (Figure 2.5). In geeral, ICD-10 appeared to 
perform better than ICD-9 codes, except where the ‘clinical modification’ (ICD-9-
CM, see Figure 2.1) was available. Studies from the UK, yielding data that might be 
considered most informative for UK Biobank, reported PPVs of 78% and 86% for 
ischaemic stroke in one study (Wright et al. 2012) (the lower value when codes for 
unspecified stroke were included), 96% for SAH in two studies (Wright et al. 2012, 
Kirkman et al. 2009) and 96% for ICH in one study.(Kirkman et al. 2009) The 
quality scores did not appear to influence PPV (Figure 2.3 to Figure 2.5). 
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Figure 2.3 Positive predictive value of codes for stroke. 
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Figure 2.3 Positive predictive value of codes for stroke 
H: hospital data, D: death certificates, H+D: hospital data and death certificates; x =number of coded events confirmed as ‘true cases’ by the reference standard;  
y= total number of coded events; x/y = PPV. 
Circles represent PPVs, and horizontal lines denote 95% confidence intervals (CIs). Circle size is proportional to the inverse variance of the PPV. Where more than 
one result was available for a particular study, the result for the largest number of coded events validated is shown. 
*Cerebrovascular codes: I60-I69+/-G45 (ICD-10) or 430- 8 (ICD-9), unless otherwise specified  
† Mean PPV (taken from the range published in the study) 
‡Excluding codes 435 (TIA) and 438 (sequelae of cerebrovascular disease) 
§Excluding code 435 (TIA) and including code 342 (hemiplegia and hemiparesis) 
¶Excluding code 435 (TIA)  
#Stroke-specific: 160, 161, 163, 164 (ICD-10), 430, 431, 434, 436 (ICD-9), 430, 431, 433.x1, 434.x1 (ICD-9-CM) 
¥Ischaemic stoke and unspecified stroke: I63, I64 (ICD-10), 434, 436 (ICD-9), 433.x1, 434.x1, 436 (ICD-9-CM)  
** Ischaemic stroke:163 (ICD-10), 434 (ICD-9), 433.x1, 434.x1 (ICD-9-CM) 
††Haemorrhagic stroke:I60, I61 (ICD-10), 430, 431 (ICD-9) 
‡‡Subarachnoid haemorrhage stroke:I60 (ICD-10), 430 (ICD-9) 
¶¶Intracerebral haemorrhage stroke codes:I61 (ICD-10), 431 (ICD-9) 
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Figure 2.4 Positive predictive values of codes for ischaemic stroke 
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Figure 2.4 Positive predictive value of codes for ischaemic stroke  
H: hospital data, D: death certificates, H+D: hospital data and death certificates; x =number of coded events confirmed as ‘true cases’ by the reference standard;    
y= total number of coded events; x/y = PPV. 
Circles represent PPVs, and horizontal lines denote 95% confidence intervals (CIs).  
Circle size is proportional to the inverse variance of the PPV.  
Where more than one result was available for a particular study, the result for the largest number of coded events validated is shown. 
†Mean PPV (taken from the range published in the study 
¥Ischaemic stoke and unspecified stroke codes: I63, I64 (ICD-10), 434, 436 (ICD-9), 433.x1, 434.x1, 436 (ICD-9-CM) 
** Ischaemic stroke codes:163 (ICD-10), 434 (ICD-9), 433.x1, 434.x1 (ICD-9-CM) 
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Figure 2.5 Positive predictive values of codes for haemorrhagic stroke 
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Figure 2.6 Positive predictive values of codes for haemorrhagic stroke 
H: hospital data, D: death certificates, H+D: hospital data and death certificates;  
x =number of coded events confirmed as ‘true cases’ by the reference standard; y= total number of coded events; x/y = PPV. 
Circles represent PPVs, and horizontal lines denote 95% confidence intervals (CIs).  
Circle size is proportional to the inverse variance of the PPV.  
Where more than one result was available for a particular study, the result for the largest number of coded events validated is shown. 
†Mean PPV (taken from the range published in the study) 
††Haemorrhagic stroke codes:I60, I61 (ICD-10), 430, 431 (ICD-9) 
‡‡Subarachnoid haemorrhage stroke codes:I60 (ICD-10), 430 (ICD-9) 
¶¶Intracerebral haemorrhage stroke codes:I61 (ICD-10), 431 (ICD-9) 
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Selection of the best code using a code hierarchy.  Two studies used a ‘code 
hierarchy’ to select a single stroke code when more than one was used for an 
individual hospital admission.(Roumie et al. 2008, Tirschwell and Longstreth 2002) 
These studies selected the single ‘best code’ for each case, based on presumed 
coding accuracy (SAH>ICH>ischaemic stroke>transient ischaemic attack [TIA]). 
This approach was no more accurate than selection of the primary position code in 
one study,(Tirschwell and Longstreth 2002) and less accurate than selection of the 
primary position code in another.(Roumie et al. 2008)(Table 2.6) 
Distinguishing ischaemic stroke subtypes.  Very few studies assessed 
accuracy of ICD codes for more detailed ischaemic stroke subtypes, and none 
assessed accuracy for subtypes of SAH or ICH. One study found that out of 106 
coded events for ischaemic stroke subtypes, >70% had unspecified ischaemic stroke 
subtype codes.(Goldstein 1998)  The PPV of the cardiac embolism subtype code was 
73% (based on only 11 coded events), but PPVs for other ischaemic subtypes were 
not reported. Another study attempted to classify ichaemic strokes into four 
subtypes (lacunar stroke, cardiac embolism, large atery atherosclerosis and other) 
based on the hospital discharge abstract (which was used to generate the ICD codes) 
rather than the codes themselves.(Aboa-Eboule et al. 2013) This approach produced 
PPVs of 66-87% (highest for cardiac embolism and lacun r ischaemic stroke), and 
sensitivities of 67-74% (highest for cardiac embolism and large artery 
atherosclerosis).  
2.4.5 Studies of Read-coded primary care data. 
Two UK-based studies reported PPVs of Read codes from primary care data, one for 
ischaemic and one for haemorrhagic stroke (Table 2.7). Neither study reported code 
sensitivity. (Ruigomez et al. 2010, Gaist et al. 2013) PPV was 89% for ischaemic 
stroke and 82% for haemorrhagic stroke, increasing to 90% for haemorrhagic stroke 
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Table 2.7 Included primary care Read-coded studies: characteristics and results 


































78 (69 to 85) 






















82 (77 to 86) 
  156 SAH 142 91  (85 to 95) 
  150 ICH 109 73 (65 to 80) 
 
*This study excluded individuals who were not admitted o hospital, who had cancer or a previous cerebrovascular event, or who also had Read codes for 
haemorrhagic stroke.  
†Read codes for unspecified stroke.  
‡Read codes for ischaemic stroke. 
§This study excluded Read code events if the primary c e record ‘free text’ suggested that events were; ischaemic; secondary to trauma; subdural haemorrhage; 
prevalent rather than incident; due to cancer, or events occurred in hospital.  
¶Diagnostic codes for Subarachnoid haemorrhage (SAH), Intracerebral haemorrhage (ICH), unspecified haemorrhage and sequelae, Procedure codes for 
evacuation/aspiration of haematoma, and Process of care codes for ‘History of subarachnoid haemorrhage.’ Gaist et.al, Pharmacoepidemiology and Drug Safety 
2013;22:176-182:Appendix I (online supplement). 
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2.4.6 Combining multiple data sources 
None of the included studies assessed the combination of primary care codes with 
hospital or death certificate codes for stroke or its main types. A few excluded 
studies compared primary care and hospital codes to search for stroke plus 
TIA.(Mant et al. 2003, Tu et al. 2013) A UK study found that, compared to hospital 
ICD codes for stroke plus TIA in a primary care population of ~5800 individuals, 
primary care Read codes increased sensitivity and decreased PPV by absolute values 
of 53% and 17% respectively.(Mant et al. 2003) Similarly, a community-based study 
in Canada found that combining primary care physician billing data with hospital 
ICD codes detected more stroke/TIA events, but withlower PPV, compared to ICD 
codes alone: sensitivity for combined data sources was 78% (95% CI 66%-83%) 
versus 37% (95% CI 28%-46%) for ICD codes alone; PPV for combined data 
sources was 40% (95% CI 33%-46%) versus 81% (95% CI 70%-92%) for ICD codes 
alone.(Tu et al. 2013)  
Two UK studies explored the possibility of using medical record extracts to reduce 
the proportion of unspecified stroke codes (I64).(Wright et al. 2012, Flynn et al. 
2010) In one, the primary care record held information o classify 74% of ICD-coded 
‘unspecified strokes’ as ischaemic or haemorrhagic.(Wright et al. 2012) In the other, 
CT brain scan reports were used to assign ~ 8400 stroke cases (identified by 
ischaemic stroke, intracerebral haemorrhage or unspecified stroke codes) to a main 
pathological type.(Flynn et al. 2010) The proportion of ‘unspecified’ stroke cases fell 
from 67% to 33% when ICD coded data plus natural langu ge processing of scan 
reports was used, versus ICD coded data alone. Using a physician’s classification of 
radiology reports of 300 randomly selected cases as a reference standard, ICD coding 
plus analysis of scan reports was more accurate for ischaemic (PPV 95%, 95% CI 
90% to 97%) than for haemorrhagic stroke (PPV 77%, 95% CI 69% to 73%).
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2.5 Discussion 
This was the first systematic assessment of the accur y of coded hospital, death 
certificate and primary care data for identifying stroke. Previous published reviews 
have been less comprehensive in their data inclusion, presentation and analysis, or 
less precise in their definition of stroke, with the inclusion of TIA, subdural 
haemorrhage, or all cerebrovascular disease in the reference standard. A previous 
review based on US studies alone reported similar results but did not include UK 
based studies or consider either ICD-10 codes or the performance of primary care 
data or combined data sources.(Andrade et al. 2012) Previous UK-based reviews of 
ICD or Read code accuracy have reviewed overall accur y for a wide range of 
diseases rather than accuracy for stroke specifically,(Thiru, Hassey and Sullivan 
2003, Herrett et al. 2010) with limited numbers of stroke/cerebrovascular disease 
studies.(Khan, Harrison and Rose 2010, Burns et al. 2011, Jordan, Porcheret and 
Croft 2004, Campbell et al. 2001)  
I found wide variation in the performance of ICD codes for stroke and its main types, 
reflecting the heterogeneity of codes assessed and variation in study settings and 
methods. These data also show a lack of consensus among stroke epidemiology 
studies about which codes should be used for identifying stroke outcomes. I have 
demonstrated that with appropriate selection of strke-specific codes, PPVs of close 
to or >90% can be achieved for stroke and each of its main pathological types. Such 
PPVs will be adequate for many large scale epidemiological studies of the 
determinants of stroke. However, I found very few studies of the accuracy for stroke 
of Read coded primary care data or of two or more overlapping data sources. 
Furthermore, the few available studies of ICD-coded ata sources for identification 
of ischaemic stroke subtypes found that the majority f ischaemic subtype codes 
were ‘unspecified’,(Goldstein 1998) and reliability of ischaemic subtype 
classification was limited.(Kessler et al. 1991, Dixon et al. 1998) I found no studies 
of the accuracy of coded data for identification of subtypes of ICH or SAH.   
Within- and between-study comparisons revealed several consistent patterns. First, 
for stroke of any pathological type, PPV was increased by use of stroke-specific 
rather than general cerebrovascular codes, making it preferable to use stroke-specific 
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codes to maximise PPV if no further adjudication of outcomes is planned after 
identification using ICD codes. Limited evidence suggests that sensitivity is poor 
when only death certificate data are used as a data source and is markedly increased 
by including data from hospital admissions, without compromising PPV.(Appelros et 
al. 2003, Koster et al. 2013a) Results from one study suggest that using general 
cerebrovascular rather than stroke-specific codes is also likely to increase sensitivity, 
albeit perhaps by only a small amount and at the exp nse of a lower PPV.(Ellekjær et 
al. 1999) To reduce the number of false positives, thi  method of identifying stroke 
outcomes is, therefore, probably best used in combination with further steps to 
confirm which cases are true positives. The best approach for this confirmation 
process requires further investigation, but could potentially use combinations of ICD 
codes with coded data from primary care or other sou ces, or more detailed medical 
record review. Second, for ischaemic stroke, a greate  number of outcomes are 
identified with little reduction in PPV by using a combination of ischaemic and 
unspecified stroke codes to identify outcomes. Third, specific codes for ICH and 
SAH were found to have generally high PPVs (range 71 to 96%). Fourth, across a 
range of codes for cerebrovascular disease, stroke and pathological stroke types, 
identification of stroke outcomes using only codes in the primary position increased 
PPV, but generally by only a modest amount and at the expense of missing true 
positive outcomes. Furthermore, the relevant studies w re of ICD-9 codes only, 
which are now rarely used outside the USA.(Leibson et al. 1994, Reker et al. 2001, 
Roumie et al. 2008, Liu et al. 1999, Tirschwell and Longstreth 2002, Benesch et al. 
1997, Leone et al. 2004, Rinaldi et al. 2003) Thus, use of appropriately selected 
codes in both the primary and secondary positions would seem appropriate for most 
purposes.  
There were some limitations. First, since I only searched two online databases, I may 
have missed a few relevant articles. However, I also reviewed bibliographies of all 
included publications to increase the sensitivity of our search strategy. Second, my 
finding that use of the primary diagnostic position mproved PPV in some studies 
may have been due to publication or reporting bias, since many studies did not report 
on this. Third, since PPV increases with increasing prevalence of the outcome 
studied, the lower prevalence of ICH and SAH (which together comprise around 
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20% of all strokes) compared with ischaemic stroke means that the PPVs of these 
different pathological types are not directly comparable.  
Fourth, some included studies had potentially less accurate sources available as a 
reference standard, such as hospital discharge summaries (a free text summary of the 
hospital admission, which is often written by less xperienced doctors), or non 
specialist primary care records (potentially based on hospital discharge summaries). I 
may have overestimated PPV of codes for haemorrhagic stroke types by using such 
reference standard data from two UK based studies.(Wright et al. 2012, Kirkman et 
al. 2009) Otherwise, all included studies used potentially more accurate reference 
standard data sources (independent medical record review and/or expert-led stroke 
registers). Although I only included studies which used WHO or equivalent 
definitions of stroke and its main types,(Hatano 1976) there is no ‘gold standard’ 
diagnosis for stroke. Indeed, even experts are inconsistent in their ability to diagnose 
stroke,(Ferro et al. 1996a, Ferro et al. 1998), while choice and timing of imaging 
(which may vary between centres and therefore between studies) influences the 
diagnostic accuracy of stroke types.(Wardlaw and Mielke 2005, Fiebach et al. 2002)  
Fifth, the paucity of specific published data about the accuracy of Read coded 
primary care data for stroke is an important further limitation, since up to half of 
stroke patients are not admitted to hospital in the UK,(Bamford et al. 1986, Rothwell 
et al. 2004) and hospitalised and non hospitalised strokes may differ in the 
distribution of pathological types and subtypes andin their risk factor 
associations.(Schulz and Rothwell 2003) Combining primary care data with other 
sources (hospital and death certificate data) should improve the detection of non 
hospitalised cases, reducing potential bias in the sel ction of cases. Although I 
identified six systematic reviews of Read code accura y for a wide range of 
diseases,(Khan et al. 2010, Thiru et al. 2003, Herrett et al. 2010, Burns et al. 2011, 
Jordan et al. 2004, Campbell et al. 2001) none included data specifically for stroke. 
Two excluded studies validated Read codes for cerebrovascular disease,(Mant et al. 
2003, Van Staa and Abenhaim 1994) against a referenc  standard diagnosis of 
‘cerebrovascular disease’. These ‘reference standards’ were potentially less accurate 
because they included hospital ICD codes and patient-self-report without medical 
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record review, or used internal validation by GP questionnaire (not an independent 
data source). In addition to improving case ascertainment, primary care data may 
enhance the sub-classification of potential stroke cases. Around 40% of ICD codes 
for stroke are of unspecified type, although this proportion may be 
declining.(http://www.isdscotland.org/ , http://www.saildatabank.com/) Diagnostic 
codes combined with investigation, procedure, and/or medication codes (in primary 
care or hospital data) may increase PPV for ischaemic or haemorrhagic stroke.(Gaist 
et al. 2013, Haesebaert et al. 2013) 
2.6 Conclusions 
Informed by this review, I recommend using 430, 431, 434, 436 (ICD-9), or I60, I61, 
I63, I64 (ICD-10), in either the primary or secondary diagnostic position to identify 
stroke cases with sufficiently high PPV for use in epidemiological studies where 
further confirmation steps are not envisaged. This may achieve PPVs of >90% for 
stroke. To increase the number of potential events identified, I suggest using all 
cerebrovascular disease ICD codes (ICD-9 430-438, or ICD-10 I60-I69, G45, G46) 
in both primary and secondary positions, but these would have to be combined with 
additional methods of stroke confirmation to maintai   high PPV. For ischaemic 
stroke we recommend codes 434, 436 (ICD-9), 433.x1, 434.x1, 436 (ICD-9-CM), 
and I63, I64 (ICD-10). For haemorrhagic stroke we recommend 430 (ICD-9) and I60 
(ICD-10) for SAH, and 431 (ICD-9) and I61 (ICD-10) for ICH. Identifying more 
detailed stroke subtypes is likely to require coded ata from investigations, 
procedures, and/or drug prescriptions, as well as diagnostic codes, and possibly more 
detailed review of medical record and imaging data. 
Ultimately, UK Biobank aims to improve the accuracy and completeness of stroke 
outcomes ascertainment by linking multiple sources of coded data. Further work is 
needed to examine the use of multiple coded data sources to maximise PPV and 
sensitivity for stroke.
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2.7 Appendix: study protocol 
2.7.1 Review Question(s) 
Primary Question 
Accuracy (positive predictive value) of coded health record data (International 
Classification of Diseases codes, ICD, or Read codes) for stroke and its main 
pathological types (ischaemic stroke, intracerebral haemorrhage, subarachnoid 
haemorrhage) using WHO or equivalent definitions in an adult population.    
Secondary Questions 
A. Sensitivity, specificity, and NPV (negative predictive value) of coded health 
record data for stroke and its main pathological types (amongst studies where the 
reference standard is population based).  
B. Influence of the range of codes selected (amongst ICD and/or Read codes for 
‘cerebrovascular disease’) on PPV and/or sensitivity for stroke and its main types. 
C. Influence of diagnostic position (primary versus econdary) on the PPV and/or 
sensitivity of ICD codes for stroke and its main pathological types. 
D. Accuracy (PPV, sensitivity, specificity, NPV) ofmultiple sources of coded data 
(ICD codes from death certificates, and/or ICD codes from hospital records, and/or 
Read codes from primary care) for stroke and its main p thological types.  
2.7.2 Searches 
We will search the following databases from 1990 to the date of search: 
MEDLINE (Ovid SP); EMBASE (Ovid SP); Clinical Research Practice Datalink; 
The Health Improvement Network 
We will review bibliographies of included publications for any additional relevant 
articles. 
One author will review all titles and abstracts (IG).  A second author (RW) will 
review a 10% sample of titles and abstracts. Two authors will independently review 
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all potentially relevant full texts and select studies for inclusion (IG and RW). Any 
areas of uncertainty will be discussed and resolved with a third (CS). 
MEDLINE search strategy 
1. (cerebrovascular disorders/ or exp basal ganglia cerebrovascular disease/ or 
exp brain ischemia/ or exp carotid artery diseases/ or exp cerebral small vessel 
diseases/ or exp intracranial arterial diseases/ or exp intracranial embolism/ and 
thrombosis/) or exp intracranial hemorrhages/ or stroke/ or exp brain infarction/ or 
stroke, lacunar/ or vertebral artery dissection/ 
2. (stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or appoplex$ 
or isch?emi$ attack$ or tia$ or SAH).tw. 
3. ((brain$ or cerebr$ or cerebell$ or cortical or ve tebrobasilar or hemisphere$ 
or intracran$ or intracerebral or infratentorial or supratentorial or MCA or anterior 
circulation or posterior circulation or basal ganglia) adj5 (isch?emi$ or infarct$ or 
thrombo$ or emboli$)).tw. 
4. ((brain$ or cerebr$ or cerebell$ or intracerebral o  intracran$ or parenchymal 
or intraventricular or infratentorial or supratentorial or basal gangli$ or subarachnoid 
or putaminal or putamen or posterior fossa) adj5 (haemorrhage$ or hemorrhage$ or 
haematoma$ or hematoma$ or bleed$)).tw. 
5. 1 or 2 or 3 or 4 
6. medical record/ or medical record review/ or Medical Records Systems, 
Computerized/ or medical information system/ 
7. (hospital or GP or medical or general practitioner or health).tw. 
8. international classification of diseases/ or Disease/cl [Classification] 
9. Clinical Coding/ 
10. read coding.tw. 
11. (ICD-10 or ICD-9 or ICD-9-CM or ICD-10-CM).tw. 
12. 6 or 7 or 8 or 9 or 10 or 11 
13. exp Sensitivity/ and Specificity/ 
14. exp Validation Studies/ or exp predictive value/ or exp Reproducibility of 
Results/ 
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15. (sensitivity or specificity or positive predictive value).tw. 
16. (validity or reproducibility).tw. 
17. 13 or 14 or 15 or 16 
18. 12 and 17 
19. 5 and 18 
EMBASE search strategy 
1. cerebrovascular disease/ or basal ganglion hemorrhage/ or exp brain 
hematoma/ or exp brain hemorrhage/ or exp brain infarction/ or exp brain ischemia/ 
or exp carotid artery disease/ or cerebal artery disease/ or cerebrovascular accident/ 
or exp occlusive cerebrovascular disease/ or exp stroke/ 
2. stroke unit/ or stroke patient.mp. [mp=title, abstract, subject headings, 
heading word, drug trade name, original title, devic  manufacturer, drug 
manufacturer, device trade name, keyword] 
3. (stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or apoplexy$ 
or isch?emi$ attack$ or tia$ or SAH).tw. 
4. ((brain$ or cerebr$ or cerebell$ or cortical or ve tebrobasilar or hemisphere$ 
or intracran$ or intracerebral or infratentorial or supratentorial or MCA or anterior 
circulation or posterior circulation or basal ganglia) adj5 (isch?emi$ or infarct$ or 
thrombo$ or emboli$)).tw. 
5. ((brain$ or cerebr$ or cerebell$ or intracerebral o  intracran$ or parenchymal 
or intraventricular or infratentorial or supratentorial or basal gangli$ or subarachnoid 
or putaminal or putamen or posterior fossa) adj5 (haemorrhage$ or hemorrhage$ or 
haematoma$ or hematoma$ or bleed$)).tw. 
6. 1 or 2 or 3 or 4 or 5 
7. medical record/ or medical record review/ or electronic medical record/ or 
medical information system/ 
8. (hospital or GP or medical or general practitioner or health).tw. 
9. "international classification of diseases"/ or disease classification/ 
10. coding/ or "read coding"/ 
11. read coding.tw. 
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12. (ICD-10 or ICD-9 or ICD-9-CM or ICD-10-CM).tw. 
13. 7 or 8 or 9 or 10 or 11 or 12 
14. "sensitivity and specificity"/ 
15. exp validation study/ or exp predictive value/ or exp reproducibility/ 
16. (sensitivity or specificity or positive predictive value).tw. 
17. (validity or reproducibility).tw. 
18. 14 or 15 or 16 or 17 
19. 13 and 18 
20. 5 and 19 
2.7.3 Types of study to be included 
We will include studies in adult populations (cohort studies, case control studies, or 
clinical trials) which compare ICD codes or Read coes for ‘cerebrovascular disease’ 
against a second source of data for stroke using WHO, or equivalent definitions.  
We will exclude studies in highly selected populations with an increased risk of 
stroke (due to the influence of prevalence on PPV).  
Studies are required to report the group(s) of codes validated and the Positive 
Predictive Value (or data from which this can be calcul ted).  
Studies should use a reference standard of ‘stroke’ (distinguished from transient 
ischaemic attack or generalised cerebrovascular disease) when calculating PPV, 
sensitivity, specificity, and NPV. 
We will exclude studies which assess < 50 coded events (due to limited precision).  
2.7.4 Condition or domain being studied 
International Classification of Diseases codes (version 9 or any later version) for 
cerebrovascular diseases based on hospital admission or death certificate diagnoses.  
Read codes (any version) for cerebrovascular disease . 
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Studies should publish the group of codes validated (so that the influence of 
individual code selection on accuracy can be explored).  
We will exclude studies of ICD version 8, or earlier primary care systems (e.g. 
OXMIS codes) because these have been superseded by newer coding systems in the 
UK.  
2.7.5 Participants/population 
Any adult population. 
2.7.6 Interventions, exposures 
Reference standard:  We accept that the inter-observer reliability of stroke 
diagnosis is imperfect, even amongst experts. In the absence of a true ‘gold standard’ 
for stroke, we will include studies which use any of the following reference standards 
for stroke: clinical examination; physician questionnaire; medical record review 
(primary care and/or hospital records); stroke regist rs (informed by multiple 
overlapping data sources, ‘hot pursuit’, and expert medical record review).  
Studies should use a clinical syndrome based definition (WHO, or equivalent) for 
diagnosing stroke.  
2.7.7 Context 
The principle criterion is accuracy of coded data (ICD or Read codes for 
cerebrovascular diseases) for the ascertainment (sensitivity) and confirmation (PPV) 
of stroke cases in relatively unselected adult populations. 
We have pre specified questions to see if PPV and/or sensitivity for stroke and/or its 
main types are influenced by the groups of cerebrovascular diseases codes selected, 
or the diagnostic position of these codes (primary versus primary or secondary).  
We will exclude studies which include subdural haemorrhage, unspecified 
cerebrovascular disease and/or TIA in their reference standard definition of stroke.  
94 
Chapter 2: Appendix 
2.7.8 Outcomes 
Primary outcomes 
We will calculate Positive predictive value (PPV) of c ded data for stroke and/or its 
main types (ischaemic stroke, intracerebral haemorrhage, subarachnoid 
haemorrhage) in all included studies using the avail ble published data. 
Secondary outcomes 
In studies which use population based reference standards, we will calculate 
sensitivity, specificity, PPV, NPV and stroke prevalence using 2x2 contingency 
tables. 
The reference standard will be grouped into hospital based versus population based 
according to the following definitions: 
Population based: primary care medical records and/or general practitioner 
questionnaires and/or population based stroke registers used to capture strokes 
diagnosed out of hospital.  
Hospital based: hospital medical records only +/- hospital physician questionnaires 
which largely capture hospitalised strokes.    
If an individual study uses more than one group of cerebrovascular disease codes, 
more than one diagnostic position (primary versus primary or secondary), or more 
than one data source (hospital versus death certifiate codes versus both), we will 
explore the influence of code selection, diagnostic position, and code source on 
PPV/sensitivity for stroke and its main types.  
Calculations will be performed independently by two authors (IG and RW) using 
available published data. Disagreements will be resolv d through discussion with a 
third (CS).  
2.7.9 Data extraction (selection and coding) 
We will extract data onto study specific proforma. 
Covariates of interest: 
- Study author 
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- Publication date 
- Country 
- Target population age (range) 
- Range of ICD/Read codes validated 
- Code version (eg. ICD-9, ICD-9-CM, ICD-10) 
- Code source (hospital, death certificate or both) 
- Number of coded events assessed 
- Diagnostic position of codes (primary, secondary or both) 
- Diagnosis sought (eg. stroke, ischaemic stroke, haemorrhagic stroke, 
intracerebral haemorrhage, subarachnoid haemorrhage, or any 
combination).  
- Reference standard used (eg expert hospital record review, population  
based stroke register) 
- Number of coded events confirmed (depending on the diagnosis sought, 
eg. stroke or one of its main types) 
- PPV of selected codes for stroke and/or its main types 
- Sensitivity of selected codes for stroke and/or its main types (when the 
reference standard is population based).    
2.7.10 Study-level quality assessment 
We will assess methodological quality using a modification of the Quality 
Assessment of Diagnostic Accuracy Studies tool (QUADAS-2). QUADAS-2 uses 
fourteen questions to assess study-level risk of bias and generalisability to the target 
population.  
QUADAS-2 was recently modified for a systematic review of the validity of 
Myocardial Infarction Diagnoses in Administrative Databases.(McCormick et al. 
2014) This new version had fewer questions for the assessment of bias and additional 
questions for the assessment of reporting quality. We will use these questions 
(because they were developed specifically for studies of the accuracy of coded data), 
removing the question ‘were the index test results interpreted without knowledge of 
the results of the reference standard’ because we feel that the codes (index test) are 
96 
Chapter 2: Appendix 
unlikely to be misinterpreted, and adding the question ‘was the study UK-based (?)’ 
to assess generalisability to the UK population.   
Our modified QUADAS-2 will therefore include five questions for the assessment of 
reporting quality, three for assessment of generalisability, and six for assessment of 
risk of bias (fourteen in total). Each question will score ‘low’, ‘high’, or ‘unclear’ 
reporting quality/generalisability/risk of bias according to the rules (below).  
An overall quality score (0-14) will be derived for each study by adding the number 
of questions which scored ‘high reporting quality’, ‘high generalisability’, and ‘low 
risk of bias’.   
2.7.11 Modified QUADAS-2 scoring methods  
1) Assessment of reporting quality  
a) Were the selection criteria clearly described? 
High reporting quality: population selection critera clearly described.  
Low reporting quality: population selection criteria unclear. 
b) Was execution of the index test described in sufficient detail to allow 
replication of the test? (The index test was the coding algorithm used in the 
study.)  
Studies were excluded from this review if the codes used were not reported.   
High reporting quality: diagnostic position of codes (primary vs. primary or 
secondary diagnoses) clearly reported.                     
Low reporting quality: diagnostic position of codes not clearly reported.  
c) Was execution of the reference standard described in sufficient detail to 
permit its replication? 
High reporting quality: reported the information used to make the reference 
standard diagnosis (eg. full medical record vs. abstr cted data, brain imaging to 
confirm stroke subtypes) and described the adjudicators’ expertise (eg. expert 
stroke physician).  
Low reporting quality: did not report the information used to make the reference 
standard diagnosis and/or did not report adjudicators’ expertise.  
d) If participants were excluded from the final analysis, were they described 
and were the reasons for this exclusion explained? 
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High reporting quality: reported the numbers excluded from the final analyses 
and the reason(s), or there were no exclusions.               
Low reporting quality: did not report the numbers excluded from the final 
analyses and the reason(s). 
e) Were uninterpretable/intermediate results reported? 
High reporting quality: ‘uncertain’ diagnoses were reported (eg. if there was 
‘insufficient information in the medical record to make a diagnosis, and/or it was 
reported if ‘possible strokes’ were included in the‘confirmed stroke’ category.)  
Low reporting quality: no reporting of ‘uncertain’ results.   
 
2) Assessment of generalisability (to UK population ) 
a) Country: was the study UK based? 
High generalisability: UK based population.  
Low generalisability: non UK based population.  
b) Population selected: was the spectrum of patients selected representative of 
the patients who will receive the diagnosis in practice? 
High generalisability: the study included patients diagnosed and treated in a 
representative mixture of specialist and non specialist settings, and the population 
was otherwise relatively unselected.  
Low generalisability: the study was performed in a more selected population (eg. 
restricted to patients admitted to a specialist stroke unit, where coding 
performance might be higher).  
Unclear: insufficient published information. 
c) Reference standard: were the same clinical data available when test results 
were interpreted as would be available when used in practice? 
High generalisability: medical record data (extracts or full record) including brain 
imaging data (original scans/written reports). Brain imaging would be used in 
current practice to exclude stroke mimics/diagnose stroke subtypes.  
Low generalisability: brain imaging (original scans/reports) not available. 
      Unclear generalisability: insufficient published information.  
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3) Assessment of risk of bias 
a) Selection bias: did the whole sample, or a random selection of the sample  
receive verification by the reference standard?                  
Low risk of bias: The whole sample/random selection of the sample received 
verification using medical records/physician questionnaire.*            
High risk of bias: some of the sample did not receive verification because 
reference standard data were missing* (missing records/unreturned 
questionnaires).                                                                                
Unclear risk of bias: insufficient information published.                                
* It is assumed that if the reference standard was a prospectively generated, 
expert led, population based stroke register, which used multiple sources of 
case ascertainment and confirmation, that this reference standard is 
‘complete’ (ie. it is unlikely to have missed ‘true positive’ stroke cases). 
b) Blinding: were the reference standard results interpreted without 
knowledge of the results of the index test?  
Low risk of bias: blinding present, or the referenc standard diagnosis was 
made prior to the study (eg., the reference standard w s a prospectively 
generated stroke register) 
High risk of bias: blinding not present, or not reported.  
c) Independence: was the reference standard independent of the index test? 
Low risk of bias: the reference standard was independent of the index test.  
High risk of bias: the index test formed part of the reference standard (eg. 
coded diagnoses were used to identify stroke cases for a population based 
register, and there was no further confirmation). 
d) Differential verification: did all patients receive the same reference 
standard regardless of the index test result? 
Low risk of bias: yes  
High risk of bias: some/all code positive cases received different reference 
standards from code negative cases eg. stroke code positive cases not present 
in a stroke register (potential false positive cases) were selected for 
subsequent medical record review, but stroke code negative cases present in 
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stroke register  (potential false negative cases) did not have subsequent 
medical record review. 
e) Reference standard: is the reference standard likely to correctly classify 
the target condition? 
Low risk of bias: the reference standard was likely to identify all hospital 
admitted strokes (plus strokes in the community for death certificate codes), 
AND, was either based on an expert (neurologist or tr ke physician) 
reviewing the full medical record, or was based on a non expert (eg. research 
assistant, research nurse, or ‘adjudicator’) following clearly described rules 
(eg. using CT reports to exclude stroke mimics or using CT reports to 
differentiate haemorrhage from ischaemic stroke, where applicable).  
High risk of bias: the study validated death certificate codes and the reference 
standard was not population based (and therefore risk d misclassifying true 
strokes diagnosed out of hospital as false positive codes), and/or the diagnosis 
was made by a non expert and there was not a clear protocol to exclude stroke 
mimics, or to differentiate haemorrhagic from ischaemic stroke.          
Unclear: insufficient published data.   
f) Timing: was the time period between the referenc standard and the 
index test short enough to be reasonably sure that the target condition did 
not change between the two tests?                 
Low risk of bias: The information used to make the reference standard 
diagnosis was the same as the information used at the time of coding.       
High risk of bias: The information used to make the ref rence standard 
diagnosis was not the same as the information used at the time of coding.  
Unclear: insufficient published data.  
 
2.7.12 Strategy for data synthesis 
We will cross classify coded stroke diagnoses with the reference standard diagnosis 
(‘stroke’ versus ‘non stroke’).   
PPV (%) = true positive codes / [true positive codes + false positive codes] x 100 
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NPV (%) = true negative codes / [true negative codes + false negative codes] x 100 
True positive codes = coded diagnosis ‘stroke’ and reference standard ‘stroke’. 
False positive codes = coded diagnosis ‘stroke’ and reference standard ‘non stroke’. 
True negative codes = coded diagnosis ‘non-stroke’ and reference standard ‘non 
stroke’. 
False negative codes= coded diagnosis ‘non stroke’ and reference standard ‘stroke’.  
Where the reference standard is population based, w will construct standard 2x2 
tables describing binary test results (coded diagnosis ‘stroke’ and coded diagnosis 
‘non stroke’) cross classified with binary referenc standard results (‘stroke’ and 
‘non stroke’). We will use this data to calculate sen itivity, specificity, PPV, NPV, 
and 95% confidence intervals. We will tabulate results for visual inspection to assess 
the influence of individual code selection, diagnostic position, and code source on 
the PPV, sensitivity, specificity and NPV of coded data for stroke/its main types. 
Where possible, and to limit the impact of between study heterogeneity, we will use 
within study as well as between study comparisons.   
We will assess heterogeneity between studies by inspection of tabulated data. 
We will not quantify publication bias as there is no assessment applicable to test 
accuracy.  
2.7.13 Dissemination plans 
We will present our findings at local, national and i ternational meetings. We plan to 
publish a full paper in a peer reviewed scientific journal.
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Chapter 3 Accuracy of patient self-report of 
stroke: a systematic review 
• The UK Biobank baseline assessment included participant self-report of 
stroke. 
• Self-report may be a useful method to ascertain and co firm potential stroke 
cases in UK Biobank. 
• In this chapter, I report the results of a systematic review of the accuracy of 
patient self-report of stroke.  
• I used a comprehensive search strategy, critically appraised study quality, 
and assessed factors affecting self-report accuracy. 
• I found that characteristics of the study population strongly influenced 
reporting accuracy.  
• In populations with low stroke prevalence (<10%), a large proportion of 
self-reported strokes (~1/3 to ~3/4) were false positive. 
• I concluded that self-report was unlikely to be helpful in identifying stroke 
cases in UK Biobank without further confirmation.  
 
3.1 Introduction 
Self-report of stroke may be a useful method to ascertain and confirm potential 
stroke cases among UK Biobank participants. Participants with confirmed stroke 
before or at the time of UK Biobank recruitment would have ‘prevalent stroke’. 
Participants who go on to develop stroke during follow-up would either have 
‘recurrent stroke’ (if they also had a past history f stroke), or ‘incident stroke’ (if 
their first-in-a-lifetime stroke event occurred during UK Biobank follow-up). For 
large prospective studies, like UK Biobank, disease outcomes need to be identified 
with adequate sensitivity (the proportion of true stroke cases which are identified by 
participant self-report), and with adequate Positive Predictive Value, PPV (the 
proportion of self-reported cases which are true cases of stroke). PPV depends on 
sensitivity, specificity (the number of true negative non stroke controls identified), 
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and stroke prevalence. Table 3.1 shows how sensitivity, specificity, PPV, NPV, and 
stroke prevalence are calculated.    
Table 3.1 Calculation of Sensitivity, Specificity, Positive Predictive Value (PPV), Negative 
Predictive Value (NPV), and stroke prevalence*. 
 
*Stroke prevalence is calculated by (TP+FN) / (TP+FN+TN) 
Maximising PPV will limit the number of false positive cases included in future 
nested case cohort or case control studies in UK Biobank of the associations between 
risk factors, stroke, its main types, and subtypes. Maximising PPV will, in turn, 
minimise loss of statistical power through misclassification of cases. False negatives 
can be tolerated more easily in nested case cohort/case control studies because they 
are diluted by the larger control population (therefo  the focus for UK Biobank is on 
maximising PPV and minimising false positives).  
3.1.1 Self-report of stroke in UK Biobank  
At recruitment to UK Biobank, participants completed a detailed questionnaire which 
included the question ‘Has a doctor ever told you that you have had a stroke?’ 
Positive responses or unclear answers were confirmed in a brief nurse led interview. 
Based on this questionnaire, the prevalence of stroke in UK Biobank at recruitment 
was ~1.4%.(http://biobank.ctsu.ox.ac.uk/crystal) The British Heart Foundation 
estimated UK stroke prevalence up to 2010, based on data from general practice 
records. (Townsend et al. 2012) Stroke prevalence was between 2 and 3.5% 
depending on region (England, Scotland, Wales), and ge er. Prevalence of stroke in 
UK Biobank is expected to be lower than UK wide stroke prevalence due to the fact 
that study participants are healthier than the population as a whole (‘healthy cohort 
103 
Chapter 3: Accuracy of patient self-report of stroke.  
effect’).(Table 1.1, Lindsted et al. 1996) UK Biobank aims to use multiple 
overlapping sources of data to identify potential stroke cases (maximising 
sensitivity), and to confirm true cases of stroke, and/or its pathological types 
(maximising PPV). Potential self-reported cases are likely to need further 
confirmation in order to maximise PPV. There have be n no previous systematic 
reviews of the accuracy of patient self-report of stroke. It is known that self-report 
accuracy varies according to the disease reported.(Harlow and Linet 1989)  
3.2 Aims 
To assess the potential contribution of participant self-report to the identification, 
and/or confirmation of stroke in UK Biobank (prevalent and/or incident cases), I 
performed a systematic review of published studies assessing the accuracy of patient 
self-report of stroke against a reference standard for stroke (using WHO, or 
equivalent definitions). I focussed on PPV, but also recorded, where possible, the 
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3.3 Methods  
A detailed study protocol is presented in Appendix 3.7 
3.3.1 Search strategy 
Using a combination of medical subject heading and text word terms for ‘stroke’, 
‘self-report’, ‘accuracy’, ‘medical records’ and ‘diagnosis’, I searched Medline and 
Embase to November 2013 for studies assessing the accuracy of self-report of stroke 
against a reference standard diagnosis of stroke.(Appendix 3.7.2) I also searched the 
Cochrane Database of Systematic Reviews for relevant reviews of diagnostic test 
accuracy of stroke self-report. Bibliographies of included publications were reviewed 
to identify any additional relevant studies. I asses ed eligibility by reviewing all titles 
and abstracts, and the full text of potentially relevant articles, and resolved any 
uncertainties through discussion with my supervisor, Professor Cathie Sudlow.  
3.3.2 Eligibility criteria 
I included studies which assessed the accuracy of patient self-report of stroke (with 
or without transient ischemic attack [TIA], or synonyms for either) against a 
reference standard diagnosis of stroke. I hypothesised that asking about TIA (or its 
synonyms) might increase sensitivity for stroke, and so I also included studies which 
compared self-report of stroke or TIA against a refer nce standard of stroke. 
Included studies had to report the method of self-repo t, the reference standard used 
(any combination of hospital/primary care medical record review, hospital/primary 
care physician questionnaire, expert clinical examination, or hospital/population 
based stroke registers), and the positive predictive value (PPV) +/- sensitivity, 
specificity, negative predictive value (NPV) of self-report (or provide data from 
which these values could be calculated, as shown in Table  3.1, above). I excluded 
studies which assessed self-report of ‘cerebrovascul r disease’, ‘symptoms’ or ‘past 
medical history’ unless stroke was specifically mentioned. I also excluded studies 
which used only coded data (e.g. International Classification of Diseases codes) as 
the reference standard to confirm cases, studies which did not distinguish confirmed 
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stroke cases from transient ischaemic attack (TIA) or other cerebrovascular disease, 
and, to improve precision, studies with <50 self-reported strokes. 
3.3.3 Data extraction 
I extracted information from each included study on: the nature of the population 
surveyed (country, age range, selection criteria); number of participants included and 
response rate (proportion of potential participants who agreed to take part and 
completed questionnaires or attended interviews); question(s) asked (stroke, or stroke 
plus TIA/synonyms); mean (or median) age at self-repo t; recall period (years or 
lifetime); reference standard(s) used and source of data (‘hospital’ which includes 
only hospital diagnosed strokes, or ‘population’ which includes strokes diagnosed in 
the community); presence or absence of missing data; presence or absence of 
blinding of adjudicators (physicians or researchers who established the reference 
standard diagnosis) to participant self-report; presence or absence of differential 
verification (use of different reference standards for self-report positive versus self-
report negative responses); PPV, sensitivity, specificity and NPV of self-report; 
number of reports of stroke which were confirmed TIAs. 
3.3.4 Data analysis 
I tabulated results for visual inspection to assess factors which might influence the 
accuracy of self-report including: estimated stroke pr valence; age at self-report 
(mean or median); recall time (years); question asked (stroke or stroke plus 
TIA/synonyms). Where possible, I used within study comparisons to assess the 
influence of age, recall time and question(s) asked on the accuracy of self-report. The 
denominator population was the final number of participants (excluding non 
responders) for whom complete reference standard data were available. Stroke 
prevalence was the number of ‘true strokes’ (TP+FN) divided by the denominator 
population (TP+FP+FN+TN). I only calculated sensitivity, specificity and stroke 
prevalence when the reference standard was population based (i.e. included general 
practitioner medical records, general practitioner questionnaires, or physician 
assessment of all participants, to capture strokes diagnosed out of hospital). 
I assessed risk of bias at individual study level using the revised Quality Assessment 
of Diagnostic Studies tool (QUADAS-2), (Whiting et al. 2011) but did not exclude 
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studies on the basis of bias assessments. Risk of bias was scored as ‘low’, ‘high’, or 
‘unclear’ in response to specific questions which considered patient selection (study 
design, sampling methods, exclusion criteria); index test (self-report questionnaire 
design, blinding to the reference standard); reference standard (source of data, 
blinding to self-report status); flow and timing (participant response rates, missing 
reference standard data, presence of differential verification). The study protocol 
(Appendix 3.7.11) provides a detailed list of questions and scoring methods. 
I calculated 95% confidence intervals for PPV, sensitivity, specificity, and NPV in 
Stata version 12 using the Wilson method for binomial proportions. I did not 
undertake formal meta-analysis or meta-regression due to the heterogeneity between 
studies in their methods, participant characteristics and reporting, and because the 
number of studies available for inclusion in any potential meta-regression analysis 
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3.4 Results  
From 1707 publications identified, I reviewed 148 full texts, and eventually included 
17 studies (Figure 3.1) 
 
Figure 3.1Study selection flow diagram 
*Reference standard is cerebrovascular disease, or includes TIA, or uses ICD codes for stroke. 
 †<50 self-reports of stroke validated, or number unpublished. 
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3.4.1 Characteristics of included studies 
Characteristics of included studies are displayed in Table 3.2. Studies were from the 
UK,(Walker et al. 1998, Britton et al. 2012, O'Mahony et al. 1995) elsewhere in 
Europe, (Machon et al. 2013, Fourrier-Reglat et al. 2010, Kriegsman et al. 1996, 
Engstad 2000, Bots et al. 1996) Japan,(Yamagishi et al. 2009) North 
America,(Simpson et al. 2004, Jin et al. 2010, Colditz et al. 1986, Okura et al. 2004, 
Heckbert et al. 2004, Bergmann et al. 1998) Australia,(Barr et al. 2009) and New 
Zealand.(Teh et al. 2013) Potential participants were s lected based on geographic 
location and/or age in all studies. The age of potential participants ranged from >20 
to >80 years old. Additional selection criteria in some studies included gender, 
(Walker et al. 1998, Simpson et al. 2004, Colditz et al. 1986, Heckbert et al. 2004) 
occupation,(Britton et al. 2012, Colditz et al. 1986) presence or absence of disability, 
(Kriegsman et al. 1996, Simpson et al. 2004) absence of moderate/severe cognitive 
impairment,(Walker et al. 1998, Simpson et al. 2004) place of residence,(Kriegsman 
et al. 1996) or medication use (non-steroidal anti-inflammatory drug 
prescription).(Fourrier-Reglat et al. 2010) 
Responses were ascertained by post,(Walker et al. 1998, Britton et al. 2012, 
O'Mahony et al. 1995, Fourrier-Reglat et al. 2010, Engstad 2000, Yamagishi et al. 
2009, Colditz et al. 1986, Okura et al. 2004, Heckbrt et al. 2004) during routine 
outpatient visits,(Machon et al. 2013) by face-to-face interview,(Kriegsman et al. 
1996, Simpson et al. 2004, Jin et al. 2010, Heckbert et al. 2004, Bergmann et al. 
1998, Barr et al. 2009, Teh et al. 2013) or by telephone.(Machon et al. 2013) 
Response rates were ≥80% in five studies,(Walker et al. 1998, O'Mahony et al. 1995, 
Machon et al. 2013, Kriegsman et al. 1996, Barr et al. 2009)] 60–79% in six,(Britton 
et al. 2012, Bots et al. 1996, Yamagishi et al. 2009, Simpson et al. 2004, Jin et al. 
2010, Bergmann et al. 1998) and <60% in three (23–57%).(Fourrier-Reglat et al. 
2010, Okura et al. 2004, Teh et al. 2013) The remaining three studies did not report 
response rates.(Engstad 2000, Colditz et al. 1986, Heckbert et al. 2004) Four studies 
compared characteristics of responders to non responders.(O'Mahony et al. 1995, 
Fourrier-Reglat et al. 2010, Okura et al. 2004, Barr et al. 2009) The two largest 
studies (including 10,000 and 120,000 potential participants) found that responders 
were older than non responders and more often female,(Fourrier-Reglat et al. 2010, 
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Barr et al. 2009) but absolute differences were small ( ean age 2 or 3 years higher, 1 
or 6% more females). 
Six studies asked participants to report ‘stroke’,(Walker et al. 1998, Bots et al. 1996, 
Simpson et al. 2004, Jin et al. 2010, Barr et al. 2009, Teh et al. 2013) five to report 
‘stroke, mini-stroke or transient ischemic attack (TIA)’,(Britton et al. 2012, 
O'Mahony et al. 1995, Okura et al. 2004, Heckbert et al. 2004, Bergmann et al. 1998) 
and three to report stroke, but including stroke synonyms in the question (cerebral 
haemorrhage/brain haemorrhage/infarction/thrombosis/subarachnoid 
haemorrhage).(Machon et al. 2013, Engstad 2000, Yamagishi et al. 2009) All but 
three studies published the specific question(s) asked.(Fourrier-Reglat et al. 2010, 
Kriegsman et al. 1996, Colditz et al. 1986) The period of recall ranged from six 
months to 5 years in five studies,(Britton et al. 201 , Jin et al. 2010, Colditz et al. 
1986, Heckbert et al. 2004, Barr et al. 2009) 10 to 22 years in three studies,(Walker 
et al. 1998, Yamagishi et al. 2009, Bergmann et al. 1998) and was lifetime in the 
remaining nine.(O'Mahony et al. 1995, Machon et al. 2013, Fourrier-Reglat et al. 
2010, Kriegsman et al. 1996, Engstad 2000, Bots et al. 1996, Simpson et al. 2004, 
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Table 3.2:Characteristics of included studies 
 Patient selection* Index test† (self-report) 
 
Reference standard Flow and timing 
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 Patient selection* Index test† (self-report) 
 












































































































































































Stroke/TIA: Has a doctor ever told you that you hada stroke, mini stroke or Transient Ischemic Attack (TIA)? 
Stroke +1: Do you have or have you ever had a stroke or cerebral haemorrhage? 
Stroke +2: Have you ever been told by a physician th t you have or have had a stroke, cerebral thrombosis, r cerebral haemorrhage? 
Stroke+3: Have you ever been told by a physician tht you had a stroke, cerebral haemorrhage, cerebral infarction, or subarachnoid haemorrhage? 
Stroke+5: Have you ever had a stroke, cerebral haemorrhage, cerebral thrombosis, brain haemorrhage, subarachnoid haemorrhage, or cerebrovascular accident?  
*The majority of included studies randomly sampled participants from within their chosen sampling frame.  
†None of the studies reported if self-report was interpreted blind to the reference standard diagnosis.  
‡Recall period for self-report of incident stroke. ‘Lifetime’= self-report of stroke at any time prior to recruitment to a study.  
§Source of reference standard data. Population: primary care medical records +/- general practitioner questionnaires +/- population based stroke registers +/- clinical 
examination of all participants. Hospital: hospital b sed records only +/- hospital physician questionnaire.  
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¶Yes: the reference standard diagnosis was made blind to self-report status. Unclear: not clearly reported. No: the reference standard diagnosis was made unblind to 
self-report status, or blinding was jeopardised (history and examination of participants, or differential verification).  
**  Proportion of potential participants who agreed to take part, completed and returned questionnaires, o  attended interviews.  
†† Yes: participants excluded from the final analysis due to missing reference standard data, or because the r ference standard diagnosis was ‘unclear’. Unclear: 
insufficient information published. No: reference standard data complete for all participants. 
‡‡Prescribed Celecoxib, Rofecoxib, or traditional non-selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). 
§§General Practitioner questionnaire only.  
¶¶Amongst these participants ~58% of GPs responded with questionnaire data. 
*** Population stroke register. Medical records were re- xamined if a patient reported stroke but the regist r was negative.  
†††Excluded those with ‘severe mental or physical disability’. 
‡‡‡General Practitioner questionnaire. Primary care records were re-examined for evidence of stroke if a patient reported stroke but the GP did not (apparent false 
positive cases). 
§§§Excluded residential or nursing home residents. 
¶¶¶Excluded participants with moderate or severe cognitive mpairment. 
****  Final sample included participants with cognitive impairment and a random sample without cognitive impairment. 
††††In this study, physicians took a history from patien s. Results of history and physical examination were used, in addition to medical record review, to determine 
the final diagnosis (presence or absence of stroke).  
‡‡‡‡ Source of the reference standard was coded hospital data plus medical record review or GP questionnaire. If self-report or coded data were positive for stroke, a 
committee reviewed data abstracted from medical records. If self-report was positive for stroke and hospital data were unavailable, GP questionnaire was requested. 
§§§§Self-report included prevalent events (baseline questionnaire) plus additional prevalent or incident events (3 year follow-up telephone interview). 
¶¶¶¶Validation included physician history and examination of patients who self-reported stroke. The final reference standard diagnosis was made by expert 
consensus using multiple sources of information. Good medical records took precedence over the physician diagnosis at home visit. 
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The reference standard was population based (primary care data, primary care plus 
hospital data, and/or clinical examination of all participants) in thirteen 
studies,(Okura et al. 2004, Walker et al. 1998, Britton et al. 2012, O'Mahony et al. 
1995, Machon et al. 2013, Fourrier-Reglat et al. 2010, Kriegsman et al. 1996, 
Engstad 2000, Bots et al. 1996) and hospital based (hospital data only) in 
four.(Colditz et al. 1986, Heckbert et al. 2004, Bergmann et al. 1998, Barr et al. 
2009) Stroke was confirmed by general practitioner questionnaire,(Fourrier-Reglat et 
al. 2010, Kriegsman et al. 1996) medical record review,(Machon et al. 2013, Bots et 
al. 1996, Colditz et al. 1986, Okura et al. 2004, Heckbert et al. 2004, Bergmann et al. 
1998, Barr et al. 2009) presence on a stroke register plus medical record 
review,(Yamagishi et al. 2009) clinical examination plus medical record 
review,(Engstad 2000) or a combination of these methods.(Walker et al. 1998, 
Britton et al. 2012, O'Mahony et al. 1995, Simpson et al. 2004, Jin et al. 2010, Teh et 
al. 2013) Stroke prevalence ranged from 0.1%-17% in ten studies which used a 
population based reference standard and published sufficient data to estimate 
prevalence.(Walker et al. 1998, O’Mahony et al. 1995, Machon et al. 2013, Fourrier-
Reglat et al. 2010, Kriegsman et al. 1996, Yamagishi et al. 2009, Simpson et al. 2004, 
Jin et al. 2010, Okura et al. 2004, Teh et al. 2013)   
3.4.2 Assessment of bias 
Detailed results of the bias assessment are displayed in Table 3.3. All studies had 
‘high’ or ‘unclear’ risk of bias in at least one category. Incomplete reference standard 
data (missing or irretrievable records),(Walker et al. 1998, O'Mahony et al. 1995, 
Fourrier-Reglat et al. 2010, Kriegsman et al. 1996, Engstad 2000, Bots et al. 1996, 
Simpson et al. 2004, Jin et al. 2010, Colditz et al. 1986, Bergmann et al. 1998, Barr 
et al. 2009, Teh et al. 2013)  absence of blinding of adjudicators to self-report status, 
(Walker et al. 1998, Britton et al. 2012, O'Mahony et al. 1995, Engstad 2000, 
Yamagishi et al. 2009,  Jin et al. 2010),  and participant response rates 
(<80%),(Britton et al. 2012, Fourrier-Reglat et al. 2010, Bots et al. 1996, Yamagishi 
et al. 2009, Simpson et al. 2004, Jin et al. 2010, Okura et al. 2004, Teh et al. 2013, 
Bergmann et al. 1998)  were the most frequent reasons for ‘high risk’ of bias. 
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Only five studies reported that adjudicators were blind to participant self-report 
results.(Fourrier-Reglat et al. 2010, Kriegsman et al. 1996, Colditz et al. 1986, Barr 
et al. 2009, Teh et al. 2013) In six, presence or absence of blinding was not clearly 
reported.(Machon et al. 2013, Bots et al. 1996, Simpson et al. 2004, Okura et al. 
2004, Heckbert et al. 2004, Bergmann et al. 1998) In one study, the reference 
standard diagnosis was made following physician examin tion of patients, unblinded 
to self-report status.(Jin et al. 2010) In five other studies blinding was jeopardised 
because the reference standard included history and examination of 
patients,(O'Mahony et al. 1995, Engstad 2000) or because records of apparent false 
positive reports were re-examined for evidence of str ke.(Walker et al. 1998, Britton 
et al. 2012, Yamagishi et al. 2009) In one of these studies, re-examination of records 
of apparent false-positive reports led to confirmation of a few additional stroke cases, 
and increased the PPV of patient self-report from 41% (95% CI 35–48) to 56% (95% 
CI 49–62). 
The self-report method most often scored ‘unclear’ risk of bias. Three studies did not 
publish the specific question(s) asked,(Fourrier-Reglat et al. 2010, Kriegsman et al. 
1996, Colditz et al. 1986) and eight (which used face-to-face interviews) did not 
report presence or absence of blinding of the interviewer to the reference standard 
diagnosis.(Machon et al. 2013, Simpson et al. 2004, Jin et al. 2010, Heckbert et al. 
2004, Bergmann et al. 1998, Barr et al. 2009, Teh et al. 2013) 
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Rules for assessment of bias are displayed in Appendix.3.7.11. 































Reglat ☺ ☺ ☺   ?   ? ☺ ☺   ☺ 
Yamagishi
 
☺ ☺ ☺ ☺ ☺ ☺   ☺  
Walker
 
☺ ☺  ☺ ☺ ☺  ☺   
Kriegsman
 
  ?   ☺     ? ☺ ☺ ☺  ☺ 
Simpson
 
☺ ☺    ? ☺ ☺   ?     ? 
Jin
 
  ?   ☺    ? ☺ ☺      ? 
Engstad
 
☺ ☺ ☺ ☺ ☺ ☺    ?  ☺ 
Barr
 
☺ ☺ ☺   ? ☺  ☺ ☺  ☺ 
Bots
 
☺ ☺ ☺   ? ☺ ☺   ?     ? 
Britton
 
☺ ☺ ☺ ☺ ☺ ☺   ☺  
Colditz
 
  ?   ☺ ☺   ?   ?  ☺   ?  ☺ 
Teh
 
  ?  ☺ ☺   ? ☺ ☺ ☺   ☺ 
Machon
 
☺ ☺ ☺   ? ☺ ☺   ? ☺ ☺ ☺ 
O’Mahony ☺ ☺ ☺ ☺ ☺ ☺  ☺   
Heckbert
 
☺ ☺ ☺   ? ☺    ?   ?   ? ☺ 
Okura
 
☺ ☺ ☺ ☺ ☺ ☺   ?  ☺ ☺ 
Bergman
 
☺ ☺ ☺   ? ☺    ?   ☺ 
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*Was consecutive or random sampling used? 
†Was a case-control design avoided?  
‡Were inappropriate exclusions avoided?  
§Was self-report interpreted blind to the reference standard diagnosis?   
¶Was the test threshold (self-report positive versus self-report negative) pre specified?  
** Is the reference standard likely to correctly classify the target condition?  
††Was the reference standard diagnosis made blind to par icipant self-report status?  
‡‡Were all participants included in the analysis? 
§§Did all participants receive a reference standard? 
¶¶Did all participants receive the same reference standard? 
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Other sources of bias included use of hospital versus population based reference 
standards,(Colditz et al. 1986, Heckbert et al. 2004, Bergmann et al. 1998, Barr et al. 
2009) exclusion of particular types of participants (e.g. based on cognitive 
impairment, severe disability, or residence in a nursing home),(Walker et al. 1998, 
Kriegsman et al. 1996, Simpson et al. 2004, Jin et al. 2010) and differential 
verification of the reference standard (different da a used to verify self-report 
positive versus negative cases).(Walker et al. 1998, Britton et al. 2012, O’Mahony et 
al. 1995, Yamagishi et al. 2009) Most studies used a source of data (primary care 
records, general practitioner questionnaire, examintio  of all participants) which 
captured strokes diagnosed out of hospital.(Walker et al. 1998, Britton et al. 2012, 
O’Mahony et al. 1995, Machon et al. 2013, Fourrier-R glat et al. 2010, Kriegsman et 
al. 1996, Yamagishi et al. 2009, Engstad 2000, Botset al. 1996, Simpson et al. 2004, 
Jin et al. 2010, Okura et al. 2004, Teh et al. 2013) The remaining studies, which used 
hospital-based reference standards,(Colditz et al. 1986, Heckbert et al. 2004, 
Bergmann et al. 1998, Barr et al. 2009) had a higher risk of bias due to the potential 
for missing ‘true’ stroke cases diagnosed out of hospital. 
3.4.3 Accuracy of self-report 
PPV of self-report ranged from 22–87%. Among ten studies which used a population 
based reference standard, and had sufficient published data, sensitivity of self-report 
varied (from 36–98%), but specificity and NPV were consistently high (from 88 to 
99.9%) (Table 3.4).(O’Mahony et al. 1995, Machon et al. 2013, Fourrier-Reglat et al. 
2010, Kriegsman et al. 1996, Yamagishi et al. 2009, Simpson et al. 2004, Jin et al. 
2010, Okura et al. 2004, Teh et al. 2013) The proportion of self-reported strokes 
which were not strokes but confirmed to be TIAs (according to the reference 
standard) ranged from 6–25% among six studies with available relevant data.(Walker 
et al. 1998, O’Mahony et al. 1995, Machon et al. 2013, Bots et al. 1996, Colditz et al. 
1986, Teh et al. 2013) In these studies, if these confirmed TIAs were considered to be 
true rather than false positive stroke cases, the revised PPV was >75% in all but one 
study (Table 3.5). 
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3.4.4 Factors influencing accuracy 
The range of PPVs for self-report was similar in the studies with very low response 
rates (<60%),(Fourrier-Reglat et al. 2010, Okura et l. 2004, Teh et al. 2013) to that 
of studies with higher response rates (≥60%).(Walker et al. 1998, O’Mahony et al. 
1995, Machon et al. 2013, Kriegsman et al. 1996, Yamagishi et al. 2009, Engstad 
2000, Bergmann et al. 1998) Overall, the range of PPVs appeared similar in blinded, 
(Fourrier-Reglat et al. 2010, Kriegsman et al. 1996, Engstad 2000, Colditz et al. 
1986, Barr et al. 2009) versus unblinded studies,(Walker et al. 1998, Jin et al. 2010) 
and in population based,(O’Mahony et al. 1995, Machon et al. 2013, Fourrier-Reglat 
et al. 2010, Kriegsman et al. 1996, Engstad 2000, Yamagishi et al. 2009, Bots et al. 
1996, Simpson et al. 2004, Jin et al. 2010, Okura et al. 2004, Teh et al. 2013) versus 
hospital based studies.(Colditz et al. 1986, Heckbert et al. 2004, Bergmann et al. 
1998, Bots et al. 1996)  
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Table 3.4 PPV, sensitivity, specificity and NPV of self-report* (all included studies). 
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* Table 3.1 Shows how PPV, sensitivity, specificity, and NPV were calculated.  
†Unless otherwise stated, the study population is the number of participants (non responders excluded) for whom reference standard data was available. If ft 
blank, the study only compared participants who self-reported stroke (TP+FP) against the reference standard.  
‡These values were published as percentages. 
§It was not possible to calculate sensitivity, specificity, or NPV in this study because validation was performed in a very small selected sample of the self-report 
negative (‘no-stroke’) participants.  
¶In these studies, although the source of reference standard data was population based (GP questionnaire i cluded to capture strokes diagnosed out of hospital), only 
those participants who self-reported stroke (‘stroke positive’ participants), plus a very small proportion of self-report negative (‘no-stroke’) were valid ted. There 
was insufficient data published to calculate sensitivity, specificity, NPV, or stroke prevalence.  
** Calculated using published PPV, sensitivity, and number of strokes confirmed by medical record review. 
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Table 3.5 The proportion of self-reported strokes which were true stroke, true TIA, or either. 
 
Stroke prevalence 





Figure 3.2 Influence of stroke prevalence on the PPV of self-report of stroke 
x/y: x = number of self-reported strokes which are confirmed; y = total number of self-reported 
strokes 
Participant age. 
Among studies which reported the average age of responders (mean or 
median),(O’Mahony et al. 1995, Fourrier-Reglat et al. 2010, Engstad 2000, Jin et al. 
2010, Okura et al. 2004, Barr et al. 2009, Teh et al. 2013) we noted increasing PPV 
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with increasing reporting age, probably because stroke prevalence increased with age 
(Table 3.6). Among five studies which published aget the time of self-report, and 
had sufficient data to calculate sensitivity,(O’Mahony et al. 1995, Fourrier-Reglat et 
al. 2010, Jin et al. 2010, Okura et al. 2004, Teh et al. 2013) the study with the highest 
mean participant age (84 years) had the lowest sensitivity for stroke (sensitivity 36%, 
95% CI 28–44).(Teh et al. 2013) Sensitivity of self-r port was stratified by age 
within one large study (~90,000 participants),(Yamagishi et al. 2009) and fell with 
increasing age (78% in those <75 years versus 69% in those ≥75 years). A similar 
pattern was observed in a second, smaller study (~1,536 participants. with 
sensitivities of 60% in those < 75 years versus 48% in those ≥ 75 years).(Jin et al. 
2010) However, limited data for sensitivity as well as heterogeneity between studies 
in population characteristics meant that it was not possible to demonstrate a clear 
association between reporting age and sensitivity. 
 
Table 3.6 The influence of age on PPV, Sensitivity, Specificity and NPV of self-report 
 
Question(s) asked. 
Overall, there was no clear difference in PPV or sensitivity between studies which 
asked about ‘stroke’ versus ‘stroke plus synonyms’ versus ‘stroke/TIA’.(Walker et 
al. 1998, Britton et al. 2012, O’Mahony et al. 1995, Machon et al. 2013, Kriegsman 
et al. 1996, Engstad 2000, Yamagishi et al. 2009, Simpson et al. 2004, Jin et al. 2010, 
Okura et al. 2004, Heckbert et al. 2004, Bergmann et al. 1998, Teh et al. 2013)  
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However, among included studies there were no within study comparisons of the 
influence of the question(s) asked on PPV or sensitivity of stroke self-report. 
 
Recall time. 
In between study comparisons, recall of events overthe last six months to one year 
(PPV 72% to 81%),(Jin et al. 2012, Heckbert et al. 2004) was not clearly more 
accurate than recall of events over the previous 2 to 5 years (PPV 38% to 
78%),(Britton et al. 2012, Colditz et al. 1986, Barr et al. 2009) or over lifetime (PPV 
22% to 87%).(Machon et al. 2013, Kriegsman et al. 1996, Fourrier-Reglat et al. 
2010, Engstad 2000, Bots et al. 1996, Simpson et al. 2004, Okura et al. 2004, Teh et 
al. 2013) Two studies stratified PPV results by recall time, and neither found a 
difference in PPV for more versus less recent events.(Yamagishi et al. 2009, Barr et 
al. 2009) One of these studies (~ 90,000 participants) found no difference in 
sensitivity for more versus less recent events.(Yamagishi et al. 2009
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3.5 Discussion 
As far as I am are aware this is the first systematic review of the accuracy of patient 
self-report of stroke. Self-report had variable PPV (range 22 to 87%) and variable 
sensitivity (range 36 to 98%) for stroke, but consistently high specificity and NPV 
(88 to 99%). In populations with low stroke prevalenc , it would take a very large 
number of false positives to reduce specificity or NPV. PPV and sensitivity are 
therefore more informative measures. PPV increased with increasing stroke 
prevalence. Although this relationship is not surprising, we have shown that in 
populations with low stroke prevalence (<10%), a large proportion of self-reported 
strokes (~1/3 to 3/4) were false positive. This has important implications for large 
prospective studies, where stroke prevalence is likely to be low. 
Reviews of the accuracy of self-report of various diseases have found that PPV and 
sensitivity vary depending on the disease reported.(Harlow and Linet 1989) For 
certain diseases, such as myocardial infarction, or cancer, a large proportion of false 
positive self-reports occur because patients confuse the diagnosis with a similar 
condition (e.g. other cardiovascular disease, or other cancer type).(Paganini-Hill and 
Chao 1993) Similarly, we found that 6–25% of indiviuals who self-reported stroke 
had a reference standard diagnosis of TIA. If doctors or other health professionals 
used the term ‘mini-stroke’ when referring to TIA, the patient may be misled into 
thinking they had had a stroke. Grouping of stroke and TIA cases might be 
acceptable for some research questions (e.g. those which explore common risk 
factors for stroke and TIA combined). If both TIA and stroke were considered true 
positive, the PPV of self-report of stroke (or stroke/TIA) was higher. 
Other research questions require accurate identification of stroke, and accurate 
exclusion of TIA cases, (e.g. those which explore risk-factors associated with the 
different pathological types and subtypes of stroke). However, there is no ‘gold 
standard’ diagnosis for stroke. The classic ‘sympto-based’ definition of stroke 
relies on symptom duration (>24 hours) to distinguish stroke from TIA.(Hatano 
1976) A newer ‘tissue-based’ definition has been proposed, which relies on the 
presence of brain infarction to diagnose stroke, irr spective of symptom duration 
(<24 hours),(Albers et al. 2002) but application of this rule reclassifies cases of ‘TIA 
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with infarction’ as stroke. Although physicians (exp rt and non expert) are 
inconsistent in diagnosing stroke using ‘symptom-based’ definitions,(Ferro et al. 
1996b) the ‘tissue-based’ definition is equally susceptible to inter-observer 
variation.(Fiebach et al. 2002, Wardlaw and Mielke 2005, Brown et al. 2003a) 
Accurate diagnosis of brain infarction depends on the choice and timing of imaging, 
and on reviewer expertise.(Fiebach et al. 2002, Wardlaw and Mielke 2005) The 
‘tissue-based’ definition is therefore likely to beparticularly susceptible to variation 
when applied across different settings (with different brain imaging 
resources).(Brown et al. 2003a) To maintain consistency, we excluded studies which 
used the ‘tissue-based’ definition from our review. However, as new definitions and 
diagnostic terms continue to emerge, this lack of consistency will contribute to the 
misreporting of stroke (as TIA and vice versa) by patients and their physicians. 
Previous primary studies have assessed the influence of gender, cognitive 
impairment, education, and number of co-morbidities on the accuracy or reliability of 
stroke self-report, with variable and sometimes conflicting results.(Kriegsman et al. 
1996, Engstad 2000, Simpson et al. 2004, Jin et al.2010, Okura et al. 2004, 
Bergmann et al. 1998, Teh et al. 2013) However, it is difficult to draw overall 
conclusions because a range of different methods were used to analyse data and 
present results. 
We observed a wide range in PPV and sensitivity of self-report, which is likely to 
reflect between study heterogeneity in both population characteristics and study 
design. Reassuringly, only a few studies had low response rates (<60%). While this 
may have introduced selection bias, the accuracy (range of PPVs) of self-report was 
not clearly affected by response rates. Neither was there any clear effect of 
incomplete blinding on the range of PPVs. The majority f included studies had 
missing reference standard data.(Walker et al. 1998, O’Mahony et al. 1995, Fourrier-
Reglat et al. 2010, Kriegsman et al. 2006, Engstad 2000, Bots et al. 1996, Simpson et 
al. 2004, Jin et al. 2010, Colditz et al. 1986, Bergmann et al. 1998, Barr et al. 2009, 
Teh et al. 2013) Although this is an important source of potential bias, incomplete 
reporting meant that it was not possible to assess the influence of missing reference 
standard data on the PPV and/or sensitivity of self-report. The reference standard 
used (hospital versus population based) was an additional potential source of bias. 
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Studies which excluded cases diagnosed out of hospital from their reference standard 
had a higher chance of misclassifying ‘true stroke cases’ as ‘false positive’ reports, 
and so of underestimating PPV. However, we did not fi d a difference in the overall 
accuracy of self-report (PPV) between hospital based and population based studies. 
Strengths of this study include our thorough search strategy, adherence to published 
guidelines for test accuracy reviews,(deVet et al. 2008) and inclusion of all relevant 
studies of stroke self-report. Although we only searched two online databases, a 
strategy which may have missed potentially relevant articles, we augmented our 
search by screening bibliographies of all included publications. Bibliography 
screening may be the most effective method of identfyi g additional relevant articles 
in systematic reviews of test accuracy.(Whiting et al. 2008) Additional strengths of 
our review include the exclusion of studies which failed to distinguish TIA from 
stroke in the reference standard, use of a single stroke definition (WHO),(Hatano 
1976) and exclusion of studies which used coded data as he only source of stroke 
confirmation. 
There were some limitations. First, variation in the accuracy and completeness of the 
reference standard may have contributed to between study variation in PPV and 
sensitivity. To improve comparability between studies, we only calculated 
sensitivity, specificity, NPV, or stroke prevalence when the reference standard was 
population based. This was possible in ten out of seventeen included studies. 
However, only two included studies used the most robust population based reference 
standard for stroke,(Sudlow and Warlow 1996) with multiple sources of case 
ascertainment and confirmation.(Britton et al. 2012, O’Mahony et al. 1995) Second, 
the true sensitivity of self-report is likely to belower than the included studies 
suggest, since non responders could not be included in the denominator population 
(non response ranged from 10–77% amongst included studie ). Third, incomplete 
reporting and limited within study comparisons of ppulation characteristics (such as 
age, gender, education, cognitive impairment, comorbidities) made it difficult to 
assess the influence of these individual factors on elf-report PPV or sensitivity. 
Fourth, as discussed above, there is no gold standard test to diagnose stroke or TIA. 
132 
Chapter 3: Accuracy of patient self-report of stroke.  
Lack of consistency in determining the ‘true’ diagnosis is likely to have contributed 
to the wide range of reported PPV, sensitivity and stroke prevalence. 
Further work is needed to assess and compare multiple overlapping sources of stroke 
detection in large epidemiological studies. Some studies have found that self-report 
increases the number of potential strokes detected ( ompared to hospital or primary 
care data).(Britton et al. 2012, Heckbert et al. 2004) However, it is uncertain whether 
using self-report is time- or cost-effective for stroke case detection in large 
prospective studies, because potential strokes would need to be confirmed, for 
example by medical record review. In addition, future work should examine the 
influence of the question asked on PPV and/or sensitivity of stroke report. We did 
not find a clear influence of the questions asked on PPV or sensitivity, but there were 
no within study comparisons of stroke specific question  versus stroke/TIA or stroke 
synonyms. Establishing the best list of questions (to improve disease specific 
sensitivity or PPV) will be important for future questionnaire design. Future work 
could also consider the influence of new stroke definitions (where used), and more 




Based on the results of this study, I suggest that self-report of stroke may be a useful 
screening tool to identify potential stroke disease in prospective studies, but not 
accurate enough on its own to confirm cases. Once potential cases are identified, a 
subsequent confirmation step using other data sources will also be required. The 
influence of stroke prevalence on PPV means that in studies with low stroke 
prevalence, like UK Biobank, a large proportion of p tential strokes identified by 
self-report may be false positives.
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3.7 Appendix 
3.7.1  Review Question(s) 
Primary Question 
Accuracy (Positive Predictive Value) of patient self-r port of stroke (for example by 
self administered questionnaire, or face-to-face int rview) for a diagnosis of stroke 
(using WHO or equivalent definitions) in an adult population.   
Secondary Questions 
A. Sensitivity and specificity of patient self-report f stroke (amongst studies where 
the reference standard is population-based).  
B. Influence of stroke prevalence on the accuracy (PPV) of self-report of stroke 
(amongst studies where the reference standard is population based).  
C. Accuracy (Positive Predictive Value) of patient self-report of stroke for a 
diagnosis of Transient Ischaemic Attack (TIA).  
D. Influence of the question(s) asked (for example stroke, or stroke plus TIA, or 
stroke plus TIA/synonyms for either) on the accuracy (PPV, sensitivity, specificity) 
of self-report of stroke. 
E. Influence of period of recall (for example lifetme history versus more recent 
events) on the accuracy (PPV, sensitivity, specificity) of self-report of stroke. 
F. Influence of participant age (mean, years) on the accuracy (PPV, sensitivity, 
specificity) of self-report of stroke.  
3.7.2 Searches 
We will search the following databases from inception to the date of search: 
MEDLINE (Ovid SP); 
EMBASE (Ovid SP) 
Cochrane Register of Diagnostic Test Accuracy Studies 
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We will review bibliographies of included publications for any additional relevant 
articles. 
MEDLINE search strategy 
1. cerebrovascular disorders/ or exp basal ganglia cerebrovascular disease/ or exp 
brain ischemia/ or exp carotid artery diseases/ or exp cerebral small vessel diseases/ 
or exp intracranial arterial diseases/ or exp "intracranial embolism and thrombosis"/ 
or exp intracranial hemorrhages/ or stroke/ or exp brain infarction/ or stroke, lacunar/ 
or vertebral artery dissection/ 
2. (stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or apoplex$ or 
isch?emi$ attack$ or tia$ or SAH).tw. 
3. ((brain$ or cerebr$ or cerebell$ or cortical or ve tebrobasilar or hemispher$ or 
intracran$ or intracerebral or infratentorial or supratentorial or MCA or anterior 
circulation or posterior circulation or basal ganglia) adj5 (isch?emi$ or infarct$ or 
thrombo$ or emboli$)).tw. 
4. ((brain$ or cerebr$ or cerebell$ or intracerebral o  intracran$ or parenchymal or 
intraventricular or infratentorial or supratentorial or basal gangli$ or subarachnoid or 
putaminal or putamen or posterior fossa) adj5 (haemorrhage$ or hemorrhage$ or 
haematoma$ or hematoma$ or bleed$)).tw. 
5. 1 or 2 or 3 or 4 
6. questionnaires/ or self report/ 
7. self concept/ or self-assessment/ or self disclosure/ or diagnostic self evaluation/ 
8. Interviews as Topic/ 
9. Medical History Taking/ 
10. truth disclosure/ 
11. (self-report$ or questionnaire$).tw. 
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12. (patient$ adj5 report$).tw. 
13. 6 or 7 or 8 or 9 or 10 or 11 
14. "reproducibility of results"/ or "sensitivity and specificity"/ or "predictive value 
of tests"/ 
15. (positive predictive value or sensitivity or specificity).tw. 
16. (agreement or validity or reliability or reproducibility or accuracy or accurate or 
concordance).tw. 
17. 14 or 15 or 16 
18. 5 and 13 and 17 
19. records as topic/ or hospital records/ or exp medical records/ or nursing records/ 
20. exp Diagnosis/ 
21. ((diagnosis or diagnosed or history) adj5 stroke).tw. 
22. ((hospital or GP or medical or general practitioner or health) adj5 (record or 
records)).tw. 
23. cerebrovascular disorders/di or exp basal ganglia cerebrovascular disease/di or 
exp brain ischemia/di or exp carotid artery diseases/di or exp cerebral small vessel 
diseases/di or exp intracranial arterial diseases/di or exp "intracranial embolism and 
thrombosis"/di or exp intracranial hemorrhages/di or stroke/di or exp brain 
infarction/di or stroke, lacunar/di or vertebral artery dissection/di 
24. 19 or 20 or 21 or 22 or 23 
25. 18 and 24 
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EMBASE search strategy 
1. cerebrovascular disease/ or basal ganglion hemorrhage/ or exp brain hematoma/ or 
exp brain hemorrhage/ or exp brain infarction/ or exp brain ischemia/ or exp carotid 
artery disease/ or cerebral artery disease/ or cerebrovascular accident/ or exp 
occlusive cerebrovascular disease/ or exp stroke/ 
2. stroke unit/ or stroke patient/ 
3. (stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or apoplex$ or 
isch?emi$ attack$ or tia$ or SAH).tw. 
4. ((brain$ or cerebr$ or cerebell$ or cortical or ve tebrobasilar or hemispher$ or 
intracran$ or intracerebral or infratentorial or supratentorial or MCA or anterior 
circulation or posterior circulation or basal ganglia) adj5 (isch?emi$ or infarct$ or 
thrombo$ or emboli$)).tw. 
5. ((brain$ or cerebr$ or cerebell$ or intracerebral o  intracran$ or parenchymal or 
intraventricular or infratentorial or supratentorial or basal gangli$ or subarachnoid or 
putaminal or putamen or posterior fossa) adj5 (haemorrhage$ or hemorrhage$ or 
haematoma$ or hematoma$ or bleed$)).tw. 
6. 1 or 2 or 3 or 4 or 5 
7. self-report/ or exp questionnaire/ or exp intervi w/ 
8. self concept/ or self evaluation/ or self discloure/ 
9. health assessment questionnaire/ or health perceptions questionnaire/ or 
interpersonal communication/ 
10. anamnesis/ or medical history/ 
11. (self-report$ or questionnaire$).tw. 
12. (patient$ adj5 report$).tw. 
13. 7 or 8 or 9 or 10 or 11 or 12 
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14. "sensitivity and specificity"/ 
15. exp validity/ or exp reliability/ or reproducability/ or accuracy/ or predictive 
value/ 
16. (positive predictive value or sensitivity or specificity).tw. 
17. (agreement or validity or reliability or reproducibility or accuracy or accurate or 
concordance).tw. 
18. 14 or 15 or 16 or 17 
19. 6 and 13 and 18 
20. medical record/ or medical record review/ or electronic medical record/ 
21. exp diagnosis/ 
22. ((diagnosis or diagnosed or history) adj5 stroke).tw. 
23. cerebrovascular disease/di or basal ganglion hemorrhage/di or exp brain 
hematoma/di or exp brain hemorrhage/di or exp brain infarction/di or exp brain 
ischemia/di or exp carotid artery disease/di or cerebral artery disease/di or 
cerebrovascular accident/di or exp occlusive cerebrovascular disease/di or exp 
stroke/di 
24. ((hospital or GP or medical or general practitioner or health) adj5 (record or 
records)).tw. 
25. 20 or 21 or 22 or 23 or 24 
26. 19 and 25 
3.7.3 Types of study to be included 
We will include studies in any adult population (cohort studies, case control studies, 
or clinical trials) which compare the self-report of stroke against a reference standard 
diagnosis of stroke (WHO, or equivalent definitions).    
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Studies are required to report the Positive Predictive Value of participant self-report 
(or data from which this can be calculated).  
Studies should use a reference standard of ‘stroke’ (distinguished from transient 
ischaemic attack or generalised cerebrovascular disease) when calculating PPV, 
sensitivity, and specificity. 
We will exclude studies which assess < 50 self-report d strokes (due to limited 
precision).  
3.7.4 Condition or domain being studied 
Index test:  Self-report of stroke, or ‘stroke plus TIA’, or ‘stroke plus 
TIA/synonyms for either’ by any method (questionnaire or interview).  
Studies should include the term ‘stroke’ in their questionnaire or interview. This 
excludes studies which assess self-report of symptos, ‘cerebrovascular disease’, or 
past medical history for stroke.  
3.7.5 Participants/population 
Any adult population. 
We will not exclude studies based on participant selection criteria (eg. age, 
cardiovascular risk, education, cognitive impairment, disability).  
We have specified secondary questions which will examine the influence of 
participant characteristics (eg. age and stroke prevalence) on the accuracy of self-
report. 
3.7.6 Interventions, exposures 
Reference standard:  We accept that the inter-observer reliability of stroke 
diagnosis is imperfect, even amongst experts. In the absence of a true ‘gold standard’ 
for stroke, we will include studies which use any of the following reference standards 
for stroke: clinical examination; physician questionnaire; medical record review 
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(primary care and/or hospital records); stroke regist rs (informed by multiple 
overlapping data sources, ‘hot pursuit’, and expert medical record review).  
To improve accuracy we will exclude studies which use coded data (eg. International 
Classification of Diseases codes) for the reference standard, unless other methods 
(above) are also used.  





The principle criterion is self-report of stroke. We aim to inform approaches to stroke 
ascertainment in large population based studies.   
Depending on the design of the study, the measure of interest could be self-report of 
prevalent (lifetime stroke) or incident (since recruitment) events. We have pre 
specified questions to see if the accuracy of self-report varies by length of recall 
time. 
In UK Biobank, participants were asked to self-report stroke by questionnaire, and 
answers were later confirmed during a brief nurse led interview. We will include 




We will calculate Positive Predictive Value (PPV) of self-report for stroke in all 
included studies using the available published data. 
Secondary outcomes 
In studies which use population-based reference standards, we will calculate 
Sensitivity, Specificity, PPV, and stroke prevalenc using 2x2 contingency tables. 
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The reference standard will be grouped into hospital based versus population based 
according to the following definitions: 
Population based: a reference standard which identifies strokes diagnosed out of 
hospital, and therefore captures as many ‘true’ strokes in the participant population 
as possible; primary care medical records; general practitioner questionnaires; 
population-based stroke registers (informed by expert m dical record review); 
physician assessment of all participants.  
Hospital based: a reference standard which only identifi s hospitalised strokes; 
hospital medical records; hospital physician questionnaires; hospital based stroke 
registers (informed by expert hospital record review).  
3.7.10 Data extraction (selection and coding) 
We will extract data onto study specific proforma. 
Covariates of interest: 
- Study author 
- Country 
- Population selection criteria (eg. random or consecutive sampling, 
inclusions/exclusion criteria) 
- Self-report method (postal questionnaire, telephone interview, face-to-face 
interview) 
- Question(s) asked  
- Participant response rates (% population who agree to take part, complete 
questionnaires, and/or attend interviews). 
- Participant age at self-report (mean, median or range).  
- Length of recall time (years, or lifetime) 
- Reference Standard used (eg., medical records, phy ician questionnaire and 
whether hospital or population based) 
- Number(s) included in final analysis (2x2 table, or true positive versus false 
positive self-reported strokes for PPV calculation).  
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- Number(s) excluded from analysis (eg. because of inc mplete reference standard 
data).  
- Blinding (to self-report status for determination f the reference standard diagnosis) 
 
3.7.11 Risk of bias (quality) assessment 
We will assess methodological quality using the revis d Quality Assessment of 
Diagnostic Accuracy Studies tool (QUADAS-2). We will focus on assessment of 
bias questions rather than generalizability. 
Modified QUADAS-2 questions for assessment of bias:  
1) Patient selection 
a) Sampling method: was consecutive or random sampling used? 
Low risk of bias: consecutive or random sampling was used. Unclear risk of bias: 
insufficient information published. High risk of bias: did not use consecutive or 
random sampling. 
b) Study design: was a case-control study design avoided? 
Low risk of bias: case-control design avoided. High risk of bias: case-control design 
used. Unclear risk of bias: insufficient information published. 
c) Population included: were inappropriate exclusions avoided? 
Low risk of bias: inappropriate exclusions were avoided. High-risk of bias: 
participants were excluded based on characteristics which might influence self-report 
accuracy (eg, education level, cognitive impairment, disability.) Unclear risk of bias: 
insufficient information published. 
2) Index test (self-report) 
a) Interpreted blind: was the index test interpreted without knowledge of the 
reference standard diagnosis?  
Risk of bias depends on the degree of interpretation of the index test (self-report) and 
the presence/absence of blinding to the reference standard diagnosis. Low risk; a 
‘yes/’no’ answer given by the participant in a self-administered questionnaire, 
irrespective of blinding; self-report by face-to-face interview and blinding present. 
Unclear risk: more than a ‘yes’/’no’ answer in a self-administered questionnaire and 
blinding not reported; a ‘yes’/’no’ answer in a face-to-face interview and blinding 
not reported; question(s) asked not published. High risk: more than a ‘yes’/’no’ 
answer in a face-to-face interview and blinding eith r not reported or not present; 
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more than a ‘yes’/’no’ answer in a self-administered questionnaire and blinding not 
present; face-to-face interview by medically trained professional, irrespective of 
blinding. 
b) Was the threshold pre-specified? 
Selecting the test threshold to optimize sensitivity/specificity may lead to 
overestimation of test performance. Low risk of bias: the question(s) asked were 
published and the answers accepted as positive self-report (e.g., stroke/stroke plus 
TIA/stroke plus TIA plus synonyms for either) were specified at the outset. Unclear 
risk of bias: the question(s) asked were not published but it was specified at the 
outset which answers were accepted as positive self-report. High risk of bias: the 
question(s) asked were not published and it was not pecified at the outset which 
answers were accepted as positive self-report. 
3) Reference standard 
a) Source of data: is the reference standard likely to correctly classify the target 
condition? 
Low risk of bias: the reference standard was ‘population-based’ and included ‘true 
stroke’ cases diagnosed out of hospital. Unclear risk of bias: insufficient information. 
High risk of bias: the reference-standard was ‘hospital-based’ and excluded ‘true 
stroke’ cases diagnosed out of hospital.  
b) Blind to self-report: were reference standard results interpreted without 
knowledge of results of the index test? 
Low risk of bias: the reference standard diagnosis wa made blind to self-report 
results. Unclear risk of bias: blinding not reported. High risk of bias: the reference 
standard diagnosis was made with knowledge of self-report results.  
4) Flow and timing 
a) Participant response rates: were all patients included in the analysis? 
Low risk of bias: participant response rates >80%. High risk of bias: participant 
response rates <80%. Unclear risk of bias: participant response rates not reported.  
b) Missing data: did all patients receive a reference standard? 
Low risk of bias: reference standard data available for all responding participants.  
Unclear risk of bias: insufficient information published.  High risk of bias: 
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responding participants excluded from the final analysis due to missing reference 
standard data or because the final reference standard diagnosis was ‘unclear’.  
c) Differential verification: did all patients receive the same reference standard? 
Low risk of bias: the same reference standard was used for all participants. Unclear 
risk of bias: different reference standards were used but it was unclear if this differed 
by self-report status. High risk of bias: a different reference standard was used if 
participants self-reported stroke (vs. self-reported no-stroke).  
d) Was there an appropriate interval between the index test and the reference 
standard? 
This question was excluded from our study because the time interval between the 
index test (self-report) and reference standard (‘tue’ diagnosis of stroke versus non-
stroke) did not influence the accuracy of the original diagnosis (which was made 
historically). The time interval could influence the availability of reference standard 
data, but this aspect of bias was already captured in question 4b (above).  
 
3.7.12 Strategy for data synthesis 
We will cross classify self-reported strokes with the reference standard diagnosis 
(‘stroke’ versus ‘non-stroke’).   
PPV (%) = true positive reports / [true positive reports + false positive reports] x 100 
True positive reports = self-report ‘stroke’ and refe nce standard ‘stroke’. 
False positive reports = self-report ‘stroke’ and refe ence standard ‘non-stroke’. 
Where the reference standard is population based, w will construct standard 2x2 
tables describing binary test results (self-report ‘st oke’ and self-report ‘non-stroke’) 
cross classified with binary reference standard results (‘stroke’ and ‘non-stroke’).  
We will use this data to calculate sensitivity, specificity, PPV, and 95% confidence 
intervals. Stroke prevalence will be calculated using ‘total reference standard stroke’/ 
‘final included population’.  
We will tabulate results for visual inspection to assess the influence of participant 
age, question(s) asked, recall time, and stroke prevalence on the PPV, sensitivity 
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and/or specificity of self-report. Where possible, and to limit the impact of between-
study heterogeneity, we will use within-study as well as between-study comparisons.   
We will assess heterogeneity between studies by inspection of tabulated data. 
We will not quantify publication bias as there is no assessment applicable to test 
accuracy.  
3.7.13 Dissemination plans 
We will present our findings at local, national and i ternational meetings. We plan to 
publish a full paper in a peer-reviewed scientific journal.
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Chapter 4 Reliability and feasibility of 
ischaemic stroke classification 
systems for large epidemiological 
studies: a systematic review 
• Ischaemic stroke subtypes may differ in the strength of their risk factor 
associations. Very large prospective studies, with large numbers of 
anticipated stroke outcomes, are required to reliably test these associations.  
• Ischaemic stroke classification systems are ‘anatomical’ or ‘mechanistic’. 
• An ideal ischaemic stroke classification system for UK Biobank would 
classify large numbers of ischaemic stroke cases to a single underlying 
mechanism without compromising reliability. It would be scalable and 
applicable in different clinical settings. 
• In this chapter I report my systematic review of the reliability of existing 
ischaemic stroke classification systems.   
• I used a comprehensive search strategy, critically appraised study quality, 
assessed factors which affected reliability, and repo ted the proportion of 
cases which were assigned to ‘undetermined cause’. 
• Reliability of classification varied widely, reflecting heterogeneity of study 
settings as well as the classification system(s) used.  
• I found that clear rules, data abstraction protocols, computer based 
classification and fewer categories all improved reliability. 
• There was insufficient evidence to suggest that newer ischaemic stroke 
classification systems were superior to older, more established systems.   
• I conclude that no single system is fit for every purpose, and recommend 
multiple approaches to ischaemic stroke classificaton in UK Biobank.  
 
4.1 Introduction 
The main types and subtypes of stroke are complex clinical conditions with multiple 
shared common risk factors. However, evidence is increasingly emerging that these 
distinct conditions are likely to differ in the strength of their risk factor associations 
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and in their causal pathways. (Jackson et al. 2010, Jackson and Sudlow 2006, Doubal 
et al. 2009, O'Donnell et al. 2010, Asia Pacific Cohort Studies Collaboration 2005, 
Biffi et al. 2010) Detecting potential differences in the strength of associations 
between shared common risk factors, such as blood pressure, and the risk of stroke 
types and sub-types requires very large observational studies, often with thousands of 
clinical outcomes for adequate statistical power.(Burton et al. 2009) The different 
outcomes also need to be classified accurately becaus  misclassification reduces 
power to detect potential differences in the strength of associations between 
them.(Jaffar et al. 2003b, Choi et al. 2002b) UK Biobank offers the perfect 
opportunity to explore the complex determinants of the main types and subtypes of 
stroke because of the detailed baseline assessment (collecting accurate information 
on a wide range of potential exposures and covariates), he large numbers of 
anticipated cases, and the planned detailed process f stroke detection, confirmation 
and sub-classification.   
In this chapter I focus on exploring the best potential method of classifying 
confirmed ischaemic stroke cases into their main pathological subtypes. 
4.1.1 Existing ischaemic stroke classification syst ems 
In clinical practice, ischaemic stroke classification depends largely on an individual 
physician’s judgement rather than clearly defined rules, which is likely to generate 
variability and possibly systematic biases.  Observational studies and clinical trials 
have developed rule based systems to improve the reliability of ischaemic stroke 
classification. The main approaches use either the presenting clinical syndrome to 
predict infarct site and size; ‘anatomical classificat on’, or use the presenting clinical 
syndrome plus results of investigations to identify the underlying pathological 
mechanism of infarction; ‘mechanistic classification’. Figure 4.1 displays the main 
approaches to ischaemic stroke classification. 
The Oxford Community Stroke Project (OCSP) is the main ‘anatomical’ method of 
ischaemic stroke classification (Bamford et al. 1991) It predicts the vascular territory 
of infarction with up to 75% accuracy based on clini al features at the time of 
presentation.(Mead et al. 2000) The four main subtypes of OCSP classification are 
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Total Anterior Circulation Stroke (TACS), Partial Anterior Circulation Stroke 
(PACS), Posterior Circulation Stroke (POCS), and Lacunar Stroke (LACS). Brain 
imaging is used to enhance accuracy, but is not an absolute requirement for 
classification.(Potter et al. 2010) When brain imaging is used, OCSP reliably 
distinguishes ‘small vessel disease’ strokes (LACS) from ‘large vessel disease’ 
strokes (TACS, PACS, POCS). Although it distinguishe  small vessel disease from 
large vessel disease, it does not identify the main mechanisms which cause large 
vessel ischaemic stroke, for example cardiac embolism or large artery 
atherosclerosis. 
Mechanistic classification systems can be either ‘single cause’, assigning the single 
most likely stroke mechanism, or ‘descriptive’, describing the contribution of each 
mechanism to the stroke, which means that multiple diff rent mechanisms can be 
considered and, if felt appropriate, can be classified with equal contribution to the 
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Figure 4.1 The main approaches to ischaemic stroke classification 
*Mechanistic classification requires investigation of the three main mechanisms of ischaemic stroke: Large rtery atherosclerosis (LAA), Cardiac Embolism (CE), 
and Small artery Occlusion (SAO).  
†Anatomical classification is based on the presenting clinical syndrome, but brain imaging may be used to improve accuracy.  
‡Trial of Org 10172 in Acute Stroke Treatment classification.  
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§Causative Classification System.  
¶The single cause mechanistic system ‘ASCO1’ is derived from the descriptive classification system ‘A-S-C-O’: Atherosclerosis, Small vessel disease, Cardiac 
source, Other cause classification. ‘ASCO1’ classifie  to a ‘single cause’ when a single mechanism has ‘gr de 1’ evidence (eg A1, S1, C1 or O1). Cases ar 
‘undetermined’ by ASCO1 if there is more than one ‘grade 1’ mechanism, no ‘grade 1’ mechanism, or any ‘grade 9’ mechanism.  
** Oxfordshire Community Stroke Project classification. 
††Complete investigation requires that minimum investigations have been performed to evaluate every mechanism routine blood tests, brain imaging, cardiac 
investigations, evaluation of the extra +/- intracranial blood vessels. Additional investigations may be required if other rare causes (Oth) are considered likely. 
‡‡Due to multiple potential mechanisms.  
§§Distinction between LACS and PACS is up to 20% inaccurate when based on the clinical syndrome alone. 
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The TOAST (Trial of Org 10172 in Acute Stroke Treatment) system is the most 
established ‘single cause’ mechanistic method. It classifies infarcts into one of four 
determined categories: Large Artery Atherosclerosis (LAA), Cardiac Embolism 
(CE), Small artery occlusion (SAO), or Other (Oth) when clinical presentation, 
imaging and ancillary investigations point to a single underlying cause.  If two or 
more potential mechanisms are present, cases are assigned to an ‘undetermined’ 
category: ‘unclassified due to multiple potential mechanisms’.(Adams et al. 1993) 
The total proportion of cases undetermined by single cause mechanistic classification 
systems is the proportion unclassified due to multiple potential mechanisms, 
incompletely investigated, or unknown despite complete investigation. Up to 50% of 
cases are ‘undetermined’ by TOAST.(Ay 2010) A large ‘undetermined’ proportion is 
a significant disadvantage because these cases are often excluded from research 
studies. Exclusion of large numbers of outcomes limits statistical power and, 
depending on the research question, may introduce cas  selection bias.   
The Causative Classification System (CCS)(Ay et al. 2005a) is a more recently 
developed ‘mechanistic’ classification system. This modified version of TOAST uses 
a hierarchy of evidence to decide between ‘multiple otential mechanisms’ where 
they exist, and assign a single mechanism. It aims to reduce the undetermined 
proportion, compared to TOAST, without compromising the reliability of 
classification.(Ay et al. 2007) 
A third major ‘single cause mechanistic system’ is ASCO1 (Atherosclerosis, Small 
Artery Disease, Cardiac Embolism, Other-1). ASCO1 is derived from A-S-C-O (a 
descriptive mechanistic system).(Amarenco et al. 2009b) A-S-C-O considers each 
potential mechanism of ischaemic stroke separately. It assigns a score to each 
mechanism, Atherosclerosis (A), Small artery disease (S), Cardiac embolism (C), or 
Other (O), depending on the presence or absence of disease and the contribution of 
that disease to the incident stroke (1 for potentially causal, 2 for causality is 
uncertain, 3 for unlikely causal but the disease is present, 0 for absence of 
disease, and 9 for insufficient workup to rule out the disease). ASCO1 is the 
‘single cause mechanistic’ counterpart of A-S-C-O.  ASCO1 classifies to a ‘single 
cause’ when a single mechanism has scored level 1 evidence for ‘potentially causal’ 
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(eg. A1, S2-3/0/9, C2-3/0/9, or O2-3/0/9). Cases are ‘undetermined unclassified’ by 
ASCO1 if there are multiple potentially causal mechanisms present (eg., A1 and 
S1/C1/O1), ‘undetermined unknown’ if there is no potentially causal mechanism 
(eg., score 2, 3 or 0 for all mechanisms), or ‘undetermined-incomplete investigation’, 
if any mechanism is incompletely investigated (‘score 9’ for any mechanism).  
The main descriptive mechanistic systems are A-S-C-O (as described above), and 
phenoyptic CCS. This version of CCS describes the contribution of each potential 
mechanism (large artery disease, cardiac embolism, small artery occlusion, other) to 
the incident stroke, described as: major disease; minor disease; absent disease; 
incompletely investigated.(Arsava et al. 2010) These systems have a very large 
number of descriptive categories (e.g. using A-S-C-O, a single case could be 
classified to any one of 625 potential categories).  
4.1.2 Reliability and agreement  
Reliability and agreement (terms often used interchangeably) are ways of 
demonstrating reproducibility: the degree to which repeated measurements in stable 
study objects provide similar results. Reliability measures how well objects can be 
distinguished from each other despite measurement errors, while agreement assesses 
exactly how close the scores for repeated measurements are.(de Vet et al. 2006) 
There are various measures of reliability depending o  the data format and nature: 
the kappa statistic (measure of ‘true agreement’ i.e. proportion of agreement beyond 
that expected by chance) used for nominal and ordinal ata; ranked intra-class 
correlation used for ordinal data; and intra class correlation coefficient used for 
continuous data.(Kottner et al. 2011) Results of reliability and agreement studies 
provide information about the amount of error inherent in a classification which in 
turn may affect its validity.(Kottner et al. 2011). 
4.1.3 Aims 
In this chapter I report a systematic review of published studies of ischaemic stroke 
classification systems, with the aim of identifying a feasible approach for ischaemic 
stroke classification in UK Biobank. An ideal classification system for large scale 
use would assign the maximum number of cases to a single determined subtype 
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without sacrificing reliability or positive predictve value, and would be robust to 
variations in the investigations performed in different clinical settings. It would 
perform well retrospectively, using clinical data routinely available in the UK, and 
the results would be reproducible between multiple observers across multiple centres.  
My focus here is on the inter-observer reliability of ischemic stroke classification 
systems and the factors which affect these measures. I as ess the inter- and/or the  
intra-observer reliability of ischaemic stroke classification systems in any human 
adult population with confirmed ischaemic stroke. Due to the importance of the 
undetermined proportion and the development of newer classification systems which 
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4.2 Methods 
4.2.1 Search strategy 
I searched Ovid Medline and Embase (1990 to November 2013) for studies which 
assessed inter- or intra-observer reliability of ischaemic stroke classification systems 
in human adults (see Appendix 4.6.1). I included foreign language articles, obtaining 
translations were necessary.  I assessed eligibility y reviewing all titles and 
abstracts, and the full text of potentially relevant rticles, and resolved uncertainties 
through discussion with my supervisor, Professor Cathie Sudlow. 
4.2.2 Eligibility criteria 
I included studies which reported inter- and/or inta-observer reliability (kappa 
statistic) of an anatomical or mechanistic ischaemic stroke classification system. 
Studies had to: describe or reference the classification system; use CT or MR brain 
imaging to exclude intracerebral haemorrhage in the majority of cases (>80%); and 
report the proportion of cases excluded from analyses. I excluded studies published 
before 1990 (since clinical practice and classification systems have evolved 
substantially since then), duplicate studies (e.g. data published in abstract form if 
later published in full), studies assessing classification of ischaemic strokes in 
children (<18 years), or studies assessing classification systems in highly selected 
cases (e.g. those involving a particular vascular territory only). I excluded studies 
which reported the proportion of cases classified to mutually exclusive subtypes if 
they did not also report observer reliability (as inter/intra-observer reliability was the 
focus of my review). I accepted anatomical definitions if they referred to the vascular 
territory of an infarct and encompassed both anterior and posterior circulations. 
Mechanistic systems had to include large artery atherosclerotic (LAA), small artery 
occlusion (SAO) and cardio-aortic or cardio-embolic (CE) subtypes.  
4.2.3 Data extraction and synthesis 
I extracted information from included studies on the classification system(s) studied, 
number of cases classified, inclusion/exclusion of haemorrhagic strokes and stroke 
mimics, number of ratings made, inter- and intra-observer reliability, and the 
proportion of cases assigned to an undetermined subtype.  I extracted both the overall 
kappa statistic for reliability across all potential c tegories, and subtype kappa 
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statistics. For most classification systems, the subtype kappa measures the reliability 
of classifying one subtype versus any other, while for descriptive mechanistic 
systems it measures the reliability of grading the contribution of each separate 
mechanism to every case (Figure 4.1). The proportion of cases undetermined by 
single cause mechanistic classification systems was the proportion unclassified due 
to multiple potential mechanisms, incompletely investigated, or unknown despite 
complete investigation. 
I assessed potential risk of bias using criteria developed specifically for this study 
that I considered might influence reliability result  (presence/absence of blinding 
between observers, and involvement or not of authors or adjudicators in 
classification system development).  
Informed by the established Guidelines for Reporting Reliability and Agreement 
Studies (GRRAS),(Kottner et al. 2011) I summarised ad itional characteristics which 
might affect reliability including: population characteristics (country, population 
sampled, age range, case selection methods, time sinc  troke); observer 
characteristics (training in classification methods, single versus consensus 
observations, single versus multiple institutions, similar versus different expertise); 
data presented to adjudicators (clinical examinatio, original medical records, 
abstracted data, or a combination of sources), methods for assigning categories 
(number of categories used, use of data abstraction protocols and/or computer based 
assignment); and time between repeated observations.  
I displayed kappa statistics in tables and/or forest plots stratified by the classification 
system used, and, where possible, by characteristics (above) which might affect 
reliability. I also examined the influence of individual investigations performed and 
the level of detail of investigation on reliability and the proportion of cases allocated 
to an undetermined category. For all reliability comparisons, I focused on within 
study comparisons rather than using a meta-regression approach, due to substantial 
heterogeneity in all study characteristics, and because the required data for          
meta-analysis were unavailable for a substantial proportion of included studies. 
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4.3 Results 
From 1,105 publications identified, 29 studies were v ntually included (Figure 4.2). 
  
4.3.1 Study characteristics 
25 studies assessed the overall inter-observer reliability of one or more ischaemic 
stroke classification systems, three assessed subtype inter-observer reliability 
only,(Marnane et al. 2010, Chen, Zhou and Wang 2013, Johnson et al. 1995) and one 
assessed intra-observer reliability only.(Cotter, Belham and Martin 2012) Studies 
were performed in Europe (one UK-based), North America, Asia, Australia, and 
Iran. The main anatomical classification system tested was OCSP.(Heuschmann et al. 
1999, Asdaghi et al. 2011, Selvarajah et al. 2009, Hand et al. 2006a, Lindley et al. 
1993, Dewey et al. 2001) The main mechanistic classification systems tested were 
TOAST,(Ay et al. 2005a, Cotter et al. 2012, Kolominsky-Rabas et al. 2001, 
Selvarajah et al. 2009, Yip et al. 1997, Goldstein et al. 2001, Gordon et al. 1993, 
Meschia et al. 2006, Han et al. 2007, Zhou, Li and Wang 2005, Nam et al. 2012, 
Wolf et al. 2012) modified versions of TOAST,(Han et al. 2007, Ghandehari et al. 
2005, Atiya et al. 2003, Hajat et al. 2001, Fure, Wyller and Thommessen 2005, 
Johnson et al. 1995) CCS,(Ay et al. 2005a, Ay et al. 2007, Arsava et al. 2010, 
Marnane et al. 2010, Marnane, Duggan and Sheehan 2009) and                                
A-S-C-O/ASCO1.(Marnane et al. 2010, Cotter et al. 2012, Wolf et al. 2012, Chen et 
al. 2013) Sample sizes ranged from 14 to 416 (median 54, interquartile range 90). 
Only six studies tested two or more classification systems in the same population and 
with the same observers.(Ay et al. 2005a, Cotter et al. 2012, Selvarajah et al. 2009, 
Han et al. 2007, Nam et al. 2012, Ghandehari et al. 2005) There were no direct 
within study comparisons of observer reliability of CCS (final computerised version) 
versus that of TOAST (Table 4.1).   
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Figure 4.2 Selection of included studies 
*Systems which classified stroke severity, disability, or prognosis only, were excluded.  
†Two studies classified anterior circulation strokes, one classified strokes occurring post coronary 
artery bypass graft surgery.  
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‡One study tested classification based on clinical ex mination versus classification based on a list of 
symptoms.  
§Nine of these publications reported ‘subtype agreement’ in addition to ‘overall agreement’.  
¶Three studies tested more than one mechanistic ischaemic stroke classification system, three tested 
both an anatomical and a mechanistic classification system.  
** Eleven studies tested original TOAST, five studies tested modified versions of TOAST (TOAST 
rules were modified).  
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Ay 2007¶¶ CCS ×  US Hospital 
admissions 
50 64 R - - Multiple - A 5 months 
Arsava¶¶ 
 
CCS ×  US Hospital 
admissions 
 
50 64 R -  Multiple Both A - 
Heusch***  OCSP  - Germany Population 
register 
 
20 73 R 5 days - Single Single E 4 hours 
Asdaghi OCSP   Canada Hospital 
admissions 
 
130††† - P 5-10 hours - Single Single E‡‡‡ - 
Marnane 
2010§§§ 




70 R > 6 months - Single Single A - 
Marnane 
2009§§§ 
CCS  - Dublin Population 
register 
38 70 R - - - - A - 








106 49 P - - Single - - - 
Kolomin**  TOAST   Germany Population 
register 
 
20 73 R < 7 days to 
> 7 days 
 
 Single - E + MR 4 hours 
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Selvarajah TOAST,  OCSP   UK Outpatient 
clinics 
 
90 64 R 14 days  Single Single A - 
Yip TOAST  - Taiwan Hospital 
register 
35 - R - - Single Single MR - 
Goldstein TOAST ×  US Hospital 
admissions 
 
14-20 - R - - Single Single MR or A - 
Gordon TOAST × - US Hospital 
register 
18 - R -  Multiple Single A - 
Meschia TOAST   US Hospital 
admissions 
 
30 70 R -  Multiple Single MR - 
Han TOAST, 
MTOAST 
×  Korea Hospital 
register 
200 63 R -  Single Single MR - 
Zhou TOAST   China Hospital 
register 
 
300 - R - - Single Single MR - 
Nam TOAST × - Korea Hospital 
register 
 
70 67 R -  Single Single A - 
Wolf TOAST, A-S-C-O ×  Germany Hospital 
admissions 
 
103 69 P -  Single Single MR - 
Ghandehari MTOAST, Other  -  Iran Hospital 
admissions 
 
20 66 R - - Single Single A - 
Atiya MTOAST, Other    US Self-reported 
stroke 
 
104-133****,†††  >45 R - - Multiple Single MR - 






R - - Single Single A 8 Weeks 
Fure MTOAST   Norway Hospital 
admissions 
 
38 66 P -  Single Single E Same day 
Chen A-S-C-O   China Hospital 
register 
 
419 65 P -  Single Single MR - 
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Hand OCSP   UK Hospital 
admissions 




× Single Single E 56 minutes 
Lindley OCSP ×  UK Hospital 
admissions 
 
85††† - P 1 day × Single Single E Same day 
 
Dewey OCSP   Australia Multicentre 
register 
54 - P <10 days to 
>3 months 
 
 Single Single E 27 hours 





R - - Multiple Both MR 6-12 years 
 






R - - Multiple Consensus A - 
Flossman Other   UK Outpatients 
with MRI 
 
133††† 73 P - - Single Single E or A - 
 
 MTOAST: TOAST rules were modified. This excludes studies which added data abstraction protocols or computerised algorithms. 
*Study authors or adjudicators independent of classification system development. 
†Blinding between adjudicators 
‡ R: Cases selected retrospectively using medical records, P: Cases selected prospectively, meaning that cases were classified shortly after or during hospital 
admission, and it may have been possible to influence the investigations performed. 
§Time from stroke to classification. Range, unless otherwise specified. 
¶Adjudicators were trained prior to the study, or alre dy had experience using the classification system. 
** Adjudicators from the same (single) or multiple institutions (multiple). 
††Single: rating is performed by a single adjudicator. Consensus: rating is a consensus between 2 or more adjudicators. 
‡‡Data presented to adjudicators. MR: adjudicators obtained information from original medical records. E: direct clinical assessment by adjudicator including 
medical history and examination (with additional access to medical records or test results if required). A: case summaries or data extract prepared by an 
independent researcher. 
§§An earlier version of CCS, before the development of a computerised algorithm. 
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¶¶These publications used the same population of cases but different adjudicators in different study settings. 
*** These publications report the same study. 
†††In these studies a small percentage of cases (<20%) were due to transient ischaemic attack, intracerebral haemorrhage, or stroke mimic. 
‡‡‡Plus CT brain 
§§§These two publications report different results from the same study population: overall reliability (2009), subtype reliability (2010). 
¶¶¶ Intra-observer reliability only. 
**** 104 cases classified by modified TOAST, 133 classified by ‘other’ anatomical. 
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4.3.2 Overall inter-observer reliability 
Kappa for overall inter-observer reliability ranged from 0.53 to 0.93 for OCSP, 0.42 
to 0.95 for TOAST, 0.49 to 0.91 for modified TOAST systems, and 0.70 to 0.90 for 
CCS, with no published data for ASCO1 on this reliabi ty measure (Figure 4.3). 
OCSP and TOAST were assessed in six countries worldide, including the UK. CCS 
was assessed in four studies, three US based.(Ay et al. 2005a, Ay et al. 2007, Arsava 
et al. 2010) 
 
4.3.3 Assessment of bias 
Authors or adjudicators were involved in development of the classification system in 
11 studies.(Ay et al. 2005a, Ay et al. 2007, Arsava et l. 2010, Goldstein et al. 2001, 
Gordon et al. 1993, Han et al. 2007, Nam et al. 2012, Wolf et al. 2012, Hajat et al. 
2001, Lindley et al. 1993, Johnson et al. 1995) Blinding between observers was not 
reported by six studies.(Marnane, Duggan and Sheehan 2009, Heuschmann et al. 
1999, Cotter et al. 2012, Yip et al. 1997, Gordon et al. 1993, Nam et al. 2012) One or 
more observers were not blind to the other’s classificat on in two studies, but these 
did not contribute results for overall inter-observer reliability.(Marnane et al. 2010, 
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Figure 4.3 Overall inter-observer reliability of the main ischaemic stroke classification systems.* 
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Figure 4.3 Overall inter-observer reliability of the main ischaemic stroke classification systems.* 
Results displayed are for the twenty-three studies which assessed overall inter-observer reliability of one of the main ischaemic stroke classification 
systems (OCSP, TOAST, CCS, Table 4.1).  
The area of each circle is proportional to the study size.  
Horizontal lines represent 95% confidence intervals (where available).  
There were no overall reliability results for ASCO1. 
*Adjudications were performed by different combinations of observers in different studies. Some are single observations and others are a consensus 
opinion.  
†Study was independent if authors and adjudicators were not involved in classification system development. 
 ‡Presence or absence of inter-observer blinding.  
§The displayed value is based on the largest number of cases tested in a single study. If the same cases were tested more than once, an average is 
displayed, or the simplest classification was chosen (e.g., 5 versus 16 category CCS). Subgroup analyses (based on smaller numbers of cases) are not 
displayed in this table.  
¶All patients had CT brain scan and this was used in addition to the clinical syndrome for OCSP classification (31% had signs of early infarction on 
CT). 
** 14 cases were classified using original medical records, 17 using a data abstraction protocol and a computerised algorithm, and a further 20 using 
the same computerised algorithm and an updated data abs raction protocol. 
††Classification was based on clinical examination and results of investigations available on the first weekday after admission to hospital. 
‡‡An early version of CCS not using computer based assignment. 
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4.3.4 Factors affecting overall inter-observer reli ability 
Bias. Based on visual inspection of kappa results (Figure 4.3), there were no 
convincing effects on reliability of either observer independence from classification 
system development or blinding, but there were insufficient data to draw reliable 
conclusions. 
Presentation of information . Studies were too heterogeneous to assess the 
impact on reliability of classification based on direct assessment of the patient, their 
medical records, or abstracted data. 
Number of categories.  As expected, within study comparisons found that 
reliability was consistently higher with fewer categories (Table 4.2).  
Clear rules, data abstraction protocols and compute rised algorithms . 
Most classification systems have rules for assignin categories. Only one study 
included in this review did not have classification rules.(Berger, Kase and Buring 
1996) In this study, clinicians used their best judgement to assign cases. Reliability 
was lower in this study (kappa 0.34) compared to any other study included in this 
review (kappa range 0.42 to 1.00). Several within study comparisons found better 
reliability with less ambiguous (CCS versus TOAST) rules,(Ay et al. 2005a) or with 
a computerised algorithm to classify cases (Table 4.3), but sample sizes were small 
and 95% confidence intervals overlapped.(Goldstein et al. 2001, Nam et al. 2012) In 
three US based studies of CCS during different stage  of its development, reliability 
was consistently high (kappa > 0.80), irrespective of data extraction protocols or 
computer based assignment.(Ay et al. 2005a, Ay et al. 2007, Arsava et al. 2010) 
There were no within study comparisons of the reliability of the fully developed 
computerised version of CCS versus TOAST.   
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0.42 (0.32 to 0.53) 
0.29 (0.21 to 0.37) 





0.90 (0.80 to 1.00) 
0.86 (0.76 to 0.96) 






0.86 (0.81 to 0.91) 
0.85 (0.80 to 0.89) 













0.80 (0.78 to 0.81) 
0.79 (0.77 to 0.80) 







0.81 (0.79 to 0.82) 
0.79 (0.77 to 0.80) 











0.54 (0.39 to 0.68) 
0.43 (0.30 to 0.47) 
 
*An early version of CCS without the computerised algorithm  
†Refinements were made to the computer software to include better explanations of terms.  
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Table 4.3 Influence of data extraction method and computerised algorithms on reliability. 
Study  Cases Classification 
system 













0.42 (0.32 to 0.53) 
b) 17 Protocol + Computer 0.54 (0.26 to 0.82) 













0.69 (0.60 to 0.78) 
b) 70  Abstracted data + Computer 0.79 (0.71 to 0.87) 
 




















Protocol + Computer 
 










Protocol + Computer 
 
0.80 (0.78 to 0.81) 
b) 50   Protocol + Computer‡‡ 0.81 (0.79 to 0.82) 
 
*Protocol: Data abstracted by an independent research r using a protocol developed to minimise error. 
Computer: Classification by computerised algorithm.  
†If there was a choice based on different numbers of categories, the value corresponding to the 
smallest number of categories was chosen. 
‡ a), b) and c) are three different sets of cases, cla sified by different numbers of adjudicators. 
§If TOAST and a modified version of TOAST were tested in the same study, results are only 
presented for TOAST, unless the modification was the method of data extraction or the development 
of a computerised algorithm. 
¶ a) and b) are the same cases classified by the samadjudicators. 
** These studies were performed within the same research group, but on different case populations. 
††These studies are based on the same 50 cases but different groups of adjudicators were used. 
‡‡ a) and b) are using the same cases and the same adjudic tors. The computer software was updated 
in b) to reduce ambiguity. 
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Adjudicator expertise.  Three of four within study comparisons (total 197 cases) 
suggested that adjudicators with a similar level of expertise were more likely to agree 
than those with different training or expertise, while a fourth, smaller study (20 
cases) showed little difference (Table 4.4).(Hand et al. 2006a, Dewey et al. 2001)  
 
Table 4.4 Influence of adjudicator expertise on reliability 


















0.58 (0.43 to 0.72) 
b) 53‡ Mixed expertise 0.38 












0.53 (0.35 to 0.70) 
b) 54 Mixed expertise 0.31 (0.12 to 0.50) 













b) 45 Expert only 1.00 (1.00 to 1.00) 














0.86 (0.66 to 1.00) 
b) 20 Mixed expertise 0.90 (0.75 to 1.00) 
 
* Expert: adjudicators are consultant level stroke specialists, study authors have used the term ‘expert’ 
adjudicators, or adjudicators are physicians/neurologists at senior registrar or consultant level. Less 
expert: Physicians 1-4 years post registration, general practitioners, nurses, or medical students with
or without stroke training. Mixed expertise: combination of expert and less expert adjudicators. 
†If there was a choice based on different numbers of categories, the value corresponding to the 
smallest number of categories was chosen. 
‡b) and c) are subsets of a)  
§a), b) and c) are the same set of cases tested with three different pairs of adjudicators. 
¶The expert trained the ‘less expert’ adjudicator in th s pairing, meaning that they are more likely to 
agree. 
** a) and b) are the same set of cases classified by different adjudicators 
 
Adjudicator confidence.  Three studies addressed the influence of adjudicator 
confidence, all on the OCSP classification. In one, agreement was higher when both 
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adjudicators were highly confident (kappa 0.68), compared to when one or both were 
less confident (kappa 0.45).(Hand et al. 2006a) In two additional studies, 
adjudicators recorded their ‘best guess’ answers when uncertain. This did not appear 
to affect reliability in one study,(Selvarajah et al. 2009) while in the other, different 
numbers of categories (reliability with or without use of a 5th ‘uncertain’ category) 
precluded a reliable comparison.(Johnson et al. 1995) 
Timing of assessment.  Two OCSP studies assessed the influence of time from 
symptom onset to classification.(Hand et al. 2006a, Dewey et al. 2001) Clinical 
examination (+/- medical record review) was performed at the time of classification. 
The first study showed that individual history and examination findings were more 
reliable when classification was performed 12-24 hours after the onset of symptoms 
(kappa range 0.44 to 0.81), compared to <12 hours (kappa range 0.25 to 0.69) or >24 
hours (kappa range 0.19 to 0.51). There were insufficient data in this study to 
compare the reliability of OCSP classification at different times after the onset of 
symptoms. The second study found that excluding cases classified >10 days after 
stroke onset increased reliability of OCSP classification. Another study examined the 
influence of timing on TOAST, comparing classificaton in the acute phase (data 
gathered on admission) to an expert consensus determined later during the admission 
(data gathered after hospital discharge).(Fure et al. 2005) Agreement was poor 
(kappa 0.30), reflecting the need for more detailed investigations (available later in 
the course of admission) for reliable mechanistic classification. 
Investigations performed.  Overall, investigations performed for TOAST, CCS, 
and ASCO1 classification were inconsistently reported. Where reported, a high 
proportion of cases had brain or vascular imaging (80-100%), but a more variable 
proportion had cardiac investigation (41-100%). From visual inspection of data, the 
proportion of cases with complete work-up (brain, vascular and cardiac imaging) had 
no clear effect on reliability. However, if ≥50% cases had more detailed brain, 
vascular, or cardiac investigation, reliability appeared higher overall (kappa 0.70 to 
0.95) than if less detailed investigations were used (kappa 0.49 to 0.65) (Table 4.5).  
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Marnane 2010 381 99***  82 75 Y 42 - 
 
*This is the proportion of patients who had either CT or MRI. If unknown, the largest proportion 
investigated (by either CT or MRI) is reported. The proportion of cases which had MRI or diffusion 
weighted MRI (DWI-MRI) was not clearly reported.  
†This is the largest proportion investigated by any (or a combination) of the following methods: 
Doppler ultrasound (USS); CT angiography (CTA); MR angiography (MRA); conventional 
angiography (angio); transcranial doppler (TCD). The proportion of cases which had evaluation of 
both intra and extra cranial circulations was not clearly reported.  
‡ECG and Echocardiogram (ECHO). This is the proportion of patients who had an ECG and either 
transthoracic or transoesophageal ECHO.  
§Detailed investigation was defined as ≥50% CTA or ≥50% MRA or ≥ 50% DWI-MRI, or ≥ 50% 
transoesophageal ECHO. Results left blank if reporting was unclear. 
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¶The undetermined category is made up of three subcategories: unclassified due to multiple potential 
mechanisms, unknown cause despite full investigation, incomplete investigation.  
** 90% DWI-MRI.  
††Patients were investigated by protocol to improve completeness of investigation.  
‡‡66% DWI-MRI  
§§Cases were selected for classification based on the investigations performed (90% of cases had the 
investigations required for TOAST classification). The reliability study was based on 20 randomly 
selected cases from this cohort. 
¶¶A single researcher classified 301 cases in the original outpatient cohort to derive the proportion 
undetermined. The 90 consecutive cases chosen for the reliability study are assumed to be 
representative of the original cohort. 
*** 50% DWI-MRI.  
†††Only 4% of cases were completely undetermined with A-S-C-O classification, meaning that every 
mechanism had been assigned either grade 0 (disease not present), or grade 9 (insufficient workup).  
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4.3.5 Proportion of cases undetermined following 
classification 
Most OCSP studies classified all cases.(Asdaghi et al. 2011) However, one 
(published only in abstract form), reported that 10% of cases were 
unclassifiable,(Heuschmann et al. 1999) while in two others a ‘best guess’ answer 
was included.(Lindley et al. 1993) For mechanistic classifications, proportions of 
cases unassigned to a single subtype were 10-61% for TOAST,(Heuschmann et al. 
1999, Cotter et al. 2012, Kolominsky-Rabas et al. 2001, Zhou et al. 2005) 24-26% 
for CCS,(Ay et al. 2005a, Marnane et al. 2010) and 31-52% for ASCO1.(Marnane et 
al. 2010, Cotter et al. 2012, Wolf et al. 2012) These studies varied with respect to 
country, sample size, and the proportion and type of investigations undertaken. In 
within study comparisons, CCS had a lower undetermined proportion than TOAST 
(24% versus 61% in one study,(Marnane et al. 2010) 26% versus 40% in 
another),(Ay et al. 2005a, Marnane et al. 2010) largely due to a lower proportion of 
cases unclassified due to multiple potential mechanisms (4% with CCS  versus 39% 
with TOAST in one study).(Ay et al. 2005a) ASCO1 performed similarly to TOAST 
in within-study comparisons.(Marnane et al. 2010, Cotter et al. 2012, Wolf et al. 
2010) Completeness of investigation did not appear to ffect the proportion 
undetermined, although incomplete reporting made it iff cult to assess the influence 
of individual investigations (Table 4.5). Even studies that selected patients based on 
investigations already completed,(Kolominsky-Rabas et al. 2001) or that used 
protocols for investigation before classifying by TOAST, modified TOAST or 
ASCO1, had a substantial undetermined proportion (ra ge 18-41%).(Wolf et al. 
2012, Ghandehari et al. 2005, Hajat et al. 2001, Fure et al. 2005)  
4.3.6 Subtype inter-observer reliability 
For OCSP, within-study comparisons showed consistently higher reliability for 
assignment of LACS and POCS compared to TACS and PACS (Table 4.6; 
definitions in Figure 4.1). For single cause mechanistic systems, assignments were 
consistently most reliable for CE and least reliable for SAO.  A-S-C-O (kappa range 
0.78 to 1.00),(Wolf et al. 2012, Chen et al. 2013) and the phenotypic CCS (kappa 
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range 0.79 to 0.95) (Ay et al. 2007) had high reliability for all ischaemic stroke 
subtypes.  
4.3.7 Intra-observer reliability 
Only four studies reported intra-observer reliability, and none provided within-study 
comparisons of different systems.(Ay et al. 2007, Cotter et al. 2012, Selvarajah et al. 
2009, Hajat et al. 2001) In between-study comparisons, intra-observer reliability 
appeared higher for CCS (kappa 0.90)(Ay et al. 2007) and ASCO1 (kappa 
1.00)(Cotter et al. 2012) than for TOAST (kappa range 0.48 to 0.93),(Selvarajah et 
al. 2009, Hajat et al. 2001) modified TOAST (kappa range 0.83 to 0.85)(Hajat et al. 
2001) or OCSP (kappa range 0.60 to 0.83),(Selvarajah et l. 2009) but differences 
between studies in adjudicators, case selection and investigations performed may 
have contributed to variation in reliability.  
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0.45 to 0.72 
0.42 to 0.74 
0.13 to 0.44 
0.15 to 0.55 
 
*Excludes descriptive mechanistic classification system . 
†Adjudications were performed by different combinations of observers in different studies. Some were 
single observations and others were based on consensu  opinion.  
‡Results are presented for the following subtypes: CE: ardiac embolism, LAA: large artery 
atherosclerosis, SAO: small artery occlusion, Oth: ther cause. TACS: Total Anterior Circulation 
Stroke, PACS: Partial Anterior Circulation Stroke, LACS: Lacunar Stroke, POCS: Posterior 
Circulation Stroke.  
§This measures reliability in the classification of an individual subtype versus any other subtype. The 
displayed value is based on the largest number of cases tested in each study.  
| | The second adjudicator was not blinded to the first.  
# The LAA category was divided into intra and extracranial subcategories. The kappa 
value of 1.00 was for one case of intracranial LAA. 

181 
Chapter 4: Reliability and feasibility of ischaemic stroke classification systems  
4.4 Discussion 
4.4.1 Summary of findings 
My systematic review found widely varying overall inter-observer reliability for 
OCSP and TOAST, reflecting heterogeneity of study settings, details of how the 
classification systems were applied, and adjudicators. Most of the studies were small 
(<100 cases classified), and very few tested more than one system in the same 
population and with the same observers. Inter-observer reliability for CCS was 
consistently high, but was not assessed as widely as TOAST or OCSP. Furthermore, 
the cases included in published studies of CCS underwent detailed investigation, 
which may have improved reliability. A-S-C-O has been much less extensively 
studied, and there were no overall reliability results for its single cause counterpart, 
ASCO1. We found evidence that clear rules, data abstraction protocols, computer 
based assignment, and fewer categories all improved reliability, and that adjudicators 
with similar (versus different) levels of expertise w re more likely to agree.  
Since the last published systematic review of the int r-observer reliability of 
ischaemic stroke classification (1996),(D'Olhaberriague et al. 1996) existing systems 
have been more widely studied and newer single cause mechanistic systems (e.g. 
CCS and ASCO1) have emerged.(Ay 2010, Amarenco et al. 2009a, Chen et al. 2012, 
Saver 2006) These have attempted to address the major ch llenge of reducing the 
proportion of cases undetermined due to multiple pot ntial mechanisms. Amongst a 
restricted group of studies (identified from our reliability focused search) we found 
that CCS reduced the proportion undetermined compared to TOAST or ASCO1. 
Since our search was completed (November 2013) one larg multicentre study 
(~16,000 cases from Europe/America) showed similar proportions undetermined by 
CCS and TOAST.(McArdle et al. 2014) However, different individual cases were 
assigned to undetermined categories by TOAST and CCS, and there was a wide 
range in between system reliability across included c ntres (which may partly reflect 
inter-observer variability). A direct comparison of the inter-observer reliability of 
CCS and TOAST is required to confirm which system (if either) is more consistently 
reliable, particularly across multiple centres.  
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By contrast with single cause mechanistic classifications, descriptive mechanistic 
classification systems (eg. A-S-C-O) classify each potential mechanism separately. 
They make use of all the available information, allow the contribution of more than 
one mechanism to be recognised, and record mechanisms unlikely to be related to the 
incident stroke. However, practical use of A-S-C-O for epidemiological research is 
limited by the very large number of possible descriptive categories (n=625). 
Anatomical classification systems are a practical option for large studies, since they 
classify all or almost all ischaemic strokes and require no or minimal investigations. 
However, they are not designed to identify potential underlying mechanisms. OCSP 
can distinguish between potential large vessel (TACS, PACS, POCS) and small 
vessel disease (LACS) (albeit with imperfect accuray),(Asdaghi et al. 2011, Mead et 
al. 2000, Potter et al. 2010) but not between cardiac embolism and large artery 
atherosclerosis. 
4.4.2 Strengths and limitations 
The strengths of my study include: its comprehensive and systematic approach; 
inclusion of all relevant studies of inter- or intra- observer reliability of anatomical 
and mechanistic ischaemic stroke classification system ; and exploration of a wide 
range of factors which might influence reliability, generating findings that are highly 
informative for large epidemiological studies. There a e some limitations. First, it 
was difficult to assess individual study quality due to incomplete reporting, and the 
subjective nature of established guidelines (Guidelines for Reporting Reliability and 
Agreement Studies).(Kottner et al. 2011) Second, the potential association between 
more detailed investigation of cases and high overall reliability may be due to 
reporting bias. Third, definitive conclusions were limited by study heterogeneity 
(meaning that meta-analysis was not appropriate), relatively few reliable within study 
comparisons of more than one classification system, and no direct comparison of 
inter-/intra-observer reliability of TOAST and CCS. Fourth, there are likely to be 
other factors, not assessed here, which influence inter-/intra-observer reliability of 
ischaemic stroke classification systems.  I was only ab e to assess those factors which 
had been assessed in within study comparisons.  Furthermore, due small numbers of 
cases, my conclusions based on these within study comparisons are subjective. Fifth, 
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I did not assess systems without published assessment  of reliability (e.g. the recently 
developed Chinese Ischaemic Stroke Subclassification system).(Chen et al. 2012, 
Gao et al. 2011) Sixth, my search was reliability focused, meaning that a number of 
studies which compared the ‘proportion of cases undetermined’ by ischaemic stroke 
classification systems have not been included. This limits the strength of my findings 
regarding proportions undetermined, but it was not the main focus of this review. 
Finally, it is important to note that reliability is only one aspect of classification 
system performance for large epidemiological studies. I did not consider the validity 
of ischaemic stroke classification systems, which would require reference to a ‘gold 
standard’ diagnosis.  
The newer classification systems CCS and ASCO1, appear promising, but further 
studies are required to assess their reliability in a wider range of settings, and 
adaptations to these systems are likely to be requir d for use in large prospective 
epidemiological studies. Study characteristics other t an the classification system 
used account for much of the variability in performance, and these characteristics 
(eg. risk factors of population under study, investigations performed, availability of 
data and abstraction methods) should be more completely r ported.  
4.5 Conclusions 
Based on the findings of this review, I propose that UK Biobank (and other large 
epidemiological studies) adopt a flexible approach to ischaemic stroke classification, 
recognising that no single system is fit for every purpose, and that the system of 
choice depends on the research question. An anatomical system could be used to 
classify the majority of cases, irrespective of investigations performed.  A 
mechanistic system could be applied after this, to classify as many cases as possible 
to a single underlying cause, whilst retaining the data sources which inform the 
classification. Regardless of the classification system(s) chosen, additional features 
which appear to enhance reliability should be included, eg. data abstraction 
protocols, computerised algorithmic assignment, and adjudicator training and 
assessment. This approach would be flexible, practic l, scalable, and resilient to 
future changes in stroke definitions or health servic  infrastructure.
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4.6 Appendix 
4.6.1 Search strategy 
EMBASE   
1. cerebrovascular disease/ or exp brain infarction/ or exp brain ischemia/ or exp 
carotid artery disease/ or cerebral artery disease/ or cerebrovascular accident/ or exp 
occlusive cerebrovascular disease/ or exp stroke/ 
2. stroke unit/ or stroke patient/ 
3. (stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or apoplex$ or 
isch?emi$ attack$ or tia$).tw. 
4. ((brain$ or cerebr$ or cerebell$ or cortical or ve tebrobasilar or hemispher$ or 
intracran$ or intracerebral or infratentorial or supratentorial or MCA or anterior 
circulation or posterior circulation or basal ganglia) adj5 (isch?emi$ or infarct$ or 
thrombo$ or emboli$)).tw. 
5. 1 or 2 or 3 or 4 
6. classification/ or exp clinical classification/ or exp disease classification/ 
7. (type$ of stroke or stroke type$ or subtype$ or classification$ or TOAST or 
BAMFORD or OCSP or SSS-TOAST or CCS or ASCO).tw. 
8. (stroke adj3 categor$).tw. 
9. 6 or 7 or 8 
10. interrater reliability/ or intrarater reliability/ or observer variation/ or 
reproducibility/ or predictive value/ 
11. ((observer or interobserver or inter-observer or intra-observer or intraobserver or 
interrater or rater or inter-rater or intra-rater or intrarater) adj5 (variation$ or 
variabilit$ or bias or reliability or agreement or comparison$ or error$ or 
concordance)).tw. 
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12. 10 or 11 
13. 5 and 9 and 12 
MEDLINE  
1. cerebrovascular disorders/cl or exp basal gangli cerebrovascular disease/cl or exp 
brain ischemia/cl or exp carotid artery diseases/cl or exp cerebral small vessel 
diseases/cl or exp intracranial arterial diseases/cl or exp "intracranial embolism and 
thrombosis"/cl or stroke/cl or exp brain infarction/cl or stroke, lacunar/cl or vertebral 
artery dissection/cl or exp intracranial arteriosclerosis/cl or exp cerebrovascular 
trauma/cl or exp carotid artery injuries/cl or exp cadasil/cl or exp cerebral arterial 
diseases/cl or exp leukomalacia, periventricular/cl or exp sneddon syndrome/cl or 
exp vasculitis, central nervous system/cl 
 
2. cerebrovascular disorders/ or exp basal ganglia cerebrovascular disease/ or exp 
brain ischemia/ or exp carotid artery diseases/ or exp cerebral small vessel diseases/ 
or exp intracranial arterial diseases/ or exp "intracranial embolism and thrombosis"/ 
or stroke/ or exp brain infarction/ or stroke, lacunar/ or vertebral artery dissection/ or 
exp intracranial arteriosclerosis/ or exp cerebrovascular trauma/ or exp carotid artery 
injuries/ or exp cadasil/ or exp cerebral arterial d seases/ or exp leukomalacia, 
periventricular/ or exp sneddon syndrome/ or exp vasculitis, central nervous system/ 
3. (stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or apoplex$ or 
isch?emi$ attack$ or tia$).tw. 
4. ((brain$ or cerebr$ or cerebell$ or cortical or ve tebrobasilar or hemispher$ or 
intracran$ or intracerebral or infratentorial or supratentorial or MCA or anterior 
circulation or posterior circulation or basal ganglia) adj5 (isch?emi$ or infarct$ or 
thrombo$ or emboli$)).tw. 
5. 2 or 3 or 4  
6. (type$ of stroke or stroke type$ or subtype$ or classification$ or TOAST or 
BAMFORD or OCSP or SSS-TOAST or CCS or ASCO).tw. 
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7. (stroke adj3 categor$).tw. 
8. 6 or 7 
9. 5 and 8 
10. 1 or 9 
11. Observer Variation/ 
12. "reproducibility of results"/ 
13. "Predictive Value of Tests"/ 
14. ((observer or interobserver or inter-observer or intra-observer or intraobserver) 
adj5 (variation$ or variabilit$ or bias or reliability or agreement or comparison$ or 
error$ or concordance)).tw. 
15. 11 or 12 or 13 or 14 




Section B: Cross referencing analyses
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Chapter 5 Choosing Read codes to identify 
stroke cases in UK Biobank  
• Studies of the determinants of stroke should include only ‘first in a lifetime’ 
events, in order to avoid reverse causality.  
• Detection of ‘first in a lifetime’ events requires identification of prevalent 
cases and exclusion of these participants from the study population. 
• In this chapter I report the process of selecting Read codes to identify stroke 
and its main pathological types in UK Biobank.  
• There are limited published data on the accuracy of coded primary care data 
(Read codes) for stroke 
• Informed by my systematic review of coding accuracy (Chapter 2), I 
searched online resources to select Read codes for a) ‘true’ stroke cases in 
UK Biobank and b) additional potential prevalent stroke cases. 
• I found that none of the existing online resources had a complete list of Read 
codes for stroke. 
• I concluded that no single code list is fit for every purpose. Care must be 
taken to select the most appropriate code groups for individual studies.   
 
5.1 Introduction 
Follow-up in UK Biobank is primarily through cohort wide linkages to routinely 
collected coded data from hospital admissions (ICD codes), death certificates (ICD 
codes), and primary care (Read codes). I previously reviewed published studies of 
the accuracy of electronic healthcare data for stroke and its main pathological types 
and recommended the best ICD codes to identify fatal and/or hospitalised stroke 
cases during follow-up in UK Biobank (Chapter 2). However, I found insufficient 
data on the accuracy of Read codes for stroke, and therefore no clear evidence to 
suggest which codes should be used for the ascertainment of non fatal, non 
hospitalised stroke cases in UK Biobank.  
Up to 50% or more of stroke cases are not admitted to hospital in the UK.(Schulz and 
Rothwell 2003) These cases would be missed if UK Biobank did not include linkages 
192 
Chapter 5: Choosing Read codes to identify stroke cas s 
to primary care coded data  (Read codes) in its follow-up strategy. Cohort wide 
linkage to primary care data should therefore improve the sensitivity of UK 
Biobank’s stroke outcomes detection, in particular for incident non fatal, non 
hospitalised stroke cases not identified through linkages to hospital admissions and 
death registration datasets, as well as for prevalent cases not ascertained through 
participant self-report and retrospective hospital admissions data. In this chapter, I 
describe how I selected primary care Read codes to search in coded linked primary 
care data for stroke cases amongst UK Biobank participants.  
5.1.1 Read codes 
Read codes are a coded thesaurus of clinical terms, and are the most widely used 
system of clinical coding in UK Primary Care. Read co es are entered by General 
Practitioners (GPs) to record details of each clinial encounter. These may include a 
patient’s symptoms, examination findings, results of investigations, processes of 
care, for example referrals to hospital (codes beginning 0 to 9), or a variety of 
clinical diagnoses (codes beginning A to Z). Multiple Read codes can be entered 
during a single consultation to capture different aspects of the clinical encounter. 
Table 5.1 displays the main chapters of the Read clinica  classification system.(Davé 
and Petersen 2009)  
Read codes are five character alphanumeric codes. At each level the code may be a 
lower (small) or upper case (capital) letter or a number. There are 58 available 
characters at each level and so a theoretical maximum of 656,356,768 available 
codes.(Chisholm 1990) Coding is hierarchical, meaning that as codes increase in 
length from 2 to 5 characters, they convey more complicated concepts or more 
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Table 5.1 Chapters of the Read clinical classification system* 
Chapter heading 
0 Occupations 
1 History & symptoms 
2 Examination and signs 
3 Diagnostic procedures 
4 Laboratory procedures 
5 Radiology & physics in medicine 
6 Preventative procedures 
7 Operations, procedures & sites 
8 Other therapeutic procedures 
9 Administration 
A Infectious and parasitic diseases 
B Neoplasms 
C Endocrine, nutrition, metabolic and immunity disorders 
D Diseases of blood and blood forming organs 
E Mental disorders 
F Nervous system and sense organ diseases 
G Circulatory system diseases 
H Respiratory system diseases 
J Digestive system diseases 
K Genitourinary system diseases 
L Complications of pregnancy, childbirth and the puerperium 
M Skin & subcutaneous tissue diseases 
N Musculoskeletal and connective tissue diseases 
P Congenital anomalies 
Q Perinatal conditions 
R Symptoms, signs and ill-defined conditions 
S Injury & poisoning 
T Causes of injury and poisoning 
U External causes of morbidity and mortality 
Z Unspecified conditions 
*Codes within each chapter (0 to 9 or A to Z) begin w th the same number or letter. For example, 
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Read codes were first used in the NHS in 1985. Read codes have been updated 
several times since then, firstly to include more detail (Version 2, released in 1990), 
and secondly with a more complex structure to allow more coding flexibility 
(Clinical Terms Version 3, CTV3, released in 1994). The Read clinical classification 
system is cross referenced to all of the widely used standard classifications such as 
the International Classification of Diseases (originally ICD-9, but more recently 
ICD-9-CM and ICD-10), the Office of Population Censuses and Surveys 
classification of surgical operations and procedures (OPCS 4), the physicians' current 
procedural terminology (CPT-4), the British National Formulary, and the OPCS 
classification of occupations.(http://systems.hscic.gov.uk/data/uktc/readcodes) 
Version 2 Read codes include the Read Drug and Appliance Dictionary (DAAD) 
which codes medications, appliances, specialist foods, and dressings (and therefore 
captures primary care prescriptions). However this dictionary has not been 
maintained for version 3, and has not been updated since 
1996.(http://systems.hscic.gov.uk/data/uktc/readcodes/drugandappliancedictionary)  
 
Table 5.2: Example of the Read code hierarchy using dividual codes from the Circulatory system 
diseases chapter. 
Level*  Read code Text definition† 
1 G…. Circulatory system diseases 
2 G6…‡ Cerebrovascular diseases‡ 
3 G64..‡ Cerebral arterial occlusion‡ 
4 G640.‡ Cerebral thrombosis‡ 
5 G6400‡ Cerebral infarction due to thrombosis of cerebral a teries‡ 
 
*The diagnostic complexity increases from level 1 to5  
†This definition is provided with each Read code (from the NHS Read code browser) 
‡A single code has been chosen to at each level (2 to 5) to illustrate the hierarchy. Too many codes 
exist at each level to be able to display them all.   
 
5.1.2 Creating medical code lists to identify cases  in primary 
care databases  
Creating code lists for research in primary care datab ses is a challenging and time 
consuming process. Redundancy in the Read code classific tion system means that a 
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single disease can be identified using many different codes. The process of selecting 
codes to identify a diagnosis, like stroke, is therefore iterative. Some diseases may be 
defined easily whereas others are more challenging, requiring combinations of codes 
representing symptoms, diagnoses, medications, and/or results of 
investigations.(Springate et al. 2014) Furthermore, th  groups of codes selected to 
identify a particular disease may depend on the resarch question. Researchers have 
to decide whether to use broad lists of codes to capture every possible case 
(maximising sensitivity), or to select codes with narrower definitions in the hope of 
minimising false positives (maximising PPV).   
5.1.3 Online resources to identify Read codes 
Research outputs based on UK coded primary care databases are rapidly increasing, 
but the bespoke ‘code lists’ used in these studies ar  generally poorly 
reported.(Springate et al. 2014) It is recognised that steps are required to improve the 
quality and reproducibility of research using coded primary care data.(Gulliford et al. 
2009, Springate et al. 2014, Davé and Petersen 2009) A number of resources have 
been developed in recent years which provide research rs with access to ready made 
code lists for specific diseases, including stroke. Examples include the CALIBER 
online data portal (CArdiovascular disease research using Linked Bespoke studies 
and Electronic health Records),(Denaxas et al. 2012) and the more recently 
developed Clinical Codes online Repository.(Springate et al. 2014) In future, 
standardisation of these code lists should make the process of Read code selection 
easier, more transparent, and should also improve cmparability between studies 
using coded primary care data.    
5.1.4 Aims  
There are at least 202 Read codes for potential stroke.(Gulliford et al. 2009) In this 
chapter, I aimed to create two Read code groups to identify stroke and its main 
pathological types.  
The first group, called ‘acute stroke codes’, would be used to identify ‘true’ 
diagnoses of ischaemic, haemorrhagic or unspecified stroke.  I aimed to include only 
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the most accurate Read codes in this group (ie. those I predicted have high PPV for 
stroke and its main pathological types, defined according to WHO definitions).  
The second group of codes, called ‘history of stroke codes’ would be used to identify 
additional UK Biobank participants who may have hada stroke in the past. This 
would enable exclusion of participants from future population based studies of ‘first 
in a lifetime stroke’. Such studies should include only ‘first in a lifetime’ events, in 
order to avoid reverse causality (see Chapter 6.1.1). I used my knowledge of ICD 
coding accuracy and my own clinical judgement to inf rm this process. 
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5.2 Methods 
When I began this work, UK Biobank had obtained linked coded primary care data 
for large subsets of participants in Scotland and Wales. These datasets use version 2 
Read codes and so I focussed on these codes (rather than Read codes version 3), for 
creating my code lists.  
5.2.1 Read code search strategy 
I used the following resources to generate a comprehensive list of Read codes for 
‘potential stroke’.  
1) Read codes for cerebrovascular diseases provided by the Technology Reference 
Data Update Distribution Service (TRUD). 
(https://isd.hscic.gov.uk/trud3/user/guest/group/0/home) These Read codes were 
provided with cross-maps to ICD-10 codes for cerebrovascular diseases (I60 to I69, 
G45, and G46).  
2) Dictionary of Read codes for cerebrovascular diseases provided by the SAIL 
(Secure Anonymised Information Linkage) databank. SAIL is an anonymous data 
linkage system which brings together routinely collected data from the population of 
Wales for research.(Ford et al. 2009) 
3) Quality Outcomes Framework (QOF) indicator sets for stroke, 
Wales.(http://www.wales.nhs.uk/) These are similar to equivalent lists in England 
and Scotland. QOF rewards GP practices for the provision of quality care, and 
measures annual performance against a set of key targets. GP practices are required 
to maintain a register of patients with stroke/TIA so that secondary prevention targets 
can be monitored. The QOF indicator sets include lists of Read codes for the 
diagnosis of stroke/TIA. 
4) CALIBER online data portal. CALIBER is a research platform of linked 
electronic health records (EHR) and administrative health data from primary care, 
secondary care and disease registries. CALIBER data sources include the Clinical 
Practice Research Datalink (CPRD), Hospital Episode Statistics England (HES), the 
Myocardial Ischaemia National Audit Project (MINAP) and mortality/social 
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deprivation data from the Office of National Statistic  (ONS). I reviewed lists of 
codes for stroke and its main pathological types provided by CALIBER, excluding 
any codes which were unique to version 3.(http://www.caliberresearch.org/)  
5.2.2 Read code selection  
1) Acute Stroke  
I had previously identified the optimum ICD codes to maximise PPV for stroke 
(Chapter 2). From my broader list of Read codes for potential stroke (gained above), 
I selected those which most closely matched the ICD ‘acute stroke codes’ (Table 5.3, 
below) using a three-step process. 
Table 5.3 International Classification of Diseases codes (ICD codes) for stroke 
Acute stroke codes 
ICD-9 430, 431, 434, 436                                                                                                
ICD-9-CM 430, 431, 433.x1, 434, 436                                                                                                   
ICD-10 I60, I61, I63, I64 
 
Firstly, I identified Read codes which had been matched by the TRUD service 
(above) to ICD-10 stroke codes I60, I61, I63 and I64.  reviewed text definitions of 
these Read codes (see Table 5.2 for examples of text definitions) to check that they 
made clinical sense for acute stroke. Secondly, after familiarising myself with the 
Read code hierarchy for stroke (displayed in Appendix 5.6.1), I used the NHS Read 
code browser (made available on the SAIL platform, hosted by Swansea University) 
to identify any additional Read codes which matched th  ICD-9 stroke codes 430, 
431, 434, 436, or the ICD-9-CM stroke codes 430, 431, 3.x1, 434.x1, 436. Table 
5.4 shows the NHS Read code browser categories I searched for ICD-9 or               
ICD-9-CM matching Read codes. I excluded Read codes which matched the         
ICD-9 code 433 for ischaemic stroke (‘occlusion/stenosis of pre-cerebral arteries 
with or without infarction’) because I had previously shown that this was a poorly 
performing code (PPV 6 to 14% for ischaemic stroke, Chapter 2).  
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Table 5.4:  Read code categories which match ICD-9 codes for acute stroke.  
Clinical definition  
(STROKE) 
ICD-9 code  
(ICD-9-CM) 
Read code categories searched* 












G61.. and subcategories 
Gy…and subcategories 




G64.. and subcategories 
Gy…and subcategories 
(433.x1, 434.x1) (Above, plus subcategories of G63..†) 




*Using the NHS Read code browser 
†The Read code G63.. maps to ICD-9 code 433, which has low PPV for ischaemic stroke (range 6 to 
14%). Read codes were only selected from the G63.. group if they mapped to the clinically modified 
ICD-9-CM codes 433.x1 and/or 434.x1, which appear to have a much higher PPVs for ischaemic 
stroke (range 82% to 96%, Chapter 2). 
Finally, I cross-checked my ICD-9 and ICD-10 matched Read code list with the 
Read code lists for stroke/cerebrovascular diseases provided by SAIL, CALIBER, 
and QOF. I reviewed the text definitions of any codes which I had not already 
selected (above) and used my clinical judgement to decide whether or not they 
should also be included for acute stroke.   
2) Past history of stroke: 
For codes that might identify additional participants with a past history of stroke, I 
used a similar process. This time I selected Read codes which matched ICD-10 codes 
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for ‘sequelae of stroke’ and in particular, codes I69.0 for ‘sequelae of SAH’, I69.1 
for ‘sequelae of ICH’, and I69.3 for ‘sequelae of cerebral infarction’. The ICD-9 
code 438 ‘sequelae of cerebrovascular diseases’, does n t include any specific Read 
code text definitions for sequelae of stroke, and so I did not include ICD-9 matching 
Read codes. I used the NHS Read code browser to search the Read code chapters 1 
‘History and symptoms’, 6 ‘Other preventative procedures’ and 9 ‘Administration’, 
to identify any other potential ‘past history of stroke’ codes based on their text 
description. As for acute stroke, above, I cross checked my final list with those from 
SAIL, CALIBER, and QOF to identify any additional potentially relevant codes. 
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5.3 Results 
5.3.1 Acute stroke 
There were 241 Read codes related to cerebrovascular diseases in the SAIL 
dictionary, including codes from chapters 0 to 9 and A to Z, but not including codes 
for medication prescriptions. Figure 5.1 shows results of the search and selection 
process, and Table 5.5 shows my final list of 57 Read codes for ‘acute stroke’, 
categorised by main pathological type. Fifty Read co es were matched to ICD-10 
acute stroke codes by the TRUD service. After reviewing each individual match, I 
removed one Read code (G65z1 for ‘intermittent cerebral ischaemia’) because the 
text description was not in keeping with acute stroke. To the 49 remaining codes, I 
added 8 by searching the NHS Read code browser. I did not find any additional acute 
stroke Read codes in the CALIBER or QOF Read code lists.  The final Read code list 
for acute stroke included 20% of the SAIL Read code dictionary for ‘cerebrovascular 
diseases’, 76% of the CALIBER ‘stroke diagnosed’ codes, and 86% of the ‘stroke 
indicator set’ QOF codes.  No single resource identifi d all of the acute stroke Read 
codes. Out of 57 Read codes for acute stroke, 86% were included in the SAIL Read 
code dictionary for cerebrovascular diseases, 88% were included in the CALIBER 
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Figure 5.1 Selection of Read codes for acute stroke 
*For Cerebrovascular Diseases.  
†Read codes matched by the Technology Reference Data Upd te Distribution (TRUD) service to   
ICD-10 codes for ‘other cerebrovascular diseases’, not stroke.  
‡Read codes which matched ICD-10 acute stroke codes I60, I61, I63 or I64.  
§Additional Read codes which matched ICD-9 and ICD-9-CM acute stroke codes 430, 431, 433.x1, 
434, or 436. 
 ¶From incident stroke, ischemic stroke and haemorrhagic stroke code lists.   
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** Did not match ICD-9 or ICD-10 acute stroke codes (based on review of text definitions).  
††Codes not found in the NHS Read code browser (searching 5 byte version 2 codes), these were 
version 3 Read codes (7 characters long) and therefor  not available in the Welsh or Scottish primary 
care datasets.  
‡‡ These codes were already selected as ‘acute stroke codes’.  
 
Table 5.5 Read codes for 'acute stroke' cross mapped to ICD codes for ischaemic, haemorrhagic 
and unspecified stroke. 
Stroke type ICD-10 
ICD-9 
(ICD-9-CM) 
READ diagnostic codes 
(5-byte Version 2 Read codes used in Welsh dataset) 
SAH I60 430 G60.. and its sub-categories, including G600. to 
G606./G60X./G60z./Gyu60/Gyu61/Gyu6E. 
ICH I61 431 G61.. and its sub-categories, including G610. to 
G619./G61X./G61X0/G61X1/G61z./Gyu62/Gyu6F 
Ischaemic stroke I63 434 
(433.x1) 
G63y0‡/G63y1‡ /G6W../ Gyu6G/ G6400/G6410/ 
G6X../Gyu63/G6760‡/Gyu64/G64z.‡/G64z0‡/ 
G64z1*,‡/ G64z2‡/ G64z3‡/G64z4‡/G64.. 
Unspecified stroke I64 436 G66..‡/G667./G668./G669.‡,§/G660. to G666.*,§ 
 
*These codes were not present in the TRUD mapped list, and were found by searching the NHS Read 
code browser for matches to ICD-9 or ICD-9-CM acute stroke codes.  
‡These codes were not present in CALIBER lists for ‘stroke diagnosed’.  
§These codes were not present in the QOF ‘stroke indicator set’ of Read codes (Wales). 
 
5.3.2 History of stroke 
I identified 18 Read codes for potential past history of stroke, and 40 Read codes for 
potential past history of Cerebrovascular Diseases (CVD) (Table 5.6). I identified 
seven of the Read codes for past history of stroke and ten of the Read codes for past 
history of CVD by cross mapping to ICD-10 codes for ‘sequelae of stroke/CVD’. I 
identified the remainder by searching chapters 0 to 9 of the NHS Read code browser. 
Table 5.6 displays the Read codes for potential past history of CVD/stroke/main 
pathological types of stroke. The text definitions of Read codes for past history of 
stroke and its main pathological types are displayed in Appendix 5.6.2.  
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Table 5.6 Read codes for 'past history of stroke’ and ‘past history of CVD' cross mapped to ICD 








(5-byte Version 2 Read codes used in the Welsh 
dataset) 
 Diagnosis codes Processes of care codes*  
SAH I69.0 - G680.  14AF.  
 






































SAH= Subarachnoid haemorrhage, ICH= Intra-cerebral haemorrhage, CVD=Cerebrovascular 
diseases. 
*Including Read codes from chapters 1 for History and Symptoms, 6 for Preventative procedures, 7 
for Operations, procedures and sites, 8 for other trapeutic procedures, and 9 for Administration. 
†These are codes for ‘non stroke CVD’ and TIA.
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5.4 Discussion 
In this chapter I used a variety of different resources to identify more than 200 Read 
codes for potential cerebrovascular diseases.  I then selected 57 Read codes for 
‘acute stroke’, and 18 Read codes for ‘past history of stroke’, based on cross 
mapping to ICD codes for ‘acute stroke’/‘stroke sequ lae’, and clinical review of 
Read code text definitions. By identifying codes from a number of different 
resources, and by selecting only those codes which matched the best ICD codes for 
acute stroke, I hope to have created a comprehensive Read code list with high PPV 
for acute stroke. In future, the Read code groups I have selected will be used to 
identify new cases of stroke during follow-up in UK Biobank, and/or to identify 
participants in UK Biobank who have had a stroke in the past. These potential cases 
should be validated by expert led adjudication to determine the PPV of Read codes 
for stroke and its main pathological types.  
An advantage of linkage to Read codes during follow-up in UK Biobank is the 
potential to identify additional non fatal, non hospitalised stroke cases which would 
not be detected by ICD codes or participant self-repo t. This approach (combining 
multiple different coded data sources) should improve the sensitivity of stroke case 
ascertainment, and increase the numbers of stroke cases included in future nested 
case cohort or case control studies of the associati ns between risk factors and 
stroke. It should also reduce the risk of outcome sel ction bias (under selection of 
milder stroke cases, which are less likely to be admitted to hospital). Whilst it is 
important to include as many cases as possible during follow-up, false positive cases 
should be kept to a minimum (misclassification of outc mes reduces power to detect 
differences between them in the strength of their risk factor associations). In 
selecting my ‘acute stroke codes’ I have therefore cussed on selecting individual 
Read codes to maximise PPV for stroke. If I had included Read codes with high 
sensitivity for potential stroke, I would risk introducing too many false positive 
cases, and therefore too many potential cases for subsequent adjudication.  
In other circumstances it may be more important to create code groups which 
maximise the number of potential stroke cases detected, placing less importance on 
PPV. In creating my ‘history of stroke group’, I aimed to detect additional 
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participants who have had a stroke in the past (in addition to those detected using 
‘acute stroke codes’ to search for prevalent stroke). Combining ‘history of stroke 
codes’ with ‘acute stroke codes’, should enable more c mplete exclusion of 
participants with a potential history of stroke from future studies of ‘first in a lifetime 
stroke’. Although this approach might exclude some ‘true’ ‘first in a lifetime cases’ 
from follow-up, it would minimise inclusion of ‘false positive’ ‘first in a lifetime 
cases’. The approach could be extended further by searching for and excluding any 
participant from such a study who had any of the ‘cerebrovascular diseases’ codes.  
Although bespoke Read codes lists are being developed for use in research,(Denaxas 
et al. 2012, Springate et al. 2014) they have not yet been validated for specific 
diseases, like stroke. Researchers still need to review individual codes for inclusion 
in any given code list and select the most relevant codes for their research question. 
In this chapter I showed that only 20% of Read codes in the SAIL dictionary for 
‘potential CVD’ matched validated ICD codes for acute stroke. Furthermore, only 
76% of CALIBER stroke codes, and only 86% of QOF stroke codes matched 
validated ICD codes for acute stroke. Many of the codes excluded from these lists 
were more likely to identify ‘old’ cases of stroke, or cases of ‘other cerebrovascular 
disease’, than ‘acute stroke’ diagnoses. I also found that no single resource (TRUD 
service, CALIBER list, or QOF code list) included all of the potentially relevant 
Read codes for ‘acute stroke’.  
The strengths of my approach therefore include searching multiple code lists to 
identify as many potentially relevant ‘stroke’ codes as possible, and selecting the 
most appropriate codes from within these lists to maxi ise PPV for acute stroke. 
Rather than relying on clinical judgement alone, I selected Read codes for acute 
stroke which best matched validated ICD codes (using knowledge gained in from a 
systematic review of the accuracy of routinely available coded data for stroke, 
Chapter 2). A study published in 2009 demonstrated poor inter-observer agreement 
in the selection of Read codes for stroke, suggesting that clinical judgement alone 
may be a poor basis for generating an accurate and reproducible code list.(Gulliford 
et al. 2009) Four independent clinical researchers w re asked to specify which Read 
codes they felt were likely to represent an ‘acute stroke’ from amongst a list of 202 
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potential codes. Overall agreement between all four researchers was low (kappa 
0.23).  Defining the disease outcome, in this case by selecting the most appropriate 
codes to maximise PPV for stroke, is a crucial partof study design. It is not only 
important for transparency and reproducibility, butit may also influence the results 
of studies which use stroke as an exposure or an outcome. For example, different 
groups of Read codes selected to represent ‘acute stroke’ have been shown to provide 
different estimates of one year post stroke mortality.(Gulliford et al. 2009) 
5.5 Conclusions 
In conclusion, I have selected groups of Read codes which will be used to identify 
potential incident and prevalent stroke cases in UK Biobank (see Chapter 6). I have 
focused on identifying groups of Read codes to maxiise PPV for stroke, using 
version 2 Read codes which will be applied to the linked Scottish and Welsh primary 
care datasets.  It will also be necessary to compile similar lists for use in the English 
primary care datasets, based on Read codes version 3. Different groups of codes are 
likely to influence the outcomes of research studies based on coded healthcare data.  
In future, wider groups of Read codes could be select d to maximise sensitivity for 
non fatal, non hospitalised stroke cases in UKB (analogous to the use of all 
cerebrovascular ICD codes, I60-I69, G45 and G46 to maximise sensitivity for 
hospitalised or fatal stroke cases, Chapter 2), but these potential cases would require 
further adjudication. In the long run it may be possible to conduct sensitivity 
analyses in UK Biobank to see how associations between parameters, like BP and 
stroke, vary depending on the groups of codes selected to define stroke (and/or its 
main pathological types), as well as on the sources of these codes (ie. use of coded 
primary care data in addition to coded hospital and death certificate data). In the next 
chapter I present numbers of prevalent and early incide t stroke cases in UK 
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5.6 Appendix  
 
5.6.1 The Read code hierarchy for cerebrovascular d iseases  
 
G…. = Circulatory system diseases 
  G6… = Cerebrovascular disease 
 G60.. = SAH 
 G61.. = ICH 
 G62.. = Other and unspecified intracranial haemorrhage 
 G63.. = Pre-cerebral arterial occlusion 
 G64.. = Cerebral arterial occlusion 
 G65.. = Transient cerebral ischaemia 
 G66.. = Stroke and CVA unspecified 
 G67.. = Other cerebrovascular diseases 
 G68.. = Late effects of cerebrovascular disease 
     G6W..= Cerebral infarction due to unsp. occlusion/stenosis of precerebral arteries 
     G6X.. = Cerebral infarction due to unsp. occlusion/stenosis of cerebral arteries 
     G6y.. = Other specified cerebrovascular disease 
     G6z.. = Cerebrovascular disease nos. 
Gy… = Other specified diseases of the circulatory system 
   Gyu.. = [X] Additional circulatory disease classification terms 
        Gyu6. = [X] Cerebrovascular diseases 
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5.6.2 Text definitions of past history of stroke Re ad codes 
 
G680. = Sequelae of SAH 
14AF. = History of SAH 
G681. = Sequelae of ICH 
G683. = Sequelae of IS 
G68X. = Sequelae of stroke not specified as haemorrhage or infarction 
Gyu6C = Sequelae of stroke not specified as haemorrhage or infarction 
14A7. = History of CVA/stroke 
14AK. = Stroke in the last year 
7P242 = Delivery of rehabilitation for stroke 
8HHM. = Referral to multidisciplinary stroke function improvement service 
1M4.. = Central post stroke pain 
661M7 = Stroke self-management plan agreed 
662M1 = Stroke 6 month review 
662e. = Stroke/CVA annual review 
662M2 = Stroke initial post discharge review 
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Text definitions of past history of cerebrovascular  diseases Read codes 
 
14AB. = History of TIA 
14AB0 = History of amaurosis fugax 
ZV12D = Personal history of TIA 
1477. = History of cerebrovascular disease 
8E24. = Dysphasia training 
14AK. = History of stroke in past year 
662M. = Stroke monitoring 
662e. = Stroke annual review 
7P242. = Delivery of rehabilitation for stroke 
8HHM. = Referral to multidisciplinary stroke function improvement service 
ZV125 = Personal history of cerebrovascular accident 
1M4.. = Central post stroke pain 
661M7 = Stroke self-management plan agreed 
662M1 = Stroke six month review 
662M2 = Stroke initial post discharge review 
8IEC. = Referral to stroke multidisciplinary function improvement service declined 
9Om.. = Stroke/transient ischaemic attack monitoring administration 
13YA. = Stroke group member 
9Om0. = Stroke/transient ischaemic attack monitoring first letter 
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9Om1. = Stroke/transient ischaemic attack monitoring second letter 
9Om2. = Stroke/transient ischaemic attack monitoring third letter 
9Om3. = Stroke/transient ischaemic attack monitoring fourth letter 
9Om4. = Stroke/transient ischaemic attack monitoring fifth letter 
6F… = Stroke prevention 
8E24. = Dysphasia training 
662o. = Haemorrhagic stroke monitoring 
Q412. = Perinatal subarachnoid haemorrhage
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Chapter 6 Identification of prevalent and early 
incident stroke cases in UK Biobank 
• Up to 50% of stroke cases in the UK are not admitted to hospital. These 
cases would be missed if UK Biobank did not included linkages to coded 
primary care data.  
• In this chapter I report the contribution of multiple overlapping sources of 
coded healthcare data to the identification of early incident and prevalent 
stroke cases in UK Biobank 
• Analyses were performed in the UK Biobank population (~500,000), and in 
a sub-cohort with complete linkage to coded primary care data (~22,000) 
• I found that the majority of prevalent stroke cases w re identified by 
participant self-report, and were mostly stroke of ‘unspecified type’. 
• Incident cases detected by coded hospital or death cer ificate data were 
mostly specified pathological type (ischaemic or haemorrhagic stroke). 
• Coded primary care data identified ~38% of incident strokes in the UKB 
sub-cohort, half of which were not detected by any other data source.  
• I concluded, as expected, that linkage to coded primary care data should 
improve the completeness of UKB stroke outcomes ascertainment. 
• In future, a large proportion of incident stroke cases in UKB may be 
classified into pathological types using coded data alone.    
 
6.1 Introduction 
In this chapter I present the numbers of prevalent and early incident stroke cases 
which were identified in UK Biobank using combinations of linked coded healthcare 
data.    
6.1.1 Definition of prevalent, incident, and recurr ent stroke 
cases 
In order to investigate new potential risk factors for stroke, or to better understand 
the associations between established risk factors, stroke, its main pathological types, 
and subtypes, it is necessary to conduct well design d prospective studies where the 
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exposure of interest is measured before the occurrence of the outcome. In UK 
Biobank, nested case cohort or case control studies will be used to explore 
associations between exposures identified at the UK Biobank baseline assessment 
and first ever stroke events identified during follow-up. Data on a wide variety of 
potential exposures were collected during the UKB baseline assessment. For each 
participant, the time prior to the baseline assessmnt is the exposure period, and the 
time after the baseline assessment is the follow-up period (Figure 6.1). It is important 
to identify only those participants who have had their first ever stroke (ie. first event 
in a lifetime) during follow-up. Participants who have had a previous stroke will 
need to be excluded to avoid reverse causality (ie. development of the risk factor 
after the occurrence of disease) which may bias studies of associations between risk 
factors, like blood pressure, and stroke. Therefore, f r the purpose of this work, 
incident stroke is defined as any first in a lifetime event, occurring after recruitment 
to UK Biobank, prevalent stroke is defined as any stroke which has occurred prior to 
UK Biobank recruitment, and recurrent stroke is defined as any subsequent event in 
an individual who has had a stroke before (irrespectiv  of the timing of this event). 
Recurrent stroke is excluded from the count of incident and/or prevalent stroke cases. 
The distinction between prevalent, incident, and recu rent stroke is illustrated in 
Figure 6.1.  
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S1: Prevalent stroke, S2: recurrent stroke, S3: incident stroke, S4: recurrent stroke, S5: incident stroke, 
S6: Prevalent stroke.  
Person B and Person C would be identified as individuals with incident stroke for inclusion in a nested 
case cohort or case control study of the associations between risk factors and stroke in UK Biobank. 
Events S3 and S5 would be used.  
*Each individual’s baseline assessment date.   
†Produced with permission from Q. Zhang and C. Sudlow.  
 
6.1.2 Data linkage in UK Biobank 
UK Biobank has planned cohort wide linkages to coded h althcare data from hospital 
admissions, death certificates, and general practices a ross England, Scotland, and 
Wales. At the time of this study, linkages were not complete for all three data sources 
in all three countries (ie. linked coded data were not available for all participants). 
Table 6.1 shows the numbers of participants for whom linked coded data were 
available in UK Biobank across England, Scotland, and Wales, and the periods of 
data coverage, stratified by the coded data source used.   
 
Figure 6.1 Illustration of prevalent, incident, and recurrent stroke in UK Biobank† 
S2 Person A 
: Recruitment date for each UKB participant* 




S5 Person C 
S6 Person D 
S4
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Table 6.1: UK Biobank data linkages. 
Coded data source Period available* Data linkages† 
(% of 502,523) 
Participants with  
records‡ (n) 
Baseline assessment 2006 - 2010 100 502,523 
Death certificates 2006 - 2014 100 8,662 
Hospital admissions 1980 - 2013 100 352,730 
Primary care records¶ 1940 - 2012 ~11 22,562 
 
*Time period for which coded data were available 
†Proportion of participants (out of 502, 523 in the whole UK Biobank cohort) for whom data linkage 
was complete  
‡Number of participants (out of those with linked data) who had at least one coded record.  
¶Linkages to primary care coded data were complete for only ~40% of UKB Welsh and Scottish 
participants, which represented ~11% of the UK Biobank cohort.  
 
Data from the UKB baseline assessment were collected between 2006 and 2010 (the 
date of recruitment varied per participant), coded hospital admission records (ICD-9 
or ICD-10 codes) from England (Hospital Episode Statistics, HES), Scotland 
(Scottish Morbidity Record, SMR01), and Wales (Patient Episode Database for 
Wales, PEDW), were available for the whole UK Biobank cohort from 1980 to 2013, 
and national death registry data (ICD-9 or ICD-10 codes based on death certificate 
diagnoses) were available for the whole cohort until the end of 2014.  Coded primary 
care data were only available for around half of UKB Welsh and Scottish participants 
(~56,663 participants were recruited in Scotland an Wales) until the end of 2012.  
6.2 Aims 
The aims of this chapter are to determine the numbers of prevalent and incident 
stroke events, and the equivalent numbers of each of the main pathological types of 
stroke (ischaemic stroke, subarachnoid haemorrhage, SAH  and intracerebral 
haemorrhage, ICH) which are identified by different coded data sources (participant 
self-report, ICD codes, and Read codes) across England, Scotland and Wales. 
Linkage between these datasets will be used to determin  the numbers of cases 
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identified by any single data source amongst UK Biobank participants, as well as the 
numbers of cases identified by combinations of coded data. This novel work should 
determine the potential contribution of each separate d ta source to the identification 
of stroke and its main types in UK Biobank. In particular, it will determine the 
number of stroke cases which can be classified into a main pathological type 
(ischaemic or haemorrhagic stroke) based on coded data alone. It will also 
demonstrate the numbers of non fatal, non hospitalised stroke cases which are 
identified using coded primary care data, thereby illustrating the important potential 
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6.3 Methods  
6.3.1 Single data sources 
We initially investigated each of the four data sources separately. We counted the 
numbers of incident and prevalent stroke cases identified using coded hospital, death 
certificate, and primary care data, as well as the number of prevalent stroke cases 
identified by participant self-report (at the UK Biobank baseline assessment). The 
denominator population for each of these analyses was the total number of 
participants who had been linked to each coded data source (Table 6.1). The 
optimum ICD and Read codes to identify ‘acute stroke’ and each of its main 
pathological types have been described in previous chapters (Chapters 2 and 5). 
Table 6.2 displays the ICD codes for ‘acute stroke’ and its main pathological types, 
along with the codes selected from the UK Biobank baseline assessment to identify 
self-reported stroke. Read codes for ‘acute stroke’ and its main pathological types are 
displayed in Chapter 5 (Table 5.5). 
Table 6.2 Codes for ‘acute stroke’ and its main pathological types 
Diagnosis sought ICD-10 ICD-9 
 
UKB self-report codes* 
 
Subarachnoid haemorrhage (SAH) I60 430 1086 
Intracerebral haemorrhage (ICH) I61 431 1491 
Ischaemic stroke (IS) I63 434 1583 
Stroke, unspecified I64 436 1081 
Stroke (all types) I60-I64 430,431,434,436 1081,1086,1491,1583 
*Codes for self-reported stroke and its main pathological types extracted from the UK Biobank 
baseline assessment dataset. Self-reported strokes wer  included from the touchscreen questionnaire 
and the nurse-led interview.  
The same groups of ICD and Read codes (‘acute stroke c des’) were used to identify 
incident and prevalent stroke cases. The definition (incident versus prevalent stroke) 
depended on the timing of the coded event in each separate data source with respect 
to UKB recruitment (shown in Figure 6.1). For simplicity, codes for ‘history of 
stroke’ (described in Chapter 5), were not used in these analyses. For cases identified 
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using ICD coded data we also determined the numbers of events which were coded 
in the primary diagnostic position versus the secondary diagnostic position. (See 
Chapter 2 for definitions of primary versus secondary diagnostic positions).   
6.3.2 Multiple data sources 
We then analysed the contribution of multiple overlapping sources of data to the 
identification of incident and prevalent stroke cases. We performed these analyses in 
the whole UK Biobank cohort (without coded primary care data), and in a sub-cohort 
of the UKB population (with coded primary care data).  
6.3.3 Whole UK Biobank cohort. 
We used combinations of coded hospital, death certifi ate, and/or self-report data to 
identify early incident and/or prevalent stroke cases in the whole UK Biobank cohort. 
Linkage was complete for all three data sources, but the periods of data coverage (the 
periods of time for which coded data were available) differed from one data source to 
another (Table 6.1). We truncated the search for ‘prevalent stroke’ (using linkages to 
coded hospital data), to the date of UK Biobank recruitment (which varied by 
individual). Self-report data were ascertained at the date of recruitment, and could 
only be used to identify ‘prevalent’ cases. We truncated the follow-up period for 
‘incident stroke’ (using linkages to either coded hospital or death certificate data), to 
the end of 2013. Primary care data were not included in these analyses because 
linkage was only complete for ~11% of the UKB cohort (Table 6.1).  
6.3.4 UK Biobank sub-cohort 
We created a sub-cohort of ~ 22,500 participants for whom linked coded data were 
available for all four data sources (Table 6.1). In this cohort we used combinations of 
coded hospital, primary care, and self-report data to search for ‘prevalent’ stroke 
(truncated to the date of UKB recruitment, as described in 6.4.1). We used 
combinations of coded hospital, death certificate, nd primary care data to search for 
incident stroke. For comparability, follow-up of inc dent stroke was truncated to the 
end of December 2012 (Table 6.1).  
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6.3.5 Identifying the main pathological type of str oke 
We determined the numbers of ischaemic, haemorrhagic (ICH and/or SAH), and 
unspecified strokes identified by each separate data source. An incident stroke of 
confirmed pathological type (ischaemic stroke, ICH, or SAH) was the first ever event 
of that type in a lifetime. A participant could have an incident haemorrhagic stroke 
(SAH or ICH), despite having a past history of ischaemic stroke, and an incident 
ischaemic stroke, despite having a past history of haemorrhagic stroke.   
Furthermore, it was theoretically possible to have multiple different stroke codes for 
the same hospital admission, either because the main pathological type of stroke, 
ischaemic versus haemorrhagic stroke, was determined lat r in the course of a 
hospital admission (therefore an unspecified stroke code was later followed by a 
specified stroke code), or because the participant h d an early stroke recurrence 
during their hospital stay (ie. an ischaemic, haemorrhagic or unspecified stroke was 
followed by a recurrent stroke of any type).  It was not possible to distinguish 
between these alternatives based on the coded diagnoses alone.  
We created the following rules to deal with multiple different coded diagnoses within 
the same hospital admission. Firstly, a single period of inpatient stay is divided into 
multiple hospital episodes. The episode is a period of inpatient hospital stay under 
the care of a specified hospital consultant, or within a particular hospital department. 
Each episode includes one primary and up to 19 secondary ICD codes, which 
represent the main condition(s) responsible for that period of inpatient stay. Codes 
within a single episode are given the same event dates. Therefore, when multiple 
stroke codes were present in sequential episodes, we elected the earliest stroke code 
(the code associated with the earliest episode within that admission) to represent 
incident stroke, and the earliest stroke code of specified pathological type to 
represent incident ischaemic or haemorrhagic stroke.  Secondly, when more than one 
stroke code was entered for a single hospital episode, therefore with same event date 
(ie. one type of stroke code in the primary diagnostic position and another type of 
stroke code in the secondary diagnostic position), we selected the primary position 
stroke code to represent the diagnosis for that admission.   
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6.3.6 Characteristics of selected participants 
We explored baseline characteristics of participants in whole UK Biobank cohort, 
compared to the population recruited in Scotland and Wales (n=56,663, of which 
~40% made up our sub-cohort). Characteristics were extracted from the linked UK 
Biobank baseline assessment dataset including age at baseline (≤44, 45-49, 50-54, 
55-59, 60-64, 65+), gender, smoking status, Townsend d privation index and 
comorbidities (including Stroke, TIA, other CVD, heart disease, diabetes, and renal 
disease). 
Statistical analyses were conducted by a statistical epidemiologist, Dr Qiuli Zhang, in 
SAS.9.2.
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6.4 Results  
6.4.1 Prevalent stroke  
Amongst 502, 523 participants in the whole UK Biobank cohort, 8,769 (~1.7%) had 
at least one stroke prior to UKB recruitment based on cohort wide linkages to 
participant self-report and coded hospital data (Figure 6.2). The majority of prevalent 
stroke cases were identified by participant self-repo t (~95%). Coded hospital data 
(ICD codes) identified an additional 465 participants with prevalent stroke (the 
remaining 5% of prevalent stroke cases), but only 2,786 participants with prevalent 
stroke overall, and only ~26% of participants who had self-reported stroke at the 
UKB baseline assessment. The prevalence of stroke in UK Biobank was ~1.6% 
based on participant self-report, and ~ 0.6% based on coded hospital data (ICD 












Figure 6.2 Participants with prevalent stroke (n=8,769) identified by self-report and coded hospital 
admissions data (ICD codes) amongst 502, 523 in the w ole UK Biobank cohort.  
*Stroke identified by participant self-report at theUK Biobank baseline assessment 
†ICD codes I60, I61, I62, I63, I64, 430, 431, 434, 436 
 
Amongst 22,562 participants in the UKB sub-cohort, 1,145 (~5%) had at least one 
stroke prior to UKB recruitment based on cohort wide linkages to coded primary care 
data (Read codes), coded hospital data (ICD codes) and self-report (Figure 6.3). 
Again, the majority of these cases were identified by participant self-report (~90%). 
An additional ~10% of prevalent stroke cases were dt cted using a combination of 
coded primary care data (Read codes) and coded hospital data (ICD codes).  The 
prevalence of stroke in this sub-cohort was ~4.6% based on self-report, ~1.8% based 
on coded hospital admissions data, and ~1% based on coded primary care data.  
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*Stroke identified by participant self-report at theUK Biobank baseline assessment 
†ICD codes I60, I61, I62, I63, I64, 430, 431, 434, 436 
§Read codes displayed in Chapter 5 (Table 5.5 ‘acute stroke’ codes)  
 
6.4.2 Incident stroke  
There were 850 incident stroke cases in the whole UK Biobank cohort using linkages 
to ICD coded data from hospital admissions and/or ICD coded data from death 
certificates until the end of December 2012 (Figure 6.4). The majority of these 
(~92%) were detected using hospital ICD codes. An additional 8% were detected 
using death certificate ICD codes.  Only 3% of incident cases were detected using 






















Figure 6.3 Participants with prevalent stroke (n=1,145) based on self-report, 
coded hospital admissions data (ICD codes), and coded primary care data (Read 
codes) amongst 22,562 in the UKB sub-cohort with complete linked data. 
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* ICD codes I60, I61, I62, I63, I64, 430, 431, 434, 436 
 
Amongst 22,562 participants in the UKB sub-cohort, 186 incident stroke cases were 
detected using linkages to ICD coded data from hospital admissions and/or death 
certificates, and/or linkages to primary care coded ata (Read codes) until the end of  
December 2012 (Figure 6.5). Around 19% of all cases detected were present in 
primary care coded data only. Of all cases detected (n=186), ~11% were identified 
using death certificate ICD codes, ~78% were identifi d using hospital ICD codes, 
and ~38% were identified using primary care Read codes. No cases were identified 
by all three data sources simultaneously. The proportion of cases identified from 
hospital admissions which were also identified by death certificates, or also 






















Figure 6.4 Incident stroke cases (n=850) identified by coded hospital data 
(ICD codes) and coded death certificate data (ICD codes) amongst 502, 



















Figure 6.5 Incident stroke cases (n=186) identified by coded hospital data (ICD 
codes), coded death certificate data (ICD codes), and coded primary care data 
(Read codes) amongst 56,663 in the UKB sub-cohort with complete linked data. 
226 
Chapter 6: Identification of stroke cases in UK Biobank 
6.4.3 Coding patterns 
The majority of stroke cases identified using coded hospital data were recorded in the 
primary diagnostic position (97%). Similarly, the majority of fatal strokes identified 
using coded death certificate data were recorded as the underlying cause of death 
(81%). Proportions were similar irrespective of region (England, Scotland, or Wales) 
and irrespective of the pathological type of stroke (ischaemic stroke, SAH, or ICH). 
Figure 6.6 shows the proportions of ICD-10 codes which were in the primary 
diagnostic position amongst all coded hospital admissions for stroke in England 
(HES), Scotland (SMR), and Wales (PEDW). Results are also displayed for each of 
the main pathological types of stroke (Subarachnoid haemorrhage, SAH, 
Intracerebral haemorrhage, ICH, and Ischaemic stroke, IS), as well as stroke, 
unspecified. In the coded hospital data, only 1.8% of stroke codes (ischaemic stroke, 
haemorrhagic stroke, or unspecified stroke codes) appe red in the same hospital 
episode (ie. had the same event date, with one coded diagnosis in the primary 
position, and ≥1 other coded diagnosis in the secondary position).   
 
Figure 6.6 Proportions of stroke cases identified using hospital coded data (ICD-10 codes only) 
from England (HES), Scotland (SMR), and Wales (PEDW), which were in the primary diagnostic 
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6.4.4 Identification of the main stroke types  
Prevalent stroke 
Amongst 502, 523 participants in the whole UK Biobank cohort there were 11, 572 
prevalent stroke cases identified by self-report and/or linkages to coded hospital data. 
The majority of these prevalent stroke cases had unspecified stroke codes (~78%), 
and only 22% had ischaemic or haemorrhagic stroke cd s (~11% ischaemic stroke, 
~7% SAH, ~5% ICH). When stratified by data source, cases identified in the coded 
hospital data were more often specified types of str ke (ischaemic or haemorrhagic) 
compared to cases reported by participants (~69% of ‘coded’ strokes were specified 
pathological types versus only ~7% of self-reported strokes). Furthermore, 
participants appeared more likely to report the type of stroke if it was haemorrhagic, 
rather than ischaemic. Amongst cases identified by participant self-report (n=11,572) 
~0.2% were ischaemic stroke, ~5% were SAH, ~1.6% were ICH, and ~93% were 
unspecified type (Table 6.3).  
Incident stroke 
A higher proportion of incident stroke cases were sp cified as ischaemic or 
haemorrhagic stroke, compared to prevalent stroke cas s (~89% versus ~22%, 
respectively). Amongst 961 incident stroke cases (where each participant could have 
more than one incident case, one of each pathological type), 55% were ischaemic 
stroke, 19% were SAH, 15% were ICH, and only 11% were unspecified type. 
Incident strokes of specified pathological type were more likely to be haemorrhagic 
stroke in coded death certificate data (~74% of 70 specified strokes), and more likely 
to be ischaemic stroke in coded hospital data (~97% of 751 specified strokes). 
Comparing coded hospital data before UKB recruitment to coded hospital data after 
UKB recruitment (and up to the end of December 2010), a higher proportion of ICD 
codes were specified ischaemic or haemorrhagic stroke after recruitment, than before 
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Table 6.3 Proportions of prevalent and incident stroke cases in the whole UK Biobank cohort 







IS‡           
(% total) 
SAH‡      
(% total) 





Hospital§ 2,786 3,135 1,257 (40) 596 (19) 311 (10) 971 (31) 
Self-report 8,304 9,507 17 (0.2) 457 (5) 155 (1.6) 8,881 (93) 
Combined 8,769 11,572 1,270 (11) 848 (7) 453 (4) 9,001 (78) 
Incident stroke 
Hospital§ 785 902 521(58) 97 (11) 133 (15) 151 (17) 
Deaths§ 95¶ 105¶ 18 (17) 26 (25) 26 (25) 35 (33) 
Combined 850 961 531(55) 178 (19) 141 (15) 111 (11) 
 
*The number of participants identified with prevalent or incident stroke.  
†The number of stroke cases identified amongst participants with prevalent or incident stroke. The 
number of cases is greater than the number of participants, because some participants had more than 
one type of stroke (ie. an incident/prevalent ischaemic stroke and an incident/prevalent haemorrhagic 
stroke).  
‡Number of cases specified as Ischaemic Stroke (IS), Subarachnoid haemorrhage (SAH), Intracerebral 
haemorrhage (ICH), or otherwise unspecified.  
§Based on ICD codes I60, I61, I63, I64, 430, 431, 434, 436. 
¶There were ten death certificates which included more than one stroke code (e.g . codes for more than 
one pathological type of stroke).  
 
6.4.5 Characteristics of the denominator population  
Characteristics of the whole UK Biobank cohort (n=502, 523) are displayed for 
comparison with characteristics of participants recruited in Scotland and Wales 
(n=56,663). Both populations were very similar (Table 6.4).   
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Table 6.4 Characteristics of the UK Biobank population (n=502, 523) and the population recruited 






Total no. of participants 502,523 56,663* 
Age group   
 ≤ 44 51,812 (10.3) 5,745 (10.1) 
45-49 66,085 (13.2) 7,892 (13.9) 
50-54 76,335 (15.2) 9,137 (16.1) 
55-59 90,826 (18.1) 10,837 (19.1) 
60-64 121,478 (24.2) 12,728 (22.5) 
65 + 95,987 (19.1) 10,324 (18.2) 
Mean (std) 56.5 (8.1) 56.3 (8.0) 
Gender   
Female 273,392 (54.4) 31,239 (55.1) 
Male 229,131 (45.6) 25,424 (44.9) 
Townsend deprivation index -1.3 (3.1) -1.3 (3.3) 
Smoking status   
Never 273,545 (54.4) 31,279 (55.2) 
Previous 173,066 (34.4) 18,357 (32.4) 
Current 52,974 (10.5) 6,784 (12.0) 
Unknown 2,938 (  0.6) 243 (  0.4) 
Alcohol drinking status   
Never 22,538 (  4.5) 2,372 (  4.2) 
Previous 18,112 (  3.6) 2,166 (  3.8) 
Current 460,381 (91.6) 52,008 (91.8) 
Unknown 1,492 (  0.3) 117 (  0.2) 
Blood pressure, mean (std)   
SBP 139.8 (19.7) 140.9 (19.6) 
DBP 82.2 (10.7) 83.2 (10.8) 
BMI, mean (std) 27.4 (  4.8) 27.6 (  4.9) 
Self-reported disease##   
   Stroke 7,169 (  1.4) 943 (  1.7) 
   TIA 1,781 (  0.3) 157 (  0.3) 
   Other CVD 16,537 (  3.3) 1,687 (  3.0) 
   High cholesterol 61,625 (12.3) 6,368 (11.2) 
   Hypertension 133,290 (26.5) 15,342 (27.1) 
   Heart disease# 22,948 (  4.6) 2,896 (  5.1) 
   Renal diseases 884 (  0.2) 116 (  0.2) 
 
#including angina, heart attack and heart failure;  
##: self-reported diseases confirmed by verbal interview 
*Our sub-cohort comprised 40% of these participants ( = 26,562). Subsequent analyses (performed 
after this thesis was written) confirm that characteris ics of the sub-cohort are very similar to the 
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6.5 Discussion 
Using cohort wide linkages to multiple combinations of coded data increased the 
number of potential strokes identified amongst UK Biobank participants. No single 
data source identified all potential cases, and each different data source generated 
different estimates of stroke incidence and prevalence. The majority of prevalent 
stroke cases were identified by participant self-repo t (range ~90 to 94% of prevalent 
cases). The majority of incident stroke cases were identified using linkages to coded 
hospital data (range ~79 to 92% of incident cases). A large proportion of incident 
cases identified using hospital or death certificate coded data were specified types of 
stroke (up to 89% were ischaemic or haemorrhagic stroke). The addition of linked 
coded primary care data increased the overall numbers of stroke cases detected. Read 
codes identified ~39% of incident stroke cases and ~49% of these (~19% of incident 
cases) were not identified by any other data source. Th se additional cases would 
have been missed if hospital data and death certifiate data (ICD codes) were the 
only source of stroke outcomes identification during UKB follow-up.  
This study provides useful estimates of the contribu ion of each data source to the 
identification of stroke cases in UK Biobank. In future, potential cases will need to 
be validated using an independent gold standard to determine the accuracy of each 
data source (sensitivity and positive predictive value, PPV, for stroke and its main 
pathological types) in the UK Biobank population. I have previously shown that the 
PPVs of selected ICD codes for ‘acute stroke’, the codes used in this study, ranged 
from 68 to 90% in various populations worldwide (Chapter 2). PPVs were generally 
higher using primary position codes than secondary position codes, albeit by only 5 
to 10% (Chapter 2).  It is therefore encouraging that e majority of our ICD coded 
stroke diagnoses were identified in the primary diagnostic position (81% and 97%, 
respectively). It is also encouraging that a high proportion of our incident stroke 
cases were a specified type of stroke. In the past,ICD codes for ischaemic and 
haemorrhagic stroke (SAH or ICH) have performed consistently well, often with 
PPVs ≥90% (Chapter 2). Assuming that ICD codes perform equally well in the UKB 
population, linkages to these data will be sufficient to identify and classify a large 
proportion of our incident stroke cases.  
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The majority of our prevalent stroke cases were ascrtained by self-report. In a 
previous chapter I demonstrated that the positive predictive value (PPV) of self-
reported stroke was low in populations with low stroke prevalence (<10%). Under 
these circumstances, around 1/3 to 3/4 of self-report d strokes were false positives. 
(Chapter 3). In this chapter the estimated prevalence of stroke in the whole UK 
Biobank cohort was ~1.7% using a combination of self-report and ICD codes. In the 
UKB sub-cohort, stroke prevalence was ~2% based on self-report, Read codes, and 
ICD codes. In light of this low stroke prevalence, many of the potential stroke cases 
identified by participant self-report are likely to be false positives.  
Self-report data generated different estimates of str ke prevalence in the UK Biobank 
sub-cohort compared to the whole UK Biobank population (4.6% versus 1.7%, 
respectively). The higher prevalence of self-reported stroke in the sub-cohort is 
potentially due to ‘over- reporting’ of stroke in this population, rather than a true 
difference in stroke prevalence. Published studies have suggested potential links 
between recent and/or frequent GP contact and over-reporting of certain medical 
conditions, including cardiovascular diseases, althoug  no definite conclusions have 
been drawn.(Kreigsmann et al. 1996, Englert et al. 2010) The UK Biobank sub-
cohort included only those individuals who had continuous registration with Scottish 
and Welsh GP practices providing data to UKB for linkage and analysis. It therefore 
excluded individuals who had not registered with a GP practice supplying data to UK 
Biobank. Although some of these excluded individuals had registered with GP 
practices not yet providing linked data to UK Biobank, others might not have 
registered with a GP. It is possible that individuals who attend their GP frequently 
are more aware of stroke/TIA as potential diagnoses, and are more likely to ascribe 
previous symptoms and signs to such a condition, compared to individuals who do 
not see their GP often. It is possible that the former group were overrepresented in 
the UK Biobank sub-cohort compared with the UK Biobank population as a whole.  
It is also possible that additional differences in characteristics between the UK 
Biobank sub-cohort and the whole UK Biobank population (e.g differences in age 
range(s) and or vascular risk-factors), may have led to a difference in stroke 
prevalence between these populations. Characteristics of the whole UK Biobank 
cohort and the UK Biobank Welsh and Scottish populations are very similar (Table 
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6.4), but I did not have access to characteristics of the ~22,000 sub-cohort 
participants. It is reassuring that when multiple ov rlapping data sources were used, 
the estimated stroke prevalence in these two groups were more similar (~1.7% in the 
whole UK Biobank cohort versus ~2%  in the sub-cohort), compared to estimates 
based on self-report alone (~1.7% versus 4.6%, respectively). Although these 
additional data sources (coded hospital, death certifi ate and primary care data) are 
not considered ‘gold standards’ for stroke diagnosis, the similar estimates of stroke 
prevalence in both populations when these multiple sources agree, supports the idea 
that stroke prevalence was ‘over-estimated’ by self-report alone, particularly in the 
UK Biobank sub-cohort.      
We have shown that large numbers of potential stroke cases were identified by 
participant self-report. If self-report were used as a screening tool in future, to 
increase the sensitivity of incident stroke detection during UKB follow-up, it is likely 
that this would generate a lot of work (ie. large numbers of potential stroke cases for 
subsequent validation, many of which may turn out t be false positive).  Therefore, 
self-report is likely to be an inefficient method for the identification of stroke 
outcomes in UK Biobank.  
For the purpose of nested case cohort or case control studies in UK Biobank, 
participants with prevalent stroke will be excluded to enable identification of 
participants with true ‘first in a lifetime stroke’ after their date of recruitment. In 
these studies it is important to exclude as many potential prevalent stroke cases at the 
outset as possible, to minimise the number of participants misclassified ‘without 
stroke’ at recruitment, and to reduce the risk of reve se causality bias. We can infer 
from this study, that self-report is likely to have high sensitivity for stroke, given the 
high proportion of cases identified using this method. Self-report is therefore likely 
to be a useful tool for the identification of ‘stroke free’ individuals at baseline, 
enabling these individuals to be included in nested case cohort or case control studies 
of the associations between risk factors and stroke.  
Different forms of coded data (data from primary care, hospital admissions, and 
death certificates) identify different proportions of the main types and subtypes of 
stroke. In this study, the pathological types of stroke identified by death certificates 
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(ICD codes) were ~74% haemorrhagic stroke and ~26% ischaemic stroke, whereas 
the converse was true for hospital admissions (main types identified were ~69% 
ischaemic stroke and ~31% haemorrhagic stroke). This is in keeping with the fact 
that haemorrhagic stroke is more likely to be fatal th n ischaemic stroke.  Excluding 
any single data source from follow-up has the potential to under represent a 
particular type or subtype of stroke from the overall outcomes identified, and this 
may introduce bias in future associations between risk factors and stroke, its main 
types, and subtypes. Therefore, although relatively small proportions of incident 
strokes were identified using coded data from death certificates (~11% of incident 
stroke cases in the whole UKB population, and ~12% of incident stroke cases in the 
UKB sub-population), linkages to these data are important in order to avoid 
exclusion of fatal, non hospitalised stroke cases. The same principle applies to the 
use of primary care coded data for follow-up of stroke outcomes. It has been shown 
previously that non-fatal, non hospitalised strokes are more likely to be ischaemic 
stroke cases, and more likely to be due to small vessel disease. These cases may not 
be detected by any other data source. Using linkage to multiple coded data sources 
therefore improves the accuracy of stroke outcomes identification by ensuring that all 
types and subtypes of stroke are fairly represented. 
Stroke prevalence in the whole UK Biobank population (~1%) is lower than 
published for the UK (~2.8% in 2010).(Townsend et al. 2012) Stroke incidence in 
UK Biobank was 850 per 502,523 from recruitment to end 2012, based on coded 
hospital and death certificate data (~0.09% per yea, assuming average time from 
recruitment to end 2012 was ~2 years). UK Stroke incidence was ~165 cases per 
100,000 in 2007, based on the same data sources (~0.17% per year).(Townsend et al. 
2012). Stroke cases should occur less frequently in UK Biobank than in the general 
population due to inclusion of healthier than averag  participants (‘the healthy cohort 
effect’).(Lindsted et al. 1996) In addition, UK Biobank included younger participants 
than the population at large, meaning that stroke incidence and prevalence will be 
lower than average during early follow-up, but should increase with time (as stroke 
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6.6 Conclusions 
In conclusion, linkages to multiple sources of coded ata are likely to improve the 
accuracy and completeness of stroke outcomes identification. Potential cases will 
need to be validated using an independent gold standard to determine the PPV and/or 
sensitivity of these data sources for stroke and its main pathological types in UK 
Biobank. However, it is likely that a large proporti n of incident strokes will be 
classified into main pathological types using coded ata alone. If these coded data 
perform similarly in UK Biobank to other populations, this should be achieved with 
high accuracy, and further validation of these cases (in terms of their main 
pathological type) may not be necessary. Future work should explore the potential of 
coded primary care data and/or data extracted from h spital discharge summaries, to 





Section C: Assessing the potential of coded 
primary care data to capture blood pressure 




 Chapter 7: Blood pressure variability and risk of stroke.  
Chapter 7 Blood pressure variability and risk 
of stroke: a review of the evidence 
• Blood pressure variability (BPV) may be an independent risk factor for 
stroke. 
•  It is unclear how BPV should be defined, measured, an  quantified to 
predict stroke risk.  
• Short-term, medium-term, and long-term BPV have different potential 
underlying causes. These different categories of BPV are only partly 
correlated, and some associate more strongly with cardiovascular risk than 
others. 
• In this chapter I report my review summarising the most recent evidence for 
an association between medium-to-long term BPV and risk of stroke. 
• I explored the influence of BPV measurement methods, a justment (or not) 
for confounding factors, and participant characteris ics, on the strength of 
the association between BPV and stroke. 
• All included studies demonstrated a trend towards an association between 
BPV and stroke, but the majority were in highly selected populations. 
• BPV appeared to increase with age, female sex, rising mean BP, and past 
history of vascular disease, but the association with stroke was stronger in 
younger age groups and in those with lower mean BP. 
• The strength of the association between BPV and stroke may depend on the  
precision of BPV measurement  
• Further large population based studies are required to reliably investigate the 
associations between BPV, stroke and its main pathological types. 
 
7.1 Introduction 
7.1.1 Blood pressure variability: a novel risk fact or for stroke 
Blood pressure (BP) is one of the most important modifiable risk factors for stroke. 
Average BP has a steep log-linear association with stroke, such that increases of 
20mmHg systolic/10mmHg diastolic approximately double stroke risk in middle to 
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old age. Recent research suggests that blood pressure variability (BPV) is an 
independent risk factor for stroke.(Rothwell et al. 2010b) If found to be true, this 
would have important potential implications for BP monitoring and treatment, and 
may lead to new insights into stroke mechanistic pathw ys. In this chapter I have 
introduced the concept of blood pressure variability. I have explored how blood 
pressure variability is defined and quantified and have reviewed the recent evidence 
that increased BPV associates with stroke risk.  
7.1.2 Treatment of blood pressure in current clinic al practice 
Blood pressure lowering drugs are among the most frequently prescribed 
medications in the UK.(Health and Social Care Information Centre 2012) Traditional 
approaches to BP monitoring and treatment have focussed on estimation of an 
individual’s ‘usual blood pressure’. ‘Usual blood pressure’ is the theoretical 
underlying value of blood pressure, which is widely considered to be the most 
important component of blood-pressure-associated vascul r risk.(Rothwell 2010) In 
epidemiological studies the association between ‘usual’, or long-term average BP, 
and vascular risk is strengthened by adjusting for within-individual BPV over time 
(adjustment for regression dilution bias).(Clarke et al. 1999) BP variability has 
therefore traditionally been considered an obstacle to the estimation of an 
individual’s ‘true’ underlying blood pressure.   
In current clinical practice hypertension is not diagnosed unless blood pressure is 
consistently elevated. British Hypertension Society Guidelines (2011) recommend 
that if clinic BP readings are >140/90mmHg a patient s referred for Ambulatory 
Blood Pressure Monitoring (ABPM), or Home Blood Pressure Monitoring (HPBM), 
to get an accurate assessment of their ‘usual blood 
pressure’.(http://www.nice.org.uk/guidance/cg127/chapter/1-recommendations) This 
recognises the fact that blood pressure is often raised in clinic compared to home 
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Results from the Health Survey for England (2006) showed that half of patients with 
hypertension remained ‘uncontrolled’ despite being prescribed anti-hypertensive 
medication.(Falaschetti et al. 2009) It has been shown that there is a tendency 
amongst primary care physicians to ‘ignore’ elevated clinic BP readings on the 
grounds that they are ‘not representative’ of a patient’s ‘usual’ BP level.(Nicodème 
et al. 2009) Non-compliance with prescribed medication is an important additional 
cause of poor BP control.(Wuerzner, Hassler and Burnier 2003, Munger, Van Tassell 
and LaFleur 2007) It is thought that ~ 40% patients who begin treatment for 
hypertension discontinue their treatment within 2 years.(MacDonald, Morant and 
Mozzafari 2007) In some cases discontinuation might be directed by the physician 
(particularly if subsequent BP readings are normal), but it is often because the patient 
experiences side effects, or fails to engage with their treatment.(Jin et al. 2008) 
Diagnosis and treatment of hypertension is challenging, and fluctuation of blood 
pressure from one clinic visit to the next certainly contributes to this challenge. What 
if identifying and treating BP variability is as important as the estimated underlying 
mean?   
Part of improving BP control, and reducing cardiovascular risk, should focus on 
improving medication compliance, and on educating ad empowering patients with 
high blood pressure to take charge of their own healt . Patients may not understand 
why they are being treated for high blood pressure, particularly if some readings are 
normal, and others not. In this case there may be a tendency (amongst patients and 
their physicians), as suggested above, to focus on the ‘normal readings’ and ignore 
the elevated readings. If it were to be shown that variability itself increases vascular 
risk, and that this should be monitored and treated in addition to the mean level, it 
might encourage patients to engage more with their own risk stratification and 
treatment. Patients’ perception of their illness plays a role in non-adherence to 
prescribed anti-hypertensive medication,(Morrison et al. 2015) and compliance is 
generally improved when a patient believes in a therapy and perceives benefits from 
it.(Jin et al 2008). Therefore, demonstrating an association between BPV and risk of 
vascular disease, including stroke, would lead to an important change in the global 
approach to blood pressure control.  
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The key questions which follow are: 
1: How do we define BP variability 
2: At what point is BP fluctuation pathological, rather than normal? 
3: How do we monitor BP variability, including over what time periods? 
4: How do we risk-stratify, ie. how do we identify ndividuals at increased risk of 
adverse outcomes due to BPV? 
7.1.3 Definitions of blood pressure variability  
The British Society of Hypertension states that: 
‘Everybody’s blood pressure is variable…further work is needed to define what is an 
acceptable level of variability and what might be considered extreme and thus 
worthy of further attention’. 
Blood pressure variability can be divided into short-, medium-, and long-term 
variability (Table 7.1). These different categories of variability have different 
potential underlying causes, not all of which are ‘pathological’. It has been shown 
that the different categories of BPV are only partly correlated, and that some 
associate more strongly with cardiovascular risk than others. For example,           
visit-to-visit BPV was more strongly associated with s roke and coronary events than 
both within-visit variability and variability during 24hr ambulatory blood pressure 
monitoring (ABPM) in post-hoc analyses of data from ~19,000 hypertensive 
individuals in the Anglo-Scandinavian Cardiac Outcomes Trial Blood Pressure 
Lowering Arm (ASCOT-BPLA).(Rothwell et al. 2010a)  
Recognised forms of short-term variability (<24hr) include circadian variability 
(night-time dip or morning rise in blood pressure), and transient BP fluctuations due 
to stress, pain, emotion, changes in posture, or activity.(Parati et al. 2013, Rothwell 
2010) White coat hypertension is a unique form of short-term variability, in which a 
patient’s blood pressure is raised in clinic, but normal at home (or, alternatively, 
when the first clinic BP reading is high, but subsequ nt ‘within-visit’ readings are 
normal).(Celis and Fagard 2004) Short term variability is most often measured by 24 
hour Ambulatory BP monitoring (24hr ABPM), or Home Blood Pressure Monitoring 
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(HBPM).(Table 7.1) Variability can also be captured by successive blood pressure 
readings within a single outpatient clinic visit (‘within-visit variability’). Some forms 
of short term variability are normal physiological responses for example to physical 
activity, or pain, but excessive variability may be pathological (and may result, for 
example, from abnormal autonomic or humoral BP control, or increased arterial 
stiffness).(Rothwell 2010, Parati et al. 2013, Nagai and Kario 2013)  
Table 7.1 Definitions and potential causes of blood pressure variability 







Multiple ‘within-visit’ BP‡ 
 
 
Autonomic BP dysregulation: 
• increased sympathetic drive 
• reduced cardiopulmonary and 
arterial reflexes 
 
Reduced arterial compliance 
Psychological stress 
Behaviour (physical activity, posture, sleep). 
Endocrine factors (eg. insulin resistance) 
 
Medium-term  
 (≤ 30 days) 
 
Multiple 24hr ABPM* 
HBPM† 
Visit-to-visit clinic BP§ 
 
Short-term BP variability 
Antihypertensive medication 
BP changes at work vs. weekend 





As for medium-term  
 
Short- and medium-term BP variability 
Seasonal BP variation 
Changes in mean BP over time 
Incident disease (eg. cardiovascular disease) 
affecting arterial compliance and autonomic 
BP regulation 
 
*ABPM: 24 hour ambulatory blood pressure monitoring. This requires at least 2 BP measurements per 
hour during waking hours, and at least one BP measur ment per hour overnight, over a 24 hour 
period. Blood pressure is measured in the patient’s usual environment using an automated BP device 
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†HBPM: Blood pressure is measured in the patient’s home, either ‘self-measured’, or taken by a health 
professional, at pre defined intervals. This may include morning and evening BP measurements to 
investigate diurnal variation in BP (short-term BPV), or morning/evening BP measurements over 
successive days (medium-term BPV).  
‡BP readings taken over a period of minutes within a single outpatient clinic visit.  
§BP readings taken at successive outpatient clinic vs ts.  
 
Medium to long-term variability is due to changes in blood pressure over days, 
weeks, months, or years. Day-to-day variability canbe captured using successive 
home BP readings, and week-to-week or month-to-month variability can be captured 
using successive outpatient clinic readings. Recognised forms of medium-to-long 
term variability include seasonal variation (BP is generally higher in winter than in 
summer),(Sega et al. 1998) and the gradual change in m an BP over time (mean BP 
tends to rise with age).(Drizd, Dannerberg and Engel 1986) Other factors which may 
contribute to medium-to-long term variability include medication (treatment with 
anti-hypertensive medication, particularly changes in treatment and/or                   
non-compliance), and incident disease (for example BP instability may occur 
following stroke).(Rothwell 2010, Parati et al. 2013)  
7.1.4 Biology of BPV and potential mechanisms of st roke 
causation 
‘Pathological’ blood pressure variability is thought to result from a combination of 
increasing arterial stiffness due to age, atherosclerosis, diabetes, chronic kidney 
disease, and reduced baroreceptor function due to age, cerebral ischaemia, diabetes, 
hypertension, endothelial dysfunction, and ‘inflammation’.(Rothwell 2010, Nagai 
and Kario 2013, Chapleau et al. 1995) In addition, what could be perceived as 
‘normal’ physiological causes of short-term BPV include stress, emotion, pain, and 
posture, and the anticipated ‘night time dip’ and ‘morning surge in blood pressure’. 
Other factors contributing to short or long-term BPV include medications (which 
modulate BP), and/or intercurrent illness, which may increase BP instability.  
The mechanism by which BPV causes stroke is thought to be due to a combination of 
BP variability over time, and increased BP ‘instability’- sudden peaks or troughs in 
BP - which together lead to cerebral hypoperfusion and ischaemia. In a normal 
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individual, autoregulation maintains cerebral perfusion over a range of blood 
pressures. Sudden peaks or troughs in BP are therefor  unlikely to cause ischaemia 
unless there are other factors which render them vulnerable to BP instability, for 
example, extracranial arterial stenosis, or cerebral sm ll vessel disease.  
It is hypothesised that when baroreceptor dysfunctio  coexists with arterial stiffness, 
there is reduced ability to buffer short-term fluctuations in BP, and this leads to an 
overall increase in BP variation. In this context, fluctuations in blood pressure 
become sudden and larger, and may be enough to cause erebral ischaemia even in 
the context of normal cerebral autoregulation. Furthermore, changes in mean BP over 
time may lead to a shift in the ‘cerebral autoregulation curve’, such that the 
thresholds of BP needed to induce ischaemia become different (for example, higher 
than normal in generally hypertensive individuals, nd lower than normal in 
generally hypotensive individuals). Changes in mean BP over time, in combination 
with ‘pathological’ BP variation (above), are thought to increase an individual’s risk 
of stroke by increasing the chance of cerebral hypoperfusion.(Rothwell 2010, Nagai 
and Kario 2013, Floras 2013). A similar mechanism i thought to underpin the 
potential association between increasing BPV and the development of brain white 
matter hyperintensities, and cognitive impairment.(Nagai and Kario 2013)  
A different hypothesis is that blood pressure variability leads to stroke via endotheial 
dysfunction, inflammation and cerebral small vessel disease, but less has been 
published about this theory.(Rothwell 2010) 
7.1.5 How is BPV quantified? 
A number of different measures of blood pressure vaiability have been described. 
The simplest method is derived from an individual’s maximum and minimum 
recorded blood pressure over a specified period of time. Individuals can be grouped 
into four categories which include: stable normotensio , episodic moderate 
hypertension, episodic severe hypertension, and stable hypertension (Table 7.2). 
Alternatively, a continuous measurement can be derived by subtracting the minimum 
BP from the maximum BP recorded within the exposure period (MMD: maximum 
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minus minimum difference). Episodic hypertension and maximum blood pressure 
reached have been associated with risk of stroke (Rothwell 2010).  
 
Table 7.2 Categorical definition of blood pressure variability  
Category  BP readings (mmHg) 
Stable normotension Max. ≤ 140mmHg 
Episodic moderate hypertension Min. ≤140mmHg 
Max. 140-179mmHg 
Episodic severe hypertension Min. ≤ 140mmHg 
Max. ≥ 180mmHg 
Stable hypertension Min. ≥140mmHg 
 
Repeated Systolic (SBP) or Diastolic (DBP) blood pressure readings (successive 
day-to-day, or visit-to-visit readings) can also be converted into continuous measures 
of blood pressure variability (Table 7.3). The more frequently used measures include 
standard deviation (SD), coefficient of variation (CV), variation independent of the 
mean (VIM), and average real variability (ARV). Stand rd deviation and coefficient 
of variation correlate with mean BP. ‘Variation independent of the mean’ (VIM) was 
developed to try and account for this co-linearity between SD and mean 
BP.(Rothwell et al. 2010b)  
Amongst any group of BP readings, BP variability could result from visit-to-visit 
variability or from a shift in the underlying BP over time. Figure 7.1 illustrates how 
SD BP fails to distinguish between two scenarios, the first (Patient A) where there is 
visit-to-visit variability about a stable mean BP, and the second (Patient B), where 
there is development of stable normotension in a previously stable hypertensive 
patient. By contrast, Average Real Variability (ARV), the average absolute 
difference between successive BP values specifically ptures BP variability from 
one visit to the next. (Mena et al. 2005) ARV SBP is therefore the best measure of 
time-series variability (variability from one reading to the next). If SD, CV and VIM 
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are used to capture BP variability, further adjustments for changes in mean BP over 
time may need to be considered. This is particularly relevant if BP variability is 
being measured over longer exposure periods where canges in the mean BP might 
be expected (eg. seasonal variation, an increase in BP with age, or a reduction in BP 
with treatment).  
 
Figure 7.1 An illustration of the difference between SD SBP and ARV SBP using ten consecutive 
BP readings from two patients with very different patterns of BPV.‡ 
*SD SBP is the same for Patient A and Patient B despite a very different pattern of BP variability. SD 
SBP captures overall variability, irrespective of whether this is variability from one visit to the next, 
or a change in the underlying BP over time.  
†ARV SBP is higher in Patient A, where visit-to-visit variability is greater, and lower in Patient B, 
where visit-to-visit variability is lower. By contrast, SD SBP is the same for both patients. ARV SBP 
is a more specific measure of visit-to-visit BP variability compared to SD SBP.  
‡Adapted from Mena et al., ‘A reliable index for the prognostic significance of blood pressure 
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Another measure of BP variability, which is less affected by changes in mean BP 
over time, is the ‘SDreg’ (Standard deviation regression). Whereas SD in SBP is the 
'average' of the deviations about the mean BP (which is assumed to be static over 
time), SDreg is the 'average' of the deviations about the regression line (which is the 
‘line of best fit’ for a linear increase in mean BP over time). Therefore in a 
participant whose BP does not change across visits, SD and SDreg are similar. In 
contrast, in a participant whose BP increases linearly over time, SD is higher than 
SDreg, and SDreg more accurately captures variability independent of the change in 
underlying mean BP.(Shimbo et al. 2012) 
 
 
Figure 7.2‡ An illustration of SD SBP and SDreg SBP using ten consecutive readings from two 
different patients , one with and one without a change in underlying BP over time.  
*SD BP calculates variability about the mean BP over time (blue line). 
†SDreg BP captures variability about the change in BP over time (red line). This is considered an 
‘adjustment’ for the change in mean BP over time.  
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Patient B: SDreg SBP is lower than SD SBP because ther  is a gradual increase in the underlying BP 
over time. SDreg therefore more accurately reflects that the visit-to-visit variability is lower for 
Patient B than for Patient A.   
‡Adapted from Shimbo et al. ‘Association Between Annual Visit-to-Visit Blood Pressure Variability 
and Stroke in postmenopausal women: data from the Women’s Health Initiative.’ Hypertension 
2012:60:625-630.  
 
Table 7.3 Quantifying medium to long term BPV 
BPV measurement Calculation 
 




1. Standard Deviation (SD) 
 
2. Coefficient of Variation (CV) SD/mean 
3. Variation Independent of  Mean (VIM) SD/mean
x 
(x derived from curve fitting) 
4. Average Real Variability (ARV) 
Average absolute difference 
between successive BP 
values 
5. Standard Deviation ‘regression’ (SDreg) 
Variation about the linear 
increase in mean BP over 
time. 
 
7.1.6 What evidence is there that BPV associates wi th risk of 
stroke? 
There is currently a lack of consensus as to whether blood pressure variability 
increases risk of stroke.(Floras 2013) A post hoc analysis of blood pressure control 
using data from the INVEST trial, 2007 (patients with hypertension randomised to 
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either verapamil or B-blocker based therapy) assessed whether vascular outcomes 
were related to consistency of BP control (% of time BP was <140/90). Risk of 
stroke (but not MI) decreased according to the proportion of visits where BP was 
controlled (analyses adjusted for baseline BP, and on-treatment mean BP). This 
suggested that mean BP does not provide the complete icture of BP related 
risk.(Mancia et al. 2007) More compelling evidence for a potential association 
between blood pressure variability and stroke, again b sed on post hoc analyses of 
trial data, was published in 2010.(Rothwell et al. 2010b) Visit-to-visit blood pressure 
variability was a strong predictor of stroke amongst a population with recent TIA 
(Top versus bottom decile HR for risk of stroke 6.22, 95% CI 4.16-9.29, adjusted for 
mean BP). These results were replicated in a number of other TIA cohorts.(Rothwell 
et al. 2010b) However, subsequent analyses have not shown consistent 
associations.(Floras 2013) The most recently published study, a meta-analysis of 2 
prospective studies (60,096 patients from US and Europe), found a marginal 
association between BPV and risk of stroke (HR 1.02, 95% CI 1.01-1.03 per 1mmHg 
increase SD SBP),(Tai et al. 2015) but this study di  not include all available, 
relevant, published data.   
7.1.7 Investigation of BPV and risk of stroke in UK B 
In order to examine the association between BPV and risk of stroke in UK Biobank, I 
need to know if there is any evidence to suggest how analyses between BPV and risk 
of stroke should be performed, including how an individual’s BP should be 
measured, and how BPV should be quantified.  For example, is there any consensus 
on the number of BP readings required, duration of measurement (days versus 
months versus years), gaps between successive measures (days versus weeks versus 
months), calculation of BPV (SD, versus CV, versus VIM, versus ARV), and 
adjustments for other factors (eg. comorbidities, anti-hypertensive medication, mean 
BP), which best predict risk of stroke? With this in mind, I performed a review of the 
literature, to summarise the most recent evidence for an association between 
medium-to-long term BPV and risk of stroke, and to investigate how BPV has been 
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7.2 Methods 
7.2.1 Search strategy and inclusion criteria 
I searched MEDLINE, EMBASE and Google Scholar until the end of June 2015 
using search terms ‘blood pressure variability’ and‘stroke’. I searched for studies of 
the association between any continuous measure of mdiu  to long-term BPV (eg. 
SD, CV, VIM, ARV, or transformations of these measures) and risk of stroke in any 
human adult population. I excluded studies which measured intermediate disease 
outcomes, (eg. carotid-intima media thickness, ‘silent infarction’, or white matter 
hyper-intensities)and excluded studies in post stroke populations because of the risk 
of reverse causality (increased blood pressure variability immediately following 
stroke). I also excluded studies which only measured short-term variability (24hr BP 
variability, or increased diurnal variability), because these measures appear to 
associate less strongly with cardiovascular outcomes than medium to long term 
variability.(Rothwell 2010) Furthermore, data on 24hr ABPM are not currently 
available in UK Biobank or any other very large prospective study. Medium-term 
blood pressure variability was defined as ‘day to day’ variability, and long-term 
blood pressure variability was defined as ‘month-to-m nth’, or ’year-to-year’ 
variability. I reviewed titles and abstracts of thefirst 300 results of each search, 
sorted by relevance, and full-texts of any potentially relevant articles. Finally, I 
reviewed bibliographies of included publications to search for additional relevant 
articles. 
7.2.2 Data extraction 
I extracted data from each included study on first author, publication year, population 
characteristics (country, age range, comorbidities), BP measurement (number of BP 
readings taken, time period over which BP measurements were repeated, time 
between repeated BP readings, if specified), stroke outcome measured and numbers 
(all stroke, fatal or non fatal stroke, ischaemic or haemorrhagic stroke), method of 
outcomes ascertainment (eg. expert medical record review, routinely coded data, or a 
combination of methods), duration of follow-up, BP variability measure(s) used, 
confounding factors accounted for in a alyses (eg. mean BP, age, sex, cardiovascular 
risk factors), and HR (95% CI) for stroke. 
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Where a number of different statistical models were us d, I extracted the result with 
the largest number of potential confounding factors accounted for (including mean 
BP at baseline and/or change in mean BP over time). I chose to report results for 
variability in systolic rather than diastolic BP because systolic BP (mean or 
variability) is a stronger predictor of stroke than diastolic BP (mean or 
variability).(Rothwell 2010) Finally, I extracted data from included studies on 
participant characteristics associated with increased BPV, and on any characteristics 
(from subgroup analyses) which increased the BPV associated risk of stroke. 
7.2.3 Data analysis 
I tabulated results for visual inspection. I did not perform meta-analysis or           
meta-regression because of heterogeneity between included studies in population 
characteristics, BP measurement methods (number of r adings, duration of 
measurement, and gap between measurements), and reporting of results.               
Visit-to-visit variability in blood pressure increases with the number of BP readings, 
the time period over which successive readings are taken, and the gap between 
successive readings.(Levitan et al. 2012) These factors need to be considered when 
comparing studies, and may introduce bias (if differences between subjects in 
numbers of BP readings, and/or period over which readings are taken, are 
independently associated with factors which increase the risk of stroke).  Where 
possible, I performed within study comparisons to investigate the influence of the 
BPV measure used on the risk of stroke (including number of BP readings, and/or 
time period over which readings were taken, and/or the statistical method used to 
quantify BPV). I also compared the influence of adjustment or not for confounding 
factors (including change in mean BP over time, and/or treatment with anti-
hypertensive medication) on prediction of risk. Finally, I looked for any evidence of 
differences (within each study) in the strength of associations between BPV and the 
main stroke types (ischaemic versus haemorrhagic stroke). 
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7.3 Results 
7.3.1 Results of search  
From 951 titles and abstracts, I reviewed 75 full-texts, and included 16 publications. 
(Figure 7.3).  
 
Figure 0.1 Flow diagram showing selection of primary studies which investigated associations 
between medium to long term BP variability and risk of stroke. 
*First 300 publications sorted by relevance out of 369,000. 
†MEDLINE and EMBASE search using the terms ‘Blood pressure variability’ and ‘stroke’.  
‡Bibliographies of included publications were searched for additional potentially relevant studies. 
 
Twelve of the excluded full-texts were reviews/commentaries and one was a 
systematic review and meta-analysis of data from two already included 
publications.(Tai et al. 2015) Seven studies were excluded because they assessed the 
composite outcomes of cardiovascular disease and/or all cause mortality instead of 
stroke, or because they assessed intermediate disease outcomes (eg. brain infarction)  
instead of stroke, (Johansson et al. 2012, Muntner et al. 2011b, Rossignol et al. 2012, 
Mancia 2012, Hsieh et al. 2012, Eguchi et al. 2012, Brickman et al. 2010) six 
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because they assessed short-term rather than medium- or long-term BP 
variability,(Pierdomenico et al. 2009, Eto et al. 2005, Meredith et al. 1995, Pringle et 
al. 2003, Frattola et al. 1993, Mena et al. 2005) seven because they assessed 
associations between mean BP (not variability) and risk of stroke,(Verdecchia et al. 
2001, Myint et al. 2008, Rapsomaniki et al. 2014, Lewington et al. 2002, Lim et al. 
2012, MacMahon et al. 1990, Ohkubo et al. 2004) four because they studied 
reproducibility in BPV measurements over time but not association of BPV with 
stroke,(Kimberlin and Winterstein 2008, Altman and Bland 1986, Muntner et al. 
2011a, Howard and Rothwell 2009) nine because they examined the relative 
effectiveness of different measures of BPV (ie. HBPM vs ABPM vs clinic BP), 
(Hodgkinson et al. 2011, Padfield 2010, Sheppard et al. 2014, Hodgkinson et al. 
2014, McManus et al. 2014, Warren et al. 2010, Dolan et al. 2005, Mann, Millar 
Craig and Raftery 1985, Mancia et al. 2012) and fourteen for a variety of reasons, 
including that they compared statistical measures of BPV but did not assess 
association between BP and outcomes (including stroke), r because they examined 
factors influencing BP variability.  
7.3.2 Characteristics of included studies 
Population characteristics 
Results are displayed in Table 7.4. Sixteen studies assessed the association between 
medium-to-long-term BP variability and risk of stroke in eighteen different 
populations. Six of these studies were post hoc analyses of data from clinical trials, 
nine were prospective observational studies, and one was a case control study.(Hata 
et al. 2000) Populations were from Europe (four UK based), US, Australia, Japan, 
China, Bangladesh, or multiple countries worldwide. Populations ranged in age from 
>18 to >70 years. Six of the populations studied were patients with 
hypertension,(Rothwell et al. 2010b, Carr et al. 2012, Chowdhury et al. 2014, Hata et 
al. 2000, Hastie et al. 2013, Yu et al. 2014) four had recent TIA,(Rothwell et al. 
2010b) one had type-2 diabetes,(Hata et al. 2013) and one had ‘vascular disease’ 
(including cardiovascular disease, type 2 diabetes, and cardiovascular risk 
factors).(Poortvliet et al. 2012) One study included men only,(Hashimoto et al. 2012) 
and another included women on dietary modification/h rmone therapy.(Shimbo et al. 
2012) The remaining studies were performed in relatively unselected 
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populations.(Schutte et al. 2012, Asayama et al. 2013, Kikuya et al. 2008, Yinon et 
al. 2013, Suchy-Dicey et al. 2013, Gao et al. 2014)  
The range of individuals with a diagnosis of hypertension was 24% to 71% amongst 
studies which did not select hypertensive participants.(Gao et al. 2014, Poortvliet et 
al. 2012, Hata et al. 2013, Kikuya et al. 2008, Schutte et al. 2012) From 2% to 39% 
of these participants were on anti-hypertensive medication at baseline.(Rothwell et 
al. 2010b, Yinon et al. 2013, Hashimoto et al 2012, Kikuya et al. 2012, Schutte et al. 
2012, Asayama et al. 2013). Amongst studies which selected for a diagnosis of 
hypertension, the proportion of participants on anti-hypertensive medication at 
baseline ranged from 50% to 100%.(Carr et al. 2012, Hata et al. 2000, Chowdhury et 
al. 2014). In general, the proportion of participants with a diagnosis of hypertension 






 Chapter 7: Blood pressure variability and risk of stroke.  



























2 home readings§ 
(28 days)   
2-4 weeks 12¶ 
Fatal stroke 
(49) 
VIM **  1.13 (0.88-1.46) 






1 SD increase ARV SBP 
MMD **  1.17 (0.92- 1.48) 










24 hours 11.9 
All stroke 
(223) 
VIM **  1.14 (1.00-1.30) 
1 SD increase VIM SBP 
ARV**  
1.13 (1.00-1.27) 
1 SD increase ARV SBP 
MMD **  1.12 (0.98-1.28) 


































24 hours 13.1¶ 








3mmHg increase SD SBP 
 
258 















































5 clinic readings 
(5 years) 















SD  1.00 (0.97-1.03) 
1 SD increase in SD SBP 
1,115 
 




















6 trial readings 
(21 months) 
























8 trial readings‡ 
(8 years)‡ 

































 7 trial readings 
(2.5 years) 
4 months ~3¶ 
All stroke 
(104) 
SD**,‡‡‡ 4.84 (3.03-7.74) 
Top vs. bottom decile SD SBP 
CV**,‡‡‡ 4.61 (3.11-6.83) 
Top vs. bottom decile CV SBP 
VIM **,‡‡‡ 3.88 (2.13-5.38) 








~ 13 trial readings 
(5.5 years) 






SD**,‡‡‡ 4.29 (1.78-10.36) 
Top vs. bottom decile SD SBP 




CV**,‡‡‡ 3.51 (1.56-7.53) 























SD**,‡‡‡ 4.39 (1.68-11.50) 
Top vs. bottom decile SD SBP 






Top vs. bottom decile CV SBP 
 
VIM **,‡‡‡ 3.57 (1.38-9.19) 







8 trial readings 
(2 years) 





Top vs. bottom decile SD SBP 
 
TIA CV**,‡‡‡ 2.22 (1.52-3.22) 
Top vs. bottom decile CV SBP 
VIM **,‡‡‡ 
1.86 (1.28-2.69) 
Top vs. bottom decile VIM SBP 
 
260 








7 trial readings 
(~ 2.5 years) 
4 months 2.6 
All stroke 
- 
SD**,‡‡‡ 3.35 (1.63-6.87) 
Top vs. bottom decile SD SBP 
Rothwell 
2010 
CV**,‡‡‡ 3.41 (1.62-7.19) 
Top vs. bottom decile CV SBP 
 VIM **,‡‡‡ 1.83 (0.76-4.39) 









~20 trial readings 
≥5 years 
2-12 weeks 5.9  
All stroke 
- 
Other§§§ 1.15 (1.01-1.31) 






































5 trial readings 
(1 year) 
 
3 months 3 
All stroke 
(158) 
SD**,§§§ 1.2  (0.8-1.9) 

















SD**,§§§ 1.3 (0.9-1.80) 





















CV****  OR 1.15 (1.03-1.29) 











































Top vs. bottom quartile ARV SBP 
 
261 



























Other§§§ 0.63 (0.28-0.44) 









≥ 6 clinic readings 
(~3 years) 
 





Top vs. bottom quartile SD SBP 
 
Shaded results are from post hoc analyses of data from clinical trials.  
*Stroke outcomes determined by medical record review, unless otherwise specified. CVD= Cerebrovascular Disease.  
†Blood Pressure Variability measure(s):VIM=Variation Independent of the mean, SD= Standard Deviation, CV= oefficient of Variation, ARV= Average Real 
Variability, MMD= Maximum minus minimum blood pressure difference, SDreg= Standard deviation regression. 
HR= Hazard Ratio. SBP= Systolic Blood Pressure 
‡Mean 
§Ten nurse measured BP readings taken on two separat occasions. 
¶Median 
** Adjusted for mean BP, age, sex, anti-hypertensive medication use (where relevant), and other cardiovascul r risk factors. 
††These data are from the same population. 
‡‡Only 48-49% of original population, because participants who were not at home/hospitalised, did not take home BP readings, or had <5 BP readings were 
excluded.   
§§ I60-I69 ICD-10 codes for stroke confirmed by verbal autopsy. 
¶¶Adjusted for age, sex, baseline SBP, heart rate, and betel leaf use. 
***  20 countries from Asia, Australasia, Europe, and North America. 
†††Adjusted for age, sex, anti-hypertensive medication, glucose control intervention, cardiovascular riskfactors, mean BP during measurement period. 
‡‡‡Also adjusted for change in mean BP over time and results were similar.  
§§§SD in SBP adjusted for change in mean BP over time.  
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¶¶¶ Case control study which used BP readings 1 year prio to development of stroke (and readings over 1 year for age matched controls).  
**** Adjusted for age, sex, presence/absence AF, frequency of hospital visits, proteinuria, smoking, status and mean BP.  Found a similar results when patients with 
diagnosed AF were excluded. 
††††This is a time to event analysis, so BPV is measured  until outcome (stroke) or death.  
‡‡‡‡Adjusted for age, sex, smoking, alcohol, BMI, cholesterol, prevalent CVD and estimated glomerular filtation  rate (eGFR). 
§§§§Based on death certificate codes ICD-9: 430-438 and ICD-10: I60-I69 
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BPV measurement methods 
 Included studies varied widely in their BP measurement methods. Blood pressure 
was measured in different environments (home vs. clinic), at different times of day 
(morning vs. evening vs. unspecified), using different observers (self-measured vs. 
clinician-measured), using different BP devices (manual vs. automated vs. 
unspecified), and with different measurement protocls (some published, some not).  
Some studies used a single BP reading per clinic vis t (or a single BP reading per 
day, if HBPM was used), whereas others used the mean of multiple ‘within-visit’ or 
‘within-day’ readings to get a single BP reading per day or per visit.  
Blood pressure variability (BPV) was estimated over days to weeks (medium-term) 
or over months to years (long-term). The number of separate ‘visits’ (home or clinic 
BP readings) used to derive visit-to-visit BPV ranged from 2 to 26, and the gap 
between these visits ranged from 24 hours to 2.2 years. One study which estimated 
BPV using only 2 visits included 5 separate BP readings from within each 
visit.(Schutte et al. 2012) The remaining studies required a minimum of 3 separate 
visits to estimate visit-to-visit BPV.  
Studies performed in trial cohorts used BP readings from ~5 to 20 outpatient visits 
taken over ~1 to 8 years. The time between successive visits was often standardised 
in clinical trials (mean gap amongst included studies ~4 months), and BP 
measurement followed published protocols. BPV measurement (number of readings, 
duration, and between visit gap) varied more widely amongst prospective 
observational studies. At one extreme, three studies us d home BP measurements 
taken over successive days for a period of ~1 month,(Asayama et al. 2013,  
Hashimoto et al. 2012, Kikuya et al. 2012) whereas at the other extreme one study 
used biennial BP readings taken over a period of 6 years.(Yinon et al. 2013) 
Four studies used routinely recorded BP measurements to estimate BPV.(Hata et al. 
2000, Hastie et al. 2013,  Gao et al. 2014, Yu et al. 2014) Blood pressure data were 
retrospectively extracted from hypertension outpatient clinics (Hata et al. 2000,  
Hastie et al. 2013), or from primary care medical records (Gao et al. 2014,  Yu et al. 
2014). Three of these studies were in hypertensive populations (Hata et al. 2000,  
Hastie et al. 2013,  Yu et al. 2014) and in the fourth ~ 70% of included individuals 
 
264 
 Chapter 7: Blood pressure variability and risk of stroke.  
were hypertensive.(Gao et al. 2014) The number of BP readings and between-visit 
gaps were not standardised in these studies.  
BPV was derived using a number of different statistical approaches. The main 
methods used (and reported) were SD, VIM, ARV, or atransformation in which SD 
SBP was adjusted for changes in mean BP over time.  
Follow-up and outcomes ascertainment  
Participants were followed up for 2 to ~13 years. In general, clinical trial populations 
were followed-up for a shorter duration (range 2 to 7 years) than prospective 
observational studies (range 1 to 13 years). Where reported, numbers of outcomes 
were generally small (38 to 318) for stroke or fatal s roke, and smaller for 
pathological types of stroke (28 to 89), apart from ne US study in women (~1,000 
stroke outcomes).(Shimbo et al. 2012)  The largest study population was ~12,600 
Chinese hypertensive patients which yielded 4,522 cerebrovascular events (combined 
stroke, TIA and other cerebrovascular disease).(Yu et al. 2014) Stroke diagnoses 
were mostly adjudicated by physician review of medical record data, or by expert 
committees. Two studies used routinely coded data for stroke outcome identification 
(International Classification of Diseases codes, ICD, for stroke, or cerebrovascular 
disease). (Gao et al. 2014, Yu et al. 2014) 
7.3.3 Overall results for BPV and stroke risk 
All included studies demonstrated at least a trend towards an association between 
increasing BPV and increased risk of stroke. Results were significant in seven studies 
(amongst these studies the hazard ratio, HR, for str ke ranged from 1.15 to 4.84 for 
higher versus lower BPV),(Kikuya et al. 2012, Shimbo et al. 2012, Rothwell et al. 
2010b,  Carr et al. 2012,  Chowdhury et al. 2014,  Hata et al. 2000, Yu et al. 2014) 
but did not reach significance, or were of marginal significance, in the remaining 
nine (amongst these studies the HR for stroke ranged from 1.03 to 1.51 for higher 
versus lower BPV).(Schutte et al. 2012, Asayama et al. 2013, Hashimoto et al. 2012,  
Yinon et al. 2013, Suchey-Dicey et al. 2013, Hata et l. 2013, Poortvliet et al. 2012, 
Hastie et al. 2013) 
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A statistically significant (or marginally significant) association between BPV and 
risk of stroke was detected in relatively unselected populations,(Asayama et al. 2013,  
Kikuya et al. 2012, Shimbo et al. 2012), as well as in populations with 
cerebrovascular disease or hypertension.(Rothwell et a . 2010b, Carr et al. 2012,  
Chowdhury et al. 2014, Hata et al. 2000, Yu et al. 2014). Associations were also 
detected when BPV was estimated over shorter (≤30 days),(Asayama et al. 2013, 
Kikuya et al. 2012) as well as over much longer time periods (years).(Shimbo et al. 
2012, Rothwell et al. 2010b, Carr et al. 2012, Yu et al. 2014) 
All but one of the included studies (Hastie et al. 2013, which used ARV to measure 
BPV) included mean BP as a covariate in Cox regression analyses.  All of the 
included studies also adjusted for age, and a selection of cardiovascular risk factors 
(Table 7.4). Three studies adjusted for renal disease (presence/absence of proteinuria, 
estimated Glomerular Filtration Rate, eGFR) (Hastie e  al. 2013, Hata et al. 2000, Yu 
et al. 2014). Ten studies adjusted for anti-hypertensive medication use.(Yu et al. 
2014, Poortvliet et al. 2012, Chowdhury et al. 2014, Rothwell et al. 2010b, Shimbo et 
al. 2012, Hata et al. 2013, Hashimoto et al. 2012,  Kikuya et al. 2012, Asayama et al. 
2013, Schutte et al. 2012) Of the nine studies which estimated BPV over ≥ 2 years, 
(Yu et al. 2014, Gao et al. 2014, Hastie et al. 2013 Poortvliet et al. 2012, Carr et al. 
2012, Rothwell et al. 2010b, Shimbo et al. 2012, Suchey-Dicey et al. 2013, Yinon et 
al. 2013), six adjusted  analyses for change in mean BP over time.(Gao et al. 2014, 
Poortvliet et al. 2012, Carr et al. 2012, Rothwell et al. 2010b, Suchy-Dicey et al. 
2013, Shimbo et al. 2012) Of those which did not consider such adjustment, one used 
average real variability as a measure of BPV.(Hastie et al. 2013)  
Influence of BPV measurement method(s) on stroke ri sk 
Rothwell showed that the predictive power of BPV may depend on the precision of 
BPV measurement.(Rothwell et al. 2010b) When the number of BP readings used to 
estimate BPV increased from  4 to 10 amongst 2,006 individuals in the UK-TIA 
cohort (nb.the time period over which measurements were taken also increased from 
~7 to ~ 36 months), the HR for stroke comparing top vs. bottom quintile SD SBP 
increased from 1.51 (95% CI 0.86-2.66) to 13.04 (95% CI 1.66-102.6).  A similar 
pattern, but smaller effect, was demonstrated in the Women’s Health Initiative 
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trial.(Shimbo et al. 2012) Using 3 to 4 BP readings (over ~ 4 years), the HR for 
stroke with 5mmHG increase SDreg SBP was 1.02 (0.91-1 14), and using 10 to 11 
BP readings (over ~11 years) the HR for stroke with 5mmHg increase in SDreg SBP 
increased to 1.44 (0.85-2.45). In studies of medium-ter  BPV and stroke risk (ie. BP 
measured over days rather than over months to years), the number of BP readings 
(and duration over which readings were taken) had a marginal or no effect on stroke 
risk.(Asayama et al. 2013, Kikuya et al. 2012) Comparing 5 readings over 5 days 
versus ~26 readings over ~26 days the HR for stroke wer  1.13 (95% CI 0.99-1.28) 
and 1.14 (95% CI 1.00-1.30), respectively.(Asayama et l. 2013) Similar results were 
found comparing BP readings over 10 days to readings over ~26 days (Second study 
in the same population).(Kikuya et al. 2012)  
Influence of statistical analysis method on stroke risk  
Five studies published results for BPV and risk of stroke using different statistical 
measures of BPV including SD, CV, VIM, ARV, and maximum minus minimum 
blood pressure difference.(Rothwell et al. 2010b, Schutte et al. 2012, Asayama et al. 
2013, Suchy-Dicey et al. 2013, Hata et al. 2013) All five studies found similar results 
regardless of the method used to quantify BPV. Two additional studies reported that 
results were similar for SD SBP and CV SBP, and chose t  report only SD 
SBP.(Kikuya et al. 2012, Poortvliet et al. 2012) 
Rothwell adjusted analyses for change in BP over time as well as for mean BP, and 
this adjustment did not alter the risk associations, however results were not 
published. Shimbo compared HR stroke with and withou  adjustment for change in 
mean BP over time by comparing HR stroke using SDreg SBP with HR stroke using 
SD SBP (BPV measured over mean duration 8 years).(Shimbo et al. 2012) Risk 
associations were slightly attenuated ‘with’ compared to ‘without' adjustment for 
change in mean BP over time’, HR for top versus bottom quartile SDreg SBP 1.46 
(95% CI 1.15-1.85) versus HR for top versus bottom quartile SD SBP 1.72 (95% CI 
1.82-2.32). Shimbo reported results from the same population treating BPV as a 
continuous rather than a categorical variable. The magnitude of effect was smaller 
when BPV was treated as a continuous variable, HR stroke with 5mmHg increase in 
SD SBP was 1.16 (95% CI 1.08-1.24) and HR stroke with 5mmHg increase in SDreg 
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SBP was 1.12 (95% CI 1.05-1.19), compared to when BPV was treated as a 
categorical variable (comparing top versus bottom quartile BPV, above). 
Blood pressure variability and the risk of main str oke types.   
Blood pressure variability was associated with a trend towards an increased risk of 
both ischaemic and haemorrhagic stroke in the Women’s Health Initiative trial 
(Shimbo et al. 2012), but the magnitude of effect was small in both cases, and 95% 
confidence intervals crossed zero for haemorrhagie stroke. HR for 5mmHg increase 
in SDreg SBP was 1.12 (95% CI 1.04-1.21) for ischaemic stroke, and 1.14 (95% CI 
0.97-1.34) for haemorrhagic stroke. In two other studies,(Kikuya et al. 2012, 
Rothwell et al. 2010b) BPV was associated with increased risk of ischaemic, but not 
haemorrhagic stroke, but smaller numbers of haemorrhagic vs. ischaemic stroke 
outcomes may have made it harder to detect an associ tion in the haemorrhagic 
subgroup. In one Japanese study HR for 3mmHg increase SD SDP was 1.26 (95% CI 
1.02-1.55) for ischaemic stroke and 0.97 (95% CI 0.65-1.46) for intracranial 
haemorrhage, based on 89 ischaemic and 29 haemorrhagic stroke outcomes.(Kikuya 
et al. 2012)   
Characteristics associated with BPV and with increa sed BPV-related 
stroke risk 
Amongst included studies, blood pressure variability increased with age,(Rothwell et 
al. 2010b, Schutte et al. 2012, Hata et al. 2013, Shimbo et al. 2012, Hastie et al. 
2013) female sex,(Hata et al. 2013, Rothwell et al. 2010b. Hastie et al. 2013) mean 
blood pressure,(Shimbo et al. 2012, Rothwell et al. 2010b, Kikuya et al. 2012, Hata 
et al. 2013, Hastie et al. 2013) and past history of vascular disease, including baseline 
chronic kidney disease.(Rothwell et al. 2010b, Hata et l. 2013, Hastie et al. 2013) 
However, the association between BPV and risk of str ke was stronger in younger 
age groups, (Rothwell et al. 2010b, Shimbo et al. 2012) and amongst those with 
lower mean BP.(Rothwell et al. 2010b, Shimbo et al. 2012)   
Influence of anti-hypertensive medication on BPV an d BPV-related 
stroke risk 
Four studies reported that antihypertensive medication use was associated with 
higher indices of blood pressure variability,(Asayama et al. 2013, Suchy-Dicey et al. 
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2013, Hata et al. 2013, Shimbo et al. 2012) one found no such association,(Hata et al. 
2000) and three reported that B-blockers were associated with increased BPV 
compared to other classes of anti-hypertensive medication.(Schutte et al. 2012, 
Rothwell et al. 2010b, Carr et al. 2012) Three studies reported analyses for the 
association between BPV and risk of stroke in subgroups of patients ‘on’ versus 
patients ‘not on’ anti-hypertensive medication.(Rothwell et al. 2010b, Suchy-Dicey 
et al. 2013, Shimbo et al. 2012) Rothwell found that visit-to-visit BPV predicted risk 
of stroke irrespective of treatment, HR for top versus bottom decile VIM SBP 3.67 
(95% CI 2.34-5.75) for those ‘on’ treatment, and 2.27 (95% CI 1.41-3.67) for those 
‘not on’ treatment.(Rothwell et al. 2010b) Suchy-Dicey found no difference in the 
association between BPV and risk of stroke amongst patients without hypertension 
and ‘not on treatment’(HR 1.03 for 1SD increase SD SBP, 95% CI 0.89-1.21), 
compared to those with hypertension on ‘stable treatm nt’ (HR 1.00, 95% CI 0.97-
1.03), or compared to those with hypertension and ‘stopping/starting’ treatment (HR 
1.06, 95% CI 0.92-1.22).(Suchy-Dicey et al. 2013) Shimbo found that increased BPV 
was significantly associated with risk of stroke in ~33,000 individuals ‘not on’ 
antihypertensive treatment (HR for stroke associated with a 5mmHg increase SDreg 
SBP was 1.21, 95% CI 1.06-1.37), but not in ~13,000 individuals ‘on’ 
antihypertensive treatment (HR 1.06, 95% CI 0.97-1.16). However, the association 
was positive in both groups, and smaller numbers of participants ‘on treatment’ may 
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7.4 Discussion 
7.4.1 Summary of findings 
All included studies demonstrated a trend towards an association between increased 
medium to long-term BPV and risk of stroke. Hazard ratios for stroke ranged from 
1.03 to 1.51 for a 1 standard deviation increase in BPV (8 studies), from 0.93 to 1.93 
for top versus bottom quartiles of BPV (4 studies) and from 1.78 to 4.84 for top 
versus bottom deciles of BPV (2 studies). One Japanese study showed that lower 
BPV reduced the risk of fatal cerebrovascular disease (HR 0.63, 95% CI 0.28-0.44 
for low versus high BPV). In the only case control study, the odds ratio for stroke 
associated with a 2% increase in CV BP was 1.15 (95% CI 1.03-1.29).  
Included studies varied widely in their BP measurement methods, approaches to 
quantifying BPV, duration of follow up (and numbers of stroke outcomes detected), 
statistical analyses (particularly approaches to adjustment for mean BP), and 
reporting of results. In a number of studies, blood pressure variability increased with 
age, female sex, rising mean BP, and past history of vascular disease. In two studies, 
the association between BPV and stroke was stronger i  younger age groups and in 
those with lower mean BPV.  
BPV is an important potential risk factor for stroke, but there is a lack of consensus 
on how BPV should be measured to best predict stroke is . This is the biggest 
challenge to investigating associations between BPVand stroke risk in future studies, 
and needs to be overcome in the long-term if BPV is to become a target for stroke 
prevention in clinical practice. 
7.4.2 Limitations of previous studies 
Included studies have had a number of limitations. First, small numbers of outcomes 
(33 to 318 strokes in all but one study) have limited statistical power to detect the 
association between BPV and risk of stroke reliably. The study with the largest 
number of stroke outcomes (n=997) did show a statistically significant association 
between increased BPV and increased risk of stroke,(Shimbo et al. 2012) but these 
data were from a clinical trial and BP measurement methods (including setting, use 
of standardised measurement protocols, and the relatively fixed gap between 
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successive ‘visits’) are therefore less generalizable to the ‘real world setting’. 
Second, many of the included studies were in selected populations (amongst 
individuals with TIA, hypertension, diabetes or other vascular risk factors), and 
results of these studies are less generalizable to the population as a whole, 
particularly if the association between BPV and stroke is stronger amongst 
individuals with already elevated vascular risk. Of note, all UK based studies 
selected individuals with hypertension. Fourth, only three studies used BP data 
captured in routine clinical practice to estimate BPV. The remaining studies 
measured BP for research purposes (clinical trials, or prospective observational 
studies which measured BPV for a fixed duration, at relatively fixed intervals, and 
following published protocols). BP measurements in these studies are therefore not 
representative of ‘real world’ clinical practice. Of the three studies which used 
‘routinely captured data’, two were in hypertensive populations, two analysed CVD 
outcomes (not stroke), and two used outpatient BP readings (rather than primary care 
data). The only study which used routinely captured primary care data to measure 
BPV was based in Japan, and this looked at fatal CVD outcomes (based on ICD 
coded data only). Sixth, it is not yet clear if differences exist in the strength of the 
association between BPV and the main stroke types (ischaemic vs. haemorrhagic 
stroke), and larger studies, accruing more outcomes ov rall, will be required to test 
these associations. Seventh, there have been no studies of the associations between 
BPV and the risk of ischaemic or haemorrhagic stroke subtypes.  
7.4.3 Strengths of the review 
This review includes more of the available, relevant data than previous published 
reviews of BPV and risk of stroke/cardiovascular disease.(Tai et al. 2015) Additional 
strengths include firstly the focus on stroke outcomes, rather than all cerebrovascular 
disease, or all cardiovascular disease. Some studie have shown differences in the 
strength of associations between BPV and risk of all cause mortality versus 
cardiovascular disease, versus stroke, versus MI.(Kikuya et al. 2012, Yinon et al. 
2013, Suchy-Dicey et al. 2013, Hata et al. 2013) Secondly, I chose to focus on 
medium-to-long term BPV, rather than all forms of BPV, because BPV over these 
different durations (<24hr versus day-to-day versus month-to-month) may represent 
different clinical or pathological phenomena.(Rothwell 2010, Parati et al. 2013) 
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Amongst included studies, I have shown that an associati n between BPV and stroke 
risk exists in relatively unselected populations, as well as in those with increased 
vascular risk (eg. TIA/hypertension cohorts), and that ‘real world data’ (eg. BP 
measurements taken in routine primary care or outpatient clinics) can be used to 
predict risk of stroke as well as more standardised data (eg. BP readings from clinical 
trials). Finally, I have shown (in a number of different within study comparisons) that 
the association between medium-to-long term BPV and stroke risk did not appear to 
be affected by the statistical measure of BPV, or by the presence or absence of 
adjustment for mean BP over time.   
7.4.4 Limitations of this review 
Although I included more of the relevant published data for stroke than previous 
similar reviews,(Tai et al. 2015, Floras 2013, Manci  2012, Nagai and Kario 2013, 
Diaz et al. 2014, Hocht 2013) I did not assess for inclusion all titles and abstracts 
from my initial search, and I may have inadvertently excluded some relevant articles. 
Furthermore, the trend towards an association between BPV and stroke may be due 
to publication bias (but this seems unlikely, given the current lack of consensus 
amongst experts as to whether BPV is a true independent risk factor for stroke). The 
association between increased BPV and risk of stroke was significant in some but not 
all included studies. This might reflect the relatively small numbers of strokes 
detected in some studies, reduced precision of BPV measurement (which may be a 
function of number of measures, duration of measurement, and gap between 
measurements), and different methods of reporting results (for example, comparing 
top versus bottom deciles or quartiles of BPV and stroke risk), or it may mean that 
increased BPV does not associate with increased risk of troke in all circumstances. 
Included studies were from a wide variety of countries and populations, and 
differences in genetics, age, vascular risk factors, and/or the distribution of main 
stroke types (haemorrhagic stroke being more common in Asia than in Western 
Europe) may influence the overall association betwen BPV and risk of stroke.  It 
was not possible to reconcile the above differences between studies, and for this 
reason it was also not possible to perform meta-analysis or meta-regression. Previous 
research has shown that visit-to-visit BP variability ncreases with the number of BP 
readings, with increased gap between BP readings (and over longer time periods), 
 
272 
 Chapter 7: Blood pressure variability and risk of stroke.  
and with single visit measures (vs. mean of multiple measures).(Levitan et al. 2012) 
It is important to consider such differences in these between studies, particularly if 
the number of BP readings taken per individual (or study) is correlated with an 
independent risk factor for stroke. Eight of the included studies did not use 
standardised numbers of BP readings amongst included participants, and therefore 
risk this form of bias.      
Included studies adjusted for different confounding factors. It is possible that the 
association detected between BPV and risk of stroke is the result of residual 
confounding in some studies. One potential factor, n t considered in many studies, 
was the presence/absence of renal disease. Chronic kid ey disease is independently 
associated with both BPV,(Nakano et al. 2015) and with stroke,(Masson et al. 2015) 
and may account for some of the BPV associated stroke risk.  However, three of the 
included studies which did adjust for some form of renal disease,(Hastie et al. 2013, 
Hata et al. 2000, Yu et al. 2014) found a marginal association, or non-significant 
trend towards an association, between BPV and risk of troke.   
Some critics of the BPV hypothesis suggest that BPV is due to an effect of            
anti-hypertensive medication (potentially variable compliance, or non-compliance) 
and that BPV associated vascular risk might be entirely avoided by better adherence 
to established BP treatment guidelines. However, one study included in this review 
found similar associations between BPV and risk of stroke in subgroup analyses of 
patients off  anti-hypertensive medication, compared to those on anti-hypertensive 
medication, or those  starting/stopping anti-hypertensive medication.(Suchy-Dicey et 
al. 2013) Other studies found similar associations between BPV and risk of stroke 
irrespective of treatment or not, whilst some found stronger associations between 
BPV and risk of stroke in those off  treatment. The argument that BPV is a definite 
physiological and pathological phenomenon is further confirmed by the fact that 
BPV is reproducible within individuals over time.(Muntner et al. 2011a, Howard and 
Rothwell 2009, Rothwell et al. 2010b) 
Other critics suggest that BPV associated vascular risk is small compared to mean 
BP, so that even if BPV is an independent risk factor for stroke, most of the risk can 
still be attributed to mean BP, and therefore this s ould remain the focus of clinical 
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risk assessment and treatment. Subgroup analyses (amongst studies included in this 
review) have shown that BPV associated stroke risk is higher in those with lower 
mean BP, and is also increased in younger versus older age groups (age groups 
which conventionally have less hypertension and less competing vascular risk factors 
overall). Therefore, although BPV may be more common amongst those with high 
blood pressure, and although BPV contributes a greater proportion of risk (relative to 
mean BP) amongst those with high BP, it may still be important to identify and treat 
BPV amongst younger individuals with normal blood pressure (for risk prevention). 
Furthermore, in the young, strokes are often cryptogenic, so it is particularly 
important to consider and investigate new risk factors in this group of individuals.  
7.5 Conclusions and future directions 
There is definite evidence that BPV is an important potential risk factor for stroke.  
We need to continue to explore which groups of individuals have increased BPV, 
and which are at most risk of stroke from increased BPV (and therefore would 
benefit most from new approaches to BP monitoring and treatment). It appears 
possible to demonstrate an association between BPV and risk of stroke using 
routinely captured ‘real world’ BP data, but previous studies which used these 
methods have had small numbers of stroke outcomes, have been in selected 
populations, or have used less precise methods of stroke confirmation (based on 
ICD-coded data only). As yet, there has been no study of the association between 
BPV and risk of stroke using data from a relatively unselected UK based primary 
care population. It is also not yet clear if the association between BPV and risk of 
stroke varies by stroke type (ischaemic versus haemorrhagic stroke), and there has 
been no study of the association between BPV and ischaemic and haemorrhagic 
subtypes. UK Biobank has the potential to overcome these limitations, due to large 
numbers of anticipated stroke outcomes, access to linked coded primary care, 
hospital and mortality data, and development of detailed stroke outcomes 
ascertainment and confirmation methods (outlined in previous chapters).  
7.5.1 Future aims 
In the following chapter I aim to explore the potential of routinely captured, coded 
primary care BP data to identify BPV in the UK-Biobank population. If coded data 
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can be used to identify individuals with increased BPV, it may be used to measure 
BPV in future studies of associations between BPV and risk of stroke, its main types 
and subtypes, in UK Biobank.
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Chapter 8 Can coded primary care data be 
used to measure blood pressure 
variability? 
• Blood pressure variability (BPV) may be an independent risk factor for 
stroke, but further large population based studies ar  required to reliably 
investigate this association.   
• Confirming an association between BPV and stroke has important potential 
implications for BP monitoring and treatment and may provide new insights 
into stroke mechanistic pathways.  
• UK Biobank has linkages for follow-up to national coded healthcare data. 
These data might be used to capture a novel exposure, ch as BPV. 
• In this chapter I report my investigation of the potential of using routinely 
collected coded primary care data to estimate visit-to-visit BPV in a         
sub-cohort of ~10,000 UK Biobank participants.  
•  I identified participants in whom visit-to-visit BPV could be measured 
using coded systolic blood pressure values (BP), explored the range of 
variability detected (SD BPV),  the generalisability of populations selected, 
and the potential accuracy of coded BP data. 
• I found that visit-to-visit BPV was captured in the majority of participants. 
Selecting participants with more coded BP data reduc  generalizability, but 
there was good variability in BPV amongst those selct d, and reasonable 
agreement between coded BP and an independent reference standard.  
• I concluded that routinely collected coded primary care data could estimate 
BPV in UK Biobank participants. This would enable future exploration of 
associations between BPV and stroke, in a ‘real word’ setting, and in larger 
numbers of individuals than previously possible.  
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In this chapter, I explored the feasibility of using routinely captured, coded primary 
care data to measure blood pressure variability in UK Biobank participants. I used 
de-identified data from >10,000 Welsh UK Biobank participants for whom linked 
coded primary care data are available through the Secure Anonymised Information 
Linkage (SAIL) platform hosted by Swansea University. In the long run, this work 
will inform potential approaches to BPV measurement in UK Biobank, enabling 
future nested case cohort or case control studies of the associations between BPV, 
stroke, its main types and subtypes. 
8.1.2  Exploring associations between BPV and strok e in UKB 
In the previous chapter, I showed that there is a trend towards an association between 
blood pressure variability and risk of stroke. However, previous studies have had a 
number of limitations including use of data from rest icted populations eg. clinical 
trial populations and, or populations with TIA, hypertension, diabetes, or other risk 
factors, and small numbers of stroke outcomes, some of which were based on less 
accurate sources of data (eg. ICD codes only).   
 UK Biobank (UKB) has the potential to overcome some of these limitations. Around 
5,000 incident stroke cases are expected to have occurred amongst UK Biobank 
participants by the end of 2017 (~4,000 ischaemic and ~1,000 haemorrhagic). These 
anticipated outcomes are around ten times the numbers available in previous studies 
(Chapter 7). Furthermore, UK Biobank is developing more accurate methods of 
stroke outcomes confirmation and sub-classification than used in previous, large, 
prospective observational studies. Therefore, if BPV could be measured in a 
sufficient proportion of UKB participants, it would enable large numbers to be 
included in future studies of the potential associations between BPV, stroke, and its 
main types in UKB.
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8.1.3 Measuring BPV: the potential of coded primary  care 
data 
UK Biobank has cohort wide linkages to routinely collected coded primary care data.  
Although these data were primarily linked for participant follow-up and outcomes 
adjudication, they could also be used to measure exposures. It may be possible to use 
primary care coded data (BP related Read codes and the coded BP values associated 
with them) to measure visit-to-visit BPV. 
The advantage of using coded primary care data to measure additional exposures 
(those not measured at the baseline assessment) is that t is an efficient and cost 
effective method because these data have already been collected. This is particularly 
relevant for the measurement of visit-to-visit blood pressure variability (BPV), which 
would require each participant to undergo multiple BP measurements at multiple 
different outpatient visits.  Using previously collected data means that a larger 
number of UKB participants would be included in any future study than would 
otherwise be possible. This would make the most of the large numbers of anticipated 
stroke outcomes (above). Furthermore, because coded primary care data are collected 
in routine clinical practice, it would enable exploration of the association between 
BPV and stroke in a ‘real world’ setting. 
8.1.4 BP in the coded primary care record: the Qual ity 
Outcomes Framework (QOF). 
Using primary care data to estimate within participant BPV requires a sufficient 
number of individuals to have a sufficient number of coded BP measurements in 
their primary care record. Since its inception in 2004, the UK primary care Quality 
Outcomes Framework (QOF) has included targets for the proportion of individuals 
aged 45 years and older, registered with a GP, who have had a BP measurement. The 
quality outcomes framework (QOF) became part of the general practitioner contract 
in April 2004. Participation is voluntary, but all practices in Wales participated. The 
QOF rewards individual GP practices for the provision of ‘quality care’ by helping to 
fund the delivery of care. Payment is contingent on a practice achieving pre specified 
targets. For example in 2004-2005, 55 to 75% of those 45 years and older in the UK 
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were required to have at least one blood pressure reading recorded within the 
previous 5 years. The proportion was increased in 2006-2007 to include at least 65 to 
80% of individuals over the age of 45. Stricter targets are in place for BP 
measurements amongst individuals with various vascul r risk factors including 
diabetes, known hypertension, cardiovascular disease (stroke, TIA and coronary 
heart disease), and renal disease. From 2004, these individuals were required to have 
a BP measurement recorded in their medical records every 15 months (or every 9 
months for those with established hypertension).  Since 2011, these targets have also 
applied to individuals with schizophrenia, bipolar disease, other psychoses, 
peripheral arterial disease, and those with rheumatoid rthritis, and from 2013 
onwards, annual BP readings have been 
required.(http://www.wales.nhs.uk/sites3/page.cfm?orgid=480&pid=10486) With 
these incentives in place, and with the fact that Welsh GP practices all participate in 
QOF, a large proportion of individuals should have t least annual or biennial BP 
readings recorded in the UK Biobank Welsh primary care dataset. Furthermore, I 
hypothesised that the number and frequency of BP readings recorded in the coded 
primary care record is likely to have increased over time (partly due to these 
incentives, and partly due to the changeover from handwritten to computerised 
medical records).  
8.1.5 Objectives 
My specific objectives for this chapter were as follows: 
1) To determine what proportion of the UKB Welsh population have sufficient coded 
primary care data to estimate visit-to-visit BPV. 
2) To determine the numbers of participants who can be identified with ‘x’ visits 
(each with coded BP readings), ‘y’ times prior to UK Biobank recruitment.  
3) To determine generalisability of individuals with coded BP values to the whole 
population (UKB Welsh participants with coded primary care data) 
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4) To determine the variability in BPV amongst selected individuals, to judge if this 
is sufficient to be able to detect an association between increasing BPV and 
increasing risk of stroke.   
5) To compare within individual agreement between the mean BP recorded at the 
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8.2 Methods 
8.2.1 Defining the denominator population 
For this work I used de-identified coded primary care data from 9,947 UK Biobank 
(UKB) participants recruited in Wales between 2006 and 2010. Coded primary care 
data were first made available to UK Biobank in early 2014 through the Secure 
Anonymised Information Linkage (SAIL) platform hosted by Swansea 
University.(Ford et al. 2009, Lyons et al. 2009) At the time of this study, SAIL 
received data from ~ 50% of Welsh GP practices, and provided linked coded primary 
care data for follow-up of 11,147 Welsh UK Biobank participants (~50% of the 
21,000 UKB participants recruited in Wales).  
I requested de-identified coded primary care data from these 11,147 UK Biobank 
participants in early 2014. I downloaded all available coded data (version 2 Read 
codes from categories A to Z, 0 to 9, or from the ‘drugs and appliances dictionary’) 
into stata version 12 at the end of June 2014.  
From the original population (n=11, 147), I excluded 1,200 who did not have 
‘continuous registration’ with a ‘SAIL GP practice’ (a Welsh GP practice which 
provided coded primary care data to SAIL). I defined continuous registration as 
having a gap of <30 days between successive SAIL GP practice registrations. 
Participants were therefore excluded if they were rgistered for >30 days outside of 
Wales, or if they spent >30 days in Wales registered with a non SAIL GP practice.  
Data provided until 31/1/2012 were assumed to be ‘complete’ for all SAIL GP 
practices.  I excluded 8,658 records entered after this date (0.2% of all records) 
because some SAIL GP practices might not have uploaded their most recent data. I 
also excluded 7,786 coded events which had an ‘impossible’ event date, ie. the event 
date was before the participant’s date of birth. The final population with continuous 
registration in a Welsh SAIL GP practice until the end of 2012 was 9,947. These 
individuals represented ~47% of Welsh UKB participants, and ~2% of the original 
UKB cohort.  
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8.2.2 Primary care data structure and definitions  
The basic structure of the primary care coded dataset (provided in the SAIL 
database) is displayed in Table 8.1. BP related Read codes are shown for illustration, 
but the original dataset included all coded events (Read codes from any chapter plus 
drug prescriptions).  
Table 8.1 Structure of the primary care coded dataset* 
PT_ID_E DOB EVENT_CD TERM_60 EVENT_DT VALUE1 VALUE2  
1† D/M/Y 662.. Hypertension monitoring§ D/M/Y‡ 0§ . § 
1† D/M/Y 246.. O/E -  BP reading D/M/Y ‡ 120 80 
1† D/M/Y 246.. O/E -  BP reading D/M/Y 110 70 
2 D/M/Y 2469. O/E -  systolic BP¶ D/M/Y 140 .  
3 D/M/Y G2… Hypertensive disease§ D/M/Y 0§ . § 
3 D/M/Y 246.. O/E – BP reading D/M/Y 0 100 
4 D/M/Y 246A. O/E -  diastolic BP¶ D/M/Y 100 . 
 
PT_ID_E: Anonymous participant identifier 
DOB: date of birth 
EVENT_CD: Read code 
TERM_60: Text definition accompanying the Read code 
EVENT_DT: Event date, which is the presumed date of the GP visit.  
VALUE1: Usually systolic BP (for a BP-related Read code). 
VALUE2: Usually diastolic BP (for a BP-related Read code). 
*BP related read codes are used as an example, however th  original dataset included the full available 
primary care coded record for each participant, and therefore included all types of Read codes 
(categories A-Z, 0 to 9, and medication codes) . 
†Each new row of data is a new record (a new Read code with its associated participant identifier, text 
definition, event date, +/- values). I grouped recods by participant identifier, and then sorted them in 
chronological order.    
‡If two different records had the same participant identifier and same event date, they were assumed to 
have originated from the same GP visit. Multiple Read codes can be entered to describe different 
aspects of a single GP visit (eg. symptom codes, examination findings, administration codes, 
prescription codes).  
§Not all BP related Read codes had associated BP values. ‘0’ and ‘.’ were ‘missing values’. 
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¶Twenty two Read codes specified the type of BP measur ment in the Read code text definition, eg. 
systolic BP or diastolic BP. These codes made up <1% of all BP codes with values. For the remainder, 
VALUE1 was assumed to be systolic BP, and VALUE2 was assumed to be diastolic BP. 
 
I defined various terms, as follows: 
1) Coded event: each new row of data. Each coded evnt included an anonymous 
participant identifier (and date of birth), a Read code with its accompanying text 
definition, and an event date. The event date was the presumed date of the GP visit 
(and the closest approximation to the date on which the event occurred). Some (but 
not all) coded events with BP related Read codes included BP values (VALUE1 
and/or VALUE2). 
2) A participant’s coded primary care record: All coded events with the same, 
unique, participant identifier made up that participant’s coded primary care record 
(represented by shading in Table 8.1).  
3) GP visit: For each participant, coded events with the same event date were 
assumed to have arisen from the same GP visit. Multiple coded events (eg. multiple 
Read codes +/- multiple coded BP values) could have been recorded at a single GP 
visit.  
8.2.3 Characteristics of the denominator population  
I counted the number of coded events included in this dataset, and the number of 
coded events included per individual. I grouped reco ds by year to count the numbers 
of events available from 1980 to the end of 2013 (note, I did this step before 
censoring records at the end of 2012, section 8.2.1, above). I investigated the 
duration of coded events, per individual, using the last coded event date – first coded 
event date. I then investigated characteristics of the denominator population 
including age, gender (% male), and % of vascular risk factors using linkage to the 
UK Biobank baseline assessment dataset (see section 8.2.8, below, for methods).  
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8.2.4 Creating Read code lists for BP 
My original dataset included Read codes for every possible diagnosis. However, I 
aimed to identify groups of individuals who had blood pressure related Read codes in 
their coded primary care record. This would enable me to identify individuals who 
had ‘probable’ or ‘possible’ hypertension, as well as individuals (with or without 
hypertension) who had their BP measured. The first step in this process was creating 
a ‘Read code list’ for blood pressure.  
I used three sources to search for Read codes related to blood pressure (specifically, 
5-byte version 2 Read codes, as this was the version u ed in SAIL at the time of my 
study). Firstly, I searched the NHS Read code browser u ing the terms ‘blood 
pressure’, ‘hypertension’, ‘hypotension’, ‘BP’, ‘hypert’, ‘blood-pressure’, ‘labile’, 
‘high’, and ‘low’. I then manually searched the browser for additional Read codes, 
looking within the following categories/subcategories: ‘family history’, 
‘cardiovascular symptoms’, ‘past medical history’, ‘history of cardiovascular disease, 
‘suspected condition’, ‘examination of cardiovascular system’, ‘on examination: 
blood pressure reading’, ‘hypertensive disease’, and ‘cardiovascular drugs’.  
Secondly, I included Read codes from the ‘QOF hypertension indicator set for 
Wales’ which I found on the NHS Wales website (http://www.wales.nhs.uk/), using 
the search terms ‘QOF’, ‘Read codes’ and ‘hypertension’. Thirdly, I searched two 
CALIBER primary care code lists for blood pressure: hypertension diagnosis, and 
‘blood pressure category’.(http://www.caliberresearch.org/)  
I included Read codes from all three sources, (ie. any Read code potentially related 
to blood pressure) apart from Read codes for cardiovascular drugs (eg. thiazide 
diuretics, calcium channel blockers, loop diuretics etc.), because these can be 
prescribed for a number of different medical conditions and are therefore less 
specific to ‘hypertension’.  
8.2.5 Identifying participants with ‘probable’ or ‘ possible’ 
hypertension based on Read code text definitions. 
After identifying as many BP related Read codes as possible, I divided codes into 
five categories based on their text definitions (see Table 8.1 for examples of ‘text 
definitions’). The five categories were: 
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1) Hypertension ‘diagnosis’ codes: diagnostic codes which identified participants 
with ‘probable’ hypertension (eg., ‘G….’ for ‘hypert nsive disease’).  
2) Hypertension ‘administration’ codes: administrative codes which identified 
participants with ‘possible’ hypertension (eg., ‘9N03.’ for ‘seen in hypertension 
clinic’) 
3) Blood pressure ‘monitoring’ codes: codes which implied that blood pressure was 
measured, some of which also identified participants wi h ‘possible’ hypertension 
(eg., ‘662..’ for ‘hypertension monitoring’). 
4) Hypotension ‘diagnosis’ codes: diagnostic codes which identified participants 
with hypotension (eg., ‘G870.’ for ‘orthostatic hypotension’) 
5) Blood pressure ‘value’ codes: codes which implied that they were associated with 
recorded BP values (eg., ‘246..’ for ‘on examination: blood pressure reading’) 
I searched for each Read code individually to see how frequently it was recorded in 
the dataset.  I then identified the number of participants (out of 9,947 in my 
denominator population) who had any Read code related to BP. From within this 
population I searched for individuals who had a ‘probable’ or ‘possible’ diagnosis of 
hypertension using combinations of Read codes from category 1 (above, for 
‘hypertension diagnosis’) and selected Read codes from categories 2 to 3 (above, for 
‘hypertension administration’, or ‘blood pressure monitoring’). See Appendix 8.6 
(Table 8.14) for the groups of Read codes used to define ‘probable’ or ‘possible’ 
hypertension. Finally, from within the population identified with ‘probable’ 
hypertension, I searched for numbers of participants who had at least one coded 
event for ‘blood pressure monitoring’ and/or at least one coded event with ‘blood 
pressure values’. I repeated this for the population of individuals without any 
‘probable hypertension’ Read codes. I constructed a Venn diagram to display the 
proportion of individuals with and without ‘probable’ hypertension who had at least 
one instance of blood pressure monitoring, and/or at least one recorded BP value. 
Analyses were performed in Stata (version 12).  
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8.2.6 Creating a dataset of systolic blood pressure  (SBP) 
values. 
I identified the proportion of BP Read codes in the dataset, stratified by category (1 
to 5, above), which had associated BP values. I expected blood pressure ‘monitoring’ 
and blood pressure ‘value’ codes to have associated BP values, whereas I did not 
expect hypertension ‘diagnosis’ or ‘administration’ Read codes to have BP values.  
If ‘monitoring’ or ‘value’ Read codes did not have BP values (either VALUE1 or 
VALUE2 present), I considered these data ‘missing’. I investigated characteristics of 
individuals with BP value data using linkage between the primary care dataset and 
the UK Biobank baseline assessment dataset (see section 8.2.7, below, for these 
methods). 
My next aim was to create a dataset of systolic blood pressure values. I chose to 
focus on systolic blood pressure, rather than diastolic blood pressure, because 
systolic BPV has been shown to associate more strongly with risk of stroke than 
diastolic BPV.(Rothwell et al. 2010b) VALUE1 was assumed to be systolic BP 
(SBP) and VALUE 2 was assumed to be diastolic BP (DBP) (Table 8.1, above). 
Having excluded all records with ‘missing’ VALUE1 values, I removed potential 
‘errors’ in SBP data entry, as follows:  
1)  I excluded records where VALUE1 (presumed SBP) ≤ VALUE2 (presumed 
DBP).  
2) If VALUE1 was present but VALUE2 was missing, I reviewed the Read code text 
definition, and included only those records which specified that the VALUE1 value 
was ‘systolic BP’.  There are twenty-two Read codes which specify (in their 
associated text definitions) that a value is ‘systolic’ r ‘diastolic’ BP. These Read 
codes are listed in the Appendix 8.4.2 (Table 8.15).  
3) I investigated the range of remaining VALUE1 values, and excluded ‘extreme’ 
values (>300mmHg). 
4) Finally, I grouped records by participant and event date to identify all VALUE1 
values which were recorded at the same GP visit. Where multiple VALUE1 values 
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were entered at the same GP visit, I selected one at random, and excluded all others. 
This resulted in an SBP dataset with one coded SBP value per GP visit. 
8.2.7 Feasibility of using primary care coded data to estimate 
visit-to-visit BPV 
I aimed to explore the feasibility of using primary care coded data (in particular 
coded SBP values at successive GP visits) to estimate within-individual visit-to-visit 
SBP variability. In the long run, these data could be used to estimate BPV as an 
‘exposure’ in UK Biobank and could be linked to outcomes, enabling investigation 
of potential associations between BPV and outcomes such a stroke.  
I used a minimum of 3 GP visits with coded BP readings to estimate BPV. It has 
previously been shown that increasing the number of visits with BP readings (from 3 
to 11) increases the reproducibility of BPV measurement.(Rothwell et al. 2010b) 
However, an optimum measurement period has not been assessed, and it has not yet 
been determined if there is a ceiling beyond which in reasing the number of included 
BP measurements fails to increase the precision of visit-to-visit BPV estimation. I 
hypothesised that there may be an inverse association between the numbers of GP 
visits with coded BP readings, the time prior to recruitment within which these BP 
readings are recorded, and the numbers of individuals identified. I sought to 
determine the best balance between these factors. My ultimate aim was to maximise 
the number of individuals in whom visit-to-visit BPV could be measured prior to 
UKB recruitment, as this would increase future power to detect potential associations 
between BPV, risk of stroke, and its main types. It was important to keep both the 
numbers of BP readings used and the BP measurement periods (prior to UKB 
recruitment) the same for each individual, because both parameters may influence 
the strength of the association between BPV and risk of troke (Chapter 7).  
Number of individuals identified with ‘x’ coded BP values over ‘y’ time 
periods 
I firstly aimed to investigate the number of participants I could identify with ‘x’ BP 
values over ‘y’ time periods prior to UK Biobank rec uitment. I focused on 
estimating BPV in the period prior to UKB recruitment in order assess the potential 
of measuring BPV as an ‘exposure’. In future studies of associations between BPV 
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and stroke outcomes, the period prior to UKB recruitment, per individual, would be 
defined as the ‘exposure period’, and the period after recruitment, per individual, 
would be defined as the ‘follow-up’ period.  
I began by counting the number of GP visits per participant which included SBP 
values. I then restricted analyses to data collected prior to UK Biobank recruitment 
(GP visit date ≤ participant’s baseline assessment date). Having explored the range of 
data available, I counted the numbers of participants who could be identified with (a 
minimum of) three, five, seven, nine, and eleven SBP readings (over the same 
number of successive GP visits). I then stratified these groups by the time prior to 
UK Biobank recruitment within which these readings were recorded (≤ 1 year, ≤ 3 
years, ≤ 5 years, ≤ 10 years before the baseline assessment date). 
Within individual frequency of coded SBP values in the coded primary 
care dataset. 
I secondly aimed to explore the frequency of recorded SBP values in each 
participant’s coded primary care record. In previous studies of the association 
between medium-to-long term BPV and stroke risk (pros ective observational 
studies and clinical trials) the gaps between successiv  outpatient visits (and 
therefore successive BP readings) were standardised. I investigated within participant 
frequency of successive GP visits with coded BP values, as follows:  
1) I calculated the gap (in days) between successiv GP visits for each participant, 
using the coded event dates.  
2) I calculated the median of the within participant gaps, per participant, prior to UK 
Biobank recruitment.  
3)  I grouped results into gaps of 6 month increments (ranging from ≥ 1 day but ≤ 6 
months, to ≥ 6 years). There were no gaps of ≤ 1 day, because coded events with the 
same date and same participant identifier were assumed to have originated from the 
same GP visit (and I had already selected one adjudicate  BP value from each GP 
visit at random, above).  
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4) I further stratified gaps of between ≥ 1 day and ≤ 18 months into groups of 30 day 
increments (from ≥1 and ≤30 days to ≥516 to ≤560 days).  
Numbers of participants identified with 3 to 11 GP visits at specified 
intervals, prior to UKB recruitment.  
I explored the numbers of participants I would include (in estimation of BPV prior to 
UKB recruitment) if both the number of BP readings used, and frequency of BP 
readings, were fixed. I first identified five groups of participants who had ≥4, ≥5, ≥6, 
≥7, and ≥8 GP visits with coded SBP values prior to UKB recruitment. I then 
specified four gap ranges (based on the frequencies of BP measurements in previous 
studies, chapter 8). The gap ranges were: 1 to 30 days, 1 to 5 months, 5 to 9 months 
and 10 to 14 months between GP visits with coded SBP values. I searched for 
participants in each of the five groups, above, who had consecutive gaps of these 
durations. In order to maximise the number of participants identified with 
consecutive gaps of each duration I ignored GP visits which took place before the 
specified time interval (eg. I ignored a GP visit whin 2 weeks of the last visit if the 
required gap was 1-5 months, and there was a subseqent GP visits in 2 months’ 
time). GP visits were therefore not necessarily consecutive. Having identified 
numbers of participants with 3,4,5,6,and 7 gaps (duration ranges specified above), 
between any 4,5,6,7,and 8 GP visits prior to UKB recruitment, I calculated the 
median within participant gap for each group.  
8.2.8 Characteristics of selected participants 
Generalisability to the UK Biobank Welsh population  
I investigated the characteristics of individuals identified with at least one coded SBP 
value in the UK Biobank Welsh primary care dataset, as well as characteristics of 
individuals with any coded data in the UK Biobank Welsh primary care dataset. I 
linked the primary care dataset to the UK Biobank baseline assessment dataset 
(individual records were linked by participant identifier). I extracted the following 
participant characteristics from the baseline assessm nt dataset (see Appendix 8.4.2, 
Table 8.16, for the codes selected): gender (male/female), mean recruitment age 
(years), Townsend deprivation score (range -6 to 12), self-reported smoking status 
(never smoked, current smoker, ex-smoker), and self-reported comorbidities 
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(including stroke, myocardial infarction, hypertension, diabetes, and renal disease). 
Self-reported comorbidities were based on answers given during a brief nurse led 
interview, which verified responses to the UKB baseline assessment touchscreen 
questionnaire.  
I then investigated characteristics of individuals in ix mutually exclusive groups: 
those with one coded SBP value, 2 values, 3 to 11 values, 12 to 20 values, 21 to 29 
values, or  >30 values, recorded at any time (before or after UKB recruitment). 
Finally, I investigated characteristics of individuals with ‘x’ numbers of SBP 
readings in ‘y’ time periods prior to UKB assessment (numbers of readings and time 
periods were chosen to maximise the number of indivduals included). To ensure that 
the same numbers of SBP readings were used for each individual in each time period 
(and to maximise the number of individuals who were able to provide SBP data for 
estimation of BPV), I selected the required number of SBP readings at random from 
all participants who had at least that number of readings in the specified time period. 
For example, to select individuals with 5 SBP readings within 5 years of UKB 
recruitment, I selected 5 SBP readings at random frall individuals identified with 
≥5 SBP readings recorded 5 years before recruitment. I calculated the median gap 
between selected SBP readings for each participant n each group (with ‘x’ SBP 
readings over ‘y’ time periods), and then calculated the median within participant 
gap for each group.   
Calculation of BP variability (BPV) and the variabi lity in BPV amongst 
individuals with ‘x’ BP readings over ‘y’ time peri ods.  
I calculated the within individual BPV (within individual SD in SBP), in each group 
with ‘x’ BP readings over ‘y’ time periods. I used this to infer the potential range of 
SBP values about the individual mean SBP. If there is sufficient variability in within 
individual BPV amongst included individuals it should still be possible to detect a 
potential association between increasing BPV and increasing risk of stroke, even if 
these individuals have higher BPV than the population as a whole. 
As above, SBP values were selected at random to ensure the same number of SBP 
readings were used for each individual. I then calcul ted the mean and standard 
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deviation of the within individual BPV (mean BPV and SD BPV) for each group 
with ‘x’ BP readings over ‘y’ time periods. Analyses were performed in Stata 
(version 12).  
Finally, I used the SD BPV to infer the likely range of BPV values in each group 
with ‘x’ BP readings over ‘y’ time periods. 95% of the range in BPV is the mean 
BPV for that group +/- 1.96 x SD BPV for that group: 
95% BPV range = mean SBP +/- 1.96 x SD BPV 
8.2.9 Agreement between UKB SBP measurements and 
primary care coded data 
I used the intraclass correlation coefficient (ICC) to assess within individual 
agreement between systolic BP recorded at the UK Biobank baseline assessment and 
systolic BP recorded in primary care coded data. Two blood pressure readings were 
recorded during the UK Biobank baseline assessment. Measurement followed a 
standard protocol, which was published online.(http://www.ukbiobank.ac.uk/) For 
each participant I used linkages to UKB baseline asses ment data to compare the 
mean SBP recorded at the baseline assessment to the mean of all SBP values 
recorded in the primary care coded data before or afte  this date (within 10 days, 30 
days, 3 months, 6 months, 1 year, 18 months and 2 years). ICC and 95% confidence 
intervals were calculated in stata (version 12) using a 2-way random effects model. 
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8.3 Results 
8.3.1 Describing the dataset 
Amongst 9,947 participants in UK Biobank Welsh primary care coded dataset, there 
were ~ 5,000,000 coded events, with up to ~6,000 coded events per individual.  
The number of coded events increased every year from 1980 to end 2012 (Figure 
8.1).  
 
Figure 8.1 Number of coded events per year 
y-axis: number of coded events 
x-axis: year (from 1980 onwards).  
 
 
The majority of participants (~80%) had coded primay care records which spanned a 
period of greater than 20 years (based on last event date – first event date)(Table 
8.2). Few participants (~4%) provided coded data over shorter durations (≤ 5 years), 
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≤1† 119† 1.2 
1 to 5 289 2.9 
5 to 10 420 4.2 
10 to 20 1,204 12.1 
>20 7,915 79.6 
 
*Based on last event date – first event date. 
†77 participants had only one event date recorded in the dataset (only one GP visit). 
 
 
8.3.2 Characteristics of the denominator population  
Characteristics of the 9,947 UKB Welsh participants with UKB linked coded 
primary care data are displayed in Table 8.3. 
Table 8.3 Characteristics of the Welsh primary care population 
Selected  
Characteristics*  
UKB Welsh participants 
(n= 9,947) 
Gender 45.5% Male 
Recruitment age 
(mean, range) 
56.1 (40 to 70) 
Townsend score 
(mean, range) 
-1.65 (-6.2 to 8.6) 













Renal disease¶ 0.1 
Diabetes**  4.4 
 
*Data from the UKB baseline assessment (see Appendix 8.4.2, Table 8.16 for the data fields used).  
†Based on data from the baseline assessment touchscreen questionnaire (participant self-report). 0.4% 
missing or ‘prefer not to answer’. 
‡Data from participant self-report verified by nurse led interview.  
§Ischaemic stroke, ICH, SAH, or unspecified stroke. 
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¶Renal/kidney failure (on dialysis or not on dialysis). 
**Type 1 or type 2 diabetes.  
 
Participants were 46% male, and aged between 40 and 70 years (mean age 56). The 
Townsend score for deprivation was -1.65 (range -6.2 to 8.6), with a lower score 
representing less deprivation. ~55% of participants were lifelong non-smokers, 
(based on self-report in the UKB baseline assessment touchscreen questionnaire), 
and the prevalence of self-reported comorbidities (v rified during the UKB nurse led 
verbal interview) were ~25% hypertension, ~2.5% stroke/MI, 0.1% renal failure, 
4.4% diabetes.  
 
8.3.3 Identification of blood-pressure related code s 
I identified ~ 296 Read codes related to blood pressure. BP related Read codes 
(excluding codes for drug prescriptions) accounted for ~ 3% of all coded events in 
the UKB Welsh coded primary care dataset (n=171,142 coded events out of a total 
~5,000,000). Blood pressure value codes accounted for the majority of all BP related 
coded events (87%), followed by blood pressure monitori g codes (9%), 
hypertension diagnosis codes (3%), and hypertension administration codes (0.65%).  
Hypotension diagnosis codes accounted for only 0.05% of BP-related coded events 
(see methods 8.2.5 for a description of these Read code categories).  
Table 8.4 shows the most frequently used BP Read codes in each of the four main 
categories. Only seven codes together accounted for 94% of all BP-related coded 
events (indicated by shading in Table 8.4). The frequencies of every BP related Read 
code (most of which accounted for <1% of all BP relat d coded events in the dataset) 
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Table 8.4 Most frequently used BP Read codes 
Code Code definition Code 
frequency* 
% of category 
total† 
Hypertension diagnosis codes 
G2… Hypertensive disease 2,074 37.5 
G20.. Essential hypertension 3,148 56.9 
G20z. Essential hypertension NOS 155 2.8 
G201. Benign essential hypertension 76 1.4 
Hypertension administration codes‡ 
9N1y2. Seen in hypertension clinic 291 26.1 
67H8. Lifestyle advice regarding hypertension 285 25.6 
9N03. 
14A2. 
Seen in hypertension clinic 





Blood pressure monitoring codes 
662.. Hypertension monitoring 5,739 39.1 
662P. Hypertension monitoring 2,659 18.1 
662d. Hypertension annual review 1,078 7.3 
662V. 
9O14. 
Blood pressure monitoring 





Blood pressure value codes 
246.. O/E blood pressure reading 144,868 96.7 
2464. O/E blood pressure normal 1,790 1.2 
 
Shading indicates Read codes which together accounted for ~ 94% of all BP related coded events 
(excluding codes for medication prescriptions).  
*Amongst 171,142 BP related codes.  
†% of total number of codes in each category.  
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8.3.4 Individuals with probable or possible hyperte nsion 
9,439 participants (95% of 9,947 UKB Welsh participants) had at least one BP 
related Read code. Of these participants, 29% had at least one Read code indicating a 
‘probable’ or ‘possible’ hypertension diagnosis (n=2,713 out of 9,439, Figure 8.2); 
24% had at least one ‘hypertension diagnosis’ code’ indicating probable 
hypertension (n=2,237), and the remaining 5% (n=476) had at least one 
‘hypertension, other’ code (administration codes or BP monitoring codes indicating 
‘possible’ hypertension). 
 
*Does not include analysis of BP values.  
†Codes for ‘possible hypertension’, which include ‘administration codes’ and selected ‘blood pressure 
monitoring codes’ (see Appendix 8.4.2, Table 8.14, for codes selected).  
‡Codes for ‘probable hypertension’, which include all ‘hypertension diagnosis’ codes (Appendix 
8.4.2, Table 8.14). 
 
The majority of participants had at least one BP value code in the coded primary care 
dataset. In total, 95% of Welsh UKB participants had  ≥1 BP value code, which 
included 99.9% of individuals with ‘probable hypertension’ and ~93% of individuals 
without ‘probable hypertension’.(Figure 8.3). Around 27% of Welsh UKB 
participants had at least one BP monitoring code, and 99.9% of these had at least 
one BP value code.  
Figure 8.2 Proportion of 9,439 individuals with BP related Read codes who 
had  'probable' or 'possible' hypertension* 
9,439 with any BP Read code  




2,182 hypertension             
‘other’
†
 codes  
1,706 531 476 
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*Codes for ‘probable hypertension’.  
 
8.3.5 Creating an SBP value dataset 
Missing data 
SBP values were missing in 14% of coded events (n=23,051 out of 164,424 coded 
events) with BP monitoring or BP value Read codes. The majority of ‘missing data’ 
came from events coded with BP monitoring Read codes; only 2.9% of these (n= 452 
out of 15,483) had associated SBP values. Around 95% of events coded with BP 
value Read codes had SBP values (n=140,921 out of 148,941 records). There were 
no SBP values associated with ‘hypertension diagnosis’ r ‘hypertension 
administration’ Read codes, but, as illustrated in Figure 8.3, 99.9% of individuals 
with ‘hypertension diagnosis’ and, or ‘hypertension administration’ Read codes also 
had BP value Read codes.  
Adjudication of SBP values 
Figure 8.4 displays the process of adjudication of the 141,374 records with potential 
SBP values. In 99% of cases (n= 140,066), both VALUE1 (presumed SBP) and 
VALUE2 (presumed DBP) were present. I excluded 60 reco ds where VALUE1 was 
≤ VALUE2. I retained ~ 27% of records which only included VALUE1 values (n= 
2,237 hypertension diagnosis 
codes*  
  
2,700 BP monitoring 
codes 







9,947 in the UKB Welsh coded primary care dataset 
Figure 8.3 Proportions of individuals (n=9,947) in the UKB Welsh coded primary care dataset who 
have  hypertension diagnosis codes, BP monitoring codes, and/or BP value codes. 
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352 out of 1,308) because ‘systolic BP’ was specifid in the Read code text 
definition (see Appendix 8.4.2, Table 8.15, for these Read codes).  
 
Figure 8.4 Adjudication of potential systolic BP (SBP) values 
*Total non-missing records with VALUE1 values (potential SBP).  
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†Includes VALUE1 values specified as diastolic BP readings (DBP)- see Appendix 8.4.2, Table 8.15 
for these Read codes- or includes unspecified VALUE1 values (ie. readings not specified as systolic 
or diastolic BP).  
‡Selected one value at random from each GP visit, per participant.  
 
The range and frequency of the remaining 140,006 VALUE1 values are presented in 
Figure 8.5. The majority of these potential SBP values (99.9%) ranged from 60 to 
260mmHg. There were only 27 records with SBP values out ide of this range, and 
from these, I excluded 17 records with ‘impossible’ values (range 430 to 
14130mmHg). I retained 10 records with SBP values ranging from 10 to 58mmHg. 
There was marked ‘digit preference’ in the dataset, such that SBP values were most 
frequently recorded to the nearest 10mmHg (eg. 110mmHG, 120mmHg, 130mmHg 
etc.). 
 
Figure 8.5 Range of SBP values*  
y-axis: Frequency (out of 140,006 VALUE1 values in the dataset) 
x-axis: Systolic BP (mmHg) 
 
Selecting one SBP value per GP visit 
When data were grouped by participant identifier and event date, there were 124,214 
separate GP visits. The number of SBP values entered per GP visit ranged from 1 to 
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GP visit. Around 90% of GP visits only recorded one SBP value.  Amongst GP visits 
with multiple SBP values (≥2 SBP values) 76% had the same value recorded 
multiple times.  
8.3.6 Feasibility of estimating BPV using primary c are coded 
data 
Characteristics of the denominator population 
In the end there were 9,288 UKB Welsh participants wi h at least one systolic BP 
reading in the final adjudicated coded primary care dataset. I had excluded 149 
participants (1.6% of all 9,437 participants with BP value Read codes) because of 
missing VALUE1 data and/or errors in VALUE1 data entry (see Figure 8.4). 
Characteristics of the 9,288 individuals with at least one adjudicated SBP value in 
the UKB Welsh primary care coded dataset are displayed in Table 8.5. 
Characteristics of 9,947 individuals with any data (at least one coded event) in the 
UKB Welsh population are displayed for comparison.  
Table 8.5 Characteristics of UKB Welsh participants with ≥1 coded (and adjudicated) SBP value 
Characteristics*  Welsh participants with 
 ≥1 coded SBP value  
 (n= 9,288) 
Welsh participants with 














-1.69 (range -6.2 to 8.6) 
 
-1.69 (range -6.2 to 8.6) 
 
Smoking status† 

















Stroke§ 0.9 0.9 
MI 0.6 0.6 
Hypertension 25.1 24.5 
Renal disease¶ 0.1 0.1 
Diabetes**  4.5 4.4 
 
*Data from the UKB baseline assessment (see Appendix 8.4.2, Table 8.16 for the data fields used).  
†Based on data from the baseline assessment touchscreen questionnaire (participant self-report). 0.4% 
missing or ‘prefer not to answer’. 
‡Data from participant self-report verified by nurse led interview.  
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§Ischaemic stroke, ICH, SAH, or unspecified stroke. 
¶Renal/kidney failure (on dialysis or not on dialysis). 
**Type 1 or type 2 diabetes.  
 
There was no material difference when characteristics of participants with ≥1 coded 
SBP value were compared to characteristics of all participants with any coded 
primary care record in the UKB Welsh population (the former population being a 
large sub-set of the latter).  
Characteristics of participants with at least one c oded SBP value, 
stratified by the number of successive GP visits wi th coded SBP values 
The number of successive GP visits with coded SBP values ranged from 1 to 242 per 
individual (median 10, IQR 4 to 21). The numbers of individuals with 1 to 20 GP 
visits with coded SBP values, and with ≥2 to ≥20 SBP values (out of all 9,288 with 
≥1 SBP value) are displayed in Table 8.6. 83% of participants had ≥3 SBP values 
(sufficient to estimate BPV). 
Table 8.6 Proportions of participants (out of 9,288 with ≥1 coded SBP value in the Welsh primary 
care dataset) with 1 to 20, and ≥1 to ≥20 coded SBP values 






















2 717 (7.7) ≥2 8,368 (90) 
3 660 (7.1) ≥3 7,669 (83) 
4 648 (6.9) ≥4 7,009 (75) 
5 543 (5.8) ≥5 6,361 (68) 
6 473 (5.1) ≥6 5,818 (63) 
7 439 (4.7) ≥7 5,345 (58) 
8 417 (4.5) ≥8 4,906 (53) 
9 417 (4.5) ≥9 4,489 (48) 
10 300 (3.2) ≥10 4,131 (44) 
11 258 (2.8) ≥11 3,831 (41) 
12 259 (2.8) ≥12 3,573 (38) 
13 221 (2.4) ≥13 3,314 (36) 
14 175 (1.9) ≥14 3,093 (33) 
15 167 (1.8) ≥15 2,918 (31) 
16 163 (1.8) ≥16 2,751 (30) 
17 147 (1.6) ≥17 2,588 (28) 
18 177 (1.9) ≥18 2,441 (26) 
19 136 (1.5) ≥19 2,264 (24) 
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Characteristics of individuals, stratified by the n umber of coded SBP 
values present in the primary care dataset.  
Individuals with increasing numbers of coded SBP values (from ≥12 to ≥21 to ≥30) 
appeared to have a greater prevalence of hypertension and diabetes than individuals 
with fewer numbers of coded SBP values (<12 SBP values). Table 8.7 displays 
characteristics of the population with coded SBP values (n=9,288), stratified by the 
total number of SBP values per individual. These values were recorded at any time 
(before or after UKB recruitment) and at any frequency (any time periods between 
successive BP values). Participants with from 3 to 11 visits with BP values in their 
coded primary care record did not differ significantly in terms of cardiovascular risk 
factors from participants with only one or two visits with BP values in their coded 
primary care record. In fact, participants with ≤11 BP values in their primary care 
record had a lower prevalence of vascular risk factors compared to the denominator 
population (24.5% hypertension, 4.4% diabetes, 0.1% renal disease and 1.5% 
cardiovascular disease, see Table 8.3). Only those participants with ≥21 visits with 
BP values in their coded primary care record appeared to have increased prevalence 
of vascular risk factors compared to the denominator population.  







(% & 95% CI) 
Diabetic 
(% & 95% CI) 
 
Renal failure 
(% & 95% CI) 
 
CVD‡ 








(10.4 to 14.7) 
 
  1.8  
 








 (0.3 to 1.4) 
2 717   9.6 (7.6 to 12.0)   1.1   (0.5 to 2.1) 0.1  (0.02 to 0.8) 0.7 (0.3 to 1.6) 
3-11 4,096   9.8 (8.9 to 10.7)   1.3   (0.9 to 1.7)  0.05 (0.01 to 0.2) 1.0  (0.7 to 1.4) 
12-20 1,552 29.1 (26.9 to 31.4)   4.9   (2.8 to 4.7)  0.06 (0.01 to 0.4) 2.6  (1.9 to 3.5) 
21-29 913 56.3  (53.1 to 59.5)   9.2   (7.5 to 11.3)    0.2 (0.06 to 0.8) 2.4  (1.6 to 3.6) 
≥30 1,108 70.7 (42.3 to 48.2)  16.1  (14.0 to 18.3)    0.4 (0.1 to 0.9) 2.3  (1.5 to 3.3) 
 
*Number of SBP values in the dataset. Each SBP value c me from a separate GP visit. 
†Out of 9,288 with at least one coded SBP value. 
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Numbers of participants with ≥ 3 GP visits with coded SBP values, 
stratified by time prior to UK Biobank recruitment 
There were 8,827 participants (~89% of 9,947 in the Welsh UKB population) who 
had at least one coded SBP value recorded prior to UKB recruitment. Table 8.8 
shows the numbers of participants who had at least 3 coded SBP values (ranging 
from ≥3 to ≥11) stratified by the time prior to UKB recruitment.  
The numbers of participants identified with ‘x’ BP readings over ‘y’ time periods 
prior to UKB recruitment decreased as both the number of SBP values required was 
increased and the measurement period was decreased. Around 68% of the Welsh 
UKB population (n= 9,947 who provided linked coded primary care data) had at 
least 3 coded SBP values in the dataset any time before UKB recruitment (Table 
8.8). However, this decreased to ~52% with ≥5 SBP values, ~40% with ≥7 SBP 
values, 32% with ≥9 SBP values, and ~27% with ≥11 SBP values any time before 
recruitment.  
Few participants in each of these categories had all of their SBP values recorded 
within 1 to 2 years prior to UKB recruitment (range 1.3 to 39% of participants in 
each category with ≥3 to ≥ 11 SBP values). Five years prior to UKB recruitment 
appeared to be the optimum exposure period to maximise the number of participants 
included, without using too long a period of time (i . extending the SBP 
measurement period up to 10 years prior to UKB recruitment, or using an 
‘unspecified’ time prior to UKB recruitment). This time period identified at least 
50% of participants in each category with ≥3 to ≥11 SBP values (See Table 8.8, 
shaded rows). The proportion of the total UKB Welsh population (n=9,947 with 
coded primary care data) who had ≥3 to ≥11 coded SBP values recorded in the 
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Table 8.8 Numbers of participants with ≥3 to ≥ 11 SBP values stratified by time before UKB 
recruitment during which these values were recorded 
SBP values* 
(range) 




% total in each 
category 

































     
≥5 ≤ 1 429 2.3 4.3 
≥5 ≤ 2 1,393 26.9 14.0 
≥5 ≤ 3 2,224 42.9 22.4 












≥7 ≤ 1 176 4.4 1.8 
≥7 ≤ 2 738 18.4 7.4 
≥7 ≤ 3 1,440 35.9 14.5 












≥9 ≤ 1 78 2.8 0.8 
≥9 ≤ 2 424 13.1 4.3 
≥9 ≤ 3 917 28.2 9.2 












≥11 ≤ 1 35 1.3 0.4 
≥11 ≤ 2 251 9.3 2.5 
≥11 ≤ 3 606 22.4 6.1 













*Each coded SBP value was recorded at a separate GP visit, therefore to have ≥3 SBP values, an 
individual would have to have had ≥3 GP visits where BP was measured and recorded in the coded 
primary care dataset. 
†Time periods prior to UKB recruitment within which SBP values are recorded.  
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Frequency of successive GP visits with coded SBP va lues 
Around 88% of UKB participants with coded SBP values prior to UKB recruitment 
(n=7,748 out of 8,827) had at least two successive GP visits with coded SBP values.  
Amongst these individuals, the median time, per participant, between successive GP 
visits with coded SBP values ranged from 1 to 8,893 days (median 326 days, IQR 
120 to 808 days). The most common gap (median time,per participant) between GP 
visits was from 1 day to 6 months long (representing ~36% of all gaps, Table 8.9), 
and the majority of gaps were less than eighteen moths in duration (~65% of all 
gaps, Table 8.9) 




Gap frequency % all gaps 
≥1 day to ≤ 6 months 2,765 35.7 
>6 months to ≤ 1  1,405 18.1 
>1 to ≤ 1.5  880 11.4 
>1.5 to ≤ 2  571 7.4 
>2 to ≤ 2.5  399 5.1 
>2.5 to ≤ 3  306 3.9 
>3 to ≤ 3.5  285 3.7 
>3.5 to ≤ 4  140 1.8 
>4 to ≤ 4.5 142 1.8 
>4.5 to ≤ 5 128 1.7 
>5 to ≤ 5.5 100 1.3 
>5.5 to ≤ 6 110 1.4 
>6  517 6.7 
Total 7,748† 100 
 
*Median time (per participant) between successive GP visits with coded SBP values. 




Attempting to specify the median within participant gap between GP visits with 
coded SBP values identified relatively small numbers of participants. Only 5% of all 
within participant median gaps were ≤ 1 month long (between 1 to 30 days), 9% 
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were around 4 months (>90 to ≤ 150 days), 10% were around 6 months (>150 to 
≤210 days) and 10% were around 1 year (>300 to ≤425 days). The frequency of gaps 
(from ≥1 day to ≤ 18 months, in 30 day increments), and numbers of participants 
with these gaps (out of 5,050 total) is presented in the Appendix 8.4.2 (Table 8.18).  
 
Table 8.10 presents numbers of participants who had consistent gaps between any 4 
to any 8 of their GP visits with coded SBP values prior to UKB recruitment (amongst 
those who had ≥4 to ≥8 GP visits), stratified by the gap duration.  
Out of 5,924 participants who had ≥4 GP visits with coded SBP values prior to UKB 
recruitment, up to 40% (range 12 to 39%) had consistent gaps between any four of 
their GP visits, and this represented only 7 to 23% of UKB Welsh participants with 
coded primary care data. (Table 8.10) Even fewer participants had larger numbers of 
GP visits (from ≥5 to ≥8 with coded SBP values prior to UKB recruitment), and 
fewer proportions of these participants had consistent gaps between any 5 to 8 of 
their GP visits.  
Furthermore, the longer the gap duration specified, the fewer the number of 
participants identified with consistent gaps of that duration (Table 8.10). Within each 
category (4 to 8 GP visits with consistent gaps), the numbers of participants 
identified fell by about 89% on average (range 67 to 99%) when the specified gap 
duration was increased from ~2 weeks (range 1-30 days) to ~1 year (range 10-14 
months). Specifying the gap between GP visits therefore resulted in exclusion of a 
large proportion of UKB participants, who would otherwise have contributed 4 to 8 
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Table 8.10 Number of participants who had consistent gaps between GP visits* prior to UKB 
recruitment, stratified by the number of GP visits and the specified gap duration.  
Gap†   
(range & 
median) 
4 GP visits 
 (n & % 
participants)‡ 
5 GP visits  
 (n & % 
participants)‡  
6 GP visits 
 (n & % 
participants)‡ 
 7 GP visits 
 (n & % 
participants)‡ 
8 GP visits  






















































≥4 GP visits 
5,924 (60) 
≥5 GP visits 
5,179 (52) 
≥6 GP visits 
4,548 (46) 
≥7 GP visits 
4,011 (40) 
≥8 GP visits 
3,623 (36) 
 
*GP visits were not successive. I excluded interim GP visits (eg. if gaps of 1-5 months were required 
between visits, I ignored visits with coded SBP values <1 month after the previous visit with coded 
SBP values).  
†Specified time between ‘n’ GP visits with coded SBP values 
‡% of 9,947 in the Welsh coded primary care dataset. 
§Unspecified gap duration. These are the denominator populations: the total numbers of participants 
with ≥4 to ≥8 GP visits with coded SBP values prior to UKB recruitment. In order to identify the 
maximum number of participants with consistent gaps between 4 to 8 GP visits, I had to include those 
with ≥4 to ≥8 GP visits, and then exclude interim visits (described above).  
 
Characteristics of participants with 3 to 11 SBP re adings, 5 years before 
UKB recruitment 
Table 8.11 displays characteristics of selected participants who had ≥3 to ≥11 coded 
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Table 8.11 Characteristics of participants with ≥3 to ≥11 SBP values within 5 years of UKB 



































≥5 3,163 (32) 45.1 53.1 10.4 2.6 5 224 
≥7 2,352 (24) 46.5 63.4 12.9 2.8 7 163 
≥9 1,845 (19) 47.6 68.6 14.5 2.7 9 122 




*Range of SBP values, per participant, available 5 yars prior to UKB recruitment 
†Number of participants (% out of 9,947 with any coded data in the UKB Welsh primary care dataset) 
with the specified range of SBP values. Participants i cluded in each row are subsets of participants in 
the rows above. 
‡HTN= hypertension, DM= Diabetes (type 1 or type 2), CVD= cardiovascular disease, which included 
myocardial infarction or stroke. Results based on participant self-report, confirmed at the UKB 
baseline assessment nurse led interview. 
§SBP values were selected at random from each partici nt, generating a group of participants with 
the same number of SBP values (from 3 to 11) within 5 years of UKB recruitment.  
¶Median of the within participant median gaps (within participant median gap is the median of all 
gaps, per participant, between ‘n’ selected SBP values) 
 
Using coded primary care data ≤5 years prior to recruitment, it was possible to 
estimate within participant BPV in up to 47% of UKB Welsh participants (n=4,658 
out of 9,947). As the number of GP visits with coded SBP values was increased from 
≥3 to ≥11, the proportion of participants with sufficient data to estimate BPV fell 
from 47 to 14%. However, absolute numbers of participants were high, and >1,000 
to >2,000  still had sufficient data to estimate BPV using SBP values from 7 to 11 
separate GP visits 5 years before recruitment.  The median gap between GP visits, 
per participant, fell as the number of GP visits with coded SBP values was increased. 
Although one might argue that standardising the number of SBP values used, per 
participant, meant loosing data (eg. selecting 3 SBP values at random from all 
participants who had ≥3 SBP values 5 years before recruitment, and dropping any 
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additional SBP values), it was important to do thiso avoid bias. It is known that the 
precision of BPV estimation increases with the number of SBP values used, and the 
strength of the observed association between BPV and stroke increases with the 
number of SBP values used to calculate it.(Rothwell et al. 2010b) It is also quite 
possible that participants with increased BP variability have an increased number and 
frequency of BP values in the dataset (compared to those with reduced BP 
variability). If the number of readings used was not standardised between 
individuals, those with more BP values (and hence those with potentially higher 
BPV), would demonstrate a stronger association betwe n BPV and stroke, and this 
might falsely increase the observed association between increasing BPV and 
increasing stroke risk. Although standardising the number of BP values used to 
calculate BPV per individual does not change the fact those with higher number of 
values to begin with are likely to have an increased prevalence of vascular risk 
factors (eg. hypertension, diabetes etc.), these factors can be adjusted for more easily 
in subsequent analyses of the associations between increasing BPV and risk of 
stroke.  
 
Generalisability of populations with 3 to 11 coded SBP values, 5 years 
before UKB recruitment 
Increasing the number of SBP values required to estimate BPV reduced the 
generalisability of the populations selected. The proportion of participants with 
hypertension increased from ~40% to ~72%, diabetes from ~8% to 15%, and 
cardiovascular disease (MI or stroke) from 2.2 to 2.5% as the number of SBP values 
used to estimate BPV was increased from 3 to 11 within 5 years of UKB recruitment 
(Table 8.11). Overall, the participants in these sel ct d groups had higher proportions 
of comorbidities than the original UKB Welsh population (n=9,947 which comprised 
25% hypertension, 4.5% diabetes, and 1.5% CVD).  
 
Mean and SD in blood pressure variability (BPV) amo ngst participants 
with 3 to 11 coded SBP values, 5 years before UKB r ecruitment 
Within participant blood pressure variability (BPV) appeared to increase as the 
number of SBP values used to estimate BPV increased. When the number of SBP 
values used to estimate SD in SBP increased from 3 to 11, the mean BPV (the mean 
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of within participant standard deviations in SBP) increased from 10.7mmHg to 
13.6mmHg. (Table 8.12). This could be due to increased precision of BPV 
estimation or due to selection of individuals with higher mean BP (and BP variability 
is known to increase as mean BP increases). The variability in BPV between selected 
participants decreased (SD in within participant BPV fell from 6.8mmHg to 
4.8mmHg). Assuming that BPV is normally distributed, then 95% of all BPV values 
should fall within 1.96 standard deviations of the m an BPV in each group of 
participants. Therefore, amongst participants select d with 11 SBP values 5 years 
before recruitment, 95% of the range in BPV should be 13.6mmHg +/- 1.96 x 
4.8mmHg = from 4.2mmHg to 23.2mmHg, or, in other words, 95% of the within 
participant SD SBP should range from 4.2mmHg to 23.2mmHg. This should be 
sufficient variability in between participant BPV to be able to detect a potential 
association between BPV and risk of stroke.  
 
Table 8.12 Mean and variability in BPV (SD BPV) amongst selected participants with 3 to 11 SBP 









3 4,658 10.68  6.8 
5 3,163 12.0 5.7 
7 2,352 12.8  5.3 
9 1,845 13.2   4.9 
11 1,421 13.6  4.8 
 
*SBP values selected at random from participants with ≥3 to ≥11 SBP values within 5 years of UK 
Biobank recruitment. 
§Mean within participant SD in SBP  
†SD in within participant SD in SBP 
 
 
8.3.7 Comparison between UKB baseline assessment BP  and 
BP values in the coded primary care dataset.  
Agreement between mean SBP using coded SBP values within 10 days to 2 years of 
the UK Biobank assessment, and the mean baseline assessment SBP was generally 
good; ICC ranged from 0.478, (95% CI 0.439 to 0.515) for mean coded SBP within 
 
312 
Chapter 8: Can coded primary care data be used to measure BPV? 
30 days of baseline assessment, to 0.534 (95% CI 0.517 to 0.551) for mean coded 
SBP within 2 years of the baseline assessment (Table 8.13).  
 
Table 8.13 Within participant agreement between mean SBP in the coded primary care dataset*, 
and mean SBP measured at the UKB baseline assessment, stratified by time from the baseline 
assessment within which mean coded SBP was measured. 
Time† Participants (n & %)‡ ICC (95% CI) 
10 days 816 (9) 0.514 (0.461 to 0.562) 
30 days 1,641 (18) 0.478 (0.439 to 0.515) 
90 days 3,137 (34) 0.460 (0.433 to 0.487) 
6 months 4,347 (47) 0.486 (0.463 to 0.509) 
12 months 5,518 (59) 0.511 (0.492 to 0.530) 
18 months 6,243 (67) 0.522 (0.504 to 0.540) 
24 months 6,716 (72) 0.534 (0.517 to 0.551) 
*Mean of ‘n’ values, per participant, which were recorded 10 days to 24 months before or after the UK 
Biobank baseline assessment. If only one SBP value was recorded in the coded primary care dataset in 
the specified time period, this single value was used.  
†Time from UKB baseline assessment within which mean coded SBP was measured, per participant.  
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8.4 Discussion 
Almost 50% of UK Biobank Welsh participants with linked, coded, primary care 
data had sufficient GP visits with coded SBP values (at least 3 GP visits with coded 
values, up to 5 years before UK Biobank recruitment) to be able to estimate within 
individual visit-to-visit BPV. Around a third to a quarter of these participants had 5 
to 7 GP visits with coded SBP values up to 5 years before UKB recruitment. Fewer 
participants were included if the gap between successiv  GP visits with coded SBP 
values was fixed. Participants in whom BPV could be measured had higher 
proportions of hypertension (range ~40% to ~72%), diabetes (range ~8% to ~15%), 
and MI/stroke (range ~2% to ~3%) than the original UKB Welsh population (total 
9,947 with linked, coded primary care data). Selecting participants based on 
increasing numbers of GP visits with coded SBP values (from 3 to 11) increased both 
the prevalence of vascular risk factors and the mean BPV, but reduced the within 
participant SD BPV (SD in within participant BPV). However, there was still 
sufficient variation in BPV between individuals (SD BPV ranged from 5.3 to 
6.8mmHg amongst participants with 3 to 11 BP readings, 5 years before UKB 
recruitment) to recommend using these selected populations in future studies of 
association between BPV and stroke. Furthermore, there was reasonable within 
participant agreement between mean BP recorded at the UK Biobank baseline 
assessment and mean BP estimated using coded primary care data (ICC for 
agreement with baseline assessment mean BP ranged from 0.46 to 0.53 when mean 
BP was estimated using coded primary care data within 2 weeks to 2 years of the 
assessment). This suggests that BP measurements extract d from coded primary care 
data are a reasonable approximation to standardised BP measurements. In 
conclusion, linkage to coded primary care data is an efficient method of estimating 
within individual visit-to-visit BP variability, particularly in large populations.  
The numbers of participants in whom BPV could be measured in this study (~2,000 
to up to ~5,000), and the measurement periods (up to 5 years) are similar to those 
used in previous studies of the associations between BPV and risk of stroke (clinical 
trials or observational studies, Chapter 6). Although it was not possible to specify the 
gap between successive GP visits with coded BP values (because too few 
participants were identified), the median of the median within participant gap (for 
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those with 3 to 7 successive BP readings within 5 years of recruitment) was ~5 
months to ~1 year, which was also similar to the frequency of GP visits used in 
previous studies.  This suggests that the coded data av ilable in primary care datasets 
should be at least sufficient to replicate previous st dies of associations between 
BPV and stroke in the UK Biobank population. However, UK Biobank has the 
additional advantages of more accurate and detailed stroke outcomes adjudication 
methods compared to many previous studies, and will offer the potential to adjust for 
potential confounding factors, like renal failure, which were not accounted for in the 
majority of previous analyses of the associations between BPV and risk of stroke.   
Coded primary care data have a number of potential advantages compared to data 
that have been used previously. Firstly, the prevalence of hypertension, diabetes, and 
cardiovascular disease (MI or stroke) was lower in populations selected using coded 
primary care data than in previous studies of the associations between BPV and risk 
of stroke, many of which exclusively included participants with hypertension, 
diabetes or CVD (Chapter 7). Secondly, primary care d ta have the potential to 
include much larger numbers of participants than possible previously (given the fact 
that measurements have already been taken in routine clinical practice). The absolute 
numbers of UK Biobank Welsh participants in whom visit-to-visit BPV could be 
measured in this study ranged from 2,352 to 4,658 (with ≥3 to ≥7 successive GP 
visits with coded SBP values, 5 years before recruitment). If these proportions were 
extrapolated to the UKB cohort as a whole (assuming the same data coverage and the 
same pattern of BP coding in the English and Scottish populations as in the UKB 
Welsh population), BPV could be measured in very lage numbers (estimated range 
~120,000 to ~200,000 with ≥3 to ≥7 coded SBP values, 5 years before recruitment in 
the whole UKB cohort). Advantages of this include firstly increased power to detect 
a potential association between BPV and risk of strke. Secondly, it should mean that 
sufficient numbers of participants with sufficient outcomes will be available to detect 
potential differences in the associations between BPV and the main types and sub-
types of stroke. Thirdly, it should be possible to conduct studies among participants 
with even more numbers of successive GP visits withcoded SBP values (eg., ≥11 
visits) Although these individuals were a relatively small proportion of the UKB 
Welsh population (eg. 14% with ≥11 GP visits with coded SBP values, 5 years 
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before recruitment), they would be relatively large group, in absolute numbers, when 
extrapolated to the whole UKB cohort (~70,000). In future, having these larger 
numbers of participants with different numbers of successive GP visits with coded 
BP values, over varying periods of time would enable sensitivity analyses of the 
influence of the number of SBP readings (and also the measurement periods) on the 
strength of the association between BPV and risk of str ke. This would potentially 
help to solve the unanswered question, ‘how many BP values do we need, over what 
time periods, and at what frequency to most accurately predict an individual’s BPV 
related stroke risk?’  
A potential limitation of using coded healthcare data to measure BPV is the risk of 
selection bias. Individuals who have sufficient BP measurements to capture BPV 
most reliably (ie. those with the most BP measurements in any given time period) are 
likely to be those with the most variable BP. This might include individuals with 
hypertension (where variable BP may, in part, be du to effects of treatment and/or 
measurement error), and/or individuals with comorbidities which predispose to more 
variable BP (eg. individuals with pre-existing cardiovascular disease or renal 
disease). These factors should be accounted for in uture analyses of the association 
between BPV and risk of stroke. In this study, I showed that selecting individuals 
with increasing numbers of GP visits with coded SBP values increased the 
prevalence of hypertension, diabetes, cardiovascular disease and renal disease. I also 
demonstrated that increasing the number of GP visits with coded SBP values 
increased the mean within individual BPV (mean within individual BPV increased 
from 10.7 to 13.6 when the number of visits increased from 3 to 11). Despite this, 
there was a sufficient range in BPV amongst included individuals, meaning that it 
would still be possible to demonstrate an association between increased BPV and 
risk of stroke.  Provided confounding factors are accounted for, results from these 
selected populations should be internally valid, albeit less generalizable to the 
population as a whole.  
A second potential limitation of using routinely collected coded healthcare data is 
that the number of BP readings taken, and time period over which they are recorded 
(including the potential gap between successive readings) is not the same for each 
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individual. Ideally, individuals should have the same number of BP readings selected 
over as similar a time period as possible to estimate BPV. Variation in these factors 
is likely to influence the precision of BPV measurement, and may also affect the 
strength of the observed association between BPV and risk of stroke (Chapter 7).  
It is possible that some of the observed association between BPV and stroke is the 
result of residual confounding (from factors like renal failure). In future, access to 
primary care coded data could be used to construct addi ional variables for the 
presence/absence of renal disease amongst UK Biobank participants (eg. based on 
combinations of diagnostic Read codes and/or laboratory results). These could be 
used to adjust for these comorbidities more accurately than possible previously, 
enabling a less biased assessment of the association between BPV and stroke risk in 
UK Biobank.   
8.5 Conclusions 
I have shown that it is possible to estimate visit-to-visit blood pressure variability in 
large numbers of individuals using primary care coded ata. In future, this type of 
data could be used to screen and select individuals, either for more detailed sub 
studies in UK Biobank (where different devices could be used to confirm BPV, like 
self-monitoring, or Ambulatory Blood Pressure Monitring, ABPM), for other large 
prospective observational studies with linkages to primary care data, or for selection 
of participants in clinical trials. Ultimately, this type of data might be used in clinical 
practice to identify individuals with increased BPV, and therefore individuals at 
potentially increased risk of stroke due to BPV.  I have shown that the BP values 
recorded in primary care can identify variation in BPV between individuals, and can 
therefore stratify individuals with higher vs. lower BPV.  This is even possible (using 
~3 BP readings) amongst individuals without a diagnosis of ‘hypertension’ and 
amongst individuals without conventional vascular risk factors. In the long run, if the 
associations between BPV and risk of stroke are confirmed, visit-to-visit BP 
measurements in primary care could be used to select individuals for more detailed 
monitoring, in the same way that individuals with high mean BP measurements are 
currently selected for home 24hr ABPM.
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8.6 Appendix  
 
Table 8.14 Selected Read codes for 'probable' and 'possible' hypertension 
 
 ‘Probable hypertension’  ‘Possible hypertension’ 
 




































*Administration and BP monitoring codes which suggest a diagnosis of hypertension. 
†I excluded the following BP monitoring codes (‘BP reading raised’ codes), because I didn’t think 
they were sufficient to diagnose ‘probable or possible hypertension’ (ie.. one off high BP reading is 
not sufficient) ‘R1y2.’, ‘662B.’, ‘662C.’
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Table 8.15  Read codes which specify 'systolic' or 'diastolic' BP in their text definition 
Specified systolic BP reading 
  
  2469. 
 
O/E systolic BP reading 
  246K. Target systolic blood pressure 
  246N. Standing systolic blood pressure 
  246Q. Sitting systolic blood pressure 
  246S. Lying systolic blood pressure 
  246j. Systolic blood pressure centile  
  246e. Ambulatory systolic BP 
  246W. Average 24hr systolic BP 
  246d. Average home systolic BP  
  246Y. Average day interval systolic blood pressure 
  246b. Average night interval systolic blood pressure 
 
Specified diastolic BP reading 
  
  246T. 
 
Lying diastolic blood pressure 
  246X. Average day interval diastolic blood pressure 
  246a. Average night interval diastolic blood pressure 
  246L. Target diastolic blood pressure 
  246A. O/E diastolic BP reading 
  246R. Sitting diastolic blood pressure 
  246f. Ambulatory diastolic BP 
  246c. Average home diastolic BP 
  246P. Standing diastolic blood pressure 
  246i. Diastolic blood pressure centile 
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Table 8.16 Selection of data for Gender, Date of birth Townsend Index, and vascular comorbidities 
from the UK Biobank baseline assessment dataset. 
Data field Coding of data Derived variables 







Townsend Index at recruitment (189) 
 
Continuous numerical data 
 






Self-reported non-cancer diagnosis* (20016) 1065=hypertension,  
1066=heart/cardiac problem 
1067=peripheral vasc. disease 














1193=renal failure (dialysis) 
1194=renal failure (no dialysis) 
1220=diabetes 
1222=type I diabetes 







(if ‘x’ in field 20016= 
1065, or 1072) 
 
Stroke 
(if ‘x’ in field 20016= 








(if ‘x’ in the field 20016= 
1192, 1193, or 1194) 
 
Diabetes 
(if ‘x’ in the field 20016= 
1220, 1222, 1223, or 
1607) 
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Table 8.17(A to E) Frequencies of individual BP-related Read codes.* 
A) Hypertension diagnosis codes 
 










G20.. Essential hypertension 3,148 
  G200. Malignant essential hypertension 2 
  G201. Benign essential hypertension 76 
  G202. Systolic hypertension 10 
  G203. Diastolic hypertension 0 
  G20z. Essential hypertension NOS 155 
G21.. Hypertensive heart disease 4 
  G210. 
  G2100 
  G2101 
  G211. 
  G2110 
  G2111 
  G21z. 
  G21z0 
Malignant hypertensive heart disease 
Malignant hypertensive heart disease without CCF 
Malignant hypertensive heart disease with CCF 
Benign hypertensive heart disease 
Benign hypertensive heart disease without CCF 
Benign hypertensive heart disease with CCF 
Hypertensive heart disease NOS 









  G21z1 
  G21zz  
G22.. 
  G220. 
Hypertensive heart disease with CCF 
Hypertensive heart disease NOS 
Hypertensive renal disease 





  G221. 
  G222. 
Benign hypertensive renal disease 
Hypertensive renal disease with renal failure 
0 
0 
G22z. Hypertensive renal disease not otherwise specified 3 
G23.. 
  G230. 
  G231. 
  G232. 
  G233. 
  G234. 
  G23z. 
Hypertensive heart and renal disease 
Malignant hypertensive heart and renal disease 
Benign hypertensive heart and renal disease 
Hypertensive heart and renal disease with CCF 
Hypertensive heart and renal disease with renal failure 
Hypertensive heart and renal disease with renal failure and CCF 








G24.. Secondary hypertension 3 
  G240. 
  G2400 
  G240z 
  G241. 
  G2410 
  G241z 
  G244. 
  G24z. 
  G24z0 
  G24z1 
Secondary malignant hypertension 
Secondary malignant renovascular hypertension 
Secondary malignant hypertension NOS 
Secondary benign hypertension 
Secondary benign renovascular hypertension 
Secondary benign hypertension NOS 
Hypertension secondary to endocrine disorders 
Secondary hypertension NOS 
Secondary renovascular hypertension NOS 











  G24zz Secondary hypertension NOS 1 
G25.. Stage 1 hypertension (NICE 2011) 0 
G26.. Severe hypertension (NICE 2011) 0 
G27.. Hypertension resistant to drug therapy 0 
G28.. Stage 2 hypertension (NICE 2011) 0 
G2y.. Other specified hypertensive disease 1 
G2z.. Hypertensive disease NOS 24 
G672. Hypertensive encephalopathy 0 
F4213 Hypertensive retinopathy 12 
F4042 Blind hypertensive eye 0 
L12.. Hypertension complicating pregnancy 5 
  L122. 
  L1220 
  L1221 
  L1223 
Other pre-existing hypertension in pregnancy/childbirth 
Other pre-existing hypertension in pregnancy/childbirth 
unspecified 
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  L122z 
  L127. 
  L127z. 
  L128. 
L1280 
  L1282 
Other pre-existing hypertension in pregnancy/childbirth not 
delivered 
Other pre-existing hypertension in pregnancy/childbirth NOS 
Pre-eclampsia or eclampsia with pre-existing hypertension 
Pre-eclampsia or eclampsia with pre-existing hypertension NOS 
Pre-existing hypertension complicating pregnancy 
Pre-existing hypertensive heart disease complicating pregnancy 







Gyu2. Hypertensive diseases 0 
Gyu20 Other secondary hypertension 0 
Gyu21 Hypertension secondary to other renal disorders 0 









Chapter 8: Appendix 
 










Referral to hypertension clinic 




8I3N. Hypertension treatment refused 1 
8BL0. 
8B26. 




8CR4. Hypertension clinical management plan 0 
14A2. History of hypertension 180 




DNA. Hypertension clinic 
Seen in hypertension clinic 




TJC7. Adverse reaction to other antihypertensives 0 
TJC7z Adverse reaction to hypertensives NOS 0 
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  9OD1. 
  9OD2.  
9OD3. 
 
Hypertension screen admin 
BP screen -1st call 
BP screen- 2nd call 






  9OD4. BP screen- call deleted 0 
  9OD5. 
  9OD6. 
  9OD7. 
BP screen – 1st recall 
BP screen- 2nd recall 




  9OD8. BP screen- recall deleted 0 
  9OD9. BP abnormal – 1st recall 7 
  9ODA. BP abnormal – 2nd recall 0 
  9ODB. BP abnormal- 3rd recall 0 




Attends hypertension monitoring 
Refuses hypertension monitoring 






  9OI6. 
Hypertension monitoring- 1st letter 
Hypertension monitoring- 2nd letter 




9OI7.     
9OI8. 
Hypertension monitoring – verbal interview  
Hypertension monitoring – phone invitation 
54 
39 
9OI9. Hypertension monitoring deleted 0 
9OIA. Hypertension monitoring check done 623 
9OIZ. Hypertension monitoring admin NOS. 0 
68B1. Hypertension screen 646 
68B4. Risk factors present at hypertension screen 12 
ZV70B Examination of blood pressure 79 
ZV7B1 Screening for hypertension 39 
8HRH. Referral for ambulatory BP monitoring 24 
8IBA. Ambulatory BP monitoring not indicated 0 
8I3Y. 
315B. 
Blood pressure procedure refused 
Ambulatory BP recording 
9 
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662..      
 6624. 
Hypertension monitoring 





 662b.      
 662c. 
 662L.  
Good hypertension control 
Hypertension follow-up default 
Moderate hypertension control  
Hypertension 6 month review  












 662P.    
 662P0 
 662d. 
Poor hypertension control 
Hypertension treatment started  
Hypertension treatment changed 
Hypertension treatment stopped 
No record of BP reading 
Good hypertension control 
Hypertension monitoring 
Hypertension 9 month review 














Pre-treatment BP reading 
Blood pressure monitoring 




 662r. Trial withdrawal of antihypertensive therapy 0 
 662B. O/E- initial high BP 5 
 662C. O/E- check high BP 5 
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R1y3 Low BP reading 9 
R1y2 Raised BP reading 705 



















O/E blood pressure reading 
 
144,868 
  2469. O/E systolic BP reading 369 
  246A. O/E diastolic BP reading 343 
  246C. Lying BP reading 3 
  246D. Standing BP reading 5 
  246E. Sitting BP reading 69 
  246F. O/E BP decreased 1 
  246J. O/E BP reading- no postural drop 1 
  2468. O/E BP reading- postural drop 47 
  246K. Target systolic blood pressure 85 
  246L. Target diastolic blood pressure 98 
  246N. Standing systolic blood pressure 0 
  246P. Standing diastolic blood pressure 1 
  246Q. Sitting systolic blood pressure 4 
  246R. Sitting diastolic blood pressure 0 
  246S. Lying systolic blood pressure 0 
  246T. Lying diastolic blood pressure 0 
  246Z. O/E blood pressure reading NOS 211 
  246i. 
  246j. 
Diastolic blood pressure centile 
Systolic blood pressure centile 
0 
0 
  246X. Average day interval diastolic blood pressure 3 
  246Y. Average day interval systolic blood pressure 6 
  246a. Average night interval diastolic blood pressure 2 
  246b. Average night interval systolic blood pressure 5 
  2460. BP unrecordable 0 
  2465. BP reading borderline raised 361 
  2466. BP reading raised 496 
  2467. BP reading very high 9 
  2461. BP reading very low 1 
  2462. BP reading low 7 
  2463. BP borderline low 2 
  2464. O/E- BP normal 1,790 
  246B. O/E – BP stable 2 
  246G. O/E – BP labile 2 
  246M. White coat hypertension 43 
  246V. Average 24hr diastolic BP 4 
  246W. Average 24hr systolic BP 6 
  246e. Ambulatory systolic BP 2 
  246f. Ambulatory diastolic BP 1 
  246c. Average home diastolic BP 0 
  246d. Average home systolic BP 6 







*Amongst 171,142 BP- related Read codes in the Welsh coded primary care dataset. Shaded rows 
indicate Read codes which were never used. 
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Table 8.18 Distribution of within-participant median gaps of ≤ 18 months 
Gap time (days) Participants (n) % (of 5,050)* % (of 7,748)† 
≥1 to ≤30  415 8.2 5.4 
>30 to  ≤60 619 12.3 7.9 
>60 to ≤90  501 9.9 6.5 
>90 to ≤120  404 8.0 5.2 
>120 to ≤150 324 6.4 4.2 
>150 to ≤180 440 8.7 5.7 
>180 to ≤210  335 6.6 4.3 
>210 to ≤240 248 4.9 3.2 
>240 to ≤270 217 4.3 2.8 
>270 to ≤300 209 4.1 2.7 
>300 to ≤330 203 4.0 2.6 
>330 to ≤365 255 5.0 3.3 
>365 to ≤395 193 3.8 2.5 
>396 to ≤425 153 3.0 1.9 
>426 to ≤455 151 2.9 1.9 
>456 to ≤485 135 2.7 1.7 
>486 to ≤515 122 2.4 1.6 
>516 to ≤550 126 2.5 1.6 
Total 5050 100 100 
*Total number of individuals who had a median within-participant gap of ≤ 18 months 
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Chapter 9 Conclusions and future directions 
9.1 Main findings of thesis 
I have used linkages to multiple different sources of routinely collected, coded 
healthcare data to detect and quantify a potential exposure, blood pressure variability 
(BPV), and to optimise the ascertainment and confirmation of an important clinical 
outcome, stroke, in a sub-cohort of the UK Biobank population. My work will 
inform the design of future nested case cohort or case control studies of the 
associations between BPV and risk of stroke in UK Biobank.   
9.1.1 Accuracy of coded healthcare data for identif ying stroke 
cases in UK Biobank 
My objective in Chapter 2 was to perform a systematic review of the accuracy of 
routinely available coded healthcare data for stroke and its main pathological types, 
to inform the selection of codes for the identification of stroke cases in UK Biobank. 
Among 37 studies, the accuracy (PPV) of coded hospital or death certificate data 
ranged from poor to excellent, but studies varied widely in their settings, methods, 
reporting, quality, and in the choice and accuracy of codes. Appropriately selected, 
‘stroke specific’ codes appeared sufficiently accurate to identify stroke cases in UK 
Biobank. Broad cerebrovascular codes were consistently l ss accurate for stroke, but 
these codes may be used to identify additional potential cases when further 
confirmation steps are planned. Few studies assessed ith r coded primary care data 
or combinations of data sources for stroke.   
9.1.2 Accuracy of patient self-report of stroke 
My objective in Chapter 3 was to perform a systematic review of the accuracy of 
patient self-report of stroke, to inform the use of participant self-report data for the 
identification of stroke cases in UK Biobank.  
Among 17 studies, the accuracy (PPV) of patient self-report of stroke, ranged from 
poor to very good. As expected, accuracy of self-repo t increased in populations with 
higher stroke prevalence. Amongst the studies with low stroke prevalence, like UK 
Biobank, between a 1/3 and 3/4 of self-reported strokes were false positive. I 
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concluded that self-report is unlikely to be helpfu for identifying stroke cases in UK 
Biobank, without subsequent confirmation. Self-report may be useful for case 
ascertainment in combination with other data sources.   
9.1.3 Reliability and feasibility of ischaemic stro ke 
classification systems 
My objective in Chapter 4 was to perform a systematic review of the inter- and   
intra-observer reliability of ischaemic stroke classification systems, and amongst 
included studies, to report the proportion of cases cla sified to a single determined 
subtype, to inform the approaches to ischaemic stroke classification in UK Biobank.  
Amongst 25 studies which assessed the overall inter-observer reliability of one or 
more of the existing ischaemic stroke classification systems, reliability ranged from 
moderate to excellent. Characteristics other than te classification system used 
contributed much of the variation in reliability. Use of clear rules, data abstraction 
protocols, computer based classification and fewer categories all improved 
reliability. There was insufficient evidence to recommend the newer ‘single cause 
mechanistic’ classification systems in place of older, more established systems. The 
proportion of cases undetermined to a single subtype was lowest using ‘anatomical’ 
or ‘descriptive mechanistic’ classification systems. I concluded that no single 
classification system was fit for every purpose. I recommended a flexible approach to 
ischaemic stroke classification in UK Biobank, along with the features (above) which 
have been shown to enhance reliability.  
 
9.1.4 Choosing Read codes to identify stroke cases in UK 
Biobank 
My objective in Chapter 5 was to select Read codes to identify ‘acute’ stroke cases in 
UK Biobank, for future nested case cohort or case control studies which require high 
accuracy (PPV) for stroke, and Read codes to identify additional ‘prevalent stroke 
cases’, for exclusion of participants from future studies of ‘first in a lifetime’ stroke. 
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I searched multiple online resources, and selected 57 Read codes for ‘acute stroke’, 
from among >200 potential codes. No single online resource included all of the 
relevant codes for stroke. I hypothesised that my ‘acute stroke’ codes would have 
high accuracy (high PPV) for stroke, based on matching to previously validated 
‘stroke specific’ International Classification of Diseases (ICD) codes (Chapter 2). I 
identified an additional 18 Read codes for possible ‘past history of stroke’, which 
could be used to identify additional ‘prevalent stroke’ cases, and exclude participants 
from future studies of ‘first in a lifetime’ stroke. Read codes matching the broader 
cerebrovascular diseases ICD codes could also be used for this purpose. I concluded 
that further studies are required to validate groups of Read codes for stroke and its 
main pathological types, and to compare the contribution of multiple overlapping 
data sources for stroke. 
9.1.5 Identification of prevalent and early inciden t stroke 
cases in UK Biobank 
My objective in Chapter 6 was to identify prevalent a d early incident stroke cases in 
UK Biobank, and in a sub-cohort of ~22,000 participants, using multiple 
overlapping coded data sources, to determine to proportion of cases identified by 
each individual source, the added contribution of linkage to coded primary care 
data, and the number of cases classified to main pathological stroke type.  
The majority of prevalent stroke cases in UK Biobank (~9,000 in the whole cohort 
and ~1,000 in the sub-cohort) were identified by participant self-report. Most of 
these cases were ‘unspecified’ pathological type. By contrast, the 850 incident cases 
identified by coded hospital and/or death certificate data in the whole UK Biobank 
population were mostly ‘specified’ pathological type. In the sub-cohort with 
complete linkage to all three coded data sources, just over a third of ~180 incident 
cases were detected using coded primary care data, and half of the of these were not 
detected by any other data source. I concluded that, as expected, linkage to coded 
primary care data should improve the completeness of troke outcomes identification 
in UK Biobank, and that the majority of cases detected using coded hospital or death 
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9.1.6 The association between blood pressure variab ility and 
risk of stroke 
My objective in Chapter 7 was to review published studies of the association between 
medium- to long-term blood pressure variability and risk of stroke, to determine the 
strength of the existing evidence, limitations of previous studies, and to inform 
potential approaches to future BPV measurement amongst UK Biobank participants. 
All sixteen studies demonstrated a trend towards an association between BPV and 
stroke risk, but in many, small numbers of stroke outc mes limited the ability to 
detect a significant association, and the effect size was often small. The majority of 
studies were in selected populations with increased vascular risk. The strength of the 
association between BPV and stroke appeared to increase with the precision of BPV 
measurement, but there was no consensus on how BPV should be measured, 
including number of BP readings and/or time period over which readings were 
recorded, to best predict stroke risk. I concluded that there was definite evidence that 
BPV is an important potential risk factor for stroke, but future, large, population 
based studies are required to reliably test this association, and to explore the 
optimum method(s) of BPV measurement for potential future BP monitoring and 
treatment.  
9.1.7 Can coded primary care data be used to measur e blood 
pressure variability? 
My objective in Chapter 8 was to investigate the potential of using routinely 
collected coded primary care data to estimate visit-to-visit BP variability (BPV) in a 
sub-cohort of ~10,000 UK Biobank participants.  
 
It was possible to estimate visit-to-visit BPV, using ≥3 GP visits with coded BP 
values before recruitment, in the majority of UK Biobank participants. Using an 
exposure period of 5 years it was possible to estimate visit-to-visit BPV in just under 
half, but these participants had a higher prevalence of hypertension, diabetes, and 
cardiovascular disease compared to the baseline UKB Welsh population. Although 
selecting participants reduced generalisability, there was good variability in BP 
variability amongst those selected (SD SBP ranged from ~5 to ~7mmHg), and there 
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was reasonable agreement between mean coded BP and an independent reference 
standard. I concluded that routinely collected coded primary care data should enable 
exploration of the associations between BPV and stroke in a ‘real world setting’ and 
in much larger numbers than previously possible. 
 
9.2 Systematic review methodology 
The systematic reviews in this study differed from conventional methodology in a 
number of ways.  
Firstly, study protocols were not registered or published in advance of the reviews 
taking place. This is now a requirement for systematic reviews to ensure that 
research methods are transparent and to avoid ‘data driven research’, where study 
methods (including inclusion/exclusion criteria and/or subgroup analyses) are 
influenced by the availability of published data and/or ‘positive’ outcomes.(The PloS 
Medicine Editors 2011) Registration of the study protocol should also reduce 
publication bias, which is an increasingly recognised problem in systematic reviews. 
My systematic review of ischaemic stroke classification systems was ‘data-driven’, 
because I focussed on the kappa statistic only after discovering that it was the most 
widely used and reported measure of the inter-rater eliability of ischaemic stroke 
classification systems. I will have excluded studies which used different statistical 
measures of reliability, and these studies although in t e minority, may have led me 
to different conclusions had they been included.  
Secondly, it is standard protocol in systematic reviews that all titles, abstracts, and 
full texts for inclusion are independently reviewed by two researchers. This process 
minimises random error and bias in study selection. In my systematic reviews, only a 
proportion of potential studies were reviewed for inclusion by a second, independent 
researcher. This means that it is more possible that I excluded relevant studies by 
mistake, or included irrelevant studies (and potentially positive studies) in a biased 
fashion. Use of a second reviewer also ensures that s udy inclusion/exclusion criteria 
are easy to follow and lead to reproducible results.  
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Thirdly, in some of my systematic reviews I excluded studies with less than 50 
included cases. Although I may have excluded important and relevant studies by 
doing this, smaller studies may be more prone to publication bias, and by excluding 
these studies I am hoping to have minimised the effect of publication bias on my 
results.  
9.3 Advantages of using routinely collected coded 
healthcare data for research in large populations 
I have illustrated multiple advantages of using routinely collected coded healthcare 
data for research in large populations.  
Describing exposures in large populations and enhan cing statistical 
power to detect exposure-outcome relationships. 
Firstly, linkage to coded data facilitated the measurement of a novel exposure, BPV, 
in a very large population. I found that BPV could be measured, using at least 3 
separate GP visits within 5 years of recruitment, in around 4,600 UK Biobank 
participants using coded primary care data (~47% of a sub-cohort of ~10,000). 
Scaled to the whole UK Biobank population of around 500,000, the numbers of 
participants in whom BPV could be estimated through primary care data linkages, 
(potentially up to ~230,000), surpasses those included in the majority of individual 
previous clinical trials or observational studies of associations between BPV and risk 
of stroke. So far, the largest individual population based study of the association 
between BPV and stroke included ~120,000 participants, all of whom had a 
diagnosis of hypertension.(Yu et al. 2014)  
As well as very large sample size, the added advantage of UKB is the unparalleled 
depth and breadth of phenotype and genotype data collected at baseline, and the 
strategy (in development) for more complete and accurate stroke case identification, 
confirmation and sub-classification during follow-up. By contrast, the previous 
study, mentioned above, ascertained stroke cases using le s accurate ICD codes 
(including codes for ‘cerebrovascular diseases’), without subsequent confirmation. 
(Yu et al. 2014). It is therefore likely to have included larger numbers of false 
positive cases during follow-up, thereby potentially underestimating the strength of 
the observed association between BPV and risk of str ke.  
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In the long run, combining UK Biobank data with data collected in other large cohort 
studies, e.g., the China Kadoorie Biobank (CKB),(Chen et al. 2005) the Prospective 
Studies Collaboration (PSC),(Prospective Studies Collab ration et al. 2002) the 
Million Women Study (MWS),(The Million Women Study Collaboration. 1999) and 
others, will increase included numbers further, andfurther increase statistical power. 
Comparing data from these different populations, for example China versus UK, 
and/or other countries worldwide, will enable regional differences in the associations 
between BPV, the risk of stroke, its main types andsubtypes to be explored.  
More representative than previous studies of the as sociations between 
BPV and risk of stroke 
Secondly, coded primary care data appeared to be mor  representative of the general 
population than data gained from highly selected clinical trial populations, where 
measurements were taken in a controlled environment, and were therefore less 
representative of the ‘real world’ setting.  I showed that the UKB participants who 
had multiple successive BP values in the coded primary care dataset had fewer 
vascular risk factors compared to participants included in the majority of previous 
studies of the association between BPV and risk of str ke. Furthermore, the selection 
of participants using routinely collected coded data did not limit the potential to 
detect a true association between BPV and increased risk of stroke. Despite the fact 
that individuals with large numbers of BP measurements had higher BPV overall 
than those with fewer BP measurements, I found that there was a wide range in 
variability in BPV amongst these individuals, even among those with >11 successive 
BP readings.  
Depth and breadth of data for well-powered and deta iled sub-group 
analyses, enabling personalised and stratified risk  prediction. 
Thirdly, data collected and coded in routine clinical practice were wider ranging than 
data collected de-novo for clinical trials and observational studies (where time and 
cost often limits the amount of data collected). I found a wide range in the number of 
successive BP measurements amongst UKB participants (from 2 to >20), over a wide 
range of durations (periods of >1 to >10 years) using linkages to coded primary care 
data. In future, these coded data could be used to conduct sensitivity analyses to 
compare the influence of the number of BP readings used, and time period over 
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which readings were taken (precision of BPV measurement), on stroke risk 
prediction. We may, therefore, be more likely to be a le to answer the question, 
‘How many BP measurements, over what time periods, and at what frequency, do we 
need to most accurately predict BPV related stroke isk?’, by analyses of coded data 
collected as part of routine practice, in addition t  or instead of data collected 
specifically for prospective observational studies or clinical trials.  
A recent published study used coded electronic healt  record data from primary care, 
hospital admissions, death certificates, and the Myocardial Ischaemia National Audit 
Project (MINAP), to investigate associations between mean blood pressure and 
cardiovascular outcomes, including stroke.(Rapsomaniki et al. 2014) The study 
demonstrated the increased risk of stroke associated wi h a 20mmHg increase in 
mean blood pressure, stratified by age group, and by different blood pressure values 
in each age group. Around 65% of the cohort (~1,300,000 of ~2,000,000) had at least 
one coded blood pressure value recorded in the primary care dataset within 2 years of 
recruitment to the study (compared with 57% of participants within 2 years of 
recruitment to UK Biobank). In agreement with my work, participants in this study 
with no coded BP values were more likely to be male and were healthier. In 
comparison to previous large studies of the associati ns between mean BP, stroke 
and its main pathological types, (PSC and APCSC) the above study demonstrated the 
association between mean BP and stroke across a wider range of blood pressures, 
and identified, for the first time, a nadir below which reducing mean BP did not 
reduce risk of stroke further (~130mmHg systolic and ~80mmHg diastolic BP). It 
provides an example of how including a wider range of xposures, which is possible 
at scale using linkages to coded healthcare data, cn provide new and valuable 
information about a previously well studied exposure-outcome relationship.  
Although selection of individuals using coded data limited generalisability to the 
population as a whole (these individuals had increased BPV and an increased 
prevalence of vascular risk factors compared to the general population), future     
sub-group analyses within these populations could be translated to sub-groups of the 
general population for personalised and stratified r sk prediction. Personalised and 
stratified medicine is a major goal of current clini al research. Powerful sub-group 
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analyses exploring the influence of age, and a variety of other baseline characteristics 
on the associations between BPV and stroke should be possible in UK Biobank, as I 
have already demonstrated that large numbers of partici nts will have sufficient 
measures of exposures (BPV estimates), and, in time, large numbers of outcomes 
(incident stroke and/or its main pathological types) should accrue.   
Linked coded data should also facilitate adjustment for more confounding factors 
than possible in previous studies, for example, renal impairment, which is an 
important potential confounder of the association between BPV and risk of stroke. 
The opportunity to link to the UKB baseline assessment, which includes a wide 
range of prospectively collected data on lifestyle, environment, co-morbidities, and 
medication use, further broadens the scope of the analyses possible in UK Biobank.  
Accuracy of coded data 
Finally, I have shown that using linked coded data for defining exposures, or for 
follow-up of disease outcomes, does not necessarily reduce accuracy. I showed good 
agreement between mean BP estimated using the codedprimary care dataset and 
mean BP measured at the UK Biobank baseline assessment. The majority of stroke 
cases identified using ICD coded data could be classified into a main pathological 
type of stroke (up to 89% of stroke cases identified using ICD codes based on 
hospital admissions and death certificates during follow-up until December 2010), 
and these codes had PPVs >90% for either ischaemic or haemorrhagic stroke (based 
on a systematic review of the published data).  
The use of multiple overlapping data sources is likely to improve the completeness of 
stroke case detection, and reduce selection bias. I showed that using multiple sources 
of linked coded data (adding coded primary care data to ICD codes from hospital 
admissions and death certificates) increased the number of stroke cases detected 
during follow-up in a subset of UK Biobank participants to the end of December 
2010.  Around 19% of these cases would not have been d tected without the addition 
of coded primary care data, and it is likely that missing these cases would under 
represent milder subtypes of ischaemic stroke (e.g.lacunar ischaemic stroke). A 
similar advantage of using multiple sources of routinely collected healthcare data 
was demonstrated in a study published in 2010. Thisshowed that the incidence of 
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myocardial infarction was underestimated by 25 to 30% if only one source of coded 
data was used for case ascertainment, compared to mul iple overlapping sources 
(primary care, hospital admissions, death certificaes, and the MINAP disease 
registry).(Herrett et al. 2013) 
9.4 Future directions 
Challenges of using routinely collected coded-healt hcare data for 
research 
Routine, coded healthcare data are not collected primarily for research purposes. 
Inconsistencies between data from different geographic l areas and/or different 
healthcare settings need to be interrogated, understood and resolved before these data 
can be used in research studies such as UK Biobank. For example, data from primary 
care and secondary care are coded differently (Read v rsus ICD), and different 
versions of Read are currently in use in England, Scotland and Wales, depending on 
the particular GP practice systems used. Furthermore, data from different regions 
may have variable completeness, and the periods of ata coverage may vary between 
region and/or data source. I rationalised these inconsistencies in my research by 
censoring data so that my denominator population (9,947 in the Welsh UKB        
sub-cohort) had as complete coverage as possible from all three data sources: 
primary care, hospital admissions, and death certifica es. However, linkages to coded 
primary care data were only ~50% complete in Wales for UK Biobank at the time of 
this study. In future, it is hoped that linkages will approach ~100% completeness for 
all UKB participants and across all three data sources, across England, Scotland, and 
Wales.   
I have found that creating code lists to define exposures, like BPV and outcomes, 
like stroke, is a time consuming process. The codes selected to represent these 
variables will depend on the research question (for example a distinction was made 
between ‘incident’ versus ‘prevalent’ stroke, and different groups of codes might be 
chosen to maximise sensitivity and/or maximise PPV of stroke 
ascertainment/confirmation). Eventually, groups of c des combined in algorithms 
used to define health related outcomes such as stroke, as well as those for additional 
exposures such as blood pressure and blood pressure variability, will be provided via 
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the UK Biobank Data Showcase website for sharing with the wider research 
community.(http://www.ukbiobank.ac.uk/) It is hoped that sharing case definitions 
will increase transparency of research using coded healthcare data, increase 
efficiency (because code lists do not have to be recreated) and improve 
reproducibility. In future, analyses in UK Biobank might investigate the influence of 
different groups of codes selected (e.g. ‘stroke specific codes’ chosen to maximise 
PPV versus more general cerebrovascular codes chosen t  maximise sensitivity) on 
the strength, shape and precision of the associations between mean BP (and or BPV) 
and risk of stroke, its main types, and subtypes.  
Validating BPV estimates and potential implications  for future research 
and clinical practice 
Although there was good within participant agreement between mean BP in primary 
care data and BP recorded at the UKB baseline assessment, I have not been able to 
validate my estimates of pressure variability (BPV). In future, I aim to determine the 
association between within participant BPV estimated using coded primary care data, 
and known correlates of BPV (e.g. renal impairment, a d/or age), using linkages to 
the UK Biobank baseline assessment dataset and/or coded primary care data. In 
collaboration with relevant experts, my supervisor’ group is now conducting 
research to create similar algorithms for renal impairment in the UK Biobank Welsh 
sub-cohort, using coded primary care data for renal function (i.e. coded values of 
measures such as creatinine and glomerular filtration rate), and/or coded diagnoses of 
renal disease. Alternatively, coded primary care data might be used to select a subset 
of participants with a range of BPV values for comparison with direct, accurate 
estimates of BPV, e.g. successive home-monitoring, or successive Ambulatory Blood 
Pressure Monitoring (ABPM), enabling calibration of the primary care based BPV 
estimates. 
In future, coded primary care data may not be sufficiently accurate to predict an 
individual’s BPV related stroke risk, but they may be used to screen for potential 
BPV (i.e. to detect UKB participants with potential increased BPV). Coded data 
might therefore be used for BPV ascertainment, and more accurate methods could be 
used for subsequent confirmation and risk stratifiction. This approach might be 
applied in UK Biobank sub-studies, in clinical trials, or in future clinical practice 
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(analogous to the use of outpatient BP screening in primary care to select individuals 
for 24hr ABPM prior to confirmation and treatment of hypertension).  
A screening test requires high sensitivity, and a limitation of using coded primary 
care data to detect individuals with/without potential BPV in a real world setting, is 
selection bias. Individuals without BP measurements a d/or with insufficient 
measurements for accurate BP estimation would be missed by any screening process 
based on routinely collected coded data. Although the majority of UK Biobank 
participants in the Welsh sub-cohort had at least one BP value, I showed that around 
40% did not have ≥ 3 BP values within 10 years of recruitment, and that individuals 
with multiple successive BP readings had a higher pr valence of vascular risk 
factors. Importantly, individuals with fewer vascular risk factors who were less likely 
to have multiple successive BP values in the primary c e dataset were also likely to 
benefit most from BPV screening and treatment.  Individuals with fewer vascular 
risk factors demonstrated a stronger association between BPV and risk of stroke in 
previous studies.(Rothwell et al. 2010b) Therefore, if the association between BPV 
and risk of stroke is confirmed in future, it would be important to highlight this 
potential ‘at risk’ population. Future public health programmes might focus on 
increasing BP screening in primary care, particularly mongst populations with low 
vascular risk. To facilitate this, future research in UK Biobank could investigate the 
minimum number of successive BP values, over the longest period of time, which 
reproducibly estimates within individual BPV. This would minimise the additional 
burden on GP workload, and increase the number of potential individuals in whom 
BPV could be estimated. 
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Developing and validating an algorithm for the iden tification, 
confirmation and sub-classification of stroke outco mes in UK Biobank  
I showed that ICD coded data classified ~89% of stroke cases into ischaemic or 
haemorrhagic stroke in the UK Biobank Welsh sub-cohort. Although these codes had 
PPVs of ≥90% for the main pathological types of stroke in previous published 
studies, they will need to be validated against an independent reference standard to 
determine their accuracy for stroke and its main types in the UK Biobank population.  
Classification should minimise inclusion of false positive cases, which reduces 
power to detect differences in the strength of the associations between BPV and 
ischaemic or haemorrhagic stroke, or between BPV and their main subtypes.  
A sub-study is now ongoing in my supervisor’s group to validate a selection of 
potential stroke cases ascertained by ICD codes from h spital admissions/death 
certificates, Read codes, participant self-report, and/or combinations of these data 
sources amongst Scottish UK Biobank participants. A panel of local experts will 
determine the reference standard ‘stroke’ versus ‘non stroke’, and the pathological 
types and subtypes of stroke, where applicable, using access to all available medical 
record data, blinded to the coded diagnosis. This will enable estimation of the 
accuracy (PPV) of selected codes for stroke, and its main pathological types in UK 
Biobank.  In addition, linkages to the Scottish Stroke Care Audit (SSCA), which 
collects data on all strokes diagnosed in Scottish hospitals, including those seen in 
outpatient clinics (representing a proportion of non fatal, non hospitalised strokes), 
could be used to estimate the sensitivity of linked, coded data for stroke.  However, a 
true population based reference standard (including all hospitalised, non hospitalised 
and fatal strokes) would need to be used to estimate the true sensitivity and PPV of 
these data sources in UK Biobank. 
I showed that there were insufficient published data on the accuracy of Read codes 
from primary care, or of multiple overlapping coded data sources for stroke, or its 
main types. The validation work (above) should provide the first results of this type, 
and may determine the potential of coded primary cae d ta to improve the 
confirmation and sub-classification of otherwise unspecified stroke cases identified 
using hospital admissions data.  For example, a proporti n of the ~11% of cases 
which were of unspecified pathological type  in theUK Biobank population  (based 
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on ICD codes alone) may be classified into main pathological types of stroke by 
cross linking to Read codes for ischaemic or haemorrhagic stroke.  
It seems unlikely that coded data alone will be sufficient to sub-classify detailed 
pathological subtypes of stroke (i.e. subtypes of ischaemic stroke and of 
subarachnoid and intracerebral haemorrhage) during follow-up in UK Biobank. 
Additional medical record data will be required forthis, but the approach should 
remain efficient and scalable across the whole UK Biobank cohort. Within my 
supervisor’s group, an algorithm is in development in a sub-cohort of the UKB 
population (NHS Lothian) to guide confirmation and classification of potential stroke 
cases identified by ICD coded data, using unstructued data extracted from electronic 
medical records. In the first phase of this work, UKB participants identified using 
ICD codes for stroke admissions were linked to the inpatient electronic healthcare 
record, which included inpatient hospital discharge letters, outpatient clinic letters, 
and results of tests (including reports of CT scans).  This information was used to 
classify 98% (95% CI  95% to100%) of confirmed stroke cases into a main 
pathological type, 88% (95% CI 78% to 98%)  of confirmed ischaemic strokes into 
ischaemic stroke subtypes using the OCSP anatomical ischaemic subtype 
classification, and 39% (95% CI 13% to 67%) of confirmed ischaemic strokes into 
ischaemic stroke subtypes using the TOAST mechanistic sub-classification. 
Subsequent phases of this work will extend this process to non hospital admitted 
stroke cases, and consider ways in which an algorithm for confirmation and           
sub-classification of stroke cases could be applied at scale throughout the UK where 
UK Biobank participants were recruited, live, and receive healthcare. To enable the 
scalability required, adjudication of stroke cases during follow-up in UK Biobank 
may be possible via a web-platform, using data extracted by a distributed network of 
clinical research staff (e.g. those engaged with the UK Clinical Research Network) 
from hospital and primary care unstructured electronic (or if necessary paper) 
medical records. Once these data are anonymised and uploaded, volunteers (stroke 
physicians and/or stroke trainees), could use this web-based platform to confirm 
potential stroke cases, and classify them into their main pathological types and 
subtypes. To maximise reliability, data should be astracted from medical records 
following written protocols, training cases could aso be included online, and 
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classification could be driven by a standardised computer-based process. I 
demonstrated that these approaches improved the inter-observer reliability of 
ischaemic stroke classification.  Furthermore, data used for classification would be 
retained on the platform, enabling different combinations of outcomes, including 
intermediate disease phenotypes (like the presence/abs nce of large artery 
atherosclerosis, or small vessel disease) to be investigated in future. This is similar to 
the ‘phenotypic classification’ approach developed for the A-S-C-O and phenotypic 
CCS ischaemic stroke classification systems.   
Investigating associations between BPV and the main  types and 
subtypes of stroke in UK Biobank 
It is not yet known whether blood pressure variabilty associates more strongly with 
haemorrhagic stroke than ischaemic stroke, or if differences exist in the strength of 
associations between BPV and the main pathological subtypes of stroke. Large 
numbers of classified cases are needed to reliably nvestigate these potential 
differences. In this research I have demonstrated that linkages to multiple sources of 
routinely collected coded healthcare data provide an xciting opportunity to begin to 
explore these research questions in a very large population. Having developed 
methods to define both exposures and outcomes in UK Biobank, I hope in the future 
to use this in depth methodological understanding to investigate in the UK Biobank 
population the associations of visit-to-visit blood pressure variability with incident 
stroke and its main pathological types, adjusting for changes in mean BP over time, 
and a range of potential confounding factors. In the long run, this work should 
improve our understanding of stroke type/subtype specific aetiology, and will 
potentially provide future targets for drug development in clinical trials (specifically 
treatment of BPV, which may provide new avenues for personalised and stratified 
stroke risk prevention).   
Wider implications of the importance of BPV 
Blood pressure variability may be a new risk factor for stroke, with implications for 
monitoring and treatment beyond mean BP.  Individuals with normal mean BP and 
high BP variability, (or normal mean BP and episodic hypertension) would not 
otherwise be considered ‘at risk’ and would not otherwise receive BP monitoring or 
treatment. The previously observed association between BPV and stroke is highest 
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amongst those with otherwise normal mean BP.(Rothwell et al. 2010b) Therefore, 
these individuals have the most potential to gain from new treatments targeted at 
BPV reduction. In addition, it is possible that BPV is one of the contributing factors 
in ‘cryptogenic stroke’, stroke without any clear aetiology, which can affect up to a 
third of ‘young stroke’ patients. Recognition of BPV as a potential risk factor may 
lead to a step forward in the prevention of cryptogenic stroke.  
Measurement of BPV is likely to be time consuming ad costly in the ‘real world’. 
This effort may add little to the treatment of indivi uals with BPV who are already 
hypertensive (for example, these individuals could receive an antihypertensive drug 
chosen to reduce both mean BP and BPV, see below). However, prevention of stroke 
in younger patients (as described above) is likely to have the most long-term 
economic impact (by reducing the longer term care burden). Future clinical trials of 
BPV reduction may have more impact if they focus on the identification and 
treatment of these groups of individuals.  
Post hoc analyses of clinical trials have demonstrated that certain antihypertensive 
medications reduce BPV more than others. In the ALLHAT trial (Antihypertensive 
and Lipid Lowering treatment to prevent Heart Attack Trial) of ~33,000 hypertensive 
individuals randomised to receive either Lisinopril o  Calcium channel blocker, there 
were small differences in mean BP between treatment groups, but large differences 
in BPV which paralleled the differences in stroke risk.(ALLHAT Collaborative 
Research Group 2002.)  Stroke risk and BPV were higher in the group treated with 
Lisinopril, compared to the group treated with calcium channel blockers. (Rothwell 
et al. 2010b, ALLHAT Collaborative Research Group 200 .) In post hoc analyses of 
the ASCOT-BPLA trial (Anglo-Scandinavian Cardiac Outcomes Trial- Blood 
Pressure Lowering Arm), episodic hypertension was greater in the group treated with 
B blockers, compared to the group treated with calcium channel blockers.(Rothwell 
2010b.) Subsequent post-hoc analyses of data from all trials of antihypertensive 
lowering drugs have shown consistent effects of drug class on group BPV; reduced 
by calcium channel blockers and increased by B blockers.(Rothwell et al. 2010a.) 
Testable future hypotheses would include clinical tri s of calcium channel blockers 
(versus placebo, or other antihypertensive drugs eg ACE-/B blockers) in patients 
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with normotension and BPV variability versus those with stable normotension. 
Similar trials could also include populations with treated hypertension, with and 
without residual BP variability. If these trials demonstrated calcium channel blockers 
reduced BPV and subsequent stroke risk, it would create new opportunities for stroke 
prevention, particularly amongst individuals with normal mean BP. It has also been 
suggested that statins reduce BPV which may explain their additional protective 
effects beyond cholesterol reduction. (Rothwell 2010b). Finally, the overall effect of 
calcium channel blockers on BPV reduction has been shown to be modest.(Rothwell 
2010b). This means that there is potential in future fo  development of newer drugs, 
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